CA2360347C

CA2360347C - Improved expression of hiv polypeptides and production of virus-like particles

Info

Publication number: CA2360347C
Application number: CA2360347A
Authority: CA
Inventors: Susan Barnett; Jan Zur Megede; Indresh Srivastava; Ying Lian; Karin Hartog; Hong Liu; Catherine Greer; Mark Selby; Christopher Walker
Original assignee: Novartis Vaccines and Diagnostics Inc
Current assignee: Novartis Vaccines and Diagnostics Inc
Priority date: 1998-12-31
Filing date: 1999-12-30
Publication date: 2013-05-07
Anticipated expiration: 2019-12-30
Also published as: WO2000039302A3; CA2360347A1; US7348177B2; US20030223964A1; JP2011019534A; EP1141313A2; US7718401B2; US20080261271A1; US20110065146A1; AU2221600A; EP2206785A1; US8168418B2; WO2000039302A2; US6602705B1; JP2011172593A; EP1980617A1; US20120269840A1; JP2002533124A

Abstract

The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides arc described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Vitus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for tire presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.

Description

DEMANDES OU BREVETS VOLUMINEUX

LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.

NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

NOTE: For additional volumes please contact the Canadian Patent Office.

IMPROVED EXPRESSION OF HIV POLYPEPTIDES AND
PRODUCTION OF VIRUS-LIKE PARTICLES

TZCZNIC.AL FIELD
Synthetic expression cassettes encoding the HIV
polypeptides (e.g., Gag-, poi-, prot-, reverse transcriptase, Env- or tat-containing polypeptides) are , described,, as are uses of the expression cassettes. The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types. Further, the invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs and high level expression of oligomeric envelope proteins.
Bkommammor z 'worn=
Acquired immune deficiency syndrome (AIDS) is recognized as one of the greatest health threats facing modern medicine. There is, as yet, no cure for this disease.
In 1983-1984, three groups independently identified the suspected etiological agent of AIDS. See, e.g., Barre-Sinoussi et al. (1983) Science 220:868-871;
Montagnier et al., in Human T-Cell Leukemia Viruses (Gallo, Essex & Gross, eds., 1984); Vilmer et al. (1984) The Lancet 1:753; Popovic et al. (1984) Science 224:497-500; Levy et al. (1984) Science 225:840-842.
These isolates were variously called lymphadenopathy-associated virus (LAV), human T-cell lymphotropic virus type III (HTLV-III), or AIDS-associated retrovirus (ARV).
All of these isolates are strains of the same virus, and were later collectively named Human Immunodeficiency Virus (HIV). With the isolation of a related AIDS-causing virus, the strains originally called HIV are now termed HIV-1 and the related virus is called HIV-2 See, e.g., Guyader et al. (1987) Nature 326:662-669;
Brun-Vezinet et al. (1986) Science 233:343-346; Clavel et al. (1986) Nature 324:691-695.
A great deal of information has been gathered about the HIV virus, however, to date an effective vaccine has not been identified. Several targets for vaccine development have been examined including the env, Gag, pol and tat gene products encoded by HIV.
Haas, et al., (Current Biology 6(3):315-324, 1996) suggested that selective codon usage by HIV-1 appeared to account for a substantial fraction of the inefficiency of viral protein synthesis. Andre, et al., (J. Viral.
72(2):1497-1503, 1998) described an increased immune response elicited by DNA vaccination employing a synthetic gp120 sequence with optimized codon usage.
Schneider, et al., (J Viral. 71(7):4892-4903, 1997) discuss inactivation of inhibitory (or instability) elements (INS) located within the coding sequences of the Gag and Gag-protease coding sequences.
The Gag proteins of HIV-1 are necessary for the assembly of virus-like particles. HIV-1 Gag proteins are involved in many stages of the life cycle of the virus including, assembly, virion maturation after particle release, and early post-entry steps in virus replication.
The roles of HIV-1 Gag proteins are numerous and complex (Freed, E.O., Virology 251:1-15, 1998).

Wolf, et al., (PCT International Application, WO
96/30523, published 3 October 1996; European Patent Application, Publication No. 0 449 116 Al, published 2 October 1991) have described the use of altered pr55 Gag of HIV-1 to act as a non-infectious retroviral-like particulate carrier, in particular, for the presentation of immunologically important epitopes. Wang, et al., (Virology 200:524-534, 1994) describe a system to study assembly of HIV Gag-f3-ga1actosidase fusion proteins into virions. They describe the construction of sequences encoding HIV Gag-13-galactosidase fusion proteins, the expression of such sequences in the presence of HIV Gag proteins, and assembly of these proteins into virus particles.
Recently, Shiver, et al., (PCT International Application, WO 98/34640, published 13 August 1998) described altering HIV-1 (CAM1) Gag coding sequences to produce synthetic DNA molecules encoding HIV Gag and modifications of HIV Gag. The codons of the synthetic molecules were codons preferred by a projected host cell.
The envelope protein of HIV-1 is a glycoprotein of about 160 kD (gp160). During virus infection of the host cell, gp160 is cleaved by host cell proteases to form gp120 and the integral membrane protein, gp41. The gp41 portion is anchored in (and spans) the membrane bilayer of virion, while the gp120 segment protrudes into the surrounding environment. As there is no covalent attachment between gp120 and gp41, free gp120 is released from the surface of virions and infected cells.
Haas, et al., (Current Biology 6(3):315-324, 1996) suggested that selective codon usage by HIV-1 appeared to account for a substantial fraction of the inefficiency of viral protein synthesis. Andre, et al., (J. Virol.

72(2):1497-1503, 1998) described an increased immune response elicited by DNA vaccination employing a synthetic gp120 sequence with optimized codon usage.

SMIGOMY OF TEE INVENTION
The present invention relates to improved expression of HIV Env-, tat-, poi-, prot-, reverse transcriptase, or Gag-containing polypeptides and production of virus-like particles.
In one embodiment the present invention includes an expression cassette, comprising a polynucleotide encoding an HIV Gag polypeptide comprising a sequence having at least 90% sequence identity to the sequence presented as SEQ ID NO:20. In certain embodiments, the polynucleotide sequence encoding said Gag polypeptide comprises a sequence having at least 90% sequence identity to the sequence presented as SEQ ID NO:9 or SEQ ID NO:4. The expression cassettes may further include a polynucleotide sequence encoding an HIV protease polypeptide, for example a nucleotide sequence having at least 90%
sequence identity to a sequence selected from the group consisting of: SEQ ID NO:5, SEQ ID NO:78, and SEQ ID
NO:79. The expression cassettes may further include a polynucleotide sequence encoding an HIV reverse transcriptase polypeptide, for example a sequence having at least 90% sequence identity to a sequence selected from the group consisting of: SEQ ID NO:80, SEQ ID
NO:81, SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:84. The expression cassettes may further include a polynucleotide sequence encoding an HIV tat polypeptide, for example a sequence selected from the group consisting of: SEQ ID
NO:87, SEQ ID NO:88, and SEQ ID NO:89. The expression cassettes may further include a polynucleotide sequence encoding an HIV polymerase polypeptide, for example a sequence having at least 90% sequence identity to the sequence presented as SEQ ID N0:6. The expression cassettes may include a polynucleotide sequence encoding an HIV polymerase polypeptide, wherein (i) the nucleotide sequence encoding said polypeptide comprises a sequence having at least 90% sequence identity to the sequence presented as SEQ ID NO:4, and (ii) wherein the sequence is modified by deletions of coding regions corresponding to reverse transcriptase and integrase. The expression cassettes described above may preserves T-helper cell and CTL epitopes. The expression cassettes may further include a polynucleotide sequence encoding an HCV core polypeptide, for example a sequence having at least 90%
sequence identity to the sequence presented as SEQ ID
NO:7.
In another aspect, the invention includes an expression cassette, comprising a polynucleotide sequence encoding a polypeptide including an HIV Env polypeptide, wherein the polynucleotide sequence encoding said Env polypeptide comprises a sequence having at least 90%
sequence identity to SEQ ID NO:71 (Figure 58) or SEQ ID
NO:72 (Figure 59). In certain embodiments, the Env expression cassettes includes sequences flanking a V1 region but have a deletion in the V1 region itself, for example the sequence presented as SEQ ID NO:65 (Figure 52, gp160.modUS4.delV1). In certain embodiments, the Env expression cassettes, include sequences flanking a V2 region but have a deletion in the V2 region itself, for example the sequences shown in SEQ ID NO:60 (Figure 47);
SEQ ID NO:66 (Figure 53); SEQ ID NO:34 (Figure 20); SEQ
ID N0:37 (Figure 24); SEQ ID NO:40 (Figure 27); SEQ ID
NO:43 (Figure 30); SEQ ID NO:46 (Figure 33); SEQ ID N0:76 (Figure 64) and SEQ ID N0:49 (Figure 36). In certain embodiments, the Env expression cassettes include sequences flanking a V1/V2 region but have a deletion in the V1/V2 region itself, for example, SEQ ID NO:59 (Figure 46); SEQ ID NO:61 (Figure 48); SEQ ID NO:67 (Figure 54); SEQ ID NO:75 (Figure 63); SEQ ID NO:35 (Figure 21); SEQ ID NO:38 (Figure 25); SEQ ID NO:41 (Figure 28); SEQ ID NO:44 (Figure 31); SEQ ID NO:47 (Figure 34) and SEQ ID NO:50 (Figure 37). The Env-encoding expression cassettes may also include a mutated cleavage site that prevents the cleavage of a gp140 polypeptide into a gp120 polypeptide and a gp41 polypeptide, for example, SEQ ID NO:57 (Figure 44); SEQ
ID NO:61 (Figure 48); SEQ ID NO:63 (Figure 50); SEQ ID
NO:39 (Figure 26); SEQ ID NO:40 (Figure 27); SEQ ID NO:41 (Figure 28); SEQ ID NO:42 (Figure 29); SEQ ID NO:43 (Figure 30); SEQ ID NO:44 (Figure 31); SEQ ID NO:45 (Figure 32); SEQ ID NO:46 (Figure 33); and SEQ ID NO:47 (Figure 34). The Env expression cassettes may include a gp160 Env polypeptide or a polypeptide derived from a gp160 Env polypeptide, for example SEQ ID NO:64 (Figure 51); SEQ ID NO:65 (Figure 52); SEQ ID NO:66 (Figure 53);
SEQ ID NO:67 (Figure 54); SEQ ID NO:68 (Figure 55); SEQ
ID NO:75 (Figure 63); SEQ ID NO:73 (Figure 61); SEQ ID
NO:48 (Figure 35); SEQ ID NO:49 (Figure 36); SEQ ID NO:50 (Figure 37); SEQ ID NO:76 (Figure 64); and SEQ ID NO:74 (Figure 62). The Env expression cassettes may include a gp140 Env polypeptide or a polypeptide derived from a gp140 Env polypeptide, for example SEQ ID NO:56 (Figure 43); SEQ ID NO:57 (Figure 44); SEQ ID NO:58 (Figure 45);
SEQ ID NO:59 (Figure 46); SEQ ID NO:60 (Figure 47); SEQ
ID NO:61 (Figure 48); SEQ ID NO:62 (Figure 49); SEQ ID
NO:63 (Figure 50); SEQ ID NO:36 (Figure 23); SEQ ID NO:37 (Figure 24); SEQ ID NO:38 (Figure 25); SEQ ID NO:39 (Figure 26); SEQ ID NO:40 (Figure 27); SEQ ID NO:41 (Figure 28); SEQ ID NO:42 (Figure 29); SEQ ID NO:43 (Figure 30); SEQ ID NO:44 (Figure 31); SEQ ID NO:45 (Figure 32); SEQ ID NO:46 (Figure 33); and SEQ ID NO:47 (Figure 34). The Env expression cassettes may also include a gp120 Env polypeptide or a polypeptide derived from a gp120 Env polypeptide, for example SEQ ID NO:54 (Figure 41); and SEQ ID NO:55 (Figure 42); SEQ ID NO:33 (Figure 19); SEQ ID NO:34 (Figure 20); and SEQ ID NO:35 (Figure 21). The Env expression cassettes may include an Env polypeptide lacking the amino acids corresponding to residues 128 to about 194, relative to strains SF162 or US4, for example, SEQ ID NO:55 (Figure 42); SEQ ID NO:62 (Figure 49); SEQ ID NO:63 (Figure 50); and SEQ ID NO:68 (Figure 55).
In another aspect, the invention includes a recombinant expression system for use in a selected host cell, comprising, one or more of the expression cassettes described herein operably linked to control elements compatible with expression in the selected host cell. The expression cassettes may be included on one or on multiple vectors and may use the same or different promoters. Exemplary control elements include a transcription promoter (e.g., CMV, CMV+intron A, SV40, RSV, HIV-Ltr, MMLV-ltr, and metallothionein), a transcription enhancer element, a transcription termination signal, polyadenylation sequences, sequences for optimization of initiation of translation, and translation termination sequences.
In another aspect, the invention includes a recombinant expression system for use in a selected host cell, comprising, any one of the expression cassettes described herein operably linked to control elements , compatible with expression in the selected host cell.
Exemplary control elements include, but are not limited to, a transcription promoter (e.g., CMV, CMV-vintron A, SV40, RSV, HIV-LTR, MMLV-LTR, and metallothionein), a transcription enhancer element, a transcription termination signal, polyadenylation sequences, sequences for optimization of initiation of translation, and translation termination sequences.
In yet another aspect, the invention includes a cell comprising one or more of the expression cassettes described herein operably linked to control elements compatible with expression in the cell. The cell can be, for example, a mammalian cell (e.g., BHK, VERO, HT1080, 293, RD, COS-7, or CHO cells), an insect cell (e.g., Trichoplusia ni (Tn5) or Sf9), a bacterial cell, a plant cell, a yeast cell, an antigen presenting cell (e.g., primary, immortalized or tumor-derived lymphoid cells such as macrophages, monocytes, dendritic cells, B-cells, T-cells, stem cells, and progenitor cells thereof).
In another aspect, the invention includes methods for producing a polypeptide including HIV Gag-, prot-, poi-, reverse transcriptase, Env- or Tat-containing polypeptide sequences, said method comprising, incubating the cells comprising one or more the expression cassettes describe herein, under conditions for producing said polypeptide.
In yet another aspect, the invention includes compositions for generating an immunological response, comprising one or more of the expression cassettes described herein. In certain embodiments, the compositions also include an adjuvant.
In a still further aspect, the invention includes methods of generating an immune response in a subject, comprising introducing a composition comprising one or more of the expression cassettes described herein into the subject under conditions that are compatible with expression of said expression cassette in the subject.
In certain embodiments, the expression cassette is introduced using a gene delivery vector. More than one expression cassette may be introduced using one or more gene delivery vectors.
In yet another aspect, the invention includes a purified polynucleotide comprising a polynucleotide sequence encoding a polypeptide including an HIV Env polypeptide, wherein the polynucleotide sequence encoding said Env polypeptide comprises a sequence having at least 90% sequence identity to SEQ ID NO:71 (Figure 58) or SEQ
ID NO:72 (Figure 59). Further exemplary purified polynucleotide sequences were presented above.
The polynucleotides of the present invention can be produced by recombinant techniques, synthetic techniques, or combinations thereof.
In another embodiment, the invention includes a method for producing a polypeptide including HIV Gag polypeptide sequences, where the method comprises incubating any of the above cells containing an expression cassette of interest under conditions for producing the polypeptide.
The invention further includes, a method for producing virus-like particles (VLPs) where the method comprises incubating any of the above-described cells containing an expression cassette of interest under conditions for producing VLPs.
In another aspect the invention includes a method for producing a composition of virus-like particles (VLPs) where, any of the above-described cells containing an expression cassette of interest are incubated under conditions for producing VLPs, and the VLPs are substantially purified to produce a composition of VLPs.
In a further embodiment of the present invention, packaging cell lines are produced using the expression cassettes of the present invention. For example, a cell line useful for packaging lentivirus vectors comprises suitable host cells that have an expression vector containing an expression cassette of the present invention wherein said polynucleotide sequence is operably linked to control elements compatible with expression in the host cell. In a preferred embodiment, such host cells may be transfected with one or more expression cassettes having a polynucleotide sequence that encodes an HIV polymerase polypeptide or polypeptides derived therefrom, for example, where the nucleotide sequence encoding said polypeptide comprises a sequence having at least 90% sequence identity to the sequence presented as SEQ ID NO:6. Further, the HIV
polymerase polypeptide may be modified by deletions of coding regions corresponding to reverse transcriptase and integrase. Such a polynucleotide sequence may preserve T-helper cell and CTL epitopes, for example when used in a vaccine application. In addition, the polynucleotide sequence may also include other polypeptides. Further, polynucleotide sequences encoding additional polypeptides whose expression are useful for packaging cell line function may also be utilized.
In another aspect, the present invention includes a gene delivery or vaccine vector for use in a subject, where the vector is a suitable gene delivery vector for use in the subject, and the vector comprises one or more of any of the expression cassettes of the present invention where the polynucleotide sequences of interest are operably linked to control elements compatible with expression in the subject. Such gene delivery vectors can be used in a method of DNA immunization of a subject, for example, by introducing a gene delivery vector into the subject under conditions that are compatible with expression of the expression cassette in the subject.
Gene delivery vectors useful in the practice of the present invention include, but are not limited to, nonviral vectors, bacterial plasmid vectors, viral vectors, particulate carriers (where the vector is coated on a polylactide co-glycolide particles, gold or tungsten particle, for example, the coated particle can be delivered to a subject cell using a gene gun), liposome preparations, and viral vectors (e.g., vectors derived from alphaviruses, pox viruses, and vaccinia viruses, as well as, retroviral vectors, including, but not limited to, lentiviral vectors). Alphavirus-derived vectors include, for example, an alphavirus cDNA construct, a recombinant alphavirus particle preparation and a eukaryotic layered vector initiation system. In one embodiment, the subject is a vertebrate, preferably a mammal, and in a further embodiment the subject is a human.
The invention further includes a method of generating an immune response in a subject, where cells of a subject are transfected with any of the above-described gene delivery vectors (e.g., alphavirus constructs; alphavirus cDNA constructs; eukaryotic layered vector initiation systems (see, e.g., U.S. Patent Number 5,814,482 for description of suitable eukaryotic layered vector initiation systems); alphavirus particle preparations; etc.) under conditions that permit the expression of a selected polynucleotide and production of a polypeptide of interest (i.e., encoded by any expression cassette of the present invention), thereby eliciting an immunological response to the polypeptide.
Transfection of the cells may be performed ex vivo and the transfected cells are reintroduced into the subject.
Alternately, or in addition, the cells may be transfected in vivo in the subject. The immune response may be humoral and/or cell-mediated (cellular).
Further embodiments of the present invention include purified polynucleotides. In one embodiment, the purified polynucleotide comprises a polynucleotide sequence having at least 90% sequence identity to the sequence presented as SEQ ID NO:20, and complements thereof. In another embodiment, the purified polynucleotide comprises a polynucleotide sequence encoding an HIV Gag polypeptide, wherein the polynucleotide sequence comprises a sequence having at least 90% sequence identity to the sequence presented as SEQ ID NO:20, and complements thereof. In still another embodiment, the purified polynucleotide comprises a polynucleotide sequence encoding an HIV Gag polypeptide, wherein the polynucleotide sequence comprises a sequence having at least 90% sequence identity to the sequence presented as SEQ ID NO:9, and complements thereof. In further embodiments the polynucleotide sequence comprises a sequence having at least 90% sequence identity to one of the following sequences: SEQ ID NO:4, SEQ ID NO:5, SEQ
ID NO:6, SEQ ID NO:7, and complements thereof.
The polynucleotides of the present invention can be produced by recombinant techniques, synthetic techniques, or combinations thereof.

These and other embodiments of the present invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.

BRIEF DESCRIPTION OF THE FIGURES
Figure 1 shows the locations of the inactivation sites for the native HIV-1SF2 Gag protein coding sequence.
Figure 2 shows the locations of the inactivation sites for the native HIV-1SF2 Gag-protease protein coding sequence.
Figures 3A and 3B show electron micrographs of virus-like particles. Figure 3A shows immature p55Gag virus-like particles in COS-7 cells transfected with a synthetic gag construct while Figure 3B shows mature (arrows) and immature VLP in cells transfected with a modified HIV-1,p, gagprotease construct (GP2, SEQ
ID NO:70). Transfected cells were fixed at 24 h (gag) or 48 h (gagprotease) post-transfection and subsequently analyzed by electron microscopy (magnification at 100,000X). Cells transfected with vector alone (pCMVKm2) served as negative control (data not shown).
Figure 4 presents an image of samples from a series of fractions which were electrophoresed on an 8-16% SDS
polyacrylamide gel and the resulting bands visualized by commassie blue staining. The results show that the native p55 Gag virus-like particles (VLPs) banded at a sucrose density of range of 1.15 - 1.19 g/m1 with the peak at approximately 1.17 g/ml.
Figure 5 presents an image similar to Figure 4 where the analysis was performed using Gag VLPs produced by a synthetic Gag expression cassette.

_ Figure 6 presents a comparison of the total amount of purified HIV p55 Gag from several preparations obtained from two baculovirus expression cassettes encoding native and modified Gag.
Figure 7 presents an alignment of modified coding sequences of the present invention including a synthetic Gag expression cassette (SEQ ID NO:4), a synthetic Gag-protease expression cassette (SEQ ID NO:5), and a synthetic Gag-polymerase expression cassette (SEQ ID
NO:6). A common region (Gag-common; SEQ ID NO:9) extends from position 1 to position 1262.
Figure 8 presents an image of wild-type Gag-HCV core expression samples from a series of fractions which were electrophoresed on an 8-16% SDS polyacrylamide gel and the resulting bands visualized by commassie staining.
Figure 9 shows the results of Western blot analysis of the gel shown presented in Figure 8.
Figure 10 presents results similar to those shown in Figure 9. The results in Figure 10 indicate that the main HCV Core-specific reactivity migrates at an approximate molecular weight of 72,000 kD, which is in accordance with the predicted molecular weight of the Gag-HCV core chimeric protein.
Figures 11A to 11D present a comparison of AT
content, in percent, of cDNAs corresponding to an unstable human mRNA (human IFNy mRNA; 11A), wild-type HIV
Gag native RNA (11B), a stable human mRNA (human GAPDH
mRNA; 11C), and synthetic HIV Gag RNA (11D).
Figure 12 shows the location of the inactivation sites for the native HIV-1SF2 Gag-polymerase sequence.
Figure 13A presents a vector map of pESN2dhfr.
Figure 13B presents a map of the pCMVIII vector.
Figure 14 presents a vector map of pCMV-LINK.

Vg)004MM PCTAUS99/31245 Figure 15 presents a schematic diagram showing the relationships between the following forms of the HIV Env polypeptide: gp160, gp140, gp120, and gp41.
Figure 16 depicts the nucleotide sequence of wild-type gp120 from SF162 (SEQ ID NO:30).
Figure 17 depicts the nucleotide sequence of the wild-type gp140 from SF162 (SEQ ID NO:31).
Figure 18 depicts the nucleotide sequence of the wild-type gp160 from SF162 (SEQ ID NO:32).
Figure 19 depicts the nucleotide sequence of the construct designated gp120.modSF162 (SEQ ID NO:33).
Figure 20 depicts the nucleotide sequence of the construct designated gp120.modSF162.delV2 (SEQ ID NO:34).
Figure 21 depicts the nucleotide sequence of the construct designated gp120.modSF162.delV1/V2 (SEQ ID
NO:35).
Figures 22A-H show the percent A-T content over the length of the sequences for IFNy (Figures 2C and 2G);
native gp160 Env US4 and SF162 (Figures 2A and 2E, respectively); GAPDH (Figures 2D and 2H); and the synthetic gp160 Env for US4 and SF162 (Figures 2B and 2F, respectively).
Figure 23 depicts the nucleotide sequence of the construct designated gp140.modSF162 (SEQ ID NO:36).
Figure 24 depicts the nucleotide sequence of the construct designated gp140.modSF162.delV2 (SEQ ID NO:37).
Figure 25 depicts the nucleotide sequence of the construct designated gp140.modSF162.delV1/V2 (SEQ ID
NO:38).
Figure 26 depicts the nucleotide sequence of the construct designated gp140.mut.modSF162 (SEQ ID NO:39).
Figure 27 depicts the nucleotide sequence of the construct designated gp140.mut.modSF162.delV2 (SEQ ID
NO:40).

Figure 28 depicts the nucleotide sequence of the construct designated gp140.mut.modSF162.delV1/V2 (SEQ ID
NO:41).
Figure 29 depicts the nucleotide sequence of the construct designated gp140.mut7.modSF162 (SEQ ID NO:42).
Figure 30 depicts the nucleotide sequence of the construct designated gp140.mut7.modSF162.delV2 (SEQ ID
NO:43).
Figure 31 depicts the nucleotide sequence of the construct designated gp140.mut7.modSF162.delV1/V2 (SEQ ID
NO:44).
Figure 32 depicts the nucleotide sequence of the construct designated gp140.mut8.modSF162 (SEQ ID NO:45).
Figure 33 depicts the nucleotide sequence of the construct designated gp140.mut8.modSF162.delV2 (SEQ ID
NO:46). Figure 34 depicts the nucleotide sequence of the construct designated gp140.mut8.modSF162.delV1/V2 (SEQ ID
NO:47).
Figure 35 depicts the nucleotide sequence of the construct designated gp160.modSF162 (SEQ ID NO:48).
Figure 36 depicts the nucleotide sequence of the construct designated gp160.modSF162.delV2 (SEQ ID NO:49).
Figure 37 depicts the nucleotide sequence of the construct designated gp160.modSF162.delV1/V2 (SEQ ID
NO:50).
Figure 38 depicts the nucleotide sequence of the wild-type gp120 from US4 (SEQ ID NO:51).
Figure 39 depicts the nucleotide sequence of the wild-type gp140 from US4 (SEQ ID NO:52).
Figure 40 depicts the nucleotide sequence of the wild-type gp160 from US4 (SEQ ID NO:53).
Figure 41 depicts the nucleotide sequence of the construct designated gp120.modUS4 (SEQ ID NO:54).

Figure 42 depicts the nucleotide sequence of the construct designated gp120.modUS4.del 128-194 (SEQ ID
NO:55).
Figure 43 depicts the nucleotide sequence of the construct designated gp140.modUS4 (SEQ ID NO:56).
Figure 44 depicts the nucleotide sequence of the construct designated gp140.mut.modUS4 (SEQ ID NO:57).
Figure 45 depicts the nucleotide sequence of the construct designated gp140.TM.modUS4 (SEQ ID NO:58).
Figure 46 depicts the nucleotide sequence of the construct designated gp140.modUS4.delV1/V2 (SEQ ID
NO:59).
Figure 47 depicts the nucleotide sequence of the construct designated gp140.modUS4.delV2 (SEQ ID NO:60).
Figure 48 depicts the nucleotide sequence of the construct designated gp140.mut.modUS4.delV1/V2 (SEQ ID
NO:61).
Figure 49 depicts the nucleotide sequence of the construct designated gp140.modUS4.del 128-194 (SEQ ID
NO:62).
Figure 50 depicts the nucleotide sequence of the construct designated gp140.mut.modUS4.del 128-194 (SEQ ID
NO:63).
Figure 51 depicts the nucleotide sequence of the construct designated gp160.modUS4 (SEQ ID NO:64).
Figure 52 depicts the nucleotide sequence of the construct designated gp160.modUS4.delV1 (SEQ ID NO:65).
Figure 53 depicts the nucleotide sequence of the construct designated gp160.modUS4.delV2 (SEQ ID NO:66).
Figure 54 depicts the nucleotide sequence of the construct designated gp160.modUS4.delV1/V2 (SEQ ID
NO:67).

-------Figure 55 depicts the nucleotide sequence of the construct designated gp160.modUS4.del 128-194 (SEQ ID
NO:68).
Figure 56 depicts the nucleotide sequence of the common region of Env from wild-type US4 (SEQ ID NO:69).
Figure 57 depicts the nucleotide sequence of the common region of Env from wild-type SF162 (SEQ ID NO:70).
Figure 58 depicts the nucleotide sequence of synthetic sequences corresponding to the common region of Env from US4 (SEQ ID NO:71).
Figure 59 depicts the nucleotide sequence of synthetic sequences corresponding to the common region of Env from SF162 (SEQ ID N0:72).
Figure 60 presents a schematic representation of an Env polypeptide purification strategy.
Figure 61 depicts the nucleotide sequence of the bicistronic construct designated gp160%modUS4.Gag.modSF2 (SEQ ID NO:73).
Figure 62 depicts the nucleotide sequence of the bicistronic construct designated gp160.modSF162.Gag.modSF2 (SEQ ID NO:74).
Figure 63 depicts the nucleotide sequence of the bicistronic construct designated gp160.modUS4.-delV1/V2.Gag.modSF2 (SEQ ID NO:75).
Figure 64 depicts the nucleotide sequence of the bicistronic construct designated gp160.modSF162.delV2.Gag.modSF2 (SEQ ID NO:76).
Figures 65A-65F show micrographs of 293T cells transfected with the following polypeptide encoding sequences: Figure 65A, gag.modSF2; Figure 65B, gp160.modUS4; Figure 65C, gp160.modUS4.delV1/V2.gag.modSF2 (bicistronic Env and Gag); Figures 65D and 65E, gp160.modUS4.delV1/V2 and gag.modSF2; and Figure 65F, gp120.modSF162.delV2 and gag.modSF2.
Figures 66A and 66B present alignments of selected modified coding sequences of the present invention including a common region defined for each group of synthetic Env expression cassettes. Figure 66A presents alignments of modified SF162 sequences. Figure 66B
presents alignments of modified US4 sequences. The SEQ
ID NOs for these sequences are presented in Tables 1A and 1B.
Figure 67 shows the ELISA titers (binding antibodies) obtained in two rhesus macaques (H445, lines with solid black dots; and J408, lines with open squares). The y-axis is the end-point gp140 ELISA titers and the x-axis shows weeks post-immunization. The dashed lines at 0, 4, and 8 weeks represent DNA immunizations.
The alternating dash/dotted line at 27 weeks indicates a DNA plus protein boost immunization.
Figure 68 (SEQ ID NO:77) depicts the wild-type nucleotide sequence of Gag reverse transcriptase from SF2.
Figure 69 (SEQ ID NO:78) depicts the nucleotide sequence of the construct designated GP1.
Figure 70 (SEQ ID NO:79) depicts the nucleotide sequence of the construct designated GP2.
Figure 71 (SEQ ID NO:80) depicts the nucleotide sequence of the construct designated FS(+).protinact.RTopt.YM. FS(+) indicates that there is a frameshift in the GagPol coding sequence.
Figure 72 (SEQ ID NO:81) depicts the nucleotide sequence of the construct designated FS(+).protinact.RTopt.YMWM.
Figure 73 (SEQ ID NO:82) depicts the nucleotide sequence of the construct designated FS(-W000/39302 PCTfUS99/31245 ).protmod.RTopt.YM. FS(-) indicates that there is no frameshift in the GagPol coding sequence.
Figure 74 (SEQ ID NO:83) depicts the nucleotide sequence of the construct designated FS(-).protmod.RTopt.YMWM.
Figure 75 (SEQ ID NO:84) depicts the nucleotide sequence of the construct designated FS(-).protmod.RTopt(+).
Figure 76 (SEQ ID NO:85) depicts the nucleotide sequence of wild type Tat from isolate SF162.
Figure 77 (SEQ ID NO:86) depicts the amino acid sequence of the tat polypeptide.
Figure 78 (SEQ ID NO:87) depicts the nucleotide sequence of a synthetic Tat construct designated Tat.SF162.opt.
Figure 79 (SEQ ID NO:88) depicts the nucleotide sequence of a synthetic Tat construct designated tat.cys22.sf162.opt. The construct encodes a tat polypeptide in which the cystein residue at position 22 of the wild type Tat polypeptide is replaced by a glycine residue.
Figures 80A to 80E are an alignment of the nucleotide sequences of the constructs designated Gag.mod.SF2, GP1 (SEQ ID NO:78), and GP2 (SEQ ID NO:79).
Figure 81 (SEQ ID NO:89) depicts the nucleotide sequence of the construct designated tataminoSF162.opt, which encodes the amino terminus of that tat protein.
The codon encoding the cystein-22 residue is underlined.
Figure 82 (SEQ ID NO:90) depicts the amino acid sequence of the polypeptide encoded by the construct designated tat.cys22.SF162.opt (SEQ ID NO:88).

DETAILED DESCRIPTION OF THE INVENTION
The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, immunology and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990);
Methods In Enzymology (S. Colowick and N. Kaplan, eds., Academic Press, Inc.); and Handbook of Experimental Immunology, Vols. [-IV (D.M. Weir and C.C. Blackwell, eds., 1986, Blackwell Scientific Publications); Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Short Protocols in Molecular Biology, 4th ed. (Ausubel et al. eds., 1999, John Wiley & Sons);
Molecular Biology Techniques: An Intensive Laboratory Course, (Ream et al., eds., 1998, Academic Press); PCR
(Introduction to Biotechniques Series), 2nd ed. (Newton &
Graham eds., 1997, Springer Verlag).
As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise. Thus, for example, reference to "an antigen"
includes a mixture of two or more such agents.
1. DEFINITIONS
In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.
"Synthetic" sequences, as used herein, refers to Env-, tat- or Gag-encoding polynucleotides whose expression has been optimized as described herein, for example, by codon substitution, deletions, replacements and/or inactivation of inhibitory sequences. "Wild-type"

._ 4 ,3 or "native" sequences, as used herein, refers to polypeptide encoding sequences that are essentially as they are found in nature, e.g., Gag encoding sequences as found in the isolate HIV-1SF2 or Env encoding sequences as found in the isolates HIV-1SF162 or HIV1US4.
As used herein, the term "virus-like particle" or "VLP" refers to a nonreplicating, viral shell, derived from any of several viruses discussed further below.
VLPs are generally composed of one or more viral proteins, such as, but not limited to those proteins referred to as capsid, coat, shell, surface and/or envelope proteins, or particle-forming polypeptides derived from these proteins. VLPs can form spontaneously upon recombinant expression of the protein in an appropriate expression system. Methods for producing particular VLPs are known in the art and discussed more . fully below. The presence of VLPs following recombinant expression of viral proteins can be detected using conventional techniques known in the art, such as by electron microscopy, biophysical characterization, and the like. See, e.g., Baker et al., Biophys. J. (1991) 60:1445-1456; Hagensee et al., J. Virol. (1994) 68:4503-4505. For example, VLPs can be isolated by density gradient centrifugation and/or identified by characteristic density banding (e.g., Example 7).
Alternatively, cryoelectron microscopy can be performed on vitrified aqueous samples of the VLP preparation in question, and images recorded under appropriate exposure conditions.By "particle-forming polypeptide" derived from a particular viral protein is meant a full-length or near full-length viral protein, as well as a fragment thereof, or a viral protein with internal deletions, which has the ability to form VLPs under conditions that favor VLP

formation. Accordingly, the polypeptide may comprise the full-length sequence, fragments, truncated and partial sequences, as well as analogs and precursor forms of the reference molecule. =The term therefore intends deletions, additions and substitutions to the sequence, so long as the polypeptide retains the ability to form a VLP. Thus, the term includes natural variations of the specified polypeptide since variations in coat proteins often occur between viral isolates. The term also includes deletions, additions and substitutions that do not naturally occur in the reference protein, so long as the protein retains the ability to form a VLP. Preferred substitutions are those which are conservative in nature, i.e., those substitutions that take place within a family of amino acids that are related in their side chains.
Specifically, amino acids are generally divided into four families: (1) acidic -- aspartate and glutamate; (2) .
basic -- lysine, arginine, histidine; (3) non-polar --alanine, valine, leucine, isoleucine, praline, phenylalanine, methionine, tryptophan; and (4) uncharged polar -- glycine, asparagine, glutamine, cystine, serine threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified as aromatic amino acids.
An "antigen" refers to a molecule containing one or more epitopes (either linear, conformational or both) that will stimulate a host's immune system to make a humoral and/or cellular antigen-specific response. The term is used interchangeably with the term "immunogen."
Normally, a B-cell epitope will include at least about 5 amino acids but can be as small as 3-4 amino acids. A T-cell epitope, such as a CTL epitope, will include at least about 7-9 amino acids, and a helper T-cell epitope at least about 12-20 amino acids. Normally, an epitope will include between about 7 and 15 amino acids, such as, 9, 10, 12 or 15 amino acids. The term "antigen" denotes both subunit antigens, (i.e., antigens which are separate and discrete from a whole organism with which the antigen is associated in nature), as well as, killed, attenuated or inactivated bacteria, viruses, fungi, parasites or other microbes. Antibodies such as anti-idiotype antibodies, or fragments thereof, and synthetic peptide mimotopes, which can mimic an antigen or antigenic determinant, are also captured under the definition of antigen as used herein. Similarly, an oligonucleotide or polynucleotide which expresses an antigen or antigenic determinant in vivo, such as in gene therapy and DNA
immunization applications, is also included in the definition of antigen herein.
For purposes of the present invention, antigens can be derived from any of several known viruses, bacteria, parasites and fungi, as described more fully below. The term also intends any of the various tumor antigens.
Furthermore, for purposes of the present invention, an "antigen" refers to a protein which includes modifications, such as deletions, additions and substitutions (generally conservative in nature), to the native sequence, so long as the protein maintains the ability to elicit an immunological response, as defined herein. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts which produce the antigens.
An "immunological response" to an antigen or composition is the development in a subject of a humoral and/or a cellular immune response to an antigen present in the composition of interest. For purposes of the present invention, a "humoral immune response" refers to an immune response mediated by antibody molecules, while a "cellular immune response" is one mediated by T-lymphocytes and/or other white blood cells. One important aspect of cellular immunity involves an antigen-specific response by cytolytic T-cells ("CTL"s).
CTLs have specificity for peptide antigens that are presented in association with proteins encoded by the major histocompatibility complex (MHC) and expressed on the surfaces of cells. CTLs help induce and promote the destruction of intracellular microbes, or the lysis of cells infected with such microbes. Another aspect of cellular immunity involves an antigen-specific response by helper T-cells. Helper T-cells act to help stimulate the function, and focus the activity of, nonspecific effector cells against cells displaying peptide antigens in association with MHC molecules on their surface. A
"cellular immune response" also refers to the production of cytokines, chemokines and other such molecules produced by activated T-cells and/or other white blood cells, including those derived from CD4+ and CD8+ T-cells.
A composition or vaccine that elicits a cellular immune response may serve to sensitize a vertebrate subject by the presentation of antigen in association with MHC molecules at the cell surface. The cell-mediated immune response is directed at, or near, cells presenting antigen at their surface. In addition, antigen-specific T-lymphocytes can be generated to allow for the future protection of an immunized host.
The ability of a particular antigen to stimulate a cell-mediated immunological response may be determined by a number of assays, such as by lymphoproliferation (lymphocyte activation) assays, CTL cytotoxic cell assays, or by assaying for T-lymphocytes specific for the antigen in a sensitized subject. Such assays are well known in the art. See, e.g., Erickson et al., J.
Immunol. (1993) 151:4189-4199; Doe et al., Eur. J.
Immuno1. (1994) 24:2369-2376. Recent methods of measuring cell-mediated immune response include measurement of intracellular cytokines or cytokine secretion by T-cell populations, or by measurement of epitope specific T-cells (e.g., by the tetramer technique)(reviewed by McMichael, A.J., and O'Callaghan, C.A., J. Exp. Med. 187(9)1367-1371, 1998; Mcheyzer-Williams, M.G., et al, Immunol. Rev. 150:5-21, 1996;
Lalvani, A., et al, J. Exp. med. 186:859-865, 1997).
Thus, an immunological response as used herein may be one which stimulates the production of CTLs, and/or the production or activation of helper T- cells. The antigen of interest may also elicit an antibody-mediated immune response. Hence, an immunological response may include one or more of the following effects: the production of antibodies by B-cells; and/or the activation of suppressor T-cells and/or y6 T-cells directed specifically to an antigen or antigens present in the composition or vaccine of interest. These responses may serve to neutralize infectivity, and/or mediate antibody-complement, or antibody dependent cell cytotoxicity (ADCC) to provide protection to an immunized host. Such responses can be determined using standard immunoassays and neutralization assays, well known in the art.
An "immunogenic composition" is a composition that comprises an antigenic molecule where administration of the composition to a subject results in the development in the subject of a humoral and/or a cellular immune response to the antigenic molecule of interest.

-------By "subunit vaccine" is meant a vaccine composition which includes one or more selected antigens but not all antigens, derived from or homologous to, an antigen from a pathogen of interest such as from a virus, bacterium, parasite or fungus. Such a composition is substantially free of intact pathogen cells or pathogenic particles, or the lysate of such cells or particles. Thus, a "subunit vaccine" can be prepared from at least partially purified (preferably substantially purified) immunogenic polypeptides from the pathogen, or analogs thereof. The method of obtaining an antigen included in the subunit vaccine can thus include standard purification techniques, recombinant production, or synthetic production.
"Substantially purified" general refers to isolation of a substance (compound, polynucleotide, protein, polypeptide, polypeptide composition) such that the substance comprises the majority percent of the sample in which it resides. Typically in a sample a substantially purified component comprises 50%, preferably 80%-85%, more preferably 90-9575 of the sample. Techniques for purifying polynucleotides and polypeptides of interest are well-known in the art and include, for example, ion-exchange chromatography, affinity chromatography and sedimentation according to density.
A "coding sequence" or a sequence which "encodes" a selected polypeptide, is a nucleic acid molecule which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vivo when placed under the control of appropriate regulatory sequences (or "control elements"). The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A coding sequence can include, but is not limited to, cDNA from viral, procaryotic or eucaryotic mRNA, genomic DNA sequences from viral or procaryotic DNA, and even synthetic DNA sequences. A
transcription termination sequence may be located 3' to the coding sequence.
Typical "control elements", include, but are not limited to, transcription promoters, transcription enhancer elements, transcription termination signals, polyadenylation sequences (located 3' to the translation stop codon), sequences for optimization of initiation of translation (located 5' to the coding sequence), and translation termination sequences, see e.g., McCaughan et al. (1995) PNAS USA 92:5431-5435; Kochetov et al (1998) FEES Letts. 440:351-355.A "nucleic acid" molecule can include, but is not limited to, procaryotic sequences, eucaryotic mRNA, cDNA
from eucaryotic mRNA, genomic DNA sequences from =
eucaryotic (e.g., mammalian) DNA, and even synthetic DNA
sequences. The term also captures sequences that include, any of the known base analogs of DNA and RNA.
"Operably linked" refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, a given promoter operably linked to a coding sequence is capable of effecting the expression of the coding sequence when the proper enzymes are present. The promoter need not be contiguous with the coding sequence, so long as it functions to direct the expression thereof.
Thus, for example, intervening untranslated yet transcribed sequences can be present between the promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence.

"Recombinant" as used herein to describe a nucleic acid molecule means a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation: (1) is not associated with all or a portion of the polynucleotide with which it is associated in nature; and/or (2) is linked to a polynucleotide other than that to which it is linked in nature. The term "recombinant" as used with respect to a protein or polypeptide means a polypeptide produced by expression of a recombinant polynucleotide. "Recombinant host cells," "host cells," "cells," "cell lines," "cell cultures," and other such terms denoting procaryotic microorganisms or eucaryotic cell lines cultured as unicellular entities, are used interchangeably, and refer to cells which can be, or have been, used as recipients for recombinant vectors or other transfer DNA, and include the progeny of the original cell which has been transfected. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA
complement to the original parent, due to accidental or deliberate mutation. Progeny of the parental cell which are sufficiently similar to the parent to be characterized by the relevant property, such as the presence of a nucleotide sequence encoding a desired peptide, are included in the progeny intended by this definition, and are covered by the above terms.
Techniques for determining amino acid sequence "similarity" are well known in the art. In general, "similarity" means the exact amino acid to amino acid comparison of two or more polypeptides at the appropriate place, where amino acids are identical or possess similar chemical and/or physical properties such as charge or hydrophobicity. A so-termed "percent similarity" then can be determined between the compared polypeptide sequences. Techniques for determining nucleic acid and amino acid sequence identity also are well known in the art and include determining the nucleotide sequence of the mRNA for that gene (usually via a cDNA intermediate) and determining the amino acid sequence encoded thereby, and comparing this to a second amino acid sequence. In general, "identity" refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of two polynucleotides or polypeptide sequences, respectively.
Two or more polynucleotide sequences can be compared by determining their "percent identity." Two or more amino acid sequences likewise can be compared by determining their "percent identity." The percent identity of two sequences, whether nucleic acid or peptide sequences, is generally described as the number of exact matches between, two aligned sequences divided by the length of the shorter sequence and multiplied by 100.
An approximate alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981). This algorithm can be extended to use with peptide sequences using the scoring matrix developed by Dayhoff, Atlas of Protein Sequences and Structure, M.O.
Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA, and normalized by Gribskov, Nucl. Acids Res. 14(6):6745-6763 (1986). An implementation of this algorithm for nucleic acid and peptide sequences is provided by the Genetics Computer Group (Madison, WI) in their BestFit utility application. The default parameters for this method are described in the Wisconsin Sequence Analysis Package Program Manual, Version 8 (1995) (available from Genetics Computer Group, Madison, WI). Other equally suitable programs for calculating the percent identity or similarity between sequences are generally known in the art.
For example, percent identity of a particular nucleotide sequence to a reference sequence can be determined using the homology algorithm of Smith and Waterman with a default scoring table and a gap penalty of six nucleotide positions. Another method.of establishing percent identity in the context of the present invention is to use the MPSRCH package of programs copyrighted by the University of Edinburgh, developed by John F. Collins and Shane S. Sturrok, and distributed by IntelliGenetics, Inc. (Mountain View, CA).
From this suite of packages, the Smith-Waterman algorithm can be employed where default parameters are used for the scoring table (for example, gap open penalty of 12, gap extension penalty of one, and a gap of six). From the data generated, the "Match" value reflects "sequence identity." Other suitable programs for calculating the percent identity or similarity between sequences are generally known in the art, such as the alignment program BLAST, which can also be used with default parameters.
For example, BLASTN and BLASTP can be used with the following default parameters: genetic code = standard;
filter = none; strand = both; cutoff = 60; expect = 10;
Matrix = BLOSUM62; Descriptions = 50 sequences; sort by HIGH SCORE; Databases = non-redundant, GenBank + EMBL +
DDBJ + PDB + GenBank CDS translations + Swiss protein +
Spupdate + PIR (contact the National Center for Biotechnology Information).

One of skill in the art can readily determine the proper search parameters to use for a given sequence in the above programs. For example, the search parameters may vary based on the size of the sequence in question.
Thus, for example, a representative embodiment of the present invention would include an isolated polynucleotide having X contiguous nucleotides, wherein (i) the X contiguous nucleotides have at least about 50%
identity to Y contiguous nucleotides derived .from any of the sequences described herein, (ii) X equals Y, and (iii) X is greater than or equal to 6 nucleotides and up to 5000 nucleotides, preferably greater than or equal to 8 nucleotides and up to 5000 nucleotides, more preferably 10-12 nucleotides and up to 5000 nucleotides, and even more preferably 15-20 nucleotides, up to the number of nucleotides present in the full-length sequences described herein (e.g., see the Sequence Listing and claims), including all integer values falling within the above-described ranges.
The synthetic expression cassettes (and purified polynucleotides) of the present invention include related polynucleotide sequences having about 80% to 100%, greater than 80-85%, preferably greater than 90-92%, more preferably greater than 95%, and most preferably greater than 98% sequence (including all integer values falling within these described ranges) identity to the synthetic expression cassette sequences disclosed herein (for example, to the sequences presented in Tables 1A and IB) when the sequences of the present invention are used as the query sequence.

Two nucleic acid fragments are considered to "selectively hybridize" as described herein. The degree of sequence identity between two nucleic acid molecules affects the efficiency and strength of hybridization events between such molecules. A partially identical nucleic acid sequence will at least partially inhibit a completely identical sequence from hybridizing to a target molecule. Inhibition of hybridization of the completely identical sequence can be assessed using hybridization assays that are well known in the art (e.g., Southern blot, Northern blot, solution hybridization, or the like, see Sambrook, et al., Molecular Cloning; A Laboratory Manual, Second Edition, (1989) Cold Spring Harbor, N.Y.). Such assays can be conducted using varying degrees of selectivity, for example, using conditions varying from low to high stringency. If conditions of low stringency are , employed, the absence of non-specific binding can be assessed using a secondary probe that lacks even a partial degree of sequence identity (for example, a probe having less than about 30% sequence identity with the target molecule), such that, in the absence of non-specific binding events, the secondary probe will not hybridize to the target.When utilizing a hybridization-based detection system, a nucleic acid probe is chosen that is complementary to a target nucleic acid sequence, and then by selection of appropriate conditions the probe and the target sequence "selectively hybridize," or bind, to each other to form a hybrid molecule. A nucleic acid molecule that is capable of hybridizing selectively to a target sequence under "moderately stringent" typically _ hybridizes under conditions that allow detection of a target nucleic acid sequence of at least about 10-14 nucleotides in length having at least approximately 70%
sequence identity with the sequence of the selected nucleic acid probe. Stringent hybridization conditions typically allow detection of target nucleic acid sequences of at least about 10-14 nucleotides in length having a sequence identity of greater than about 90-95%
with the sequence of the selected nucleic acid probe.
Hybridization conditions useful for probe/target hybridization where the probe and target have a specific degree of sequence identity, can be determined as is known in the art (see, for example, Nucleic Acid Hybridization: A Practical Approach, editors B.D. Hames and S.J. Higgins, (1985) Oxford; Washington, DC; IRL
Press).
With respect to stringency conditions for hybridization, it is well known in the art that numerous equivalent conditions can be employed to establish a particular stringency by varying, for example, the following factors: the length and nature of probe and target sequences, base composition of the various sequences, concentrations of salts and other hybridization solution components, the presence or absence of blocking agents in the hybridization solutions (e.g., formamide, dextran sulfate, and polyethylene glycol), hybridization reaction temperature and time parameters, as well as, varying wash conditions. The selection of a particular set of hybridization conditions is selected following standard methods in the art (see, for example, Sambrook, et al., Molecular Cloning: A

Laboratory Manual, Second Edition, (1989) Cold Spring Harbor, N.Y.).
A first polynucleotide is "derived from" second polynucleotide if it has the same or substantially the same basepair sequence as a region of the second polynucleotide, its cDNA, complements thereof, or if it displays sequence identity as described above.
A first polypeptide is "derived from" a second polypeptide if it is (i) encoded by a first polynucleotide derived from a second polynucleotide, or (ii) displays sequence identity to the second polypeptides as described above.
Generally, a viral polypeptide is "derived from" a particular polypeptide of a virus (viral polypeptide) if it is (i) encoded by an open reading frame of a polynucleotide of that virus (viral polynucleotide), or (ii) displays sequence identity to polypeptides of that.
virus as described above.
"Encoded by" refers to a nucleic acid sequence which codes for a polypeptide sequence, wherein the polypeptide sequence or a portion thereof contains an amino acid sequence of at least 3 to 5 amino acids, more preferably at least 8 to 10 amino acids, and even more preferably at least 15 to 20 amino acids from a polypeptide encoded by the nucleic acid sequence. Also encompassed are polypeptide sequences which are immunologically identifiable with a polypeptide encoded by the sequence.
"Purified polynucleotide" refers to a polynucleotide of interest or fragment thereof which is essentially free, e.g., contains less than about 50%, preferably less than about 70%, and more preferably less than about 90%, of the protein with which the polynucleotide is naturally associated. Techniques for purifying polynucleotides of interest are well-known in the art and include, for example, disruption of the cell containing the polynucleotide with a chaotropic agent and separation of the polynucleotide(s) and proteins by ion-exchange chromatography, affinity chromatography and sedimentation according to density.
By "nucleic acid immunization" is meant the introduction of a nucleic acid molecule encoding one or more selected antigens into a host cell, for the in vivo expression of an antigen, antigens, an epitope, or epitopes. The nucleic acid molecule can be introduced directly into a recipient subject, such as by injection, inhalation, oral, intranasal and mucosal administration, or the like, or can be introduced ex vivo, into cells which have been removed from the host. In the latter case, the transformed cells are reintroduced into the subject where an immune response can be mounted against . the antigen encoded by the nucleic Acid molecule.
"Gene transfer" or "gene delivery" refers to methods , or systems for reliably inserting DNA or RNA of interest into a host cell. Such methods can result in transient expression of non-integrated transferred DNA, extrachromosomal replication and expression of transferred replicons (e.g., episomes), or integration of transferred genetic material into the genomic DNA of host cells. Gene delivery expression vectors include, but are not limited to, vectors derived from bacterial plasmid vectors, viral vectors, non-viral vectors, alphaviruses, pox viruses and vaccinia viruses. When used for immunization, such gene delivery expression vectors may be referred to as vaccines or vaccine vectors.
"T lymphocytes" or "T cells" are non-antibody producing lymphocytes that constitute a part of the cell-mediated arm of the immune system. T cells arise from immature lymphocytes that migrate from the bone marrow to =

the thymus, where they undergo a maturation process under the direction of thymic hormones. Here, the mature lymphocytes rapidly divide increasing to very large numbers. The maturing T cells become immunocompetent based on their ability to recognize and bind a specific antigen. Activation of immunocompetent T cells is triggered when an antigen binds to the lymphocyte's surface receptors.
The term "transfection" is used to refer to the uptake of foreign DNA by a cell. A cell has been "transfected" when exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are generally known in the art. See, e.g., Graham et al. (1973) Virology, 52:456, Sambrook et al.
(1989) Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratories, New York, Davis et al. (1986) Basic Methods in Molecular Biology, Elsevier, and Chu et al. (1981) Gene 13:197. Such techniques can be used to introduce one or mpre exogenous DNA moieties into suitable host cells. The term refers to both stable and transient uptake of the genetic material, and includes uptake of peptide- or antibody-linked DNAs.
A "vector" is capable of transferring gene sequences to target cells (e.g., bacterial plasmid vectors, viral vectors, non-viral vectors, particulate carriers, and liposomes). Typically, "vector construct," "expression vector," and "gene transfer vector," mean any nucleic acid construct capable of directing the expression of a gene of interest and which can transfer gene sequences to target cells. Thus, the term includes cloning and expression vehicles, as well as viral vectors.
Transfer of a "suicide gene" (e.g., a drug-susceptibility gene) to a target cell renders the cell sensitive to compounds or compositions that are relatively nontoxic to normal cells. Moolten, F.L.
(1994) Cancer Gene Ther. 1:279-287. Examples of suicide genes are thymidine kinase of herpes simplex virus (HSV-tk), cytochrome P450 (Manome et al. (1996) Gene Therapy 3:513-520), human deoxycytidine kinase (Manome et al.
(1996) Nature Medicine 2(5):567-573) and the bacterial enzyme cytosine deaminase (Dong et al. (1996) Human Gene Therapy 7:713-720). Cells which express these genes are rendered sensitive to the effects of the relatively nontoxic prodrugs ganciclovir (HSV-tk), cyclophosphamide (cytochrome P450 2B1), cytosine arabinoside (human deoxycytidine kinase) or 5-fluorocytosine (bacterial cytosine deaminase). Culver et al. (1992) Science 256:1550-1552, Huber et al. (1994) Proc. Natl. Acad. Sci.
USA 91:8302-8306.
A "selectable marker" or "reporter marker" refers to p nucleotide sequence included in a gene transfer vector that has no therapeutic activity, but rather is included to allow for simpler preparation, manufacturing, characterization or testing of the gene transfer vector.
A "specific binding agent" refers to a member of a specific binding pair of molecules wherein one of the molecules specifically binds to the second molecule through chemical and/or physical means. One example of a specific binding agent is an antibody directed against a selected antigen.
By "subject" is meant any member of the subphylum chordata, including, without limitation, humans and other primates, including non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses;
domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like. The term does not denote a particular age. Thus, both adult and newborn individuals are intended to be covered. The system described above is intended for use in any of the above vertebrate species, since the immune systems of all of these vertebrates operate similarly.
By "pharmaceutically acceptable" or "pharmacologically acceptable" is meant a material which is not biologically or otherwise undesirable, i.e., the material may be administered to an individual in a formulation or composition without causing any undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
By "physiological pH" or a "pH in the physiological range" is meant a pH in the range of approximately 7.2 to 8.0 inclusive, more typically in the range of approximately 7.2 to 7.6 inclusive.
As used herein, "treatment" refers to any of (I) the prevention of infection or reinfection, as in a traditional vaccine, (ii) the reduction or elimination of symptoms, and (iii) the substantial or complete elimination of the pathogen in question. Treatment may be effected prophylactically (prior to infection) or therapeutically (following infection).
"Lentiviral vector", and "recombinant lentiviral vector" are derived from the subset of retroviral vectors known as lentiviruses. Lentiviral vectors refer to a nucleic acid construct which carries, and within certain embodiments, is capable of directing the expression of a nucleic acid molecule of interest. The lentiviral vector includes at least one transcriptional promoter/enhancer or locus defining element(s), or other elements which control gene expression by other means such as alternate splicing, nuclear RNA export, post-translational modification of messenger, or post-transcriptional modification of protein. Such vector constructs must also include a packaging signal, long terminal repeats (LTRS) or portion thereof, and positive and negative strand primer binding sites appropriate to the lentiviral vector used (if these are not already present in the retroviral vector). Optionally, the recombinant lentiviral vector may also include a signal which directs polyadenylation, selectable markers such as Neo, TK, hygromycin, phleomycin, histidinol, or DHFR, as well as one or more restriction sites and a translation termination sequence. By way of example, such vectors typically include a 5' LTR, a tRNA binding site, a packaging signal, an origin of second strand DNA
synthesis, ,and a 3'LTR or a portion thereof.
"Lentiviral vector particle" as utilized within the present invention refers to a lentivirus which carries at least one gene of interest. The retrovirus may also contain a selectable marker. The recombinant lentivirus is capable of reverse transcribing its genetic material (RNA) into DNA and incorporating this genetic material into a host cell's DNA upon infection. Lentiviral vector particles may have a lentiviral envelope, a non-lentiviral envelope (e.g., an ampho or VSV-G envelope), or a chimeric envelope.
"Nucleic acid expression vector" or "Expression cassette" refers to an assembly which is capable of directing the expression of a sequence or gene of interest. The nucleic acid expression vector includes a promoter which is operably linked to the sequences or gene(s) of interest. Other control elements may be present as well. Expression cassettes described herein may be contained within a plasmid construct. In addition to the components of the expression cassette, the plasmid construct may also include a bacterial origin of replication, one or more selectable markers, a signal which allows the plasmid construct to exist as single-stranded DNA (e.g., a M13 origin of replication), a multiple cloning site, and a "mammalian" origin of replication (e.g., a SV40 or adenovirus origin of replication).
"Packaging cell" refers to a cell which contains those elements necessary for production of infectious recombinant retrovirus (e.g., lentivirus) which are lacking in a recombinant retroviral vector. Typically, such packaging cells contain one or more expression cassettes which are capable of expressing proteins which encode Gag, pal and env proteins.
"Producer cell" or "vector producing cell" refers to a cell which contains all elements necessary for production of recombinant retroviral vector partic,les.
2. MODES OF CMUTDM Owrvis INVENTION
Before describing the present invention in detail, it is to be understood that this invention is not limited to particular formulations or process parameters as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.
Although a number of methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred materials and methods are described herein.

2.1 SYNTHETIC EXPRESSION CASSETTES
2.1.1 MODIFICATION OF HIV-1 GAG NUCLEIC ACID CODING
SEQUENCES
One aspect of the present invention is the generation of HIV-1 Gag protein coding sequences, and related sequences, having improved expression relative to the corresponding wild-type sequence. An exemplary embodiment of the present invention is illustrated herein modifying the Gag protein wild-type sequences obtained from the HIV-1SF2 strain (SEQ ID NO:1; Sanchez-Pescador, R., et al., Science 227(4686): 484-492, 1985; Luciw, P.A., et al. U.S. Patent No. 5,156,949, issued October 20, 1992; Luciw, P.A., et al., U.S. Patent No. 5,688,688, November 18, 1997). Gag sequence obtained from other HIV
variants may be manipulated in similar fashion following the teachings of the present specification. Such other variants include, but are not limited to, Gag protein encoding sequences obtained from the isolates HI
HIVõ,, HIV-1SF162 HIV-1m,70, HIVIJV, HIV1, HIV, HIV-1em235õ
other HIV-1 strains from diverse subtypes (e.g., subtypes, A through G, and 0), HIV-2 strains and diverse subtypes (e.g., HIV-2m1 and HIV-2m72), and simian immunodeficiency virus (Sly). (See, e.g., Virology, 3rd Edition (W.K. Joklik ed. 1988); Fundamental Virology, 2nd Edition (B.N. Fields and D.M. Knipe, eds. 1991);
Virology, 3rd Edition (Fields, EN, DM Knipe, PM Howley, Editors, 1996, Lippincott-Raven, Philadelphia, PA; for a description of these and other related viruses).
First, the HIV-1 codon usage pattern was modified so that the resulting nucleic acid coding sequence was comparable to codon usage found in highly expressed human genes (Example 1). The HIV codon usage reflects a high content of the nucleotides A or T of the codon-triplet.

CA 02360347 20)1-06-29 The effect of the HIV-1 codon usage is a high AT content in the DNA sequence that results in a decreased translation ability and instability of the mRNA. In comparison, highly expressed human codons prefer the nucleotides G or C. The Gag coding sequences were modified to be comparable to codon usage found in highly expressed human genes. In Figure 11 (Example 1), the percent A-T content of cDNA sequences corresponding to the mRNA for a known unstable mRNA and a known stable mRNA are compared to the percent A-T content of native HIV-1SF2 Gag cDNA and to the synthetic Gag cDNA sequence of the present invention. Experiments performed in support of the present invention showed that the synthetic Gag sequences were capable of higher level of protein production (see the Examples) relative to the native Gag sequences. The data in Figure 11 suggest that one reason for this increased production is iucreased stability of the mRNA corresponding to the synthetic Gag coding sequences versus the mRNA corresponding to the native Gag coding sequences.
Second, there are inhibitory (or instability) elements (INS) located within the coding sequences of the Gag coding sequences (Example 1). The RRE is a secondary RNA structure that interacts with the HIV encoded Rev-protein to overcome the expression down-regulating effects of the INS. To overcome the post-transcriptional activating mechanisms of RRE and Rev, the instability elements were inactivated by introducing multiple point mutations that did not alter the reading frame of the encoded proteins. Figure 1 shows the original SF2 Gag sequence, the location of the INS sequences, and the modifications made to the INS sequences to reduce their effects. The resulting modified coding sequences are presented as a synthetic Gag expression cassette (SEQ ID
NO:4).
Modification of the Gag polypeptide coding sequences resulted in improved expression relative to the wild-type coding sequences in a number of mammalian cell lines (as well as other types of cell lines, including, but not limited to, insect cells). Further, expression of the sequences resulted in production of virus-like particles (VLPs) by these cell lines (see below). Similar Gag polypeptide coding sequences can be obtained from a variety of isolates (families, sub-types, strains, etc.) including, but not limited to such other variants include, but are not limited to, Gag polypeptide encoding sequences obtained from the isolates HIVH,õ, HIV,õ, HIV-1SF162 HIV-1õ170, HIV,,, HIVõõ HIV, HIV-1,s4, other HIV-1 strains from diverse subtypes(e.g., subtypes, A through G, and 0), HIV-2 strains and diverse subtypes (e.g., HIV-21 and HIV-2), and simian immunodeficiency virus (Sly). (See, e.g., Virology, 3rd Edition (W.K.
Joklik ed. 1988); Fundamental Virology, 2nd Edition (B.N.
Fields and D.M. Knipe, eds. 1991; Virology, 3rd Edition (Fields, BN, DM Knipe, PM Howley, Editors, 1996, Lippincott-Raven, Philadelphia, PA). Gag polypeptide encoding sequences derived from these variants can be optimized and tested for improved expression in mammals by following the teachings of the present specification (see the Examples, in particular Example 1).

2.1.2 FURTHER MODIFICATION OF SEQUENCES INCLUDING HIV-1 GAG NUCLEIC ACID CODING SEQUENCES

Experiments performed in support of the present Invention have shown that similar modifications of HIV-1 Gag-protease, Gag-reverse transcriptase and Gag-polymerase sequences also result in improved expression of the polyproteins, as well as, the production of VLPs formed by polypeptides produced from such modified coding sequences.
For the Gag-protease sequence (wild type, SEQ ID
NO:2; modified, SEQ ID NOs:5, 78, 79), the changes in codon usage were restricted to the regions upstream of the -1 frameshift (Figure 2). Further, inhibitory (or instability) elements (INS) located within the coding sequences of the Gag-protease polypeptide coding sequence were altered as well (indicated in Figure 2). Exemplary constructs (which include the -1 frameshift) encoding modified Gag-protease sequences include those shown in SEQ ID NOs:78 and 79 (Figures 69 and 70). These are: GPI
(SEQ ID NO:78) in which the protease region was also codon optimized and INS inactivated and GP2 (SEQ ID
NO:79), in which the protease region was only subjected to INS inactivation.
For other Gag-containing sequences, for example the Gag-polymerase sequence (wild type, SEQ ID NO:3;
modified, SEQ ID NO:6) or Gag-reverse transcriptase (wild type, SEQ ID NO:77; modified SEQ ID NOB:80-84), the changes in codon usage are similar to those for the Gag-protease sequence. Those expression cassettes which contain a frameshift in the GagPol coding sequence are designated "FS(+)" (SEQ ID NOs:80 and 81, Figures 71 and 72) while the designation "FS(-)" (SEQ ID Nos: 82, 83 and 84, Figures 73, 74 and 75) indicates that there is no frameshift utilized in this coding sequence.
In addition to polyproteins containing HIV-related sequences, the various Gag-, Gag-prot, Gag-pol, Gag-reverse transcriptase encoding sequences of the present invention can be fused to other polypeptides (creating chimeric polypeptides) for which an immunogenic response is desired. An example of such a chimeric protein is the joining of the improved expression Gag encoding sequences to the Hepatitis C Virus (HCV) core protein. In this case, the HCV-core encoding sequences were placed in-frame with the HIV-Gag encoding sequences, resulting in the Gag/HCV-core encoding sequence presented as SEQ ID
NO:7 (wild type sequence presented as SEQ ID NO:8).
Further sequences useful in the practice of the present invention include, but are not limited to, sequences encoding viral epitopes/antigens {including but not limited to, HCV antigens (e.g., El, E2; Houghton, M.., et al., U.S. Patent No. 5,714,596, issued February 3, 1998; Houghton, M.., et al., U.S. Patent No.
5,712,088, issued January 27, 1998; Houghton, M.., et al., U.S. Patent No. 5,683,864, issued November 4, 1997;
Weiner, A.J., et al., U.S. Patent No. 5,728,520, issued March 17, 1998; Weiner, A.J., et al., U.S. Patent No.
4 5,766,845, issued June 16, 1998; Weiner, A.J., et al., U.S. Patent No. 5,670,152, issued September 23, 1997), ' HIV antigens (e.g., derived from ner, tat, rev, vpu, vif, vpr and/or env); and sequences encoding tumor antigens/epitopes. Additional sequences are described below. Also, variations on the orientation of the Gag and other coding sequences, relative to each other, are also described below.Gag, Gag-protease, Gag-reverse transcriptase and/or Gag-polymerase polypeptide coding sequences can be obtained from any HIV isolates (different families, subtypes, and strains) including but not limited to the isolates HIVõ,b, HIVm,H1V5F262, HIVus4, HIV1, HIV) (see, e.g., Myers et al. Los Alamos Database, Los Alamos National Laboratory, Los Alamos, New Mexico (1992); Myers et al., Human Retroviruses and Aids, 1997, Los Alamos, New Mexico: Los Alamos National Laboratory).
Synthetic expression cassettes can be generated using in such coding sequences as starting material by following the teachings of the present specification (e.g., see Example 1). Further, the synthetic expression cassettes of the present invention include related Gag polypeptide coding sequences having greater than 75%, preferably greater than 80-85%, more preferably greater than 90-95%, and most preferably greater than 98% sequence identity (or any integer value within these ranges) to the synthetic expression cassette sequences disclosed herein (for example, SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; and SEQ ID NO:20, the Gag Major Homology Region).

2.1.3 EXPRESSION Or SYNTHETIC SEQUENCES ENCODING H117-1 GAG AND RELATED ROLYPEPTIDES
Several synthetic Gag-encoding sequences (expression cassettes) of the present invention were cloned into a number of differen.t expression vectors (Example 1) to .
evaluate levels of expression and production of VLPs.
Two modified synthetic coding sequences are presented as a synthetic Gag expression cassette (SEQ ID NO:4) and a synthetic Gag-protease expression cassette (SEQ ID NOs:78 and 79). Other synthetic Gag-encoding proteins are presented, for example, as SEQ ID NOs:80 through 84. The synthetic DNA fragments for Gag-encoding polypeptides (e.g., Gag, Gag-protease, Gag-polymerase, Gag-reverse transcriptase) were cloned into expression vectors described in Example 1, including, a transient expression vector, CMV-promoter-based mammalian vectors, and a shuttle vector for use in baculovirus expression systems.
Corresponding wild-type sequences were cloned into the same vectors.
These vectors were then transfected into a several different cell types, including a variety of mammalian cell lines, (293, RD, COS-7, and CHO, cell lines available, for example, from the A.T.C.C.). The cell lines were cultured under appropriate conditions and the levels of p24 (Gag) expression in supernatants were evaluated (Example 2). The results of these assays demonstrated that expression of synthetic Gag-encoding sequences were significantly higher than corresponding wild-type sequences (Example 2; Table 2).
Further, Western Blot analysis showed that cells containing the synthetic Gag expression cassette produced the expected 55 kD (p55) protein at higher per-cell concentrations than cells containing the native expression cassette. The Gag p55 protein was seen in both cell lysates and supernatants. The levels of production were significantly higher in cell supernatants for cells transfected with the synthetic Gag expression cassette of the present invention. Experiments performed in support of the present invention suggest that cells .containing the synthetic Gag-prot expression cassettes produced the expected Gag-prot protein at comparably higher per-cell concentrations than cells containing the wild-type expression cassette.
Fractionation of the supernatants from mammalian cells transfected with the synthetic Gag expression cassette showed that it provides superior production of both p55 protein and VLPs, relative to the wild-type Gag sequences (Examples 6 and 7).
Efficient expression of these Gag-containing polypeptides in mammalian cell lines provides the following benefits: the Gag polypeptides are free of baculovirus contaminants; production by established methods approved by the FDA; increased purity; greater yields (relative to native coding sequences); and a novel method of producing the Gag-containing polypeptides in CHO or other mammalian cells which is not feasible in the absence of the increased expression obtained using the constructs of the present invention. Exemplary Mammalian cell lines include, but are not limited to, BHK, VERO, HT1080, 293, 293T, RD, COS-7, CHO, Jurkat, HUT, SUPT, C8166, MOLT4/clone8, MT-2, MT-4, H9, PM1, CEM, myeloma cells (e.g., SB20 cells) and CEMX174, such cell lines are available, for example, from the A.T.C.C.).
A synthetic Gag expression cassette of the present invention also demonstrated high levels of expression and VLP production when transfected into insect cells (Example 7). Further, in addition to a higher total protein yield, the final product from the synthetic p55-expressed Gag consistently contained lower amounts of contaminating baculovirus proteins than the final purified product from the native p55-expressed Gag.
Further, synthetic Gag expression cassettes of .the present invention have also been introduced into yeast vectors which gere transformed into and efficiently.
expressed by yeast cells (Saccharomyces cerevisea; using vectors as described in Rosenberg, S. and Tekamp-Olson, P., U.S. Patent No. RE35,749, issued, March 17, 1998).
In addition to the mammalian and insect vectors described in the Examples, the synthetic expression cassettes of the present invention can be incorporated into a variety of expression vectors using selected expression control elements. Appropriate vectors and control elements for any given cell type can be selected by one having ordinary skill in the art in view of the teachings of the present specification and information known in the art about expression vectors.
For example, a synthetic Gag expression cassette can be inserted into a vector which includes control elements operably linked to the desired coding sequence, which allow for the expression of the gene in a selected cell-type. For example, typical promoters for mammalian cell expression include the SV40 early promoter, a CMV
promoter such as the CMV immediate early promoter (a CMV
promoter can include intron A), RSV, HIV-LTR, the mouse mammary tumor virus LTR promoter (MMLV-LTR), FIV-LTR, the adenovirus major late promoter (Ad MLP), and the herpes simplex virus promoter, among others. Other nonviral promoters, such as a promoter derived from the murine metallothionein gene, will also find use for mammalian expression. Typically, transcription termination and polyadenylation sequences will also be present, located 3' to the translation stop codon. Preferably, a sequence for optimization of initiation of translation, located 5' to the coding sequence, is also present. Examples of transcription terminator/polyadenylation signals include .those derived from SV40, as described in Sambrook, et al., supra, as well as a bovine growth hormone terminator .sequence. Introns, containing splice donor and acceptor sites, may also be designed into the constructs for use with the present invention (Chapman et al., Nuc. Acids Res. (1991) 19:3979-3986).
Enhancer elements may also be used herein to increase expression levels of the mammalian constructs.
Examples include the SV40 early gene enhancer, as described in Dijkema et al., EMBO J. (1985) 4:761, the enhancer/promoter derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus, as described in Gorman et al., Proc. Natl. Acad. Sci. USA (1982b) 79:6777 and elements derived from human CMV, as described in Boshart et al., Cell (1985) 41:521, such as elements included in the CMV intron A sequence (Chapman et al., Nuc. Acids Res. (1991) 19:3979-3986).

The desired synthetic Gag polypeptide encoding sequences can be cloned into any number of commercially available vectors to generate expression of the polypeptide in an appropriate host system. These systems include, but are not limited to, the following:
baculovirus expression {Reilly, P.R., et al., EACULOVIRUS
EXPRESSION VECTORS: A LABORATORY MANUAL (1992) ; Beames, et al., Biotechniques 11:378 (1991); Pharmingen; Clontech, Palo Alto, CA)), vaccinia expression {Earl, P. L., et a/., "Expression of proteins in mammalian cells using vaccinia" In Current Protocols in Molecular Biology (F.
M. Ausubel, et a/. Eds.), Greene Publishing Associates &
Wiley Interscience, New York (1991); Moss, B., et al., U.S. Patent Number 5,135,855, issued 4 August 1992), expression in bacteria (Ausubel, P.M., et al., CURRENT
PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley and Sons, Inc., Media PA; Clontech)., expression in yeast {Rosenberg, S. .
and Tekamp-Olson, P., U.S. Patent No. RE35,749, issued, March 17, 1998; Shuster, J.R., U.S. Patent No. 5,629,2031 issued May 13, 1997; Gellissen, G., et al., Antonie Van Leeuwenhoek, 62(1-2):79-93 (1992); Romanos, M.A., et a/., Yeast 8(6):423-488 (1992); Goeddel, D.V., Methods in Enzymology 185 (1990); Guthrie, C., and G.R. Fink, Methods in Enzymology 194 (1991)1, expression in mammalian cells {Clontech; Gibco-BRL, Ground Island, NY;
e.g., Chinese hamster ovary (CHO) cell lines (Haynes, J., et al., Nuc. Acid. Res. 11:687-706 (1983); 1983, Lau, Y.F., et al., Mol. Cell. Biol. 4:1469-1475 (1984);
Kaufman, R. J., "Selection and coamplification of heterologous genes in mammalian cells," in Methods in Enzymology, vol. 185, pp537-566. Academic Press, Inc., San Diego CA (1991)), and expression in plant cells {plant cloning vectors, Clontech Laboratories, Inc., Palo Alto, CA, and Pharmacia LIKE Biotechnology, Inc., yum Pistcataway, NJ; Hood, E., et al., J. Bacteriol.
168:1291-1301 (1986); Nagel, R., et al., FEMS Microbiol.
Lett. 67:325 (1990); An, et a/., "Binary Vectors", and others in Plant Molecular Biology Manual A3:1-19 (1988);
Miki, B.L.A., et a/., pp.249-265, and others in Plant DNA
Infectious Agents (Hohn, T., et al., eds.) Springer-Verlag, Wien, Austria, (1987); Plant Molecular Biology:
Essential Techniques, P.G. Jones and J.M. Sutton, New York, J. Wiley, 1997; Miglani, Gurbachan Dictionary of Plant Genetics and Molecular Biology, New York, Food Products Press, 1998; Henry, R. J., Practical Applications of Plant Molecular Biology, New York, Chapman & Hall, 1997).
Also included in the invention is an expression vector, such as the CMV promoter-containing vectors described in Example 1, containing coding sequences and expression' control elements which allow expression of the coding regions in a suitable host. The control elements generally include a promoter, translation initiation codon, and translation and transcription termination sequences, and an insertion site for introducing the insert into the vector. Translational control elements have been reviewed by M. Kozak (e.g., Kozak, M., Mamm.
Genome 7(8):563-574, 1996; Kozak, M., Biochimie 76(9):815-821, 1994; Kozak, M., J Cell Biol 108(2):229-241, 1989; Kozak, M., and Shatkin, A.J., Methods Enzymol 60:360-375, 1979).
Expression in yeast systems has the advantage of commercial production. Recombinant protein production by vaccinia and CHO cell line have the advantage of being mammalian expression systems. Further, vaccinia virus expression has several advantages including the following: (i) its wide host range; (ii) faithful post-transcriptional modification, processing, folding, transport, secretion, and assembly of recombinant proteins; (iii) high level expression of relatively soluble recombinant proteins; and (iv) a large capacity to accommodate foreign DNA.
The recombinantly expressed polypept ides from synthetic Gag-encoding expression cassettes are typically isolated from lysed cells or culture media. Purification can be carried out by methods known in the art including salt fractionation, ion exchange chromatography, gel filtration, size-exclusion chromatography, size-fractionation, and affinity chromatography.
Immunoaffinity chromatography can be employed using antibodies generated based on, for example, Gag antigens.
Advantages of expressing the Gag-containing proteins of the present invention using mammalian cells include, but are not limited to, the following:. well-established protocols for scale-up production; the ability to produce VLPs; cell lines are suitable to meet good manufacturing process (GMP) standards; culture conditions for mammalian cells are known in the art.

2.1.4 MODIFICATION OF II/V-1 ENV NUCLEIC ACID CODING
SEQUENCES
One aspect of the present invention is the generation of HIV-1 Env protein coding sequences, and related sequences, having improved expression relative to the corresponding wild-type sequence. Exemplary embodiments of the present invention are illustrated herein modifying the Env protein wild-type sequences obtained from the HIV-1 subtype B strains HIV-1US4 and HIV-1SF162 (Myers et al., Los Alamos Database, Los Alamos National Laboratory, Los Alamos, New Mexico (1992); Myers et al., Human Retroviruses and Aids, 1997, Los Alamos, New Mexico: Los Alamos National Laboratory). Env sequence obtained from other HIV variants may be manipulated in similar fashion following the teachings of the present specification. Such other variants include those described above in Section 2.1.1, First, the HIV-1 codon usage pattern was modified so that the resulting nucleic acid coding sequence was comparable to codon usage found in highly expressed human genes (Example 1). The HIV codon usage reflects a high content of the nucleotides A or T of the codon-triplet.
The effect of the HIV-1 codon usage is a high AT content in the DNA sequence that results in a decreased translation ability and instability of the mRNA. In comparison, highly expressed human codons prefer the nucleotides G or C. The Env coding sequences were modified to be comparable to codon usage found in highly expressed human genes. Experiments performed in support of the present invention showed that the synthetic Env sequences were capable of higher level of protein production (see the Examples) relative to the native Env sequences. One reason for this increased production may be increased stability of the mRNA corresponding to the synthetic Env coding sequences versus the mRNA
corresponding to the native Env coding sequences.
Modification of the Env polypeptide coding sequences resulted in improved expression relative to the wild-type coding sequences in a number of mammalian cell lines.
Similar Env polypeptide coding sequences can be obtained from a variety of isolates (families, sub-types, etc.).
Env polypeptide encoding sequences derived from these variants can be optimized and tested for improved expression in mammals by following the teachings of the present specification (see the Examples, in particular Example 2).

2.1.5 Furrun MODIFICATION or HIV-1 ENv NUCLEIC ACID
CODING SEQUENCES
In addition to proteins containing HIV-related sequences, the Env encoding sequences of the present invention can be fused to other polypeptides (creating chimeric polypeptides). Also, variations on the orientation of the Env and other coding sequences, relative to each other, are contemplated. Further, the HIV protein encoding cassettes of the present invention can be co-expressed using one vector or multiple vectors.
In addition, the polyproteins can be operably linked to the same or different promoters.
Env polypeptide coding sequences .can be obtained from any HIV isolates (different families, subtypes, and etrains) including but not limited to the isolates HIVõõ, HIV, HIVõ, HIV,nõ HIV) (see, e.g., Myers et al., Los Alamos Database, Los Alamos National Laboratory, Los Alamos, New Mexico (1992); Myers et al., Human Retroviruses and Aids, /997, Los Alamos, New Mexico: Los Alamos National Laboratory). Synthetic expression cassettes can be generated using such coding sequences as starting material by following the teachings of the present specification (e.g., see Example 1).
Further, the synthetic expression cassettes (and purified polynucleotides) of the present invention include related Env polypeptide coding sequences having greater than 90%, preferably greater than 92%, more preferably greater than 95%, and most preferably greater than 98% sequence identity to the synthetic expression cassette sequences disclosed herein (for example, SEQ ID NOs:71-72; and/or the sequences presented in Tables 1A and 1B) when the sequences of the present invention are used as the query sequence.

2.1.6 EXPRESSION OF SYNTHETIC SEQUENCES ENCODING EUE17-1 ENV AND RELATED POLYPEPTIDES
Several synthetic Env-encoding sequences (expression cassettes) of the present invention were cloned into a number of different expression vectors (Example 1) to evaluate levels of expression and production of Env polypeptide. A modified synthetic coding sequence is presented as synthetic Env expression cassettes (Example 1, e.g., Tables 1A and 15). The synthetic DNA fragments for Env were cloned into eucaryotic expression vectors described in Example 1 and in Section 2.1.3 above, including, a transient expression vector and CMV-promoter-based mammalian vectors. Corresponding wild- =
type sequences were cloned into the same vectors.
These vectors were then .transfected into a several =
different cell types, including a variety of mammalian cell lines, (293, RD, COS-7, and CHO, cell lines available, for example, from the A.T.C.C.). The cell lines were cultured under appropriate conditions and the levels of gp120, gp140 and gp160 Env expression in supernatants were evaluated (Example 2). Env polypeptides include, but are not limited to, for example, native gp160, oligomeric gp140, monomeric gp120 as well as modified sequences of these polypeptides. The results of these assays demonstrated that expression of synthetic Env encoding sequences were significantly higher than corresponding wild-type sequences (Example 2;
Tables 3 and 4).
Further, Western Blot analysis showed that cells containing the synthetic Env expression cassette produced the expected protein (gp120, gp140 or gp160) at higher per-cell concentrations than cells containing the native expression cassette. The Env proteins were seen in both cell lysates and supernatants. The levels of production were significantly higher in cell supernatants for cells transfected with the synthetic Env expression cassettes of the present invention as compared to wild type.
Fractionation of the supernatants from mammalian cells transfected with the synthetic Env expression cassettes showed that it provides superior production of Env proteins, relative to the wild-type Env sequences (Examples 2 and 3).
Efficient expression of these Env-containing polypeptides in mammalian cell lines provides the following benefits: the Env polypeptides are free of baculovirus or other viral contaminants; production by established methods approved by the FDA; increased purity; greater yields (relative to native coding sequences); and a novel method of producing the Env-containing polypeptides in CHO cells which is less feasible in the absence of the increased expression obtained using the constructs of the present invention.
Exemplary cell lines (e.g., mammalian, yeast, insect, etc.) include those described above in Section 2.1.3 for Gag-containing constructs. Further, appropriate vectors and control elements (e.g., promoters, enhancers, polyadenylation sequences, etc.) for any given cell type can be selected, as described above in Section 2.1.3, by one having ordinary skill in the art in view of the teachings of the present specification and information known in the art about expression vectors. In addition, the recombinantly expressed polypeptides from synthetic Env-encoding expression cassettes are typically isolated and purified from lysed cells or culture media, as described above for Gag-encoding expression cassettes.
An exemplary purification is described in Example 4 and shown in Figure 60.

2.1.7 MODIFICATION OF HIV-1 TAT NUCLEIC ACID CODING
SEQUENCES
Another aspect of the present invention is the generation of HIV-1 tat protein coding sequences, and related sequences, having improved expression relative to the corresponding wild-type sequence. Exemplary embodiments of the present invention are illustrated herein modifying the tat wild-type nucleotide sequence (SEQ ID NO:85, Figure 76) obtained from SF162 as described above. Exemplary synthetic tat constructs are shown in SEQ ID NO:87, which depicts a tat construct encoding a full-length tat polypeptide from strain SF162;
SEQ ID NO:88, -which depicts a tat construct encoding a tat polypeptide having the cystein residue at position 22 changed; and SEQ ID NO:89, which depicts a tat construct encoding the amino terminal portion of a tat polypeptide from strain SF162. The amino portion of the tat protein appears to contain many of the epitopes that induce an immune response. In addition, further modifications include replacement or deletion of the cystein residue at position 22, for example with a valine residue, an alanine residue or a glycine residue (SEQ ID Nos: 88 and 89, Figures 79 and 81), see, e.g., Caputo et al. (1996) Gene Ther. 3:235. In Figure 81, which depicts a tat construct encoding the amino terminal portion of a tat polypeptide, the nucleotides (nucleotides 64-66) encoding the cystein residues are underlined. The design and construction of suitable construct can be readily done using the teachings of the present specification. As with Gag, pol, prot and Env, tat polypeptide coding sequences can be obtained from a variety of isolates (families, sub-types, etc.).
Modification of the tat polypeptide coding sequences result in improved expression relative to the wild-type coding sequences in a number of cell lines (e.g., mammalian, yeast, bacterial and insect cells). Tat polypeptide encoding sequences derived from these variants can be optimized and tested for improved expression in mammals by following the teachings of the present specification (see the Examples, in particular Example 2).
Various forms of the different embodiments of the invention, described herein, may be combined. For example, polynucleotides may be derived from the polynucleotide sequences of the present invention, including, but not limited to, coding sequences for Gag polypeptides, Env polyppptides, polymerase polypeptides, protease polypeptides, tat polypeptides, and reverse transcriptase polypeptides. Further, the polynucleotide coding sequences of the present invention may be combined into multi-cistronic expression cassettes where typically each coding sequence for each polypeptide is preceded by IRES sequences.

2.2 PRODUCTION OF VMS-LIKE PARTICLES AND USE OF THE

CONSTRUCTS OF THE PRESENT INVENTION TO CREATE PACKAGING

CELL LINES
The group-specific antigens (Gag) of human immunodeficiency virus type-1 (HIV-1) self-assemble into noninfectious virus-like particles (VLP) that are released from various eucaryotic cells by budding (reviewed by Freed, E.O., Virology 251:1-15, 1998). The synthetic expression cassettes of the present invention provide efficient means for the production of HIV-Gag virus-like particles (VLPs) using a variety of different cell types, including, but not limited to, mammalian cells.
Viral particles can be used as a matrix for the proper presentation of an antigen entrapped or associated therewith to the immune system of the host. For example, U.S. Patent No. 4,722,840 describes hybrid particles comprised of a particle-forming fragment of a structural protein from a virus, such as a particle-forming fragment of hepatitis B virus (HBV) surface antigen (HBsAg), fused to a heterologous polypeptide. Tindle et al., Virology (1994) 200:547-557, describes the production and use of chimeric HBV core antigen particles containing epitopes of human papillomavirus (HPV) type 16 E7 transforming protein.
Adams et al., Nature (1987) 329:68-70, describes the recombinant production of hybrid,HIVgp120:Ty VLPs in yeast and Brown et al., Virology (1994) 198:477-488, the production of chimeric proteins consisting of the VP2 protein of human parvovirus B19 and epitopes from human herpes simplex virus type 1, as well as mouse hepatitis virus A59. Wagner et al., (Virology (1994) 200:162-175, Brand et al., J. Virol. Meth. (1995) al:153-168; Virology (1996) 220:128-140) and Wolf, et al., (EP 0 449 116 Al, published 2 October 1991; WO 96/30523, published 3 October 1996) describe the assembly of chimeric HIV-1 p55Gag particles. U.S. Patent No. 5,503,833 describes the use of rotavirus VP6 spheres for encapsulating and delivering therapeutic agents.

2.2.1 VLP PRODUCTION USING THE SYNTHETIC EXPRESSION
CASSETTES OF THE PRESENT INVENTION
Experiments performed in support of the present invention have demonstrated that the synthetic expression cassettes of the present invention provide superior production of both protein and VLPs, relative to native coding sequences (Examples 7 and 15). Further, electron microscopic evaluation of VLP production (Examples 6 and 15, Figures 3A-B and 65A-F) showed that free and budding immature virus particles of the expected size were produced by cells containing the synthetic expression cassettes.
Using the synthetic expression cassettes of the present invention, rather than native coding sequences, for the production of virus-like particles provide several advantages. First, VLPs can be produced in enhanced quantity making isolation and purification of the VLPs easier. Second, VLPs can be produced in a variety of cell types using the synthetic ,expression cassettes, in particular, mammalian cell lines can be used for VLP production, for example, CHO cells.
Production using CHO cells provides (i) VLP formation;
(ii) correct myristylation and budding; (iii) absence of non-mammalian cell contaminants (e.g., insect viruses and/or cells); and (iv) ease of purification. The synthetic expression cassettes of the present invention are also useful for enhanced expression in cell-types other than mammalian cell lines. For example, infection of insect cells with baculovirus vectors encoding the synthetic expression cassettes resulted in higher levels of total protein yield and higher levels of VLP
production (relative to wild-type coding sequences).
Further, the final product from insect cells infected with the baculovirus-Gag synthetic expression cassettes consistently contained lower amounts of contaminating insect proteins than the final product when wild-type coding sequences were used (Examples).
VLPs can spontaneously form when the particle-forming polypeptide of interest is recombinantly expressed in an appropriate host cell. Thus, the VLPs produced using the synthetic expression cassettes of the present invention are conveniently prepared using recombinant techniques. As discussed below, the Gag polypeptide encoding synthetic expression cassettes of the present invention can include other polypeptide coding sequences of interest (for example, Env, tat, rev, HIV protease, HIV polymerase, HCV core; see, Example 1).
Expression of such synthetic expression cassettes yields VLPs comprising the product of the synthetic expression cassette, as well as, the polypeptide of interest.
Once coding sequences for the desired particle-forming polypeptides have been isolated or synthesized, they can be cloned into any suitable vector or replicon for expression. Numerous cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice. See, generally, Ausubel et al, supra or Sambrook et al, supra.
The vector is then used to transform an appropriate host cell. Suitable recombinant expression systems include, but are not limited to, bacterial, mammalian, baculovirus/insect, vaccinia, Semliki Forest virus (SFV), Alphaviruses (such as, Sindbis, Venezuelan Equine Encephalitis (VEE)), mammalian, yeast and Xenopus expression systems, well known in the art. Particularly preferred expression systems are mammalian cell lines, vaccinia, Sindbis, insect and yeast systems.
For example, a number of mammalian cell lines are known in the art and include immortalized cell lines available from the American Type Culture Collection (A.T.C.C.), such as, but not limited to, Chinese hamster ovary (CI-(0) cells, 293 cells, HeLa cells, baby hamster kidney (BHK) cells, mouse myeloma (SB20), monkey kidney cells (COS), as well as others. Similarly, bacterial hosts such as E. coil, Bacillus subtilis, and Streptococcus spp., will find use with the present expression constructs. Yeast hosts useful in the present invention include inter alia, Saccharomyces cerevisiae, Candida albicans, Candida maltosa, Hansenula polymorpha, Kluyveromyces fragilis, Kluyveromyces lactis, Pichia guillerimondii, Pichia pastoris, Schizosaccharomyces pombe and Yarrowia lipolytica. Insect cells for use with baculovirus expression vectors include, inter alia, Aedes aegypti, Autographa californica, Bombyx mori, Drosophila melanogaster, Spodoptera frugiperda, and Trichoplusia ni.
See, e.g., Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987). Fungal hosts include, for example, Aspergillus.
Viral vectors can be used for the production of particles in eucaryotic cells, such as those derived from the pox family of viruses, including vaccinia virus and avian poxvirus. Additionally, a vaccinia based infection/transfection system, as described in Tomei et al., J. Virol. (1993) 67:4017-4026 and Selby et al., J.
Gen. Virol. (1993) 74:1103-1113, will also find use with the present invention. In this system, cells are first infected in vitro with a vaccinia virus recombinant that encodes the bacteriophage T7 RNA polymerase. This polymerase displays exquisite specificity in that it only transcribes templates bearing T7 promoters. Following infection, cells are transfected with the DNA of interest, driven by a T7 promoter. The polymerase expressed in the cytoplasm from the vaccinia virus recombinant transcribes the transfected DNA into RNA
which is then translated into protein by the host translational machinery. Alternately, T7 can be added as a purified protein or enzyme as in the "Progenitor"
system (Studier and Moffatt, J. Mol. Biol. (1986) 189113-130). The method provides for high level, transient, cytoplasmic production of large quantities of RNA and its translation product(s).
Depending on the expression system and host selected, the VLPS are produced by growing host cells transformed by an expression vector under conditions whereby the particle-forming polypeptide is expressed and VLPs can be formed. The selection of the appropriate growth conditions is within the skill of the art. If the VLPs are formed intracellularly, the cells are then disrupted, using chemical, physical or mechanical means, which lyse the cells yet keep the VLPs substantially intact. Such methods are known to those of skill in the art and are described in, e.g., Protein Purification Applications: A Practical Approach, (E.L.V. Harris and S. Angal, Eds., 1990).
The particles are then isolated (or substantially purified) using methods that preserve the integrity thereof, such as, by density gradient centrifugation, e.g., sucrose gradients, PEG-precipitation, pelleting, and the like (see, e.g., Kirnbauer et al. J. Virol.
(1993) 67:6929-6936), as well as standard purification techniques including, e.g., ion exchange and gel filtration chromatography.
VLPs produced by cells containing the synthetic expression cassettes of the present invention can be used to elicit an immune response when administered to a subject. One advantage of the present invention is that VLPs can be produced by mammalian cells carrying the synthetic expression cassettes at levels previously not possible. As discussed above, the VLPs can comprise a variety of antigens in addition to the Gag polypeptides (e.g., Env, tat, Gag-protease, Gag-polymerase, Gag-HCV-core). Purified VLPs, produced using the synthetic expression cassettes of the present invention, can be administered to a vertebrate subject, usually in the form of vaccine compositions. Combination vaccines may also be used, where such vaccines contain, for example, other subunit proteins derived from HIV or other organisms (e.g., env) or gene delivery vaccines encoding such antigens. Administration can take place using the VLPs formulated alone or formulated with other antigens.
Further, the VLPs can be administered prior to, concurrent with, or subsequent to, delivery of the synthetic expression cassettes for DNA immunization (see below). and/or delivery of other vaccines. lso, the site of VLP administration may be the same or different as other vaccine compositions that are being aOministered.
Gene delivery can be accomplished by a number of methods including, but are not limited to, immunization with DNA, alphavirus vectors, pox virus vectors, and vaccinia virus vectors.
VLP immune-stimulating (or vaccine) compositions can include various excipients, adjuvants, carriers, auxiliary substances, modulating agents, and the like.
The immune stimulating compositions will include an amount of the VLP/antigen sufficient to mount an immunological response. An appropriate effective amount can be determined by one of skill in the art. Such an amount will fall in a relatively broad range that can be determined through routine trials and will generally be an amount on the order of about 0.1 pg to about 1000 pg, _ more preferably about 1 pg to about 300 dig, of VLP/antigen.
A carrier is optionally present which is a molecule that does not itself induce the production of antibodies harmful to the individual receiving the composition.
Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycollic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles. Examples of particulate carriers include those derived from polymethyl methacrylate polymers, as well as microparticles derived from poly(lactides) and poly(lactide-co-glycolides), known as PLG. See, e.g., Jeffery et al., Pharm. Res. (1993) 10:362-368; McGee JP, et al., J Microencapsul. 14(2):197-210, 1997; O'Hagan DT, et al., Vaccine 11(2):149-54, 1993. Such carriers are well known to those of ordinary skill in the art.
Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen may be conjugated to a bacterial toxoid, such as toxoid from diphtheria, tetanus, cholera, etc., as well as toxins derived from E. coil.
Such adjuvants include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc.; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59 (International Publication No. WO 90/14837), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE (see below), although not required) formulated *Trade-mark 66 into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, MA), (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5%
pluronic-blocked polymer L121, and thr-MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribim adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detoxm); (3) saponin adjuvants, such as Stimulonm (Cambridge Bioscience, Worcester, MA) may be used or particle generated therefrom such as ISCOMs (immunostimulating complexes); (4) Complete Freunds Adjuvant (CFA) and Incomplete Freunds Adjuvant (IFA); (5) cytokines, such as interleukins (IL-1, IL-2, etc.), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), beta chemokines (MIP, 1-alpha, 1-beta Rantes, etc.); (6) detoxified mutants of a bacterial ADP-ribosylating toxin such as a cholera toxin (CT), a pertussis toxin (PT), or an E. coli heat-labile toxin (LT), particularly LT-K63 (where lysine is substituted for the wild-type amino acid at position 63) LT-R72 (where arginine is substituted for the wild-type amino acid at position 72), CT-S109 (where serine is substituted for the wild-type amino acid at position 109), and PT-K9/G129 (where lysine is substituted for the wild-type amino acid at position 9 and glycine substituted at position 129) (see, e.g., International Publication Nos. W093/13202 and W092/19265); and (7) other substances that act as immunostimulating agents to enhance the effectiveness of the composition.
Muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acteyl-normuramyl-L-alanyl-D-isogluatme (nor-MDP), N-acetylmuramyl-L-alanyl-D-isogluatminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-huydroxyphosphoryloxy)-ethylamine (MTP-PE), etc.
Dosage treatment with the VLP composition may be a single dose schedule or a multiple dose schedule. A
multiple dose schedule is one in which a primary course of vaccination may be with 1-10 separate doses, followed by other doses given at subsequent time intervals, chosen to maintain and/or reinforce the immune response, for example at 1-4 months for a second dose, and if needed, a subsequent dose(s) after several months. The dosage = regimen will also, at least in part, be determined by the potency of the modality, the vaccine delivery employed, = the need of the subject and be dependent on the judgment of the practitioner.
If prevention of disease is desired (e.g., reduction of symptoms, recurrences or of disease progression), the antigen carrying VLPs are generally administered prior to primary infection with the pathogen of interest. If treatment is desired, e.g., the reduction of symptoms or recurrences, the VLP compositions are generally administered subsequent to primary infection.

2.2.2 USING THE SYNTHETIC EXPRESSION CASSETTES OF THE
PRESENT INVENTION TO CREATE PACKAGING CELL LINES
A number of viral based systems have been developed for use as gene transfer vectors for mammalian host cells. For example, retroviruses (in particular, lentiviral vectors) provide a convenient platform for gene delivery systems. A coding sequence of interest (for example, a sequence useful for gene therapy applications) can be inserted into a gene delivery vector and packaged in retroviral particles using techniques known in the art. Recombinant virus can then be isolated and delivered to cells of the subject either in vivo or ex vivo. A number of retroviral systems have been described, including, for example, the following: (U.S.
Patent No. 5,219,740; Miller et al. (1989) Biotechniques 7:980; Miller, A.D. (1990) Human Gene Therapy 1:5; Scarpa et al. (1991) Virology 180:849; Burns et al. (1993) Proc.
Natl. Acad. Sci. USA 90:8033; Boris-Lawrie et al. (1993) Cur. Opin. Genet. Develop. 2:102; GB 2200651; EP 0415731;
EP 0345242; WO 89/02468; WO 89/05349; WO 89/09271; WO
90/02806; WO 90/07936; WO 90/07936; WO 94/03622; WO
93/25698; NO 93/25234; WO 93/11230; WO 93/10218; WO
91/02805; in U.S. 5,219,740; U.S. 4,405,712; U.S.
4,861,719;.U.S. 4,980,289 and U.S. 4,777,127; in U.S.
Serial No. 07/800,921; and in Vile (1993) Cancer Res 53:3860-3864; Vile (1993) Cancer Res 53:962-967; Ram (1993) Cancer Res 53:83-88; Takamiya (1992) J Neurosci Res 33:493-503; Baba (1993) J Neurosurg 79:729-735; Mann (1983) Cell 33:153; Cane (1984) Proc Natl Acad Sci USA
81;6349; and Miller (1990) Human Gene Therapy 1.
Sequences useful for gene therapy applications include, but are not limited to, the following. Factor VIII cDNA, Including derivatives and deletions thereof (International Publication Nos. WO 96/21035, WO 97/03193, WO 97/03194, WO 97/03195, and WO 97/03191). Factor IX
cDNA (Kurachi et al. (1982) Proc. Natl. Acad. Sci. USA
79:6461-6464). Factor V cDNA can be obtained from pMT2-V
(Jenny (1987) Proc. Natl. Acad. Sci. USA 84:4846, A.T.C.C. Deposit No. 40515). A full-length factor v cDNA, or a 13 domain deletion or B domain substitution thereof, can be used. B domain deletions of factor V.

include those reported by Marquette (1995) Blood 86:3026 and Kane (1990) Biochemistry 29:6762. Antithrombin III
cDNA (Prochownik (1983) J. Biol. Chem. 258:8389, A.T.C.C.
Deposit No. 57224/57225). Protein C encoding cDNA
(Foster (1984) Proc. Natl. Acad. Sci. USA 81:4766;
Beckmann (1985) Nucleic Acids Res. 13:5233). Prothrombin cDNA can be obtained by restriction enzyme digestion of a published vector (Degen (1983) Biochemistry 22:2087).
The endothelial cell surface protein, thrombomodulin, is a necessary cofactor for the normal activation of protein C by thrombin. A soluble recombinant form has been described (Parkinson (1990) J. Biol. Chem. 265:12602;
Jackman (1987) Proc. Natl. Acad. Sci. USA 84:6425; Shirai (1988) J. Biochem. 103:281; Wen (1987) Biochemistry 26:4350; Suzuki (1987) EMBO.J. 6:1891, A.T.C.C. Deposit =
No. 61348, 61349).
Many genetic diseases caused by inheritance of defective genes result in the failure to produce normal gene products, for example, thalassemia, phenylketonuria, Lesch-Nyhan syndrome, severe combined immunodeficiency (SCID), hemophilia A and B, cystic fibrosis, Duchenne's Muscular Dystrophy, inherited emphysema and familial hypercholesterolemia (Mulligan et al. (1993) Science 260:926; Anderson et al. (1992) Science Za:808; Friedman et al. (1989) Science 244:1275). Although genetic diseases may result in the absence of a gene product, endocrine disorders, such as diabetes and hypopituitarism, are caused by the inability of the gene to produce adequate levels of the appropriate hormone insulin and human growth hormone respectively.
In one aspect, gene therapy employing the constructs and methods of the present invention involves the introduction of normal recombinant genes into T cells so that new or missing proteins are produced by the T cells after introduction or reintroduction thereof into a patient. A number of genetic diseases have been selected for treatment with gene therapy, including adenine deaminase deficiency, cystic fibrosis, a1-antitrypsin deficiency, Gaucher's syndrome, as well as non-genetic diseases.
In particular, Gaucher's syndrome is a genetic disorder characterized by a deficiency of the enzyme glucocerebrosidase. This enzyme deficiency leads to the accumulation of glucocerebroside in the lysosomes of all cells in the body. For a review see Science 256:794 (1992) and Scriver et al., The Metabolic Basis of Inherited Disease, 6th ed., vol. 2, page 1677). Thus, gene transfer vectors that express glucocerebrosidase can be construct,0 for use in the treatment of this di.sorder.
Likewise, gene transfer vectors encoding lactase can be used in the treatment of hereditary lactose intolerance, those expressing AD can be used for treatment of ADA
deficiency, and gene transfer vectors encoding (1,-antitrypsin can be used to treat (y1-antitrypsin deficiency. See Ledley, F.D. (1987) J. Pediatrics 110:157-174, Verma, I. (Nov. 1987) Scientific American pp. 68-84, and International Publication No. WO 95/27512 entitled "Gene Therapy Treatment for a Variety of Diseases and Disorders," for a description of gene therapy treatment of genetic diseases.
In still further embodiments of the invention, nucleotide sequences which can be incorporated into a gene transfer vector include, but are not limited to, proteins associated with enzyme-deficiency disorders, such as the cystic fibrosis transmembrane regulator (see, for example, U.S. Patent No. 5,240,846 and Larrick et al.

(1991) Gene Therapy Applications of Molecular Biology, Elsevier, New York and adenosine deaminase (ADA) (see U.S. Patent No. 5,399,346); growth factors, or an agonist or antagonist of a growth factor (Bandara et al. (1992) DNA and Cell Biology, 11:227); one or more tumor suppressor genes such as p53, Rb, or C-CAMI (Kleinerman et al. (1995) Cancer Research 55:2831); a molecule that modulates the immune system of an organism, such as a HLA
molecule (Nabel et al. (1993) Proc. Natl. Acad. Sci. USA
90:11307); a ribozyme (Larsson et al. (1996) Virology 219:161); a peptide nucleic acid (Hirshman et al. (1996) J. Invest. Med. 44:347); an antisense molecule (Bordier et al. (1995) Proc. Natl. Acad. Sci. USA 92:9383) which can be used to down-regulate the expression or synthesis of aberrant or foreign proteins, such as HIV proteins or a wide variety of oncogenes such as p53 (Hesketh, The Oncogene Facts Book, Academic Press, New York, (1995); a biopharmaceutical agent or antisense molecule used to treat HIV-infection, such as an inhibitor of p24 (Nakashima et al. (1994) Nucleic Acids Res. 22:5004); or reverse-transcriptase (see, Bordier, supra).
Other proteins of therapeutic interest can be expressed in vivo by gene transfer vectors using the methods of the invention. For instance sustained in vivo expression of tissue factor inhibitory protein (TFPI) is useful for treatment of conditions including sepsis and DIC and in preventing reperfusion injury. (See International Publications Nos. WO 93/24143, WO 93/25230 and WO 96/06637). Nucleic acid sequences encoding various forms of TFPI can be obtained, for example, as described in US Patent Nos. 4,966,652; 5,106,833; and 5,466,783, and incorporated into the gene transfer vectors described herein.

Erythropoietin (EPO) and leptin can also be expressed in vivo from genetically modified T cells according to the methods of the invention. For instance EPO is useful in gene therapy treatment of a variety of disorders including anemia (see International Publication No. WO 95/13376 entitled "Gene Therapy for Treatment of Anemia"). Sustained delivery of leptin by the methods of the invention is useful in treatment of obesity. See International Publication No. WO 96/05309 for a description of the leptin gene and the use thereof in the treatment of obesity.
A variety of other disorders can also be treated by the methods of the invention. For example, sustained in vivo systemic production of apolipoprotein E or apolipoprotein A from genetically modified T cells can be used for treatment of hyperlipidemia (see Breslow et al.
(1994) Biotechn9logy )2:365). Sustained production of angiotensin receptor inhibitor (Goodfriend et al. (1996) N. Engl. J. Med., 334:1469) can be provided by the methods described herein. As yet an additional example, the long term in vivo systemic production of angiostatin is useful in the treatment of a variety of tumors. (See O'Reilly et al. (1996) Nature Med. 2:689).
In other embodiments, gene transfer vectors can be constructed to encode a cytokine or other immunomodulatory molecule. For example, nucleic acid sequences encoding native IL-2 and gamma-interferon can be obtained as described in US Patent Nos. 4,738,927 and 5,326,859, respectively, while useful muteins of these proteins can be obtained as described in U.S. Patent No.
4,853,332. Nucleic acid sequences encoding the short and long forms of mCSF can be obtained as described in US
Patent Nos. 4,847,201 and 4,879,227, respectively. In particular aspects of the invention, retroviral vectors _ expressing cytokine or immunomodulatory genes can be produced as described herein (for example, employing the packaging cell lines of the present invention) and in International Application No. PCT US 94/02951, entitled "Compositions and Methods for Cancer Immunotherapy."
Examples of suitable immunomodulatory molecules for use herein include the following: IL-1 and IL-2 (Karupiah et al. (1990) J. Immunology 144:290-298, Weber et al.
(1987) J. Exp. Med. 166:1716-1733, Gansbacher et al.
(1990) J. Exp. Med. 172:1217-1224, and U.S. Patent No.
4,738,927); IL-3 and IL-4 (Tepper et al. (1989) Cell 57:503-512, Golumbek et al. (1991) Science 254:713-716, and U.S. Patent No. 5,017,691); IL-5 and IL-6 (Brakenhof et al. (1987) J. Immunol. 139:4116-4121, and International Publication No. WO 90/06370); IL-7 (U.S.
Patent No. 4,965,195); IL-8, IL-9, IL-10, IL-11, IL-12, ancl IL-13 (Cytokine Bulletin, Summer 1994); IL-14 and IL-15; alpha interferon (Finter et al. (1991) Drugs 42;749-765, U.S. Patent Nos. 4,892,743 and 4,966,843, International Publication No. WO 85/02862, Nagata et al.
(1980) Nature 284:316-320, Familletti et al. (1981) Methods in Enz. 78:387-394, Twu et al. (1989) Proc. Natl.
Acad. Sci. USA 86:2046-2050, and Faktor et al. (1990) Oncogene 5:867-872); beta-interferon (Seif et al. (1991) J. Virol. 65:664-671); gamma-interferons (Radford et al.
(1991) The American Society of Hepatology 20082015, Watanabe et al. (1989) Proc. Natl. Acad. Sci. USA
86:9456-9460, Gansbacher et al. (1990) Cancer Research 50:7820-7825, Maio et al. (1989) Can. Immunol.
Immunother. 30:34-42, and U.S. Patent Nos. 4,762,791 and 4,727,138); G-CSF (U.S. Patent Nos. 4,999,291 and 4,810,643); GM-CSF (International Publication No. WO
85/04188); tumor necrosis factors (TNFs) (Jayaraman et al. (1990) J. Immunology 144:942-951); CD3 (Krissanen et al. (1987) Immunogenetics 26:258-266); ICAM-1 (Altman et al. (1989) Nature 338:512-514, Simmons et al. (1988) Nature 331:624-627); ICAM-2, LFA-1, LFA-3 (Wallner et al.

(1987) J. Exp. Med. 166:923-932); MHC class I molecules, MHC class II molecules, B7.1-.3, f32-microglobulin (Parnes et al. (1981) Proc. Natl. Acad. Sci. USA 78:2253-2257);

chaperones such as calnexin; and MHC-linked transporter proteins or analogs thereof (Powis et al. (1991) Nature 354:528-531). Immunomodulatory factors may also be agonists, antagonists, or ligands for these molecules.

For example, soluble forms of receptors can often behave as antagonists for these types of factors, as can mutated forms of the factors themselves.
Nucleic acid molecules that encode the above-described substances, as well as other nucleic acid molecules that are advantageous for use within the present invention, may be readily obtained from a variety of sources, including, for example, depositories such as the American Type .Culture Collection, or from commerciaa sources such as British Bio-Technology Limited (Cowley, Oxford England). Representative examples include BEG 12 (containing the GM-CSF gene coding for the mature protein of 127 amino acids), BBG 6 (which contains sequences encoding gamma interferon), A.T.C.C. Deposit No. 39656 (which contains sequences encoding TNF), A.T.C.C. Deposit No. 20663 (which contains sequences encoding alpha-interferon), A.T.C.C. Deposit Nos. 31902, 31902 and 39517 (which contain sequences encoding beta-interferon), A.T.C.C. Deposit No. 67024 (which contains a sequence which encodes Interleukin-lb), A.T.C.C. Deposit Nos.

39405, 39452, 39516, 39626 and 39673 (which contain sequences encoding Interleukin-2), A.T.C.C. Deposit Nos.
59399, 59398, and 67326 (which contain sequences encoding Interleukin-3), A.T.C.C. Deposit No. 57592 (which contains sequences encoding Interleukin-4), A.T.C.C.
Deposit Nos. 59394 and 59395 (which contain sequences encoding Interleukin-5), and A.T.C.C. Deposit No. 67153 (which contains sequences encoding Interleukin-6).
Plasmids containing cytokine genes or immunomodulatory genes (International Publication Nos. WO
94/02951 and WO 96/21015)can be digested with appropriate restriction enzymes, and DNA fragments containing the particular gene of interest can be inserted into a gene transfer vector using standard molecular biology techniques. (See, e.g., Sambrook et al., supra., or Ausubel et al. (eds) Current Protocols in Molecular Biology, Greene Publishing and Wiley-Interscience).
Exemplary hormones, growth factors and other proteins which are useful for long term expression are described, for example, in European Publication No.
0437478E1, entitled "Cyclodextrin-.Peptide Complexes."
Nucleic acid sequences encoding a variety of hormones can be used, including those encoding human growth hormone, insulin, calcitonin, prolactin, follicle stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (HCG), and thyroid stimulating hormone (TSH). A variety of different forms of IGF-1 and IGF-2 growth factor polypeptides are also well known the art and can be incorporated into gene transfer vectors for long term expression in vivo. See, e.g., European Patent No. 0123228BI, published for grant September 19, 1993, entitled "Hybrid DNA Synthesis of Mature Insulin-like Growth Factors." As an additional example, the long term in vivo expression of different forms of fibroblast growth factor can also be effected employing the compositions and methods of invention. See, e.g., U.S.
Patent Nos. 5,464,774, 5,155,214, and 4,994,559 for a description of different fibroblast growth factors.

Polynucleotide sequences coding for the above-described molecules can be obtained using recombinant methods, such as by screening cDNA and genomic libraries from cells expressing the gene, or by deriving the gene from a vector known to include the same. For example, plasmids which contain sequences that encode altered cellular products may be obtained from a depository such as the A.T.C.C., or from commercial sources. Plasmids containing the nucleotide sequences of interest can be digested with appropriate restriction enzymes, and DNA
fragments containing the nucleotide sequences can be inserted into a gene transfer vector using standard molecular biology techniques.
Alternatively, cDNA sequences for use with the present invention may be obtained from cells which express or contain the sequences, using standard techniques, such as phenol extraction and PCR of cDUA or genomic DNA. See, e.g., Sambrook et al., supra, for a description of techniques used to obtain and isolate DNA.
Briefly, mRNA from a cell which expresses the gene of interest can be reverse transcribed with reverse transcriptase using oligo-dT or random primers. The single stranded cDNA may then be amplified by PCR (see U.S. Patent Nos. 4,683,202, 4,683,195 and 4,800,159, see also PCR Technology: Principles and Applications for DNA
Amplification, Erlich (ed.), Stockton Press, 1989)) using oligonucleotide primers complementary to sequences on either side of desired sequences.
The nucleotide sequence of interest can also be produced synthetically, rather than cloned, using a DNA
synthesizer (e.g., an Applied Biosystems Model 392 DNA
Synthesizer, available from ABI, Foster City, California). The nucleotide sequence can be designed with the appropriate codons for the expression product desired. The complete sequence is assembled from overlapping oligonucleotides prepared by standard methods and assembled into a complete coding sequence. See, e.g., Edge (1981) Nature 292:756; Nambair et al. (1984) Science 223:1299; Jay et al. (1984) J. Biol. Chem.
259:6311.
The synthetic expression cassettes of the present invention can be employed in the construction of packaging cell lines for use with retroviral vectors.
One type of retrovirus, the murine leukemia virus, or "MLV", has been widely utilized for gene therapy applications (see generally Mann et al. (Cell 33:153, 1993), Cane and Mulligan (Proc, Nat'l. Acad. Sci. USA
81:6349, 1984), and Miller et al., Human Gene 21erapy 1:5-14,1990.
Lentiviral vectors typically, comprise a 5' lentiviral LTR, a tRNA binding site, a packaging signal, a promoter operably linked to one or more genes of interest, an origin of second strand DNA synthesis and a 3' lentiviral LTR, wherein the lentiviral vector contains a nuclear transport element. The nuclear transport element may be located either upstream (5') or downstream (3') of a coding sequence of interest. Within certain embodiments, the nuclear transport element is not RRE.
Within one embodiment the packaging signal is an extended packaging signal. Within other embodiments the promoter is a tissue specific promoter, or, alternatively, a promoter such as CMV. Within other embodiments, the lentiviral vector further comprises an internal ribosome entry site.
A wide variety of lentiviruses may be utilized within the context of the present invention, including for example, lentiviruses selected from the group consisting of HIV, HIV-1, HIV-2, FIV and Sly.

+.4*

In one embodiment of the present invention synthetic Env and/or Gag-polymerase expression cassettes are provided comprising a promoter and a sequence encoding synthetic Gag-polymerase (SEQ ID NO:6) and at least one of vpr, vpu, net or vif, wherein the promoter is operably linked to Gag-polymerase and vpr, vpu, nef or vif.
Within yet another aspect of the invention, host cells (e.g., packaging cell lines) are provided which contain any of the expression cassettes described herein.
For example, within one aspect packaging cell line are provided comprising an expression cassette that comprises a sequence encoding synthetic Env and/or Gag-polymerase, and a nuclear transport element, wherein the promoter is operably linked to the sequence encoding Env and/or Gag-polymerase. Packaging cell lines may further comprise a promoter and a sequence encoding tat, rev, or an envelope, wherein the promoter is operably linked to the sequence encoding tat, rev, or, the envelope. The . packaging cell line may further comprise a sequence encoding any one or more of nef, vif, vpu or vpr.
In one embodiment, the expression cassette (carrying, for example, the synthetic Env, synthetic tat and/or synthetic Gag-polymerase) is stably integrated.
The packaging cell line, upon introduction of a lentiviral vector, typically produces viral particles.
The promoter regulating expression of the synthetic expression cassette may be inducible. Typically, the packaging cell line, upon introduction of a lentiviral vector, produces viral particles that are essentially free of replication competent virus.
Packaging cell lines are provided comprising an expression cassette which directs the expression of a synthetic Env (or Gag-polymerase) gene, an expression cassette which directs the expression of a Gag (or Env) gene optimized for expression (e.g., Andre, S., et al., Journal of Virology 72(2):1497-1503, 1998; Haas, J., et al., Current Biology 6(3):315-324, 1996). A lentiviral vector is introduced into the packaging cell line to produce a vector particle producing cell line.
As noted above, lentiviral vectors can be designed to carry or express a selected gene(s) or sequences of interest. Lentiviral vectors may be readily constructed from a wide variety of lentiviruses (see RNA Tumor Viruses, Second Edition, Cold Spring Harbor Laboratory, 1985). Representative examples of lentiviruses included HIV, HIV-1, HIV-2, FIV and SIV. Such lentiviruses may either be obtained from patient isolates, or, more preferably, from depositories or collections such as the American Type Culture Collection, or isolated from known sources using available techniques.
Portions of the lentiviral gene delivery vectors (or vehicles) may be derived from different viruses. For example, in a given recombinant lentiviral vector, LTRs may be derived from an HIV, a packaging signal from Sly, and an origin of second strand synthesis from HrV-2.
Lentiviral vector constructs may comprise a 5' lentiviral LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand DNA
synthesis and a 3' LTR, wherein said lentiviral vector contains a nuclear transport element that is not RRE.
Briefly, Long Terminal Repeats ("LTRs") are subdivided into three elements, designated U5, R and U3.
These elements contain a variety of signals which are responsible for the biological activity of a retrovirus, including for example, promoter and enhancer elements which are located within U3. LTRs may be readily identified in the provirus (integrated DNA form) due to their precise duplication at either end of the genome.

As utilized herein, a 5' LTR should be understood to include a 5' promoter element and sufficient LTR sequence to allow reverse transcription and integration of the DNA
form of the vector. The 3' LTR should be understood to include a polyadenylation signal, and sufficient LTR
sequence to allow reverse transcription and integration of the DNA form of the vector.
The tRNA binding site and origin of second strand DNA synthesis are also important for a retrovirus to be biologically active, and may be readily identified by one of skill in the art. For example, retroviral tRNA binds to a tRNA binding site by Watson-Crick base pairing, and is carried with the retrovirus genome into a viral particle. The tRNA is then utilized as a primer for DNA
synthesis by reverse transcriptase. The tRNA binding site may be readily identified based upon its location just downstream from the 5'LTR. Similarly, the origin of second strand DNA synthesis is, as its name implies, important for the second strand DNA synthesis of a retrovirus. This region, which is also referred to as the poly-purine tract, is located just upstream of the 3'LTR.
In addition to a 5' and 3' LTR, tRNA binding site, and origin of second strand DNA synthesis, recombinant retroviral vector constructs may also comprise a packaging signal, as well as one or more genes or coding sequences of interest. In addition, the lentiviral vectors have a nuclear transport element which, in preferred embodiments is not RRE. Representative examples of suitable nuclear transport elements include the element in Rous sarcoma virus (Ogert, et al., J ViroL
70, 3834-3843, 1996), the element in Rous sarcoma virus (Liu & Mertz, Genes & Dev., 9, 1766-1789, 1995) and the element in the genome of simian retrovirus type I

(Zolotukhin, et al., J Virol. 68, 7944-7952, 1994).
Other potential elements include the elements in the histone gene (Kedes, Annu. Rev. Biochem. 48, 837-870, 1970), the a-interferon gene (Nagata et al., Nature 287, 401-408, 1980), the (3-adrenergic receptor gene (Koilka, et al., Nature 329, 75-79, 1987), and the c-Jun gene (Hattorie, et al., Proc. Natl. Acad. Sci. USA 85, 9148-9152, 1988).
Recombinant lentiviral vector constructs typically lack both Gag-polymerase and env coding sequences.
Recombinant lentiviral vector typically contain less than 20, preferably 15, more preferably 10, and most preferably 8 consecutive nucleotides found in Gag-polymerase or env genes. One advantage of the present invention is that the synthetic Gag-polymerase expression cassettes, which can be used to construct packaging cell lines for the recombinant retroviral vector constructs, =
have little homology to wild-type Gag-polymerase sequences and thus considerably reduce or eliminate the =
= 20 possibility of homologous recombination between the synthetic and wild-type sequences.
Lentiviral vectors may also include tissue-specific promoters to drive expression of one or more genes or sequences of interest. For example, lentiviral vector particles of the invention can contain a liver specific promoter to maximize the potential for liver specific expression of the exogenous DNA sequence contained in the vectors. Preferred liver specific promoters include the hepatitis B X-gene promoter and the hepatitis B core protein promoter. These liver specific promoters are preferably employed with their respective enhancers. The enhancer element can be linked at either the 5' or the 3' end of the nucleic acid encoding the sequences of interest. The hepatitis B X gene promoter and its enhancer can be obtained from the viral genome as a 332 base pair EcoRV-NCoI DNA fragment employing the methods described in Twu, et al., J Virol. 61:3448-3453, 1987.
The hepatitis B core protein promoter can be obtained from the viral genome as a 584 base pair BamHI-BglII DNA
fragment employing the methods described in Gerlach,et al., Virol 189:59-66, 1992. It may be necessary to remove the negative regulatory sequence in the BamHI-BglII fragment prior to inserting it. Other liver specific promoters include the AFP (alpha fetal protein) gene promoter and the albumin gene promoter, as disclosed in EP Patent Publication 0 415 731, the -1 antitrypsin gene promoter, as disclosed in Rettenger, et al., Proc.
Natl. Acad. Sci. 91:1460-1464, 1994, the fibrinogen gene promoter, the APO-Al (Apolipoprotein Al) gene promoter, and the promoter genes for liver transference enzymes such as, for example, SGOT, SGPT and glutamyle transferase. See also PCT Patent Publications WO
90/07936 and WO 91/02805 for a description of the use of liver specific promoters in lentiviral vector particles.
Lentiviral vector constructs may be generated such that more than one gene of interest is expressed. This may be accomplished through the use of di- or oligo-cistronic cassettes (e.g., where the coding regions are separated by 80 nucleotides or less, see generally Levin et al., Gene 108:167-174, 1991), or through the use of Internal Ribosome Entry Sites ("IRES").
Packaging cell lines suitable for use with the above described recombinant retroviral vector constructs may be readily prepared given the disclosure provided herein.
Briefly, the parent cell line from which the packaging cell line is derived can be selected from a variety of WO 00/39302 PCT/1.1599/31245 mammalian cell lines, including for example, 293, RD, COS-7, CHO, BHK, VERO, HT1080, and myeloma cells.
After selection of a suitable host cell for the generation of a packaging cell line, one or more expression cassettes are introduced into the cell line in order to complement or supply in trans components of the vector which have been deleted.
Representative examples of suitable expression cassettes have been described herein and include synthetic Env, tat, Gag, synthetic Gag-protease, synthetic Gag-reverse transcriptase and synthetic Gag-polymerase expression cassettes, which comprise a promoter and a sequence encoding, e.g., Env, tat, or Gag-polymerase and at least one of vpr, vpu, nef or vif, wherein the promoter is operably linked to Env, tat or Gag-polymerase and vpr, vpu, nef or vif. As described above, optimized Env, Gag and/or tat coding sequences may also be utilized in various combinations in the generation of packaging cell lines.
Utilizing the above-described expression cassettes, a wide variety of packaging cell lines can be generated.
For example, within one aspect packaging cell line are provided comprising an expression cassette that comprises a sequence encoding synthetic HIV (e.g., Gag, Env, tat, Gag-polymerase, Gag-reverse transcriptase or Gag-protease) polypeptide, and a nuclear transport element, wherein the promoter is operably linked to the sequence encoding the HIV polypeptide. Within other aspects, packaging cell lines are provided comprising a promoter and a sequence encoding Gag, tat, rev, or an envelope (e.g., HIV env), wherein the promoter is operably linked to the sequence encoding Gag, tat, rev, or, the envelope.
Within further embodiments, the packaging cell line may comprise a sequence encoding any one or more of nef, vif, vpu or vpr. For example, the packaging cell line may contain only nef, vif, vpu, or vpr alone, nef and vif, nef and vpu, nef and vpr, vif and vpu, vif and vpr, vpu and vpr, nef vif and vpu, nef vif and vpr, nef vpu and vpr, vvir vpu and vpr, or, all four of nef vif vpu and vpr.
In one embodiment, the expression cassette is stably integrated. Within another embodiment, the packaging cell line, upon introduction of a lentiviral vector, produces particles. Within further embodiments the promoter is inducible. Within certain preferred embodiments of the invention, the packaging cell line, upon introduction of a lentiviral vector, produces particles that are free of replication competent virus.
The synthetic cassettes containing optimized coding sequences are transfected into a selected cell line.
= Transfected cells are selected that (i) carry, typically, integrated, stable copies of the Gag, Pol, and Env coding sequences, and (ii) are expressing acceptable levels of these polypeptides (expression can be evaluated by methods known in the prior art, e.g., see Examples 1-4).
The ability of the cell line to produce VLPs may also be verified (Examples 6, 7 and 15).
A sequence of interest is constructed into a suitable viral vector as discussed above. This defective virus is then transfected into the packaging cell line.
The packaging cell line provides the viral functions necessary for producing virus-like particles into which the defective viral genome, containing the sequence of interest, are packaged. These VLPs are then isolated and can be used, for example, in gene delivery or gene therapy.
Further, such packaging cell lines can also be used to produce VLPs alone, which can, for example, be used as adjuvants for administration with other antigens or in vaccine compositions. Also, co-expression of a selected sequence of interest encoding a polypeptide (for example, an antigen) in the packaging cell line can also result in the entrapment and/or association of the selected polypeptide in/with the VLPs.

2.3 DNA Ita4uNizATIoN AND GENE DELIVERY
A variety of polypeptide antigens can be used in the practice of the present invention. Polypeptide antigens can be included in DNA immunization constructs containing, for example, any of the synthetic expression cassettes described herein fused in-frame to a coding sequence for the polypeptide antigen, where expression of the construct results in VLPs presenting the antigen of interest. Antigens can be derived from a wide variety of viruses, bacteria, fungi, plants, protozqans and other parasites. For example, the present invention will find use for stimulating an immune response against a wide variety of proteins from the herpesvirus family, including proteins derived from herpes simplex virus (HSV) types 1 and 2, such as HSV-1 and HSV-2 gB, gD, 9E, VP16 and VP22; antigens derived from varicella zoster virus (VZV), Epstein-Barr virus (EBV) and cytomegalovirus (CMV) including CMV gB and gH; and antigens derived from other human herpesviruses such as HHV6 and HHV7. (See, e.g. Chee et al., Cytomegaloviruses (J.K. McDougall, ed., Springer-Verlag 1990) pp. 125-169, for a review of the protein coding content of cytomegalovirus; McGeoch et al., J. Gen. Virol. (1988) 69:1531-1574, for a discussion of the various HSV-1 encoded proteins; U.S. Patent No.
5,171,568 for a discussion of HSV-1 and HSV-2 gB and gD
proteins and the genes encoding therefore; Baer et al., Nature (1984) 310:207-211, for the identification of protein coding sequences in an EBV genome; and Davison and Scott, J. Gen. Virol. (1986) 67:1759-1816, for a review of VZV.) Additionally, immune responses to antigens from the hepatitis family of viruses, including hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), the delta hepatitis virus (HDV), hepatitis E virus (HEV), and hepatitis G virus, can also be stimulated using the constructs of the present invention. By way of example, the HCV genome encodes several viral proteins, including El (also known as E) and E2 (also known as E2/NSI), which will find use with the present invention (see, Houghton et al. Ilepatology (1991) 14:381-388, for a discussion of HCV proteins, including El and E2). The 6-antigen from HDV can also be used (see, e.g., U.S. Patent No.
5,389,528, for a description of the 5-antigen).
Similarly, influenga virus is another example of a virus for which the present invention will be particularly useful. Specifically, the envelope glycoproteins HA and NA of influenza A are of particular interest for generating an immune response. Numerous HA
subtypes of influenza A have been identified (Kawaoka et al., Virology (1990) 179:759-767; Webster et al.
"Antigenic variation among type A influenza viruses," p.
127-168. In: P. Palese and D.W. Kingsbury (ed.), Genetics of influenza viruses. Springer-Verlag, New York).
Other antigens of particular interest to be used in the practice of the present invention include antigens and polypeptides derived therefrom from human papillomavirus (HPV), such as one or more of the various early proteins including E6 and E7; tick-borne encephalitis viruses; and HIV-1 (also known as HTLV-III, LAV, ARV, etc.), including, but not limited to, antigens such as gp120, gp41, gp160, Gag and pol from a variety of isolates including, but not limited to, HIVõ,,, HIVõ2, HIV-1õ"2, HIV- 1õ"" HIVõõõ, HIV" HIV, õ HIV-1õ, other HIV-1 strains from diverse subtypes(e.g., subtypes, A through G, and 0), HIV-2 strains and diverse subtypes (e.g., HIV-2,1 and HIV-2õ). See, e.g., Myers, et al., Los Alamos Database, Los Alamos National Laboratory, Los Alamos, New Mexico; Myers, et al., Human Retroviruses and Aids, 1990, Los Alamos, New Mexico: Los Alamos National Laboratory.
Proteins derived from other viruses will also find use in the claimed methods, such as without limitation, proteins from members of the families Picornaviridae (e.g., polioviruses, etc.); Caliciviridae; Togaviridae (e.g., rubella virus, dengue virus, etc.); Flaviviridae;
Coronaviridae; Reoviridae; Birnaviridae; Rhabodoviridae (e.g., rabies virus, etc.); Filoviridae; Paramyxoviridae (e.g., mumps virus, measles virus, respiratory syncytial virus, etc.); Orthomyxoviridae (e.g., influenza virus types A, B and C, etc.); Bunyaviridae; Arenaviridae;
Retroviradae, e.g., HTLV-I; HTUV-II; HIV-1; HIV-2; simian immunodeficiency virus (Sly) among others. See, e.g.
Virology, 3rd Edition (W.K. Joklik ed. 1988); Fundamental Virology, 2nd Edition (B.N. Fields and D.M. Knipe, eds.
1991; Virology, 3rd Edition (Fields, BN, DM Knipe, PM
Howley, Editors, 1996, Lippincott-Raven, Philadelphia, PA) for a description of these and other viruses.
Particularly preferred bacterial antigens are derived from organisms that cause diphtheria, tetanus, pertussis, meningitis, and other pathogenic states, including, without limitation, antigens derived from Corynebactcrium diphtheriae, Clostridium tetani, Bordetella pertusis, Neisseria meningitidis, including serotypes Meningococcus A, B, C, Y and WI35 (MenA, 8, C, Y and WI35), Haemophilus influenza type B (Hib), and Helicobacter pylori. Examples of parasitic antigens include those derived from organisms causing malaria, tuberculosis, and Lyme disease.
Furthermore, the methods described herein provide means for treating a variety of malignant cancers. For example, the system of the present invention can be used to enhance both humoral and cell-mediated immune responses to particular proteins specific to a cancer in question, such as an activated oncogene, a fetal antigen, or an activation marker. Such tumor antigens include any of the various MAGEs (melanoma associated antigen E), including MAGE 1, 2, 3, 4, etc. (Boon, T. Scientific American (March 1993):82-89); any of the various tyrosinases; MART 1 (melanoma antigen recognized by T
cells), mutant ras; mutant p53; p97 melanoma antigen; CEA
(carcinoembryonic antigen), among others.
DNA immunization using esynthetic expression cassettes of the present invention has been demonstrated to be efficacious (Examples 8 and 10-12). Animals were immunized with both the synthetic expression cassette and the wild type expression cassette. The results of the immunizations with plasmid-DNAs showed that the synthetic expression cassettes provide a clear improvement of immunogenicity relative to the native expression cassettes. Also, the second boost immunization induced a secondary immune response, for example after two to eight weeks. Further, the results of CTL assays showed increased potency of synthetic expression cassettes for induction of cytotoxic T-lymphocyte (CTL) responses by DNA immunization.
It is readily apparent that the subject invention can be used to mount an immune response to a wide variety of antigens and hence to treat or prevent a large number of diseases.

-2.3 .1 DEL/VERY OF THE SYNTHETIC EXPRESSION CASSETTES OF THE
PRESENT INVENTION
Polynucleotide sequences coding for the above-described molecules can be obtained using recombinant methods, such as by screening cDNA and genomic libraries from cells expressing the gene, or by deriving the gene from a vector known to include the same. The sequences can be analyzed by conventional sequencing techniques.
Furthermore, the desired gene can be isolated directly from cells and tissues containing the same, using standard techniques, such as phenol extraction and PCR of cDNA or genomic DNA. See, e.g., Sambrook et al., supra, for a description of techniques used to obtain, isolate and sequence DNA. Once the sequence is known, the gene of interest can also be produced synthetically, rather than cloned. The nucleotide sequence can be designed with the appropriate codons for the particular. amino acid sequence desired. In general, one will select preferred codons for the intended host in which the sequence will be expressed. The complete sequence is assembled from overlapping oligonucleotides prepared by standard methods and assembled into a complete coding sequence. See, e.g., Edge, Nature (1981) 292:756;
Nambair et al., Science (1984) 223:1299; Jay et al., J.
Biol. Chem. (1984) 259:6311; Stemmer, W.P.C., (1995) Gene 164:49-53.
Next, the gene sequence encoding the desired antigen can be inserted into a vector containing a synthetic expression cassette of the present invention (e.g., see Example 1 for construction of various exemplary synthetic expression cassette). The antigen is inserted into the synthetic coding sequence such that when the combined sequence is expressed it results in the production of VLPs comprising the polypeptide and/or the antigen of interest. Insertions can be made within the Gag coding sequence or at either end of the coding sequence (5', amino terminus of the expressed polypeptide; or 3', carboxy terminus of the expressed polypeptide -- e.g., see Example 1)(Wagner, R., et al., Arch Viral. 127:117-137, 1992; Wagner, R., et al., Virology 200:162-175, 1994; Wu, X., et al., J. Viral. 69(6):3389-3398, 1995;
Wang, C-T., et al., Virology 200:524-534, 1994; Chazal, N., et al., Virology 68(1):111-122, 1994; Griffiths, J.C., et al., J. Virol. 67(6):3191-3198, 1993; Reicin, A.S., et al., J. Virol. 69(2):642-650, 1995).
Up to 50% of the coding sequences of p55Gag can be deleted without affecting the assembly to virus-like particles and expression efficiency (Borsetti, A., et al, J. Virol. 72(11):9313-9317, 1998; Gamier, L., et al., J
Virol 72(6):4667-4677, 1998; Zhang, Y., et al., J Virol = 72(3):1782-1789, 1998; Wang, C.,. et al., J Virol 72(10):
7950-7959, 1998). In one embodiment of the present invention, immunogenicity of the high level expressing synthetic p55GagMod and p55GagProtMod expression cassettes can be increased by the insertion of different structural or non-structural HIV antigens, multiepitope cassettes, or cytokine sequences into deleted, mutated or truncated regions of p55GagMod sequence. In another embodiment of the present invention, immunogenicity of the high level expressing synthetic Env expression cassettes can be increased by the insertion of different structural or non-structural HIV antigens, multiepitope cassettes, or cytokine sequences into deleted regions of gp120Mod, gp140Mod or gp160Mod sequences. Such deletions may be generated following the teachings of the present invention and information available to one of ordinary skill in the art. One possible advantage of this approach, relative to using full-length modified Env sequences fused to heterologous polypeptides, can be higher expression/secretion efficiency and/or higher immunogenicity of the expression product. Such deletions may be generated following the teachings of the present invention and information available to one of ordinary skill in the art. One possible advantage of this approach, relative to using full-length Env, Gag or Tat sequences fused to heterologous polypeptides, can be higher expression/secretion efficiency and/or immunogenicity of the expression product.
When sequences are added to the amino terminal end of Gag (for example, when using the synthetic p55GagMod expression cassette of the present invention), the polynucletide can contain coding sequences at the 5' end that encode a signal for addition of a myristic moiety to the Gag-containing polypeptide (e.g., sequences that encode Met-Gly).
The ability of Gag-containing polypeptide constructs to form VLPs can be empirically determined following the teachings of the present specification.
HIV polypeptide/antigen synthetic expression cassettes include control elements operably linked to the coding sequence, which allow for the expression of the gene in vivo in the subject species. For example, typical promoters for mammalian cell expression include the SV40 early promoter, a CMV promoter such as the CMV
immediate early promoter, the mouse mammary tumor virus LTR promoter, the adenovirus major late promoter (Ad MLP), and the herpes simplex virus promoter, among others. Other nonviral promoters, such as a promoter derived from the murine metallothionein gene, will also find use for mammalian expression. Typically, transcription termination and polyadenylation sequences will also be present, located 3' to the translation stop codon. Preferably, a sequence for optimization of initiation of translation, located 5 to the coding sequence, is also present. Examples of transcription terminator/polyadenylation signals include those derived from SV40, as described in Sambrook et al., supra, as well as a bovine growth hormone terminator sequence.
Enhancer elements may also be used herein to increase expression levels of the mammalian constructs.
Examples include the SV40 early gene enhancer, as described in Dijkema et al., EMBO J. (1985) 4:761, the enhancer/promoter derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus, as described in Gorman et al., Proc. Natl. Acad. Sci. USA (1982b) 79:6777 and elements derived from human CMV, as described in Boshart et al., Cell (1985) 41:521, such as elements included in the CMV intron A sequence.
Furthermore, plasmids can be constructed which include a chimeric antigen-coding gene sequences, encoding, e.g., multiple antigens/epitopes of interest, for example derived from a single or from more than one viral isolate.
Typically the antigen coding sequences precede or follow the synthetic coding sequences and the chimeric transcription unit will have a single open reading frame encoding both the antigen of interest and the synthetic Gag coding sequences. Alternatively, multi-cistronic cassettes (e.g., bi-cistronic cassettes) can be constructed allowing expression of multiple antigens from a single mRNA using the EMCV IRES, or the like. Lastly, antigens can be encoded on separate transcripts from independent promoters on a single plasmid or other vector.
Once complete, the constructs are used for nucleic acid immunization or the like using standard gene delivery protocols. Methods for gene delivery are known in the art. See, e.g., U.S. Patent Nos. 5,399,346, 5,580,859, 5,589,466. Genes can be delivered either directly to the vertebrate subject or, alternatively, delivered ex vivo, to cells derived from the subject and the cells reimplanted in the subject.
A number of viral based systems have been developed for gene transfer into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. Selected sequences can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to cells of the subject either in vivo or ex vivo. A number of retroviral systems have been described (U.S. Patent No. 5,219,740;

Miller and Rosman, BioTechniques (1989) 7:980-990;

Miller, A.D., Human Gene Therapy (1990) 1:5-14; Scarpa.et al., Virology (1991) 180:849-852; Burns et al., Proc.

Natl. Acad. Sci. USA (1993) 90:8033-8037; and Boris- .
Lawrie and Temin, Cur. Opin. Genet. Develop. (1993) 3:102-109.
A number of adenovirus vectors have also been described. Unlike retroviruses which integrate into the host genome, adenoviruses persist extrachromosomally thus minimizing the risks associated with insertional mutagenesis (Haj-Ahmad and Graham, J. Virol. (1986) 57:267-274; Bett et al., J. Virol. (1993) .E2:5911-5921;

Mittereder et al., Human Gene Therapy (1994) 5:717-729;

Seth et al., J. Virol. (1994) 68:933-940; Barr et al., Gene Therapy (1994) 1:51-58; Berkner, K.L. BioTechniques (1988) 6:616-629; and Rich et al., Human Gene Therapy (1993) 1:461-476).
Additionally, various adeno-associated virus (AAV) vector systems have been developed for gene delivery.

AAV vectors can be readily constructed using techniques well known in the art. See, e.g., U.S. Patent Nos.
5,173,414 and 5,139,941; International Publication Nos.
WO 92/01070 (published 23 January 1992) and WO 93/03769 (published 4 March 1993); Lebkowski et al., Molec. Cell.
Biol. (1988) a:3988-3996; Vincent et al., Vaccines 90 (1990) (Cold Spring Harbor Laboratory Press); Carter, B.J. Current Opinion in Biotechnology (1992) 3:533-539;
Muzyczka, N. Current Topics in Microbiol. and Immunol.
(1992) 158:97-129; Kotin, R.M. Human Gene Therapy (1994) 5:793-801; Shelling and Smith, Gene Therapy (1994) 1:165-169; and Zhou et al., J. Exp. Med. (1994) 179:1867-1875.
Another vector system useful for delivering the polynucleotides of the present invention is the enterically administered recombinant poxvirus vaccines described by Small, Jr., P.A., et al. (U.S. Patent No.
5,676,950, issued October 14, 1997).
Additional viral vectors which will find use for delivering the nucleic acid molecules encoding the antigens of interest include those derived from the pox family of viruses, including vaccinia virus and avian poxvirus. By way of example, vaccinia virus recombinants expressing the genes can be constructed as follows. The DNA encoding the particular synthetic Gag/antigen coding sequence is first inserted into an appropriate vector so that it is adjacent to a vaccinia promoter and flanking vaccinia DNA sequences, such as the sequence encoding thymidine kinase (TK). This vector is then used to transfect cells which are simultaneously infected with vaccinia. Homologous recombination serves to insert the vaccinia promoter plus the gene encoding the coding sequences of interest into the viral genome. The resulting TK recombinant can be selected by culturing the cells in the presence of 5-bromodeoxyuridine and picking viral plaques resistant thereto.
Alternatively, avipoxviruses, such as the fowlpox and canarypox viruses, can also be used to deliver the genes. Recombinant avipox viruses, expressing immunogens from mammalian pathogens, are known to confer protective immunity when administered to non-avian species. The use of an avipox vector is particularly desirable in human and other mammalian species since members of the avipox genus can only productively replicate in susceptible avian species and therefore are not infective in mammalian cells. Methods for producing recombinant avipoxviruses are known in the art and employ genetic recombination, as described above with respect to the production of vaccinia viruses. See, e.g., WO 91/12882;
WO 89/03429; and WO 92/03545.
Molecular conjugate vectors, such as the adenovirus chimeric vectors described in Michael et al., J. Biol.
Chem. (1993) 268:6866-6869.and Wagner et al., Proc. Natl.
Acad. Sci. USA (1992) 89:6099-6103, can also be used for gene delivery.
Members of the Alphavirus genus, such as, but not limited to, vectors derived from the Sindbis, Semliki Forest, and Venezuelan Equine Encephalitis viruses, will also find use as viral vectors for delivering the polynucleotides of the present invention (for example, a synthetic Gag- or Env-polypeptide encoding expression cassette as described in Example 14 below). For a description of Sindbis-virus derived vectors useful for the practice of the instant methods, see, Dubensky et al., J. Virol. (1996) 70:508-519; and International Publication Nos. WO 95/07995 and WO 96/17072; as well as, Dubensky, Jr., T.W., et al., U.S. Patent No. 5,843,723, issued December 1, 1998, and Dubensky, Jr., T.W., U.S.
Patent No. 5,789,245, issued August 4, 1998.
A vaccinia based infection/transfection system can be conveniently used to provide for inducible, transient expression of the coding sequences of interest (for example, a synthetic Gag/HCV-core expression cassette) in a host cell. In this system, cells are first infected in vitro with a vaccinia virus recombinant that encodes the bacteriophage T7 RNA polymerase. This polymerase displays exquisite specificity in that it only transcribes templates bearing T7 promoters. Following infection, cells are transfected with the polynucleotide of interest, driven by a T7 promoter. The polymerase expressed in the cytoplasm from the vaccinia virus recombinant transcribes the transfected DNA into RNA
which is then translated into protein by the host translational machinery. The method provides.for high level, transient, cytoplasmic production of large quantities of RNA and its translation product. See, e.g., Elroy-Stein and Moss, Proc. Natl. Acad. Sci. USA
(1990) 87:6743-6747; Fuerst et al., Proc. Natl. Acad.
Sci. USA (1986) Q2:8122-8126.
As an alternative approach to infection with vaccinia or avipox virus recombinants, or to the delivery of genes using other viral vectors, an amplification system can be used that will lead to high level expression following introduction into host cells.
Specifically, a T7 RNA polymerase promoter preceding the coding region for T7 RNA polymerase can be engineered.
Translation of RNA derived from this template will generate T7 RNA polymerase which in turn will transcribe more template. Concomitantly, there will be a cDNA whose expression is under the control of the T7 promoter.
Thus, some of the T7 RNA polymerase generated from -translation of the amplification template RNA will lead to transcription of the desired gene. Because some T7 RNA polymerase is required to initiate the amplification, T7 RNA polymerase can be introduced into cells along with the template(s) to prime the transcription reaction. The polymerase can be introduced as a protein or on a plasmid encoding the RNA polymerase. For a further discussion of T7 systems and their use for transforming cells, see, e.g., International Publication No. WO 94/26911; Studier and Moffatt, J. Mol. Biol. (1986) 189:113-130; Deng and Wolff, Gene (1994) 143:245-249; Gao et al., Biochem.
Biophys. Res. Commun. (1994) 200:1201-1206; Gao and Huang, Nbc. Acids Res. (1993) 21:2867-2872; Chen et al., NUc. Acids Res. (1994) 22:2114-2120; and U.S. Patent No.
5,135,855.
The synthetic expression cassette of interest can also be delivered without a. viral vector. For example, the synthetic expression cassette can be packaged as DNA
or RNA in liposomes prior tp delivery to the subject or to cells derived therefrom. Lipid encapsulation is generally accomplished using liposomes which are able to stably bind or entrap and retain nucleic acid. The ratio of condensed DNA to lipid preparation can vary but will generally be around 1:1 (mg DNA:micromoles lipid), or more of lipid. For a review of the use of liposomes as carriers for delivery of nucleic acids, see, Hug and Sleight, Biochim. Biophys. Acta. (1991) 1097:1-17;
Straubinger et al., in Methods of Enzymology (1983), Vol. 101, pp. 512-527.
Liposomal preparations for use in the present invention include cationic (positively charged), anionic (negatively charged) and neutral preparations, with cationic liposomes particularly preferred. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Feigner et al., Proc. Natl.
Acad. Sci. USA (1987) 84:7413-7416); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA (1989) 86:6077-6081); and purified transcription factors (Debs et al., J. Biol.
Chem. (1990) 265:10189-10192), in functional form.
Cationic liposomes are readily available. For example, N(1-2,3-dioleyloxy)propyll-N,N,N-triethyl-ammonium (DOTMA) liposomes are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, NY.
(See, also, Feigner et al., Proc. Natl. Acad. Sci. USA
(1987) 84:7413-7416). Other commercially available lipids include (DDAB/DOPE) and DOTAP/DOPE (Boerhinger).
Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g., Szoka et al., Proc. Natl. Acad. Sci. USA
(1978) 75:4194-4198; PCT Publication No. WO 90/11092 for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes.
Similarly, anionic and neutral liposomes are. readily available, such as, from Avanti Polar Lipids (Birmingham, AL), or can be easily prepared using readily available materials. Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphoshatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios.
Methods for making liposomes using these materials are well known in the art.The liposomes can comprise multilammelar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs). The various liposome-nucleic acid complexes are prepared using methods known in the art. See, e.g., Straubinger et al., in METHODS OF

IMMUNOLOGY (1983), Vol. 101, pp. 512-527; Szoka et al., Proc. Nat/. Acad. Sci. USA (1978) 75:4194-4198;
Papahadjopoulos et al., Biochim. Biophys. Acta (1975) 394:483; Wilson et al., Cell (1979) 17:77); Deamer and Bangham, Biochim. Biophys. Acta (1976) 443:629; Ostro et al., Biochem. Biophys. Res. Commun. (1977) 76:836; Fraley et al., Proc. Natl. Acad. Sci. USA (1979) 76:3348); Enoch and Strittmatter, Proc. Natl. Acad. Sci. USA (1979) 76:145); Fraley et al., J. Biol. Chem. (1980) 255:10431;
Szoka and Papahadjopoulos, Proc. Natl. Acad. Sci. USA
(1978) 75:145; and Schaefer-Ridder et al., Science (1982) 215:166.
The DNA and/or protein antigen(s) can also be delivered in cochleate lipid compositions similar to those described by Papahadjopoulos et al., Biochem.
Biophys. Acta. (1975) 394:483-491. See, also, U.S.
Patent Nos. 4,663,161 and 4,871,488.
The synthetic expression cassette of interest (e.g., any.of the synthetic expression cassettes described in ExaMple 1) may also be encapsulated, adsorbed to, or associated with, particulate carriers. Such carriers present multiple copies of a selected antigen to the immune system and promote migration, trapping and retention of antigens in local lymph nodes. The particles can be taken up by profession antigen presenting cells such as macrophages and dendritic cells, and/or can enhance antigen presentation through other mechanisms such as stimulation of cytokine release.
Examples of particulate carriers include those derived from polymethyl methacrylate polymers, as well as microparticles derived from poly(lactides) and poly(lactide-co-glycolides), known as PLC. See, e.g., Jeffery et al., Pharm. Res. (1993) 10362-368; McGee JP, et al., J Microencapsul. 14(2):197-210, 1997; O'Hagan DT, et al., Vaccine 11(2):149-54, 1993.
Furthermore, other particulate systems and polymers can be used for the in vivo or ex vivo delivery of the gene of interest. For example, polymers such as polylysine, polyarginine, polyornithine, spermine, spermidine, as well as conjugates of these molecules, are useful for transferring a nucleic acid of interest.
Similarly, DEAE dextran-mediated transfection, calcium phosphate precipitation or precipitation using other insoluble inorganic salts, such as strontium phosphate, aluminum silicates including bentonite and kaolin, chromic oxide, magnesium silicate, talc, and the like, will find use with the present methods. See, e.g., Feigner, P.L., Advanced Drug Delivery Reviews (1990) 5:163-187, for a review of delivery systems useful for gene transfer. Peptoids (Zuckerman, R.N., et al., U.S.
Patent No. 5,831,005, issued November 3, 1998) may also be used for delivery of a construct of the present invention.
Additionally, biolistic delivery systems employing particulate carriers such as gold and tungsten, are especially useful for delivering synthetic expression cassettes of the present invention. The particles are coated with the synthetic expression cassette(s) to be delivered and accelerated to high velocity, generally under a reduced atmosphere, using a gun powder discharge from a "gene gun." For a description of such techniques, and apparatuses useful therefore, see, e.g., U.S. Patent Nos. 4,945,050; 5,036,006; 5,100,792; 5,179,022;
5,371,015; and 5,478,744. Also, needle-less injection systems can be used (Davis, H.L., et al, Vaccine 12:1503-1509, 1994; Bioject, Inc., Portland, OR).

. , Recombinant vectors carrying a synthetic expression cassette of the present invention are formulated into compositions for delivery to the vertebrate subject.
These compositions may either be prophylactic (to prevent infection) or therapeutic (to treat disease after infection). The compositions will comprise a "therapeutically effective amount" of the gene of interest such that an amount of the antigen can be produced in vivo so that an immune response is generated in the individual to which it is administered. The exact amount necessary will vary depending on the subject being treated; the age and general condition of the subject to be treated; the capacity of the subject's immune system to synthesize antibodies; the degree of protection desired; the severity of the condition being treated; the particular antigen selected and its mode of administration,. among other factors. An appropriate, effective amount can be readily determined by one of skill in the art. Thus, a "therapeutically effectivv amount" will fall in a relatively broad range that can be determined through routine trials.
The compositions will generally include one or more "pharmaceutically acceptable excipients or vehicles" such as water, saline, glycerol, polyethyleneglycol, hyaluronic acid, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH
buffering substances, surfactants and the like, may be present in such vehicles. Certain facilitators of immunogenicity or of nucleic acid uptake and/or expression can also be included in the compositions or coadministered, such as, but not limited to, bupivacaine, cardiotoxin and sucrose.
Once formulated, the compositions of the invention can be administered directly to the subject (e.g., as described above) or, alternatively, delivered ex vivo, to cells derived from the subject, using methods such as those described above. For example, methods for the ex vivo delivery and reimplantation of transformed cells into a subject are known in the art and can include, e.g., dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, lipofectamine and LT-1 mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) (with or without the corresponding antigen) in liposomes, and direct microinjection of the DNA into nuclei.
Direct delivery of synthetic expression cassette compositions in vivo will generally be accomplished with or without viral vectors, as described above, by injection using either a conventional syringe, needless devices, such as Bioject or a gene gun, such.as the Accell gene delivery system (PowderJect Technologies, Inc., Oxford, England). The constructs can be delivered (e.g., injected) either subcutaneously, epidermally, intradermally, intramuscularly, intravenous, intramucosally (such as nasally, rectally and vaginally), intraperitoneally or orally. Delivery of DNA into cells of the epidermis is particularly preferred as this mode of administration provides access to skin-associated lymphoid cells and provides for a transient presence of DNA in the recipient. Other modes of administration include oral ingestion and pulmonary administration, suppositories, needle-less injection, transcutaneous and transdermal applications. Dosage treatment may be a single dose schedule or a multiple dose schedule.

2 . 3 . 2 Ex VIVO DELIVERY OF THE SYNTHETIC EXPRESSION
CASSETTES OF THE PRESENT INVENTION
In one embodiment, T cells, and related cell types (including but not limited to antigen presenting cells, such as, macrophage, monocytes, lymphoid cells, dendritic cells, B-cells, T-cells, stem cells, and progenitor cells thereof), can be used for ex vivo delivery of the synthetic expression cassettes of the present invention.
T cells can be isolated from peripheral blood lymphocytes (PBLs) by a variety of procedures known to those skilled in the art. For example, T cell populations can be "enriched" from a population of PBLs through the removal of accessory and B cells. In particular, T cell enrichment can be accomplished by the elimination of non-T cells using anti-MHC class II monoclonal antibodies.
Similarly, other antibodies can be used to deplete specific populations of non-T cells. .For example, anti-Ig antibody molecules can be used to deplete B cells and anti-MacI antibody molecules can be used to deplete macrophages.
T cells can be further fractionated into a number of different subpopulations by techniques known to those skilled in the art. Two major subpopulations can be isolated based on their differential expression of the cell surface markers CD4 and CD8. For example, following the enrichment of T cells as described above, CD4* cells can be enriched using antibodies specific for CD4 (see Coligan et al., supra). The antibodies may be coupled to a solid support such as magnetic beads. Conversely, C08+
cells can be enriched through the use of antibodies specific for CD4 (to remove CD4* cells), or can be isolated by the use of CD8 antibodies coupled to a solid support. CD4 lymphocytes from HIV-1 infected patients can be expanded ex vivo, before or after transduction as described by Wilson et. al. (1995) J. Infect. Dis. 172:88.
Following purification of T cells, a variety of methods of genetic modification known to those skilled in the art can be performed using non-viral or viral-based gene transfer vectors constructed as described herein.
For example, one such approach involves transduction of the purified T cell population with vector-containing supernatant of cultures derived from vector producing cells. A second approach involves co-cultivation of an irradiated monolayer of vector-producing cells with the purified T cells. A third approach involves a similar co-cultivation approach; however, the purified T cells are pre-stimulated with various cytokines and cultured 48 hours prior to the co-c4tivation with the irradiated vector producing cells. Pre-stimulation prior to such transduction increases effective gene transfer (Nolta et al. (1992) Exp. Hemato/.=20:1065). Stimulation of these cultures to proliferate also provides increased cell populations for re-infusion into the patient. Subsequent to co-cultivation, T cells are collected from the vector producing cell monolayer, expanded, and frozen in liquid nitrogen.
Gene transfer vectors, containing one or more synthetic expression cassette of the present invention (associated with appropriate control elements for delivery to the isolated T cells) can be assembled using known methods.
Selectable markers can also be used in the construction of gene transfer vectors. For example, a marker can be used which imparts to a mammalian cell transduced with the gene transfer vector resistance to a = W000/39302 PCT/US99/31245 cytotoxic agent. The cytotoxic agent can be, but is not limited to, neomycin, aminoglycoside, tetracycline, chloramphenicol, sulfonamide, actinomycin, netropsin, distamycin A, anthracycline, or pyrazinamide. For example, neomycin phosphotransferase II imparts resistance to the neomycin analogue geneticin (G418).
The T cells can also be maintained in a medium containing at least one type of growth factor prior to being selected. A variety of growth factors are known in the art which sustain the growth of a particular cell type. Examples of such growth factors are cytokine mitogens such as rIL-2, IL-10, IL-12, and IL-15, which promote growth and activation of lymphocytes. Certain types of cells are stimulated by other growth factors such as hormones, including human chorionic gonadotropin (hCG) and human growth hormone. The selection of an appropriate growth factor for a particular cell population is readily accomplished by one of skill in the art.
For example, white blood cells such as differentiated progenitor and stem cells are stimulated by a variety of growth factors. More particularly, IL-3, IL-4, IL-5, IL-6, IL-9, GM-CSF, M-CSF, and G-CSF, produced by activated TH and activated macrophages, stimulate myeloid stem cells, which then differentiate into pluripotent stem cells, granulocyte-monocyte progenitors, eosinophil progenitors, basophil progenitors, megakaryocytes, and erythroid progenitors.
Differentiation is modulated by growth factors such as GM-CSF, IL-3, IL-6, IL-11, and EPO.
Pluripotent stem cells then differentiate into lymphoid stem cells, bone marrow stromal cells, T cell progenitors, B cell progenitors, thymocytes, TH Cells, T, cells, and B cells. This differentiation is modulated by W000/39302 PCT/US99/31:g5 growth factors such as IL-3, IL-4, IL-6, IL-7, GM-CSF, M-CSF, G-CSF, IL-2, and IL-5.
Granulocyte-monocyte progenitors differentiate to monocytes, macrophages, and neutrophils. Such differentiation is modulated by the growth factors GM-CSF, M-CSF, and IL-8. Eosinophil progenitors differentiate into eosinophils. This process is modulated by GM-CSF and IL-5.
The differentiation of basophil progenitors into mast cells and basophils is modulated by GM-CSF, IL-4, and IL-9. Megakaryocytes produce platelets in response to GM-CSF, EPO, and IL-6. Erythroid progenitor cells differentiate into red blood cells in response to EPO.
Thus, during activation by the CD3-binding agent, T
cells can also be contacted with a mitogen, for example a cytokine such as IL-2. In particularly preferred embodiments, the IL-2 is added to the popuLltion of T
cells at a concentration of about 50 to 100 g/ml.
Activation with the CD3-binding agent can be. carried out for 2 to 4 days.
Once suitably activated, the T cells are genetically modified by contacting the same with a suitable gene transfer vector under conditions that allow for transfection of the vectors into the T cells. Genetic modification is carried out when the cell density of the T cell population is between about 0.1 x 10' and 5 x 106, preferably between about 0.5 x 106 and 2 x 106. A number of suitable viral and nonviral-based gene transfer vectors have been described for use herein.
After transduction, transduced cells are selected away from non-transduced cells using known techniques.
For example, if the gene transfer vector used in the transduction includes a selectable marker which confers resistance to a cytotoxic agent, the cells can be contacted with the appropriate cytotoxic agent, whereby non-transduced cells can be negatively selected away from the transduced cells. If the selectable marker is a cell surface marker, the cells can be contacted with a binding agent specific for the particular cell surface marker, whereby the transduced cells can be positively selected away from the population. The selection step can also entail fluorescence-activated cell sorting (FACS) techniques, such as where FACS is used to select cells from the population containing a particular surface marker, or the selection step can entail the use of magnetically responsive particles as retrievable supports for target cell capture and/or background removal.
More particularly, positive selection of the transduced cells can be performed using a FACS cell sorter (e.g. a FACSVantage Cell Sorter, Becton Dickinson Immunocytometry Systems, San Jose, CA) to sort and collect transduced cells expressing a selectable cell surface marker. Following transduction, the cells are stained with fluorescent-labeled antibody molecules directed against the particular cell surface marker. The amount of bound antibody on each cell can be measured by passing droplets containing the cells through the cell sorter. By imparting an electromagnetic charge to droplets containing the stained cells, the transduced cells can be separated from other cells. The positively selected cells are then harvested in sterile collection vessels. These cell sorting procedures are described in detail, for example, in the FACSVantage' Training Manual, with particular reference to sections 3-11 to 3-28 and 10-1 to 10-17.
Positive selection of the transduced cells can also be performed using magnetic separation of cells based on expression or a particular cell surface marker. In such separation techniques, cells to be positively selected are first contacted with specific binding agent (e.g., an antibody or reagent the interacts specifically with the cell surface marker). The cells are then contacted with retrievable particles (e.g., magnetically responsive particles) which are coupled with a reagent that binds the specific binding agent (that has bound to the positive cells). The cell-binding agent-particle complex can then be physically separated from non-labeled cells, for example using a magnetic field. When using magnetically responsive particles, the labeled cells can be retained in a container using a magnetic filed while the negative cells are removed. These and similar separation procedures are known to those of ordinary skill in the art.
Expression of the vector in the selected transduced cells can by assessed by a number of assays known. to those skilled in the art. For example, Western blot or Northern analysis can be employed depending on the nature of the inserted nucleotide sequence of interest. . Once expression has been established and the transformed T
cells have been tested for the presence of the selected synthetic expression cassette, they are ready for infusion into a patient via the peripheral blood stream.
The invention includes a kit for genetic modification of an ex vivo population of primary mammalian cells. The kit typically contains a gene transfer vector coding for at least one selectable marker and at least one synthetic expression cassette contained in one or more containers, ancillary reagents or hardware, and instructions for use of the kit.

EXPERIMENTAL
Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.
Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

Example 1 Generation of Synthetic Gag and Env Expression Cassettes A. Modification of HIV-1 Gag, Gag-Protease, Gag-reverse transcriptase and Gag-Dolymerase Nucleic Acid Coding Sequences The Gag (SEQ ID NO: 1), Gag-protease (SEQ ID NO:2), Gag-polymerase (SQ ID NO:3), and Gag-reverse transcriptase (SEQ ID NO:77) coding sequences were selected from the HIV-1SF2 strain (Sanchez-Pescador, R., et al., Science 227(4686): 484-492, 1985; Luciw, P.A., et al. U.S. Patent No. 5,156,949, issued October 20, 1992;
Luciw, P.A., et al., U.S. Patent No. 5,688,688, November 18, 1997). These sequences were manipulated to maximize expression of their gene products.
First, the HIV-1 codon usage pattern was modified so that the resulting nucleic acid coding sequence was comparable to codon usage found in highly expressed human genes. The HIV codon usage reflects a high content of the nucleotides A or T of the codon-triplet. The effect of the HIV-1 codon usage is a high AT content in the DNA
sequence that results in a high AU content in the RNA and in a decreased translation ability and instability of the mRNA. In comparison, highly expressed human codons prefer the nucleotides G or C. The Gag-encoding sequences were modified to be comparable to codon usage found in highly expressed human genes.
Figure 11 presents a comparison of the percent A-T
content for the cDNAs of stable versus unstable RNAs (comparison window size = 50). Human IFNy mRNA is known to (i) he unstable, (ii) have a short half-life, and (iii) have a high A-U content. Human GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) mRNA is known to (i) be a stable RNA, and (i) have a low A-U content.
In Figure 11, the percent A-T content of these two sequences are compared to the percent A-T content of native HIV-1SF2 Gag cDNA and to the synthetic Gag cDNA
sequence of the present invention. The top two panels of the figure show the percent A-T content over the length of the sequences for IFNy and native Gas. The bottom two panels of the figure show the percent A-T content over the length of the sequences for GAPDH and the synthetic Gag. Experiments performed in support of the present invention showed that the synthetic Gag sequences were capable of higher level of protein production (see the Examples) than the native Gag sequences. The data in Figure 11 suggest that one reason for this increased production may be increased stability of the mRNA
corresponding to the synthetic Gag coding sequences versus the mRNA corresponding to the native Gag coding sequences.
Second, there are inhibitory (or instability) elements (INS) located within the coding sequences of the Gag and Gag-protease coding sequences (Schneider R, et al., J Viro1. 71(7):4892-4903, 1997). RRE is a secondary RNA structure that interacts with the HIV encoded Rev-protein to overcome the expression down-regulating effects of the INS. To overcome the requirement for post-transcriptional activating mechanisms of RRE and Rev, and to enhance independent expression of the Gag polypeptide, the INS were inactivated by introducing multiple point mutations that did not alter the reading frame of the encoded proteins. Figure 1 shows the original SF2 Gag sequence, the location of the INS
sequences, and the modifications made to the INS
sequences to reduce their effects.
For the Gag-protease sequence (wild type, SEQ ID
NO:2; synthetic, SEQ ID NOs:5, 78 and 79), the changes in codon usage were restricted to the regions up to the -1 frameshift and starting again at the end of the Gag reading frame (Figure 2; the region indicated in lower case letters in Figure 2 is the unmodified region).
Further, inhibitory (or instability) elements (INS) located within the coding sequences of the Gag-protease polypeptide coding sequence were altered as well (indicated in Figure 2). The synthetic coding sequences were assembled by the Midland Certified Reagent Company (Midland, Texas).
Modification of the Gag-polymerase sequences (wild type, SEQ ID NO:3; synthetic, SEQ ID NO:6) and Gag-reverse transcriptase sequences (SEQ ID NOs:80 through 84) include similar modifications as described for Gag-protease in order to preserve the frameshift region.
Locations of the inactivation sites and changes to the sequence to alter the inactivation sites are presented in Figure 12 for the native HIV- 1sn Gag-polymerase sequence.
In one embodiment of the invention, the full length polymerase coding region of the Gag-polymerase sequence is included with the synthetic Gag sequences in order to increase the number of epitopes for virus-like particles expressed by the synthetic, optimized Gag expression cassette. Because synthetic HIV-1 Gag-polymerase expresses the potentially deleterious functional enzymes reverse transcriptase (RT) and integrase (INT) (in addition to the structural proteins and protease), it is important to inactivate RT and INT functions. Several in-frame deletions in the RT and INT reading frame can be made to achieve catalytic nonfunctional enzymes with respect to their RT and INT activity. (Jay. A. Levy (Editor) (1995) The Retroviridae, Plenum Press, New York.
ISBN 0-306-45033X. Pages 215-20; Grimison, B. and Laurence, J. (1995), Journal Of Acquired Immune Deficiency Syndromes and Human Retrovirology 9(1):58-68;
Wakefield, J. K.,et al., (1992) Journal Of Virology 66(11):6806-6812; Esnouf, R.,et al., (1995) Nature Structural Biology 2(4):303-308; Maignan, S., et al., (1998) Journal Of Molecular Biology 282(2):359-368; Katz, R. A. and Skalka, A. M. (1994) Annual Review Of Biochemistry 73 (1994); Jacobo-Molina, A., et al., (1993) Proceedings Of the National Academy Of Sciences Of the United States Of America 90(13):6320-6324; Hickman, A.
B., et al., (1994) Journal Of Biological Chemistry 269(46):29279-29287; Goldgur, Y., et al., (1998) Proceedings Of the National Academy Of Sciences Of the United States Of America 95(16):9150-9154; Goette, M., et al., (1998) Journal Of Biological Chemistry 273(17):10139-10146; Gorton, J. L., et al., (1998) Journal of Virology 72(6):5046-5055; Engelman, A., et al., (1997) Journal Of Virology 71(5):3507-3514; Dyda, F., et al., Science 266(5193):I981-1986; Davies, J. F., et al., (1991) Science 252(5002):88-95; Bujacz, G., et al., (1996) Febs Letters 398(2-3):175-178; Beard, W. A., et al., (1996) Journal Of Biological Chemistry 271(21):12213-12220; Kohlstaedt, L. A., et al., (1992) Science 256(5065):1783-1790; Krug, M. S. and Berger, S.
L. (1991) Biochemistry 30(44):10614-10623; Mazumder, A., et al., (1996) Molecular Pharmacology 49(4):621-628;
Palaniappan, C., et al., (1997) Journal Of Biological Chemistry 272(17):11157-11164; Rodgers, D. W., et al., (1995) Proceedings Of the National Academy Of Sciences Of the United States Of America 92(4):1222-1226; Sheng, N.
and Dennis, D. (1993) Biochemistry 32(18):4938-4942;
Spence, R. A., et al., (1995) Science 267(5200):988-993.1 Furthermore selected B- and/or T-cell epitopes can be added to the Gag-polymerase constructs within the deletions of the RT- and INT-coding sequence to replace and augment any epitopes deleted by the functional modifications of RT and INT. Alternately, selected B-and T-cell epitopes (including CTL epitopes) from RT and INT can be included in a minimal VLP formed by expression of the synthetic Gag or synthetic GagProt cassette, described above. (For descriptions of known HIV B- and T-cell epitopes see, HIV Molecular Immunology Database CTL
Search Interface; Los Alamos Sequence Compendia, 1987-1997).

The resulting modified coding sequences are presented as a synthetic Gag expression cassette (SEQ ID
NO:4), a synthetic Gag-protease expression cassette (SEQ
ID NOs:5, 78 and 79), and a synthetic Gag-polymerase expression cassette (SEQ ID NO:6). Synthetic expression cassettes containing codon modifications in the reverse transcriptase region are shown in SEQ ID NOs:80 through 84. An alignment of selected sequences is presented in Figure 7. A common region (Gag-common; SEQ ID NO:9) extends from position 1 to position 1262.
The synthetic DNA fragments for Gag and Gag-protease were cloned into the following expression vectors:

pCMVKm2, for transient expression assays and DNA
immunization studies, the pCMVKm2 vector was derived from pCMV6a (Chapman et al., Nuc. Acids Res. (1991) 19:3979-3986) and comprises a kanamycin selectable marker, a Co1E1 origin of replication, a CMV promoter enhancer and Intron A, followed by an insertion site for the synthetic sequences described below followed by a polyadenylation signal derived from bovine growth hormone -- the pCMVKm2 vector differs from the pCMV-link vector only in that a polylinker site was inserted into pCMVKm2 to generate pCMV-link (Figure 14, polylinker at positions 1646 to 1697); pESN2dhfr (Figure 13A) and pCMVPLEdhfr (also known as pCMVIII as shown in Figure 13B), for expression in Chinese Hamster Ovary (CHO) cells; and, pAcC13, a shuttle vector for use in the Baculovirus expression system (pAcC13, was derived from pAcC12 which was described by Munemitsu S., et al., Mol Cell Biol. 10(11):5977-5982, 1990).
A restriction map for vector pCMV-link is presented in Figure 14. In the figure, the CMV promoter (CMV IS
ENH/PRO), bovine growth hormone terminator (BGH pA), kanamycin selectable marker (kan), and a Co1E1 origin of replication (Co1E1 on) are indicated. A polycloning site is also indicated in the figure following the CMV
promoter sequences.
A restriction map for vector pESN2dhfr is presented in Figure 13A. In the figure, the CMV promoter (pCMV, hCMVIE), bovine growth hormone terminator (BGHpA), SV40 origin of replication (SV40ori), neomycin selectable marker (Neo), 5V40 polyA (SV40pA), Adenovirus 2 late promoter (Ad2VLP), and the murine dhfr gene (mu dhfr) are indicated. A polycloning site is also indicated in the figure following the CMV promoter sequences.

Briefly, construction of pCMVPLEdhfr (pCMVIII) was as follows. To construct a DHFR cassette, the EMCV IRES
(internal ribosome entry site) leader was PCR-amplified from pCite-4a+ (Novagen, Inc., Milwaukee, WI) and inserted into pET-23d (Novagen, Inc., Milwaukee, WI) as an Xba-Nco fragment to give pET-EMCV. The dhfr gene was PCR-amplified from pESN2dhfr to give a product with a Gly-Gly-Gly-Ser spacer in place of the translation stop codon and inserted as an Nco-BamH1 fragment to give pET-E-DHFR. Next, the attenuated neo gene was PCR amplified from a pSV2Neo (Clontech, Palo Alto, CA) derivative and inserted into the unique BamH1 site of pET-E-DHFR to give pET-E-DHFR/Neoow. Then, the bovine growth hormone terminator from pCDNA3 (Invitrogen, Inc., Carlsbad, CA) was inserted downstream of the neo gene to give pET-E-DHFR/NeoowBGHt. The EMCV-dhfr/neo selectable marker cassette fragment was prepared by cleavage of pET-E- =
DHFR/Neo0,03GHt. The CMV enhancer/promoter plus Intron A
was transferred from pCMV6a (Chapman et al., Nuc. Acids =
Res. (1991) 19:3979-3986) as a HindIII-Sall fragment into pUC19 (New England Biolabs, Inc., Beverly, MA). The vector backbone of pUC19 was deleted from the Ndel to the Sapl sites. The above described DHFR cassette was added to the construct such that the EMCV IRES followed the CMV
promoter to produce the final construct. The vector also contained an amp' gene and an SV40 origin of replication.
Selected pCMVKm2 vectors containing the synthetic expression cassettes have been designated as follows:
pCMVKm2.GagMod.SF2, pCMVKm2.GagprotMod.SF2, and pCMVKm2.GagpolMod.SF2, pCMVKm2.GagprotMod.SF2.GP1 (SEQ ID
NO:78) and pCMVKm2.GagprotMod.SF2.GP2 (SEQ ID NO:79).
Other exemplary Gag-encoding expressing cassettes are shown in the Figures and as Sequence Listings.

B. Modification of HIV-1 Gag/Hepatitis C Core Chimeric Protein Nucleic Acid Coding Seouences Generation of Synthetic Expression Cassettes To facilitate the ligation of the Gag and HCV core coding sequences, PCR amplification was employed. The synthetic p55Gag expression cassette was used as a PCR
template with the following primers: GAG5(SEQ ID NO:11) and P55-SAL3 (SEQ ID NO:12). The PCR amplification was conducted at 55 C for 25 cycles using Stratagene's Pfu polymerase. The resulting PCR product was rendered free of nucleotides and primers using the Promega PCR clean-up kit and then subjected to EcoRI and Sall digestions. For HCV core coding sequences, the following primers were used with an HCV template (Houghton, M., et al., U.S.
Patent No. 5,714,596, issued February 3, 1998; Houghton, M., et al., U.S. Patent No. 5,712,088, issued January 27, 1998; Houghton, M., et al., U.S. Patent No. 5,683,864, issued November 4, 1997; Weiner, A.J., et al., U.s.
Patent No: 5,728,520, issued March 17, 1998; Weiner, A.J., et al., U.S. Patent No. 5,766,845, issued" June 16, 1998; Weiner, A.J., et al., U.S. Patent No. 5,670,152, issued September 23, 1997): CORESAL 5 (SEQ ID NO:13) and 173CORE(SEQ ID NO:14) using the conditions outlined above. The purified product was digested with Sail and BamHI restriction enzymes. The digested Gag and HCV core PCR products were ligated into the pCMVKm2 vector digested with EcoRI and BamHI. Ligation of the PCR
products at the Sail site resulted in a direct fusion of the final amino acid of p55Gag to the second amino acid of HCV core, serine. Amino acid 173 of core is a serine and is followed immediately by a TAG termination codon.
The sequence of the fusion clone was confirmed. The pCMVKm2 vector containing the synthetic expression cassette was designated as pCMVKm2.GagModHCVcore.
The EcoRI-BamHI fragment of p55Gag-core 173 was also cloned into EcoRI-BamHI-digested pAcC13 for baculovirus expression. Western blots confirmed expression and sucrose gradient sedimentation along with electron microscopy confirmed particle formation. To generate the above clone but containing the synthetic Gag sequences (instead of wild-type), the following steps were performed: pCMVKm2-modified p55Gag was used as template for PCR amplification with MS65 (SEQ ID NO:15) and MS66(SEQ ID NO:16) primers. The region amplified corresponds to the BspHI and Sall sites at the C-terminus of synthetic Gag sequence. The amplification product was digested with BspHI and Sail and ligated to SalI/BamHI
digested pCMV-link along with the Sal/BspHI fragment from pCMV-Km-p55modGag , representing the amino terminal end . of modified Gag, and the SalIMamHI fragment from pCMV-p55Gag-core173. Thereafter, a T4-blunted-SalI
partial/BamHI fragment was liga.ted into pAcC4-SmaI/BamHI
to generate pAcC4-p55GagMod-core173 (containing the synthetic sequence presented as SEQ ID NO:7).

C. Defining of the Major Homology Region (MHR) of HIV-1 p55Gaq The Major Homology Region (MHR) of HIV-1 p55 (Gag) is located in the p24-CA sequence of Gag. It is a conserved stretch of 20 amino acids (SEQ ID NO:19). The position in the wild type Gag protein is from aa 286-305 and spans a region from nucleotides 856-915 in the native HIV- lv, Gag DNA-sequence. The position in the synthetic Gag protein is from aa 288-307 and spans a region from nucleotides 862-921 for the synthetic Gag DNA-sequence.
The nucleotide sequence for the MHR in the synthetic GagMod.SF2 is presented as SEQ ID NO:20. Mutations or deletions in the amino acid sequence of the MHR can severely impair particle production (Borsetti, A., et al., J. Virol. 72(11):9313-9317, 1998; Mammano, F., et al., J Virol 68(8):4927-4936, 1994).
Percent identity to the MHR nucleotide sequence can be determined, for example, using the MacDNAsis program (Hitachi Software Engineering America Limited, South San Francisco, CA), Higgins algorithm, with the following exemplary parameters: gap penalty = 5, no. of top diagonals = 5, fixed gap penalty = 5, K-tuple = 2, window size = 5, and floating gap penalty . 10.

D. Generation of Synthetic Env Expression Cassettes Env coding sequences of the present invention include, but are not limited to, polynucleotide sequences encoding the following HIV-encoded polypeptides: gp160, gp140, and gp120 (see, e.g., U.S. Patent No. 5,792,459 for a description of the HIV- 1õ ("SF2") Env polypeptide). The relationships between these polypeptides is shown schematically in Figure 15 (in the figure: the polypeptides are indicated as lines, the amino and carboxy termini are indicated on the gp160 line; the open circle represents the oligomerization domain; the open square represents a transmembrane spanning domain (TM); and "c" represents the location of a cleavage site, in gp140.mut the "X" indicates that the cleavage site has been mutated such that it no longer functions as a cleavage site). The polypeptide gp160 includes the coding sequences for gp120 and gp41. The polypeptide gp41 is comprised of several domains including an oligomerization domain (OD) and a transmembrane spanning domain (TM). In the native envelope, the oligomerization domain is required for the non-covalent association of three gp41 polypeptides to form a trimeric structure: through non-covalent interactions with the gp41 trimer (and itself), the gp120 polypeptides are also organized in a trimeric structure.
A cleavage site (or cleavage sites) exists approximately between the polypeptide sequences for gp120 and the polypeptide sequences corresponding to gp41. This cleavage site(s) can be mutated to prevent cleavage at the site. The resulting gp140 polypeptide corresponds to a truncated form of gp160 where the transmembrane spanning domain of gp41 has been deleted. This gp140 polypeptide can exist in both monomeric and oligomeric (i.e. trimeric) forms by virtue of the presence of the oligomerization domain in the gp41 moiety. In the situation where the cleavage site has been mutated to prevent cleavage and the transmembrane portion of gp41 has been deleted the resulting polypeptide product is designated "mutated" gp140 (e.g., gp140.mut). As will be apparent to those in the field, the cleavage site can be mutated in a variety of ways. The native amino acid sequence in the SF162 cleavage sites is: APTKAKRRVVQREKR
(SEQ ID NO:21), where KAKRR (SEQ ID NO:22) is termed the "second" site and REKR (SEQ ID NO:23) is the "first site". Exemplary mutations include the following constructs: gp140.mut7.modSF162 which encodes the amino acid sequence APTKAISSVVQSEKS (SEQ ID NO:24) in the cleavage site region; gp140.mut8.modSF162 which encodes the amino acid sequence APTIAISSVWSEKS (SEQ ID NO:25) in the cleavage site region and gp140mut.modSF162 which encodes the amino acid sequence APTKAKRRVVQREKS (SEQ ID
NO:26). Mutations are denoted in bold. The native amino acid sequence in the US4 cleavage sites is:
APTQAKRRVVQREKR (SEQ ID NO: 27), where QAKRR (SEQ ID
NO:28) is termed the "second" site and REKR (SEQ ID

--------NO:23) is the "first site". Exemplary mutations include the following construct: gp140.mut.modUS4 which encodes the amino acid sequence APTQAKRRVVOREKS (SEQ ID NO:29) in the cleavage site region. Mutations are denoted in bold.
E. Modification of HIV-1 Env (Envelope) Nucleic Acid Coding Sequences In one embodiment of the present invention, wild-type Env coding sequences were selected from the HIV-1,õ62 ("SF162") strain (Cheng-Mayer (1989) PNAS USA 86:8575-8579). These SF162 sequences were as follows: gp120, SEQ ID NO:30 (Fig. 16); gp140, SEQ ID NO:31 (Fig. 17);
and gp160, SEQ ID NO:32 (Fig. 18).
In another embodiment of the present invention, wild-type Env coding sequences were selected from the HIV-US4 strain (Mascola, et al. (1994) J. Infect. Dis.
169:48-54). These US4 sequences were as follows: gp120, =
SEQ ID NO:51 (Fig. 38); gp140, SEQ ID NO:52 (Fig. 39);
and gp160, SEQ ID NO:53 (Fig. 40). =
These Env coding sequences were manipulated to maximize expression of their gene products.
First, the wild-type coding region was modified in one or more of the following ways. In one embodiment, sequences encoding hypervariable regions of Env, particularly V1 and/or V2 were deleted. In other embodiments, mutations were introduced into sequences encoding the cleavage site in Env to abrogate the enzymatic cleavage of oligomeric gp140 into gp120 monomers. (See, e.g., Earl et al. (1990) PNAS USA
87:648-652; Earl et al. (1991) J. Virol. 65:31-41). In yet other embodiments, hypervariable region(s) were deleted, N-glycosylation sites were removed and/or cleavage sites mutated.
Second, the HIV-1 codon usage pattern was modified so that the resulting nucleic acid coding sequence was comparable to codon usage found in highly expressed human genes. The HIV codon usage reflects a high content of the nucleotides A or T in the codon-triplet. The effect of the HIV-1 codon usage is a high AT content in the DNA
sequence that results in a decreased translation ability and instability of the mRNA. In comparison, highly expressed human codons prefer the nucleotides G or C.
The Env coding sequences were modified to be comparable to codon usage found in highly expressed human genes.
Figures 22A-22H present comparisons of the percent A-T content for the cDNAs of stable versus unstable RNAs (comparison window size = 50). Human IFNy mRNA is known to (i) be unstable, (ii) have a short half-life, and (iii) have a high A-U content. Human GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) mRNA is known to (i) be a stable RNA, and (i) have a low A-U content.
In Figures 22A-H, the percent A-T content of these two sequences are compared to the percept A-T content of (1) native HIV-1 US4 Env gp160 cDNA, a synthetic US4 Env gp160 cDNA sequence (i.e., having modified codons) of the present invention; and (2) native HIV-1 SF162 Env gp160 cDNA, a synthetic SF162 Env gp160 cDNA sequence (i.e., having modified codons) of the present invention.
Figures 22A-H show the percent A-T content over the length of the sequences for IFNy (Figures 22C and 22G);
native gp160 Env US4 and SF162 (Figures 22A and 22E, respectively); GAPDH (Figures 22D and 22H); and the synthetic gp160 Env for US4 and SF162 (Figures 22B and 22F). Experiments performed in support of the present invention showed that the synthetic Env sequences were capable of higher level of protein production (see the Examples) than the native Env sequences. The data in Figures 22A-}i suggest that one reason for this increased production is increased stability of the mRNA
corresponding to the synthetic Env coding sequences versus the mRNA corresponding to the native Env coding sequences.
To create the synthetic coding sequences of the present invention the gene cassettes were designed to comprise the entire coding sequence of interest.
Synthetic gene cassettes were constructed by oligonucleotide synthesis and PCR amplification to generate gene fragments. Primers were chosen to provide convenient restriction sites for subcloning. The resulting fragments were then ligated to create the entire desired sequence which was then cloned into an appropriate vector. The final synthetic sequences were (i) screened by restriction endonuclease digestion and analysis, (ii) subjected to DNA sequencing in order to confirm that the desired sequence had been obtained and (iii) the identity and integrity of the expressed protein confirmed by SDS-PAGE and Western blotting (See, Examples. The synthetic coding sequences were assembled at Chiron Corp. or by the Midland Certified Reagent Company (Midland, Texas).
Exemplary modified coding sequences are presented as synthetic Env expression cassettes in Table lA and 113.
The following expression cassettes (i) have unique, terminal EcoRI and XbaI cloning sites; (ii) include Kozak sequences to promote optimal translation; (iii) tPA
signal sequences (to direct the ENV polypeptide to the cell membrane, see, e.g., Chapman et al., infra); (iv) open reading frames optimized for expression in mammalian cells; and (v) a translational stop signal codon.

Table 1A: Exemplary Synthetic Env Expression Cassettes (SF162) Expression Cassette Seq Further Information Id gp120 SF162 30 wild-type; Figure 16 gp140 SF162 31 wild type; Figure 17 gp160 SF162 32 wild-type; Figure 18 gp120.modSF162 33 none; Figure 19 gp120.modSF162.delV2 34 deleted V2 loop; Figure 20 gp120.modSF162.delV1/V2 35 deleted V1 and V2; Figure 21 gp140.modSF162 36 none; Figure 23 gp140.modSF162.delV2 37 deleted V2 loop; Figure 24 gp140.modSF162.delV1/v2 38 deleted V1 and V2; Figure 25 gp140.mut.modSF162 39 mutated cleavage site; Fig. 26 gp140.mut.modSF162.delV2 40 deleted V2; mutated cleavage site; Figure 27 gp140.mut.modSF162.delV1/V 41 deleted V1 & V2; mutated = 2 cleavage site; Figure 28 gp140.mut7.modSF162 42 mutated cleavage site; Fig. 29 gp140.mut7.modSF162.delV2 43 mutated cleavage site; deleted V2; Figure 30 gp140.mut7.modSF162.delV1/ 44 mutated cleavage site; deleted V2 V1 and V2; Figure 31 gp140.mut8.modSF162 45 mutated cleavage site; Fig. 32 gp140.mut8.modSF162.delV2 46 mutated cleavage site; deleted V2; Figure 33 gp140.mut8.modsF162.delV1/ 47 mutated cleavage site; deleted V2 V1 and V2; Figure 34 gp160.modSF162 48 none; Figure 35 gp160.modSF162.delV2 49 deleted V2 loop; Figure 3E
gp160.modSF162.delV1/V2 50 deleted V1 & V2; Figure 37 Table 1B:
Exemplary Synthetic Env Expression Cassettes (US4) Expression Cassette Seq Further Information Id gp120 US4 51 wild-type; Figure 38 gp140 US4 52 wild-type; Figure 39 gp160 US4 53 wild-type; Figure 40 gp120.modUS4 54 none; Figure 41 gp120.modUS4.del 128-194 55 deletion in V1 and V2 regions;
Figure 42 gp140.modUS4 56 none; Figure 43 gp140.mut.modUS4 57 mutated cleavage site; Figure gp140TM.modUS4 58 native transmembrane region;
Figure 45 gp140.modUS4.delV1/V2 59 deleted V1 and V2; Figure 46 gp/40.modUS4.delV2 60 deleted Vi; Figure 47 gp140.mut.modUS4.delV1/V2 61 mutated cleavage site; deleted V1 and V2; Figure 48 gpi40.modUS4.del 128-194 62 deletion in V1 and V2 regions;
Figure 49 gp140.mut.modUS4.del 128- 63 mutated cleavage site; deletion 194 in V1 and V2 regions; Figure 50 gp160.modUS4 64 none; Figure 51 gp160.modUS4.delV1 65 deleted Vi; Figure 52 gpi60.modus4.delV2 66 deleted V2; Figure 53 gp160.modUS4.delV1/V2 67 deleted V1 and V2; Figure 54 gp160.modUS4del 128-194 68 deletion in V1 and V2 regions;
Figure 55 Alignments of the sequences presented in the above tables are presented in Figures 66A and 66B.
A common region (Env-common) extends from nucleotide position 1186 to nucleotide position 1329 (SEQ ID NO:69, Fig. 56) relative to the wild-type US4 sequence and from nucleotide position 1117 to position 1260 (SEQ ID NO:79, Fig. 57) relative to the wild-type SF162 sequence. The synthetic sequences of the present invention corresponding to these regions are presented, as SEQ ID
NO:71 (Figure 58) for the synthetic Env US4 common region and as SEQ ID NO:72 (Figure 59) for the synthetic Env SF162 common region.
Percent identity to this sequence can be determined, for example, using the Smith-Waterman search algorithm (Time Logic, Incline Village, NV), with the following exemplary parameters: weight matrix = nuc4x4hb; gap opening penalty = 20, gap extension penalty = 5, reporting threshold = 1; alignment threshold = 20.
Various forms of the different embodiments of the present invention (e.g., constructs) may be combined.

F. Cloning Synthetic Env Expression Cassettes of the Present Invention.
The synthetic DNA fragments encoding the Env polypeptides were typically cloned into the eucaryotic expression vectors described above for Gag, for example, pCMVKm2/pCMV1ink (Figure 4), pCMV6a, pESN2dhfr (Figure 13A), pCMVIII (Figure 13E; alternately designated as the pCMV-PL-E-dhfr/neo vector).
Exemplary designations for pCMV1ink vectors containing synthetic expression cassettes of the present invention are as follows: pCMV1ink.gp140.modSF162;
pCMV1ink.gp140.-modSF162.delV2;
pCMV1ink.gp140.mut.modSF162;
pCMV1ink.gp140.mut.modSF162.delV2; pCMVKm2.gp140modUS4;
pCMVKm2.gp140.modUS4.delV2; pCMVKm2.gp140.mut.modUS4;
and, pCMVKm2.gp140.mut.modUS4.delV1/V2.

G. Generation of Synthetic Tat Expression Cassettes Tat coding sequences have also been modified according to the teachings of the present specification.
The wild type nucleotide sequence encoding tat from variant SF162 is presented in Figure 76 (SEQ ID NO:85).
The corresponding wild-type amino acid sequence is presented in Figure 77 (SEQ ID NO:86). Figure 81 (SEQ ID
NO:89) shows the nucleotide sequence encoding the amino terminal of the tat protein and the codon encoding cystein-22 is underlined. Other exemplary constructs encoding synthetic tat polypeptides are shown in Figures 78 and 79 (SEQ ID NOs:87 and 88). In one embodiment (SEQ
ID NO:88), the cystein residue at position 22 is replaced by a glycine. Caputo et al. (1996) Gene Therapy 3:235 have shown that this mutation affects the trans activation domain of Tat.
Various forms of the different embodiments of the invention, described herein, may be combined.

H. Deposit of'Vectors Selected exemplary constructs shown below and described herein are deposited at Chiron Corporation, Emeryville, CA, 94662-8097, and were sent to the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209 on December 27, 1999.

Plasmid Name Chiron Date Sent Deposit # to ATCC

pCMVgp160.modUS4 5094 27 Dec 99 pCMVgp160delI.modUS4 5095 27 Dec 99 pCMVgp160de12.modUS4 5096 27 Dec 99 pCMVgp160del-2.modUS4 5097 27 Dec 99 pCMVgp160de1128-194.mod.US4 5098 27 Dec 99 pCMVgp140mut.modUS4de1128-194 5100 27 Dec 99 pCMVgp140.mut.mod.US 5101 27 Dec 99 pCMVgp160.modSF162 5125 27 Dec 99 pCMVgp160.modSF162.delV2 5126 27 Dec 99 pCMVgp160.modSF162.delV1V2 5127 27 Dec 99 pCMVgp140.mut.modSF162delV2 5128 27 Dec 99 pCMVgp140.mut7.modSF162 5129 27 Dec 99 pCMVgp140.mut7.modSF162delV2 5130 27 Dec 99 pCMVgp140.mut8.modSF162 5131 27 Dec 99 pCMVgp14,0.mut8.modSF162delV2 5132 27 Dec 99 pCMVgp140.mut8.modSF162delV1V2 5133 27 Dec 99 pCMVKm2.Gagprot.Mod.SF2.GP1 5150 27 Dec 99 pCMVKm2.Gagprot.Mod.SF2.GP2 5151 27 Dec 99 Example 2 Expression Assays for the Synthetic Gag, Env and Tat Coding Seauences A, Gag and Gag-Protease Coding Sequences The HIV-1SF2 wild-type Gag (SEQ ID NO:1) and Gag-protease (SEQ ID NO:2) sequences were cloned into expression vectors having the same features as the vectors into which the synthetic Gag (SEQ ID NO:4) and Gag-protease (SEQ ID NOs:5, 78 or 79)) sequences were cloned.

= W000/39302 PCTfUS99/31245 Expression efficiencies for various vectors carrying the HIV-1SF2 wild-type and synthetic Gag sequences were evaluated as follows. Cells from several mammalian cell lines (293, RD, COS-7, and CHO; all obtained from the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209) were transfected with 2 jig of DNA in transfection reagent LT1 (PanVera Corporation, 545 Science Dr., Madison, WI). The cells were incubated for 5 hours in reduced serum medium (Opt!-MEM, Gibco-BRL, Gaithersburg, MD). The medium was then replaced with normal medium as follows: 293 cells, IMDM, 10% fetal calf serum, 2% glutamine (BioWhittaker, Walkersville, MD); RD and COS-7 cells, D-MEM, 10% fetal calf serum, 2% glutamine (Opti-MEN, Gibco-BRL, Gaithersburg, MD); and CHO cells, Ham's F-12, 10% fetal calf serum, 2% glutamine (Opti-MEM, Gibco-BRL, Gaithersburg, MD). The cells were incubated for either 48 or 60 hours. Supernatants were harvested and filtered through 0.45 Am syringe filters and, optionally, stored .
at -20 C.
Supernatants were evaluated using the Coulter p24-assay (Coulter Corporation, Hialeah, FL, US), using 96-well plates coated with a murine monoclonal antibody directed against HIV core antigen. The HIV-1 p24 antigen binds to the coated wells. Biotinylated antibodies against HIV recognize the bound p24 antigen. Conjugated strepavidin-horseradish peroxidase reacts with the biotin. Color develops from the reaction of peroxidase with TMB substrate. The reaction is terminated by addition of 4N H2SO4. The intensity of the color is directly proportional to the amount of HIV p24 antigen in a sample.
The results of these expression assays are presented in Tables 2A and 2B. Tables 2A and 2B shows data obtained using the synthetic Gag-protease expression cassette of SEQ ID NO:5. Similar results were obtained using the Gag-protease expression cassettes of SEQ ID
NOs:78 and 79.

Table 2: in vitro gag and gagprot p24 expression TABLE 2a. Increased in vitro expression from modified vs. native gag plasmids in supernatants and lysates from transiently trans f ected cells native (nat) a supernatant (sup) hours post total ng p24 experiment modified (mod)" lysate (lys) cell line transfection (fold increase) 1 nat sup 293 48 3.4 mod sup 293 48 1260 (371) nat sup 293 60 3.2 mod sup 293 60 2222 (694) 2 nat sup 293 60 1.8 mod sup 293 60 1740 (966) 3 nat sup 293 60 1.8 mod sup 293 60 580 (322) 4 nat lys 293 60 1.5 . mod lys 29.3 60 85 (57) 1 nat sup RD 48 5.6 = mod sup RD 48 66(12) = nat sup RD 60 7.8 mod sup RD 60 70.2 (9) 2 nat lys RD 60 1.9 mod lys RD 60 7.8 (4) 1 nat sup COS-7 48 0.4 mod sup COS-7 48 33.4 (84) 2 nat sup COS-7 48 0.4 mod sup COS-7 48 10(25) nat lys COS-7 48 3 mod lys COS-7 48 14 (5) a pCbCVLink . Gag . SF2 .PRE

b pCMVXm2 . GagMod . SF2 õ¨...
¨

= WO 00/39302 TABLE 2b. In vitro expression from modified gag and gagprotease plasmids in supernatants and lysates from transiently transfected cells plasmid supematant (sup) cell line hours post total ng p24 lysate (lys) transfection Gag' sup 293 60 760 GagProt(GP1) 6 sup 293 60 380 GagProt(GP2)` sup 293 60 320 Gag lys 293 60 78 GagProt(GP1) lys 293 60 1250 GagProt(GP2) lys 293 60 400 Gag sup COS-7 72 40 GagProt(GP1) sup COS-7 72 150 GagProt(GP2) sup COS-7 72 290 Gag lys COS-7 72 60 GagProt(GP1) lys COS-7 72 63 GagProt(GP2) lys COS-7 72 58 3pCMVKm2:GagMod.5F2 =

b pCMVKm2.GagProtMod.SF2(GP1) gagprotease with codon optimization and inactivation of INS in protease ' pCMVKm2.GagProtMod.SF2(0P2) gagprotease with only inactivation of INS in protease d Shown are representative results from 3 independent experiments for each cell line tested.

The data showed that the synthetic Gag and Gag-protease expression cassettes provided dramatic increases in production of their protein products, relative to the native (HIV-1SF2 wild-type) sequences, when expressed in a variety of cell lines.

B. Env Coding Sequences The HIV-SF162 ("SF162") wild-type Env (SEQ ID NO:1-3) and HIV-US4 ("US4") wild-type Env (SEQ ID NO:22-24) sequences were cloned into expression vectors having the same features as the vectors into which the synthetic Env sequences were cloned.
Expression efficiencies for various vectors carrying the SF162 and US4 wild-type and synthetic Env sequences were evaluated essentially as described above for Gag except that cell lysates were prepared in 40 pl lysis buffer (1.0 % NP40, 0.1 M Tris pH 7.5) and frozen at -C and capture ELISAs were performed as follows.
For Capture ELISAs, 250 ng of an ammonium sulfate 20 IgG cut of goat polyclonal antibody to gp120SF2/env2-3 =
was used to coat each well of a 96-well plate (Corning, Corning, NY). Serial dilutions of gp120/SF2 protein (MID
167) were used to set the quantitation curve from which expression of US4 or SF162 gp120 proteins from transfection supernatant and lysates were calculated.
Samples were screened undiluted and, optionally, by serial 2-fold dilutions. A human polyclonal antibody to HIV-1 gp120/5F2 was used to detect bound gp120 envelope protein, followed by horse-radish peroxidase (HRF)-labeled goat anti-human IgG conjugates. TMB (Pierce, Rockford, IL) was used as the substrate and the reaction is terminated by addition of 4N H2SO4. The reaction was quantified by measuring the optical density (OD) at 450 nm. The intensity of the color is directly proportional to the amount of HIV gp120 antigen in a sample. Purified SF2 gp120 protein was diluted and used as a standard.
The results of the transient expression assays are presented in Tables 3 and 4. Table 3 depicts transient expression in 293 cells transfected with a pCMVKm2 vector carrying the Env cassette of interest. Table 4 depicts transient expression in RD cells transfected with a pCMVKm2 vector carrying the Env cassette of interest.

=

= = ' Lrt C

g g Table 3 i L Native (N) Cell Total Sup fold Total cell Cell lysate Total Total fold ' k Synthetic(S) Line sup increase lysate fold increase (ng) increase 1 F (n5.) 0 v. NI 0250 (S v.
N) (S v. NI ;
p , P
, 21-gp120.17S4 RD 87 <1 88 I., i w 8-gp120.mcdU84 RD 690 a 2 s 693 a w .i, , I-. N-gp140.13S4 RD 526 o 526 w ' S-gp140.mcdUS4 RD 1305 2 - . 1. 2 1306 _ T
8-gpl4estut.mcdUS4 RD 35 N/A 25 NIA 60 NIA
1 . .
to 8-gp140TM.stodUS4 RD 0 N/A 5 N/A 5 NIA
' , N-gp160.1384 RD , 0 8 8 . .

8-gp160.modU84 RD _0 o 30 4 30 4 n cl) m, t m, , u, i Table 4 CHO Cell Lines Expression Level of US4 Envelope Constructs Constructs CHO Clone # MTX Expression Level.

Level (ng/ml) gp120.modUS4 1 3.2pM 250-450 2 1.6pM 350-450 3 200nM 230-580 4 200nM 300-500 gp140.modUS4 1 1pM 155-300 2 1pM 100-260 3 1pM 200-430 gp.140.mut. 1 1pM 110-270 modUS4 2 1pM 100-235 = 3 1 M 100-220 gp140.modUS4 1 50n14 313-587-.delV1/V2 2 50nM 237-667"
,3 50nM 492-527"

gp140.mut. 1 50nM 46-328"
modUS4.delV1 2 50nM 82-318-/V2 3 50nM 204-385"
'All samples measured at T-75 flask stage unless otherwise indicated -at 24 well and 6 well plate stages ***in a three liter bioreactor perfusion culture this clone yielded approximately 2-5 pg/ml.

The data showed that the synthetic Env and expression cassettes provided a significant increase in production of their protein products, relative to the native (HIV-1SF162 or US4 wild-type) sequences, when expressed in a variety of cell lines.

C. CHO Cell line Env expression data Chinese hamster ovary (CHO) cells were transfected with plasmid DNA encoding the synthetic HIV-1 gp120 or gp140 proteins (e.g., pESN2dhfr or pCMVIII vector backbone) using Mirus TransIT-LT1 polyamine transfection reagent (Pan Vera) according to the manufacturers instructions and incubated for 96 hours. After 96 hours, media was changed to selective media (F12 special with 250 Ag/m1 G418) and cells were split 1:5 and incubated for an additional 48 hours. Media was changed every 5-7 days until splonies started forming at which time, the colonies were picked, plated into 96 well plates and screened by 9p120 Capture ELISA. Positive clones ,were expanded in 24 well plates and screened several times for Env protein production by Capture ELISA, as described above. After reaching confluency in 24 well plates, positive clones were expanded to T25 flasks (Corning, Corning, NY). These were screened several times after confluency and positive clones were expanded to T75 flasks.
Positive T75 clones were frozen in LN2 and the highest expressing clones amplified with 0-5 AM
methotrexate (MTX)at several concentrations and plated in 100mm culture dishes. Plates were screened for colony formation and all positive closed were again expanded as described above. Clones were expanded an amplified and screened at each step by gp120 capture ELISA. Positive clones were frozen at each methotrexate level. Highest = WO 00/39302 PCI7US99/31245 producing clones were grown in perfusion bioreactors (310 100L) for expansion and adaptation to low serum suspension culture conditions for scale-up to larger bioreactors.
Tables 5 and 6 show Capture ELISA data from CHO
cells transfected with pCMVIII vector carrying a cassette encoding synthetic HIV-US4 and SF162 Env polypeptides (e.g., mutated cleavage sites, modified codon usage and/or deleted hypervariable regions). Thus, stably transfected CHO cell lines which express Env polypeptides (e.g., gp120, gp140-monomeric, and gp140-oligomeric) have been produced.

=
=

Table 5 CHO Cell Lines Expression Level of US4 Envelope Constructs Constructs CHO Clone # MTX
Expression Lever Level (ng/ml) gp120.modUS4 1 3.2AM 250-2 1.6AM 350-450 3 200nM 230-580***
4 200nM 300-500 gp140.modUS4 1 lAM

2 lAM 100-260 ,3 lAM 200-430 gp140.mut. 1 lAM

modUS4 2 lAM

3 lAM 100-220 gp140.modUS4 1 50nM
313-587.-.delV1/V2 2 50nM

= 3 50nM 492-527¨
gp140.mut. 1 50nM
46-328¨
modUS4.delV1 2 50nM
82-318¨
/V2 3 50nM
204-385¨
indicated'All samples measured at T-75 flask stage unless otherwise -¨at 24 well and 6 well plate stages ***in a three liter bioreactor perfusion culture this clone yielded approximately 2-5 pg/ml.

Table 6 CHO Cell Lines Expression Level of SF162 Envelope Constructs Constructs CHO Clone # MTX Expression Lever Level (ng/ml) gp120.modSF162 1 0 755-2705 9p140.modSF162 1 20 nM 180-350 gp140.mut. 1 20 nM 164-451 modSF162 2 20 nM 188-487 3 20 nM 233-804 gp120.modSF162 1 800nM 528-1560 .delV2 2 800nM 487-1878 3 800nM 589-1212 gp140.modSF162 1 800nM 300-600 .delV2 2 800nM. 200-400 3 800nM. 200-500 gp140.mut. 1 800nM 300-700 modSF162.delV2 2 400nM 1161 3 800nM 400-600 4 400nM 1600-2176 'All samples measured at T-75 flask stage unless otherwise -indicated The results presented above demonstrate the ability of the constructs of the present invention to provide expression of Env polypeptides in CHO cells. Production of polypeptides using CHO cells provides (i) correct glycosylation patterns and protein conformation (as determined by binding to panel of MAbs); (ii) correct binding to CD4 receptor molecules; (iii) absence of non-mammalian cell contaminants (e.g., insect viruses and/o-cells); and (iv) ease of purification.

D. Tat Coding Seauences The HIV-SF162 ("SF162") wild-type Tat (SEQ ID NO:85) sequences were cloned into expression vectors having the same features as the vectors into which the synthetic Tat sequences were cloned (SEQ ID NOs:87, 88 and 89).
Expression efficiencies for various vectors carrying the SF162 wild-type and synthetic Tat sequences are evaluated essentially as described above for Gag and Env using capture ELISAs with the appropriate anti-tat antibodies and/or CHO cell assays. Expression of the polypeptides encoded by the synthetic cassettes is improved relative to wild type.

= Example 3 Western Blot Analysis of Expression A. Gag and Gag-Protease Coding Sequences Human 293 cells were transfected as described in Example 2 with pCMV6a-based vectors containing native or synthetic Gag expression cassettes. Cells were cultivated for 60 hours post-transfection. Supernatants were prepared as described. Cell lysates were prepared as follows. The cells were washed once with phosphate-buffered saline, lysed with detergent [1% NP40 (Sigma Chemical Co., St. Louis, MO) in 0.1 M Tris-HC1, pH 7.5], and the lysate transferred into fresh tubes. SDS-polyacrylamide gels (pre-cast 8-16%; Novex, San Diego, CA) were loaded with 20 1 of supernatant or 12.5 1 of cell lysate. A protein standard was also loaded (5 1, broad size range standard; BioRad Laboratories, Hercules, CA). Electrophoresis was carried out and the proteins were transferred using a BioRad Transfer Chamber (BioRad Laboratories, Hercules, CA) to Immobilon P membranes (Millipore Corp., Bedford, MA) using the transfer buffer recommended by the manufacturer (Millipore), where the transfer was performed at 100 volts for 90 minutes. The membranes were exposed to HIV-1-positive human patient serum and immunostained using o-phenylenediamine dihydrochloride (OPD; Sigma).
The results of the immunoblotting analysis showed that cells containing the synthetic Gag expression cassette produced the expected p55 protein at higher per-cell concentrations than cells containing the native expression cassette. The Gag p55 protein was seen in both cell lysates and supernatants. The levels of production were significantly higher in cell supernatants for cells transfected with the synthetic Gag expression cassette of the present invention. Experiments performed in support of the present invention suggest that cells containing the synthetic Gag-prot expression cassette produced the expected Gag-prot protein at comparably higher per-cell concentrations than cells containing the =
native expression cassette.
In addition, supernatants from the transfected 293 cells were fractionated on sucrose gradients. Aliquots of the supernatant were transferred to Polyclear' ultra-centrifuge tubes (Beckman Instruments, Columbia, MD), under-laid with a solution of 20% (wt/wt) sucrose, and subjected to 2 hours centrifugation at 28,000 rpm in a Beckman SW28 rotor. The resulting pellet was suspended in PBS and layered onto a 20-60% (wt/wt) sucrose gradient and subjected to 2 hours centrifugation at 40,000 rpm in a Beckman SW4lti rotor.
The gradient was then fractionated into approximately 10 x 1 ml aliquots (starting at the top, 20%-end, of the gradient). Samples were taken from fractions 1-9 and were electrophoresed on 8-16% SDS
polyacrylamide gels. Fraction number 4 (the peak fraction) corresponds to the expected density of Gag protein VLPs. The supernatants from 293/synthetic Gag cells gave much stronger p55 bands than supernatants from 293/native Gag cells, and, as expected, the highest concentration of p55 in either supernatant was found in fraction 4.
These results demonstrate that the synthetic Gag expression cassette provides superior production of both p55 protein and VLPs, relative to the native Gag coding sequences.

B. Env Coding Sequences Human 293 cells were transfected as described in Example 2 with pCMVKm2-based; pCMV1ink-based; p-CMVII-based or pESN2-based vectors cpntaining native or synthetic Env expression cassettes. Cells were cultivated for 48 or 60 hours post-transfection. Cell . 20 lysates and supernatants were prepared as described =
(Example 2). Briefly, the cells were washed once with phosphate-buffered saline, lysed with detergent [1% NP40 (Sigma Chemical Co., St. Louis, MO)] in 0.1 M Tris-HC1, pH 7.5], and the lysate transferred into fresh tubes.
SDS-polyacrylamide gels (pre-cast 8-16%; Novex, San Diego, CA) were loaded with 20 pl of supernatant or 12.5 gl of cell lysate. A protein molecular weight standard and an HIV SF2 gp120 positive control protein (5 gl, broad size range standard; BioRad Laboratories, Hercules, CA) were also loaded. Electrophoresis was carried out and the proteins were transferred using a BioRad Transfer Chamber (BioRad Laboratories, Hercules, CA) to Immobilon P membranes (Millipore Corp., Bedford, MA) using the transfer buffer recommended by the manufacturer (Millipore), where the transfer was performed at 100 volts for 90 minutes. The membranes were then reacted against polyclonal goat anti-gp120SF2/env2-3 anti-sera, followed by incubation with swine anti-goat IgG-peroxidase (POD) (Sigma, St. Louis, MO). Bands indicative of binding were visualized by adding DAB with hydrogen peroxide which deposits a brown precipitate on the membranes.
The results of the immunoblotting analysis showed that cells containing the synthetic Env expression cassette produced the expected Env gp proteins of the predicted molecular weights as determined by mobilities in SDS-polyacrylamide gels at higher per-cell concentrations than cells containing the native expression cassette. The Env proteins were seen in both cell lysates and supernatants. The levels of production were significantly higher in cell supernatants for cells .
transfected with the synthetic Env expression cassette of the present invention.
C. Tat Coding Sequences Human 293 cells are transfected as described in Example 2 with various vectors containing native or synthetic Tat expression cassettes. Cells are cultivated and isolated proteins analyzed as described above.
Immunoblotting analysis shows that cells containing the synthetic Tat expression cassette produced the expected Tat proteins of the predicted molecular weights as determined by mobilities in SDS-polyacrylamide gels at higher per-cell concentrations than cells containing the native expression cassette.

Example 4 Purification of Env poll/peptides A. Purification of Oligomeric qp140 Purification of oligomeric gp140 (o-gp140 U54) was conducted essentially as shown in Figure GO. For the experiments described herein, o-gp140 refers to oligomeric gp140 in either native or modified (e.g., optimized expression sequences, deleted, mutated, truncated, etc.) form. Briefly, concentrated (30-50X) supernatants obtained from CHO cell cultures were loaded onto an anion exchange (DEAE) column which removed DNA
and other serum proteins. The eluted material was loaded onto a ceramic hydroxyapatite column (CHAP) which bound serum proteins but not HIV Env proteins. The flow-through from the DEAE and CHAP columns was loaded onto a Protein A column as a precautionary step to remove any remaining serum immunoglobulins. The Env proteins in the flow-through were then captured using the lectin gluvanthus.navalis (GNA, Vector Labs, Burlingame, CA).
GNA has high affinity for mannose rich carbohydrates such as Env. The Env proteins were then eluted with GNA
substrate. To remove other highly glycosylated proteins, a cation exchange column (SP) was used to purify gp140/gp120. In a final step, which separates gp120 from o-gp140, a gel filtration column was used to separate oligomers from monomers. Sizing and chromatography analysis of the final product revealed that this strategy lead to the successful isolation of oligomeric gp140.

B. Purification of gp120 Purification of gp120 was conducted essentially as previously described for other Env proteins. Briefly, concentrated supernatants obtained from CHO cell cultures were loaded onto an anion exchange (DEAE) column which removed DNA and other serum proteins. The eluted material was loaded onto a ceramic hydroxyapatite column (CHAP) which bound serum proteins but not HIV Env proteins. The flow-through from the CHAP column was loaded a cation exchange column (SP) where the flow-through was discarded and the bound fraction eluted with salt. The eluted fraction(s) were loaded onto a Suprose 12/Superdex 200 Tandem column (Pharmacia-Upjohn, Uppsala, Sweden) from which purified gp120 was obtained. Sizing and chromatography analysis of the final product revealed that this strategy successfully purified gp120 proteins.

Example 5 Analysis_ of Purified Env Poly-Peptides A. Analysis of o-gp140 It is well documented that HIV Env protein binds to CD4 only in its correct conformations. Accordingly, the ability of o-gp140 US4 polypeptides, produced and .purified as described above, to bind CD4 cells was tested. 0-gp140 US4 was incubated for 15 minutes with FITC-labeled CD4 at room temperature and loaded onto a Biosil 250 (BioRad) size exclusion column using Waters HPLC. CD4-FITC has the longest retention time (2.67 minutes), followed by CD4-FITC-gp120 (2.167 min). The shortest retention time (1.9 min) was observed for CD4-FITC-o-gp140 U54 indicating that, as expected, o-gp140 US4 binds to CD4 forming a large complex which reduces retention time on the column. Thus, the o-gp140 US4 produced and purified as described above is of the correct size and conformation.
In addition, the US4 o-gp140, purified as described above, was also tested for its ability to bind to a variety of monoclonal antibodies with known epitope specificities for the CD4 binding site, the CD4 inducible site, the V3 loop and oligomer-specific gp41 epitope. 0-gp140 bound strongly to these antibodies, indicating that the purified protein retains its structural integrity.

B. Analysis of gp120 As described above, CD4-FITC binds gp120, as demonstrated by the decreased retention time on the HPLC
column. Thus, U54 gp120 purified by the above method retains its conformational integrity. In addition, the properties of purified gp120 can be tested by examining its integrity and identity on western blots, as well as, by examining protein concentration, pH, conductivity, endotoxin levels, bioburden and the like. US4 gp120, purified as described above, was also tested for its ability to bind to a variety of monoclonal antibodies with known epitope specificities for the CD4 binding . site, the CD4 inducible site, the V3 loop and oligomer-specific gp41 epitope. The pattern of mAb binding to gp120 indicated that the purified protein retained its structural integrity, for example, the purified gp120 did =
not bind the mAb having the oligomer-specific gp41 epitope (as expected).

Example 6 Electron Microscopic Evaluation of VLP Production The cells for electron microscopy were plated at a density of 50-70% confluence, one day before transfection. The cells were transfected with 10 jig of DNA using transfection reagent LT1 (Panvera) and incubated for 5 hours in serum-reduced medium (see Example 2). The medium was then replaced with normal medium (see Example 2) and the cells were incubated for 14 hours (COS-7) or 40 hours (CHO). After incubation the cells were washed twice with PBS and fixed with 2%

glutaraldehyde. Electron microscopy was performed by Prof. T.S. Benedict Yen, Veterans Affairs, Medical Center, San Francisco, CA).
Electron microscopy was carried out using a transmission electron microscope (Zeiss 10c). The cells were pre-stained with osmium and stained with uranium acetate and lead citrate. The magnification was 100,000X.
Figures 3A and 33 show micrographs of CHO cells transfected with pCMVKM2 carrying the synthetic Gag expression cassette (SEQ ID NO:5) or carrying the Gag-prot expression cassette (SEQ ID NO:79). In the figure, free and budding immature virus-like-particles (VLP) of the expected size (100 nm) are seen for the Gag expression cassette (Figure 3A) and both immature and mature VLPs are seen for the Gag-prot expression cassette (Figure 3B). COS-7 cells tranpfected with the same vector have the same expression pattern. VLP can also be found intracellularly in CHO and COS-7 cells.
. 20 Native and synthetic Gag expression cassettes were compared for their associated levels of VLP production when used to transfect human 293 cells. The comparison was performed by density gradient ultracentrifugation of cell supernatants and Western-blot analysis of the gradient fractions. There was a clear improvement in production of VLPs when using the synthetic Gag construct.

Example 7 Expression of Virus-like Particles in the Baculovirus System A. Expression of Native HIV P55 Gag To construct the native HIV p55 Gag baculovirus shuttle vector, the prototype SF2 HIV p55 plasmid, pTM1-= W000/39302 PCT/US99/31245 Gag (Selby N.J., et al., J Virol. 71(10):7827-7831, 1997), was digested with restriction endonucleases Ncol and BamHI to extract a 1.5 Kb fragment that was subsequently subcloned into pAcC4 (Bio/Technology 6:47-55, 1988), a derivative of pAc436. Generation of the recombinant baculovirus was achieved by co-transfecting 2 pg of the HIV p55 Gag pAcC4 shuttle vector with 0.5 pg of linearized, Autographa californica baculovirus (AcNPV) wild-type viral DNA into Spodoptera frugiperda (Sf9) cells (Kitts, P.A., Ayres M.D., and Possee R.D., Nucleic Acids Res. 18:5667-5672, 1990). The isolation of recombinant virus expressing HIV p55 Gag was performed according to standard techniques (O'Reilly, D.R., L.K.
Miller, and V. A. Luckow, Baculovirus Expression Vector:
A Laboratory Manual, W.H. Freeman and Company, New York, 1992).
Expression of' the HIV p55 Gag was achieved using a=
500 ml suspension culture of Sf9 cells grown in serum-free medium (Miaorella, B., D. Inlow, A. Shauger, and D:
Harano, Bio/Techndlogy 6:1506-1510, 1988) that had been' infected with the HIV p55 Gag recombinant baculovirus at a multiplicity of infection (MOI) of 10. Forty-eight hours post-infection, the supernatant was separated by centrifugation and filtered through a 0.2 pm filter.
Aliquots of the supernatant were then transferred to PolyclearTM (Beckman Instruments, Palo Alto, CA) ultracentrifuge tubes, underlaid with 20% (wt/wt) sucrose, and subjected to 2 hours centrifugation at 24,00 rpm using a Beckman SW28 rotor.
The resulting pellet was suspended in Trig buffer (20 mM Tris HC1, pH 7.5, 250 mM NaCl, and 2.5 mM
ethylenediaminetetraacetic acid [EDTA1), layered onto a 20-60% (wt/wt) sucrose gradient, and subjected to 2 hours centrifugation at 40,000 rpm using a Beckman SW4lti rotor. The gradient was then fractionated starting at the top (20% sucrose) of the gradient into approximately twelve 0.75 ml aliquots. A sample of each fraction was electrophoresed on 8-16% SDS polyacrylamide gels and the resulting bands were visualized after commassie staining (Figure 4). Additional aliquots were subjected to refractive index analysis.
The results shown in Figure 4 indicated that the p55 Gag virus-like particles banded at a sucrose density of range of 1.15 - 1.19 g/ml with the peak at approximately 1.17 g/ml. The peak fractions were pooled and concentrated by a second 20% sucrose pelleting. The resulting pellet was suspended in 1 ml of Tris buffer (described above). The total protein yield as estimated by Bicimchrominic Acid (BCA) (Pierce Chemical, Rockford, IL) was 1.6 mg.

B. ExDression of Synthetic HIV D55 Gaq A baculovirus shuttle vector containing the synthetic p55 Gag sequence was constructed as follows.
The synthetic HIV p55 expression cassette (Example 1) was digested with restriction enzyme Sail followed by incubation with T4-DNA polymerase. The resulting fragment was isolated (PCR Clean-Upm, Promega, Madison, WI) and then digested with BamHI endonuclease. The shuttle vector pAcC13 (Munemitsu S., et al., Mol Cell Biol. 10(11):5977-5982, 1990) was linearized by digestion with Ecol, followed by incubation with T4-DNA polymerase, and then isolated (PCR Clean-Upm). The linearized vector was digested with BamHI, treated with alkaline phosphatase, and isolated by size fragmentation in an agarose gel. The isolated 1.5 kb fragment was ligated with the prepared pAcC13 vector. The resulting clone was designated pAcC13-Modif.p55Gag.

= 110:00(0002 PcT/US99/31245 The expression conditions for the synthetic HIV p55 VLPs differed from those of the native p55 Gag as follows: a culture volume of 1 liter used instead of 500 ml; Trichoplusia ni (Tn5) (Wickham, T.J., and Nermerow, G.R., BioTechnology Progress, 9:25-30, 1993) insect cells were used instead of Sf9 insect cells; and, an MOI of 3 was instead of an MOI of 10. Experiments performed in support of the present invention showed that there was no appreciable difference in expression level between the Sf9 and Tn5 insect cells with the native p55 clone. In terms of MOI, experience with the native p55 clone suggested that an MOI of 10 resulted in higher expression (approximately 2-fold) of VLPs than a lower MOI.
The sucrose pelleting and banding methods used for the synthetic p55 VLPs were similar to those employed for the native p55 VLPs (described above), with the following = exceptions: pelleted VLPs were suspended in 4 ml of phosphate buffered saline (PBS) instead of 1.0 ml of the Tris buffer; and four, 20-60% ,sucrose gradients were used = 20 instead of a single gradient. = Also, due to the high concentration of banded VLPs, further concentration by pelleting was not required. The peak fractions from all 4 gradients were simply dialyzed against PBS. The approximate density of the banded VLPs ranged from 1.23-1.28 g/ml. A total protein yield as estimated by BCA was 46 mg. Results from the sucrose gradient banding of the synthetic p55 are shown in Figure 5.
A comparison of the total amount of purified HIV p55 Gag from several preparations obtained from the two baculovirus expression cassettes has been summarized in Figure 6. The average yield from the native p55 was 3.16 mg/liter of culture (n=5, standard deviation (sd) +1.07, range = 1.8-4.8 mg/L) whereas the average yield from the synthetic p55 was more than ten-fold higher at 44.5 mg/liter of culture (n=2, sd=+6.4).
In addition to a higher total protein yield, the final product from the synthetic p55-expressed Gag consistently contained lower amounts of contaminating baculovirus proteins than the final product from the native p55-expressed Gag. This difference can be seen in the two commassie-stained gels Figures 4 and 5.

C. Expression of Native and Synthetic Gaq-Core Expression of the HIV p55 Gag/HCV Core 173 (SEQ ID
NO:8) was achieved using a 2.5 liter suspension culture of Sf9 cells grown in serum-free medium (Miaorella, B., D. Inlow, A. Shauger, and D. Harano. 1988 Bio/Technology 6:1506-1510). The cells were infected with an HIV p55 Gag/HCV Core 173 recombinant baculovirus. Forty-eight hours post-infection, the supernatant was separated fr9m the cells by centrifugation and filtered through a 0.2 pm filter. Aliquots.of the supernatant were then transferred to a PolyclearTM (Beckman Instruments, Palo-Alto, CA) ultracentrifuge tubes containing 30% (wt/wt) sucrose, and subjected to 2 hours of centrifugation at 24,000 rpm in a Beckman SW28 rotor and ultracentrifuge.
The resulting pellet was suspended in Tris buffer (50 mM Tris-HC1, pH 7.5, 500 mM NaCl) and layered onto a 30-60% (wt/wt) sucrose gradient and subjected to 2 hours centrifugation at 40,000 rpm in a Beckman SW4lti rotor and ultracentrifuge. The gradient was then fractionated starting at the top (30%) of the gradient into approximately 11 x 1.0 ml aliquots. A sample of each fraction was electrophoresed on 8-16% SDS polyacrylamide gels and the resulting bands were visualized after commassie staining.

A subset of aliquots were also subjected to Western blot analysis using monoclonal antibody 76C.5EG (Steimer, K.S., et al., Virology 150:283-290, 1986) which is specific for HIV p24 (a subunit of HIV p55). The peak fractions from the sucrose gradient were pooled and concentrated by a second 20% sucrose pelleting. The resulting pellet was suspended in 1 ml of buffer Tris buffer and the total protein yield as estimated by BCA
(Pierce Chemical, Rockford, IL) was - 1.0 mg.
The results from the SDS PAGE are shown in Figure B
and the anti- p24 Western blot results are shown in Figure 9. Taken together, these results indicate that the HIV p55 Gag/HCV Core 173 chimeric VLPs banded at a sucrose density similar to that of the HIV p55 Gag VLPs and the visible protein band that migrated at a molecular weight of - 72,000 kd was reactive with the HIV p24-specific monoclonal antibody. An additional.
immunoreactive band at approximately 55,000 kd also appeared to be reactive with the anti-p24 antibody and may be a degradation product.
Although aliquots from the above preparation were not tested for reactivity with an HCV Core-specific antibody (an anti-CD22 rabbit serum), results from a similar preparation are shown in Figure 10 and indicate that the main HCV Core-specific reactivity migrates at an approximate molecular weight of 72,000 kd which is in accordance with the predicted molecular weight of the chimeric protein.
The expression conditions for the synthetic HIV p55 Gag/HCV Core 173 (SEQ ID NO:8) VLPs differed from those of the native p55 Gag and are as follows: a culture volume of 1 liter used instead of 2.5 liters, Trichoplusia ni (Tn5)(Wickham, T.J., and Nemerow, G.R.
1993 BioTechnology Progress, 9:25-30) insect cells were used instead of Sf9 insect cells and an MOI of 3 was instead of an MOI of 10. The sucrose pelleting and banding methods used for the synthetic HIV p55 Gag/HCV
Core 173 VLPs were similar to those employed for the native HIV p55 Gag/HCV Core 173 VLPs. However, differences included: pelleted VLPs were suspended in 1 ml of phosphate buffered saline (PBS) instead of 1.0 ml of the Tris buffer, and a single 20-60% sucrose gradients was used. A comparison of the total amount of purified HIV p55 Gag/HCV Core 173 from multiple preparations obtained from the two baculovirus expression cassettes showed that there was an increase in expression using the synthetic HIV p55 Gag/HCV Core 173 cassette.

D. Alternative method for the enrichment of HIV D55 Gag VLPs In apldition to purification from the media, p55 (Gag protein) expressed in baculovirus (e.g., using a synthetic. expression cassette of the present invention) can also be purified as virus-like particles from the infected insect cells. For example, forty-eight hours post infection, the media and cell pellet are separated by centrifugation and the cell pellet is stored at -70 C
until future use. At the time of processing, the cell pellet is suspended in 5 volumes of hypotonic lysis buffer (20 mM Tris-HC1, pH
8.2, 1 mM EGTA; 1 mM MgC1, and Complete Protease Inhibitor (Boehringer Mannheim Corp., Indianapolis, IN]). If needed, the cells are then dounced 8-10 times to complete cell lysis.
The lysate is then centrifuged at approximately 1000-1500 x g for 20 minutes. The supernatant is decanted into UltraClearTM tubes, underlayed with 20%
sucrose (w/w) and centrifuged at 24,000 rpm in SW28 buckets for 2 hours.
The resulting pellet is suspended in Tris buffer (20 mM
Tris HC1, pH 7.5, 250 mM NaC1, and 2.5 mM ethylene-diamine-tetraacetic acid (EDTA) with 0.1% IGEPAL
detergent (Sigma Chemical, St. Louis, MO) and 250 units/ml of benzonase (American International Chemical, Inc., Natick, MA) and incubated at 4 C for at least 30 minutes. The suspension is subsequently layered onto a 20-60% sucrose gradient and spun at 40,000 rpm using an SW4lti rotor for 20-24 hours.
After ultracentrifugation, the sucrose gradient is fractionated and aliquots run on SDS PAGE to identify peak fractions. .The peak fractions are dialyzed against PBS and measured for protein content. Negatively stained electron mircographs typically show non-enveloped VLPs somewhat smaller in diameter (80-120 nm) than the budded VLPs. HIV Gag VLPs prepared in this manner are also capable of generating Gag-specific CTL responses in mice.

In Vivo Immunocienicitv of Synthetic Gaq_ExpressionExample 8 Cassettes A. Immunization To evaluate the possibly improved immunogenicity of the synthetic Gag expression cassettes, a mouse study was performed. The plasmid DNA, pCMVKM2 carrying the synthetic Gag expression cassette, was diluted to the following final concentrations in a total injection volume of 100 pl: 20 pg, 2 gig, 0.2 pg, and 0.02 pg. To overcome possible negative dilution effects of the diluted DNA, the total DNA concentration in each sample was brought up to 20 pg using the vector (pCMVKM2) alone.
As a control, plasmid DNA of the native Gag expression cassette was handled in the same manner. Twelve groups of four Balb/c mice (Charles River, Boston, MA) were intramuscularly immunized (50 pl per leg, intramuscular injection into the tibialis anterior) according to the schedule in Table 7.
Table 7 Group Gag Expression Concentration Immunized at Cassette of Gag plasmid time (weeks):
DNA (pg) 1 Synthetic 20 01, 4 2 Synthetic 2 0, 4 3 Synthetic 0.2 0, 4 4 Synthetic 0.02 0, 4 5 Synthetic 20 0 6 Synthetic , 2 0 7 Synthetic 0.2 0 8 Synthetic 0.02 0 9 Native 20 0 10 Native 2 0 11 Native 0.2 0 112 _ Native 0.02 ,0 1 = initial immunization at "week 0"
Groups 1-4 were bled at week 0 (before immunization), week 4, week 6, week 8, and week 12.
Groups 5-12 were bled at week 0 (before immunization) and at week 4.

B. Humoral Immune Response The humoral immune response was checked with an anti-HIV Gag antibody ELISAs (enzyme-linked immunosorbent assays) of the mice sera 0 and 4 weeks post immunization (groups 5-12) and, in addition, 6 and 8 weeks post immunization, respectively, 2 and 4 weeks post second immunization (groups 1-4).
The antibody titers of the sera were determined by anti-Gag antibody ELISA. Briefly, sera from immunized mice were screened for antibodies directed against the HIV p55 Gag protein. ELISA microtiter plates were coated with 0.2 yg of HIV- p24 -Gag protein per well overnight and washed four times; subsequently, blocking was done with PBS-0.2% Tween (Sigma) for 2 hours. After removal of the blocking solution, 100 yl of diluted mouse serum was added. Sera were tested at 1/25 dilutions and by serial 3-fold dilutions, thereafter. Microtiter plates were washed four times and incubated with a secondary, peroxidase-coupled anti-mouse IgG antibody (Pierce, Rockford, IL). ELISA plates were washed and 100 pl of 3, 31, 5, 5'-tetramethyl benzidine (TMB; Pierce) was added per well. The optical density of each well was measured after 15 minutes. The titers reported are the reciprocal of the dilution of serum that gave a half-maximum optical density (0.D.). The ELISA results are presented in Table 8.

Table 8 Group Inoculum Expression Sera - Sera - Sera -I (pg) cassette Week 4' ,Week 6 _Week 8 1 20 S' - gag 98 ,455 551 2 2 ,S - gag 59 1408 227 3 0. S - gag 29 186 61 4 0.02 S - gag < 20 ,< 20 < 20 -- , 5 20 S - gag 67 n. a .4 n.a.

6 2 S - gag 63 n.a. , n.a.
-, 7 0. S - gag 57 n.a. n.a.

8 0.02 S - gag ,< 20 n.a. n.a.

9 ,20 N2 - gag 43 n.a. n.a.
, 10 2 N -gag < 20 ,n.a. n.a.
, , 11 0. N - gag < 20 n.a. n.a.

12 , 0.02 N - gav< 20 n.a. n.a.
. _ . _ _ 1 = synthetic gag expression cassette (SEQ ID NO: 4) 2 = native gag expression cassette (SEQ ID NO: 1) 3 = geometric mean antibody titer 4 = not applicable .

The results of the mouse immunizations with plasmid-.

DNAs show that the synthetic expression cassettes provide a clear improvement of immunogenicity relative to the native expression cassettes. Also, the second boost immunization induced a secondary immune response after two weeks (groups 1-3).

C Cellular Immune Response The frequency of specific cytotoxic T-lymphocytes (CTL) was evaluated by a standard chromium release assay of peptide pulsed Baltic mouse CD4 cells. Gag expressing vaccinia virus infected CD-8 cells were used as a positive control (vvGag). Briefly, spleen cells (Effector cells, E) were obtained from the BALB/c mice immunized as described above (Table 8) were cultured, restimulated, and assayed for CTL activity against Gag , ........

peptide-pulsed target cells as described (Doe, B., and Walker, C.M., AIDS 10(7):793-794, 1996). The HIV-1,n Gag peptide used was p7g SEQ ID NO:10. Cytotoxic activity was measured in a standard "Cr release assay. Target (T) cells were cultured with effector (E) cells at various E:T ratios for 4 hours and the average cpm from duplicate wells was used to calculate percent specific "Cr release.
The results are presented in Table 9.
Cytotoxic T-cell (CTL) activity was measured in splenocytes recovered from the mice immunized with HIV
Gag DNA (compare Effector column, Table 9, to immunization schedule, Table 8). Effector cells from the Gag DNA-immunized animals exhibited specific lysis of Gag p7g peptide-pulsed SV-BALB (MHC matched) targets cells indicative of a CTL response. Target cells that were peptide-pulsed and derived from an MHC-unmatched mouse strain (MC57) were not lysed (Table 9; MC/p7g), Table 9 Table 9. Cytotoxic T-lymphocyte (CTL) responses in mice immunized with HIV-1 gag DNA
Percent specific lysis of Immunization 'E:T
SVBALB
target cells'SVBALB RMA
, _ none p7g p7g 20 jig DNA 100:1 <1 gagmod 30:1 <1 ,10:1 <1 <1 2 jig DNA 100:1 <1 gagmod 30:1 <1 10:1 <1 <1 0.2 jig DNA 100:1 <1 gagmod 30:1 <1 10:1 1 <1 0.02 jig DNA 100:1 <1 gagmod = 30:1 .<1 10:1 1 <1 20 jig DNA 100:1 .<1 gag native 30:1 .<1 ,10:1 1 <1 2 jig DNA 100:1 <1 <1 gag native 30:1 <1 10:1 _ 1 <1 0.2 jig DNA 100:1 <1 gag native 30:1 <1 10:1 2 <1 0.02 pg DNA 100:1 <I
gag native 30:1 <1 10:1 1 <1 representative results of two animals per DNA-dose;
positive CTL responses are indicated by boxed data The results of the CTL assays show increased potency of synthetic Gag expression cassettes for induction of cytotoxic T-lymphocyte (CTL) responses by DNA immunization.

, Example 9 In vivo Immunization with Env polypeptides A. Immunocienicity Study of US4 o-qp140 in Ras-3c Adluvant System Studies have been conducted using rabbits immunized with US4 o-gp140 purified as described above. Studies are also underway in animals to determine immunogenicity of US4 gp120, SF162 o-gp140 and SF162 gp120.
Two rabbits (#1 and #2) were immunized intramuscularly at 0, 4, 12 and 24 weeks with 50 Ag of US4 o-gp140 in the adjuvant system (RAS-3c), (Ribi Immunochem, Hamilton, MT) containing 2% Sgualene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL, Ribi Immunochem, Hamilton, MT).
In each experiment described herein, o-gp140 can be native, mutated and/or modified. Antibody responses directed against the US4 o:gp140 protein were measured by ELISA.
Results are shown in Table 10.

=

Rabbit/sample Table 10 Approximate o-gp140 ELISA
e titer pre-immunization #1: postl (0 week immuniz) #1: post2 (4 week immuniz) 15,000 #1: post3 (12 week 50,000 immuniz) #1: post4 (24 week immuiz) 100,000 #2: postl (0 week immuniz) 10 #2: post2 (4 week immuniz) 12,000 #2: post3 (12 week immuniz) 25,000 #2: post4 (24 week immuiz) 55,000 15 The avidities of antibodies directed against the US4 =
o-gp140 protein were measured in a similar ELISA format employing successive washes with increasing concentrations = of ammonium isothiocynate. Results are shown in Table 11.

Table 11 Time of sample Approx. Antibody avidity (NH41-1CN Conc. in M) pre-immunization 0.02 postl (0 week immuniz) 1.8 25 I post2 (4 week immuniz) 3.5 post3 (12 week 5.5 immuniz) post4 (24 week 5.1 30 immuniz) a_ These results show that US4 o-gp140 is highly immunogenic and able to induce substantial antibody responses after only one or two immunizations.

B. ImmunogeniCiLY of US4 o-gro140 in MF59-based Adiuvants Groups of 4 rabbits were immunized intramuscularly at 0, 4, 12 and 24 weeks with various doses of US4 o-gp140 protein in three different MF59-based adjuvants (MF59 is described in International Publication No. WO 90/14837 and typically contains 5% Squalene, 0.5% Tween 80, and 0.5%
Span 85). Antibody titers were measured post-third by ELISA
using SF2 gp120 to coat the plates. QHC is a quill-based adjuvant (Iscotek, Uppsala, Sweden). Results are shown in Table 12.
Table 12 AF-77077.1tiger49) Adjuvant Anti-gp1208,2 Ab GMT*
12.5 MF59 7231 12.5 MF59/MPL 24146 *GMT = geometric mean titer Thus, adjuvanted o-gp140 generated antigen-specific antibodies. Further, the antibodies were shown to increased in avidity over time.
C. Neutralizing Antibodies Neutralizing antibodies post-third immunization were measured against HIV-1 SF2 in a T-cell line adapted virus (TCLA) assay and against PBMC-grown HIV-1 variants SF2, SF162 and 119 using the CCR5+ CEMx174 LTR-GFP reporter cell line, 5.25 (provided by N. Landau, Salk Institute, San Diego, CA) as target cells. Results are shown in Table 13.

Table 13 Neutralizing antibody responses in rabbits immunized with o-gp140.modUS4 protein 10 Group Animal , TCLA* PBMCI
PBMC" PBMC*
Experiment 1 o-gp140/
217 >640 100% 49 Ras-3c 50 mg 218 >640 . 15 Experiment 2 ,o-gp140/
792 . 45 26 _ .

50 mg 793 .

4 .
794 . 59 0 .

o-gp140/ 804 MF59 + MPL
50 mg 805 806 N.D.**

807 , 441 o-gp140/MF59 + MPL + QHC
50 mg 809 810 >640 81192 _ 92 *TCLA neutralizing antibody titers (50% inhibition).
**Not Determined " % Inhibition at 1:10 dilution of sera with any detectable non-specific inhibition in pre-bleeds subtracted.

_ , The above studies in rabbits indicate that the US4 o-gp140 protein is highly immunogenic. When administered with adjuvant, this protein was able to induce substantial antibody responses after only one or two immunizations.
Moreover, the adjuvanted o-gp140 protein was able to generate antigen-specific antibodies which increased in avidity after successive immunizations, and substantial neutralizing activity against T-cell line adapted HIV-1.
Neutralizing activity was also observed against PBMC-grown primary HIV strains, including the difficult to neutralize CCR5 co-receptor (R5)-utilizing isolates, SF162 and 119.

Example 10 In Vivo Immunogenicitv of Synthetic Env Expression Cassettes A. General Immunization Methods To evaluate the immunogenicity of the synthetic EnY
expression cassettes, studies using guinea pigs, rabbits-, mice, rhesus macaques and baboons were performed. The studies were structured as follows: DNA immunization alone (single or multiple); DNA immunization followed by protein immunization (boost); DNA immunization followed by Sindbis particle immunization; immunization by Sindbis particles alone.
B. Humoral Immune Response The humoral immune response was checked in serum specimens from immunized animals with an anti-HIV Env antibody ELISAs (enzyme-linked immunosorbent assays) at various times post-immunization. The antibody titers of the sera were determined by anti-Env antibody ELISA as described above. Briefly, sera from immunized animals were screened for antibodies directed against the HIV gp120 or gp140 Env protein. Wells of ELISA microtiter plates were coated overnight with the selected Env protein and washed four times; subsequently, blocking was done with PBS-0.2% Tween (Sigma) for 2 hours. After removal of the blocking solution, 100 gl of diluted mouse serum was added. Sera were tested at 1/25 dilutions and by serial 3-fold dilutions, thereafter. Microtiter plates were washed four times and incubated with a secondary, peroxidase-coupled anti-mouse IgG antibody (Pierce, Rockford, IL). ELISA
plates were washed and 100 Al of 3, 3', 5, 5'-tetramethyl benzidine (TMB; Pierce) was added per well. The optical density of each well was measured after 15 minutes. Titers are typically reported as the reciprocal of the dilution of serum that gave a half-maximum optical density (0.D.).
=

= Example 11 DNA-immunization of Baboons Using Synthetic Gag =
Expression Cassettes A. Baboons Four baboons were immunized 3 times (weeks 0, 4 and 8) bilaterally, intramuscular into the quadriceps using lmg pCMVKM2.GagMod.SF2 plasmid-DNA (Example 1). The animals were bled two weeks after each immunization and a p24 antibody ELISA was performed with isolated plasma. The ELISA was performed essentially as described in Example 5 except the second antibody-conjugate was an anti-human IgG, g-chain specific, peroxidase conjugate (Sigma Chemical Co., St. Louis, MD 63178) used at a dilution of 1:500. Fifty gg/ml yeast extract was added to the dilutions of plasma -samples and antibody conjugate to reduce non-specific background due to preexisting yeast antibodies in the baboons. The antibody titer results are presented in Table 14.

Table 14 Lmmunizatil Weeks I Antigen lwpi '/ Baboon No. Ab-titer b on no.
0 gagmod 0 w/219 < 10 DNA 0 w/220 < 10 0 w/221 < 10 0 w/222 < 10 6 2 wp lst/219 < 10 2 wp lst/220 < 10 2 wp lst/221 < 10 2 wp lst/222 15 4 14 gagmod 2 wp 4th/219 < 10 DNA 2 wp 4th/220 88 2 wp 4th/221 < 10 2 wp 4th/222 56 5 30 gagmod 2 wp 5th/219 < 10 DNA 2 wp 5th/220 391 = 2 wp 5th/221 237 = 2 wp 5th/222 222 6 46 gag VLP 2 wp 6th/219 753 protein 2 wp 6th/219 4330 2 wp 6th/219 5000 2 wp 6th/219 2881 a weeks post immunization bgeometric mean antibody titer In Table 14, pre-bleed data are given as Immunization No. 0; data for bleeds taken 2 weeks post-first immunization are given as Immunization No. 1; data for bleeds taken 2 weeks post-second immunization are given as Immunization No. 2; and, data for bleeds taken 2 weeks post-third immunization are given as Immunization No. 3.

Further, lymphoproliferative responses to p24 antigen were also observed in baboons 221 and 222 two weeks post-fourth immunization (at week 14), and enhanced substantially post-boosting with VLP (at week 44 and 76).
Such proliferation results are indicative of induction of T-helper cell functions.

B. Rhesus Macaques The improved potency of the codon-modified gag expression plasmid observed in mouse and baboon studies was confirmed in rhesus macaques. Four of four macaques had detectable Gag-specific CTL after two or three 1 mg doses of modified gag plasmid. In contrast, in a previous study, only one of four macaques given 1 mg doses of plasmid-DNA encoding the wild-type HIV-l2 Gag showed strong CTL activity that was not apparent until =
after the seventh immunization. Further evidence of the potency of the modified gag plasmid was the observation that CTL from two of the four rhesus macaques reacted with three nonoverlapping Gag peptide pools, suggesting that as many as three different Gag peptides are recognized and indicating that the CTL response is polyclonal. Additional quantification and specificity studies are in progress to further characterize the T
cell responses to Gag in the plasmid-immunized rhesus macaques. DNA immunization of macaques with the modified gag plasmid did not result in significant antibody responses, with only two of four animals seroconverting at low titers. In contrast, in the same study the majority of macaques in groups immunized with p55Gag protein seroconverted and had strong Gag-specific antibody titers. These data suggest that a prime-boost strategy (DNA-prime and protein-boost) could be very promising for the induction of a strong CTL and antibody response.

In sum, these results demonstrate that the synthetic Gag plasmid DNA is immunogenic in non-human primates.
When similar experiments were carried out using wild-type Gag plasmid DNA no such induction of anti-p24 antibodies was observed after four immunizations.

Example 12 DNA- and Protein Immunizations of Animals Using Env Expression Cassettes and Polypentides A. Guinea Pigs Groups comprising six guinea pigs each were .immunized intramuscularly at 0, 4, and 12 weeks with plasmid DNAs encoding the gp120.modUS4, gp140.modUS4, .gp140.modUS4.delV1, gp140.modUS4.delV2, "gp140.modUS4.delV1/V2, or gp160.modUS4 coding sequences of the US4-derived Env. The animals were subsequently boosted at 18 weeks with a single intramuscular dose of 15S4 o-gp140.mut.modUS4 protein in MF59 adjuvant. Anti-gp120 SF2 antibody titers (geometric mean titers) were measured at two weeks following the third DNA
immunization and at two weeks after the protein boost.
Results are shown in Table 15.

Table 15 Group GMT post-DNA GMT post-protein immuniz. boost gp120.modUS4 2098 9489 9p140.modUS4 190 5340 gp140.modUS4.delV1 341 7808 gp140.modUS4.delV2 386 8165 gp140.modUS4.delV1/V 664 8270 gp160.modUS4 235 9928 These results demonstrate the usefulness of the synthetic constructs to generate immune responses, as well as, the advantage of providing a protein boost to enhance the immune response following DNA immunization.

B. Rabbits Rabbits were immunized intramuscularly and intradermally using a Bioject needless syringe with plasmid DNAs encoding the following synthetic SF162 Env polypeptides: gp120.modSF162, gp120.modSF162.delV2, gp140.modSF162, gp140.modSF162.delV2, gp140.mut.modSF162, gp140.mut.modSF162.delV2, gp160.modSF162, and gp160.modSF162.delV2. Approximately 1 mg of plasmid DNA
(pCMV1ink) carrying the synthetic Env expression cassette was used to immunize the rabbits. Rabbits were immunized with plasmid DNA at 0, 4, and 12 weeks. At two weeks after the third immunization all of the constructs were shown to have generated significant antibody titers in the test animals. Further, rabbits immunized with constructs containing deletions of the V2 region W000/39302 PCTfUS99/31245 generally generated similar antibody titers relative to rabbits immunized with the companion construct still containing the V2 region.
The nucleic acid immunizations are followed by protein boosting with o-gp140.modSF162.delV2 (0.1 mg of purified protein) at 24 weeks after the initial immunization. Results are shown in Table 16.
Table 16 Group GMT 2wks GMT 2wks - GMT 2w3cs post-2nd DNA post-3rd DNA post-protein immunization immunization boost ,gp120.modSF162 4573 5699 26033 gp120.modSF162.delV2 3811 3122 29606 gp140.modSF162 1478 710 12882 gp140.modSF162.de11/2 1572 819 11067 gp140.mut.modSF162 1417 788 8827 gp140.mut.modSF162.de1V 1378 1207 13301 gp160.modSF162 23 81 7050 gp160.modSF162.delV2 85 459 _11568 All constructs are highly immunogenic and generate substantial antigen binding antibody responses after only 2 immunizations in rabbits.

C. Baboons Groups of four baboons were immunized intramuscularly with 1 mg doses of DNA encoding different forms of synthetic US4 gp140 (see the following table) at 0, 4, 8, 12, 28, and 44 weeks. The animals were also boosted twice with US4 0-gp140 protein (gp140.mut.modUS4) at 44 and 76 weeks using MF59 as adjuvant. Results are shown in Table 17.

Table 17 Animal Treatment 2 Wks Post 2 Wks post 2 Wks post 5th DNA 6th DNA 7th DNA
immuniza- (plus o- (0-gp140 tion gp140 prot. protein , immuniz.) only) CY 215 8.3 446 CY 216 gp140.modUS4 8.3 433 . Geomean: , , 26.2 951.4 1812.1 , CY 219 8.3 8.3 CY 220 gp140.modUS4 8.3 8.3 CY 221 + p55gag.SF2 8.3 954 CY 222 8.3 - 71 Geomean: . 8.3 46.5 1011.5 CY 223 41.4 10497 CY 224 gp1.40.mut. 8.3 979 .470 CY 225 modUS4 135 2935 CY 226 , 47 1209 4009 .
Geomean: 68.3 2457.4 4289.6 _ CY 227 8.3 56 CY 228 gp140TM. 8.3 806 CY 229 modUS4 8.3 48 CY 230 8.3 38 GMT*: 8.3 95.3 3375.3 *GMT = geometric mean titer The results in Table 17 demonstrate the usefulness of the synthetic constructs to generate immune responses in primates such as baboons. In addition, all animals ......-.- .---._ showed evidence of antigen-specific (Env antigen) lymphoproliferative responses.

D. Rhesus Macaques Two rhesus macaques (designated H445 and J408) were immunized with 1 mg of DNA encoding SF162 gp140 with a deleted V2 region (SF162.gp140.delV2) by intramuscular (IM) and intradermal (ID) routes at 0, 4, 8, and 28 weeks. Approximately 100 pg of the protein encoded by the SF162. gp140mut.delV2 construct was also administered in MF59 by IM delivery at 28 weeks.
ELISA titers are shown in Figure 61. Neutralizing antibody activity is shown Tables 18 and 19.
Neutralizing antibody activity was determined against a variety of primary HIV-1 isolates in a primary lymphocyte or "PBMC-based" assay (see the following tables).
Further, the phenotypic co-receptor usage for each of the primary isolates is indicated. As can be seen in the tables neutralizing antibodies were detected against every isolate tested, including the HIV-1 primary isolates (i.e., SF128A, 92US660, 92HT593, 92US657, 92US714, 91U5056, and 91US054).

Table 16 Treatment Bleed Bleed I Bleed 2 0 , .
Animal 1st 2nd 1st 2nd 2 Wks Immunization Immunization Imm'n ¨
Imm'n post 2nd .

8.3 45 8.3 254 EO 458 25gg 120mod (None) 8.3 8.3 8.3 43 8.3 8.3 8.3 47 8.3 80 EO 463 25pg 120mod 25gg 120mod 8.3 89 8.3 8.3 8.3 69 1127 , . 15 EO 466 = 8.3 8.3 112 EO 468 50gg 120mod (None).
8.3 94 - 8.3 58 8.3 95 ..

8.3 110 8.3 8.3 EO 473 50pg 120mod 50gg 120mod 8.3 49 8.3 59 8.3 8.3 8.3 8.3 87 EO 478 25pg 120mod Sindbin/Env 8.3 76 8.3 8.3 71 Table 19 Treatment Bleed Bleed 1 Bleed 2 Animal 1st 2nd 1st 2nd 2 Wks Immunization Immunization Imm'n Imm'n post 2nd EO 481 8.3 8.3 8.3 BO 482 6.3 8.3 8.3 EO 483 Sindbis/Env (None) 8.3 78 103 130 484 8.3 8.3 32 BO 485 8.3 76 207 EO 486 8.3 8.3 458 EO 487 8.3 8.3 345 EO 488 Sindbis/Env Sindbis/Env 0.3 8.3 331 EO 489 8.3 103 111 EO 490 8.3 8.3 5636 Lymphoproliferative activity (LPA) was also determined by antigenic stimulation followed by uptake of 3H-thymidine in these animals and is shown in Table 20.
Experiment 1 was performed at 14 weeks post third DNA
immunization and Experiment 2 was performed at 2 weeks post fourth DNA immunization using DNA and protein. For gp120ThaiE, gp120SF2 and US4 o-gp140, appropriate background values were used to calculate Stimulation Indices (S.I.; Antigenic stimulation CPM/Background CPM).
Table 20 Calculated as Ag CPM/Background CPM
Animal/ gp120Thai gp120 SF2 env2-3SF2 0-exp# J408/#1 E 2 1 1 gp140US4 5 H445/#1 1 1 J408/#2 1 1 H445/#2 0 _ 0 As can be seen by the results presented in Table 20 lymphoproliferative responses to o-gp140.US4 antigen were also in all four animals at both experimental time points. Such proliferation results are indicative of induction of T-helper cell functions.
The results presented above demonstrate that the synthetic gp140.modSF162.delV2 DNA and protein are immunogenic in non-human primates.

Example 13 In vitro expression of recombinant Sindbis RNA and DNA containing the synthetic Gag or Env expression cassettes A. Synthetic Gag expression cassettes To evaluate the expression efficiency of the synthetic Gag expression cassette in Alphavirus vectors, the synthetic Gag expression cassette was subcloned into both plasmid DNA-based and recombinant vector particle-based Sindbis virus vectors. Specifically, a cDNA vector construct for in vitro transcription of Sindbis virus RNA
vector replicons (pRSIN-luc; Dubensky, et al., J Virol.
70:508-519, 1996) was modified to contain a PmeI site for plasmid linearization and a polylinker for insertion of heterologous genes. A polylinker was generated using two oligonucleotides that contain the sites XhoI, Pm1I, ApaI, Nan, XbaI, and NotI (XPANXNF, SEQ ID NO:17, and XPANXNR, SEQ ID NO:18).
The plasmid pRSIN-luc (Dubensky et al., supra) was *
digested with XhoI and NotI to remove the luciferase gene insert, blunt-ended using Klenow and dNTPs, and purified from an agarose get using GeneCleanII (Bio101, Vista, CA). The oligonucleotides were annealed to each other and ligated into the plasmid. The resulting construct was digested with NotI and Sad l to remove the minimal Sindbis 3'-end sequence and Aõ, tract, and ligated with an approximately 0.4 kbp fragment from PKSSIN1-BV (WO
97/38087). This 0.4 kbp fragment was obtained by digestion of pKSSIN1-BV with NotI and Sad, and purification after size fractionation from an agarose gel. The fragment contained the complete Sindbis virus 3'-end, an A40 tract and a Rale' site for linearization.
This new vector construct was designated SINBVE.

The synthetic HIV Gag coding sequence was obtained from the parental plasmid by digestion with EcoRI, blunt-ending with Klenow and dNTPs, purification with GeneCleanII, digestion with Sail, size fractionation on an agarose gel, and purification from the agarose gel using GeneCleanII. The synthetic Gag coding fragment was ligated into the SINBVE vector that had been digested with XhoI and Pm1I. The resulting vector was purified using GeneCleanII and designated SINBVGag. Vector RNA
replicons may be transcribed in vitro (Dubensky et al., supra) from SINBVGag and used directly for transfection of cells. Alternatively, the replicons may be packaged into recombinant vector particles by co-transfection with defective helper RNAs or using an alphavirus packaging cell line as described, for example, in U.S. Patent Numbers 5,843,723 and 5,789,245, and then administered in vivo as described..
The DNA-based Sindbis virus vector pDCMVSIN-beta-gal (Dubensky, et al., J Viroi.. 70:508-519, 1996) was digested with Sail and XbaI, to remove the beta- =
galactosidase gene insert, and purified using GeneCleanII
after agarose gel size fractionation. The HIV Gag gene was inserted into the the pDCMVSIN-beta-gal by digestion of SINBVGag with Sail and XhoI, purification using GeneCleanII of the Gag-containing fragment after agarose gel size fractionation, and ligation. The resulting construct was designated pDSIN-Gag, and may be used directly for in vivo administration or formulated using any of the methods described herein.
BHK and 293 cells were transfected with recombinant Sindbis vector RNA and DNA, respectively. The supernatants and cell lysates were tested with the Coulter p24 capture ELISA (Example 2).

BHK cells were transfected by electroporation with recombinant Sindbis RNA. The expression of p24 (in ng/ml) is presented in Table 21. In the table, SINGag#1 and 2 represent duplicate measurements, and SINfigal represents a negative control. Supernatants and lysates were collected 24h post transfection.

Construct Supernatant LysateTable 21 SIMgal RNA

SINGag#1 RNA
7 ng Max (approx.
1 big) SINGag#2 RNA
1 ng 700 ng 293 cells were transfected using LT-1 (Example 2) with recombinant Sindbis DNA. Synthetic pCMVKM2GagMod.SF2 was used as a positive control.
Supernatants and lysates were collected 48h post transfection. The expression of p24 (in ng/ml) is presented in Table 22. Construct Table 22 Supernatant Lysate SINGag DNA

pCMVKM2.GagMod.SF2 DNA

The results presented in Tables 21 and 22 demonstrate that Gag proteins can be efficiently expressed from both DNA and RNA-based Sindbis vector systems using the synthetic Gag expression cassette (p55Gag.mod).

B. Synthetic Env expression cassettes To evaluate the expression efficiency of the synthetic Env expression cassette in Alphavirus vectors, synthetic Env expression cassettes were subcloned into both plasmid DNA-based and recombinant vector particle-based Sindbis virus vectors as described above for Gag.
The synthetic HIV Env coding sequence was obtained from the parental plasmid by digestion with Sall and XbaI, size fractionation on an agarose gel, and purification from the agarose gel using GeneCleanII. The synthetic Env coding fragment was ligated into the SINBVE
vector that had been digested with XhoI and XbaI. The resulting vector was purified using GeneCleanII and designated SINBVEnv. Vector RNA replicons may be transcribed in vitro (Dubensky et al., supra) from SINBVEnv and used directly for transfection of cells.
Alternatively, the replicons may be packaged into recombinant vector particles by co-transfection with defective helper RNAs or using an alphavirus packaging cell line and administered as described above for Gag.
The DNA-based Sindbis virus vector pDCMVSIN-beta-gal (Dubensky, et al., J Virol. 70:508-519, 1096) was digested with Sall and XbaI, to remove the beta-galactosidase gene insert, and purified using GeneCleanII
after agarose gel size fractionation. The HIV Env gene was inserted into the the pDCMVSIN-beta-gal by digestion of SINBVEnv with XbaI and XhoI, purification using GeneCleanII of the Env-containing fragment after agarose gel size fractionation, and ligation. The resulting construct was designated pDSIN-Env, and may be used directly for in vivo administration or formulated using any of the methods described herein.
BHK and 293 cells were transfected with recombinant Sindbis vector RNA and DNA, respectively. The supernatants and cell lysates were tested by capture ELISA.

BHK cells were transfected by electroporation with recombinant Sindbis RNA. The expression of Env (in ng/ml) is presented in Table 23. In the table, the Sindbis RNA containing synthetic Env expression cassettes are indicated and Ogal represents a negative control.
Supernatants and lysates were collected 24h post transfection.

Table 23 Construct Supernatant Lysate (Neat)ng/m1 (1:10 dilution)ng/m1 I3gal RNA 0 0 gp140.modUS4 726 7147 gp140.modSF162 3529 7772 gp140.modUS4.delV1/V2 1738 6526 gp140.modUS4.delV2 960 3023 gp140.modSF162.delV2 2772 3359 293 cells were transfected using LT-1 mediated transfection (PanVera) with recombinant Sindbis DNA
containing synthetic expression cassettes of the present invention and Ogal sequences as a negative control.
Supernatants and lysates were collected 48h post transfection. The expression of Env (in ng/m1) is presented in Table 24.

Table 24 Construct Supernatant Lysate (Neat)ng/m1 (1:10 dilution)ng/m1 Pogal 0 0 gp140.modSF162.delV2 1977 801 gp140.modSF162 949 746 The results presented in Tables 23 and 24 demonstrated that Env proteins can be efficiently expressed from both DNA and RNA-based Sindbis vector systems using the synthetic Env expression cassettes of the present invention.

Example 14 A. In vivo Immunization with Gag-containing DNA and/or Sindbis particles =
CB6F1 mice were immunized intramuscularly at 0 and 4 weeks with plasmid DNA and/or Sindbis vector RNA-containing particles each containing GagMod.SF2 sequences as indicated in Table 25. Animals were challenged with recombinant vaccinia expressing SF2 Gag at 3 weeks post second immunization (at week 7). Spleens were removed from the immunized and challenged animals 5 days later for a standard 51C release assay for CTL activity. Values shown in Table 25 indicate the results from the spleens of three mice from each group. The boxed values in Table 25 indicate that all groups of mice receiving immunizations with pCMVKm2.GagMod.SF2 DNA and/or SindbisGagMod.SF2 virus particles either alone or in combinations showed antigen-specific CTL activity.

Table 25 Cytotoxic T-lymphocyte (CTL) responses in mice immunized with HIV-1 gagmod DNA and Sindbis gagmod virus particles Percent specific lysis of target cells*
Immunization E:T SVBALB SVBALB RMA
none P79 P79 pCMVKm2.GagMod.SF2 DNA a 100:1 5 20 at 0, 4 wks 25:1 5 20 <1 6:1 4 B <1 SindbisGagMod.SF2 100:1 10 49 <1 virus particles b 25:1 7 20 <1 at 0, 4 weeks 6:1 5 12 <1 , pCMVKm2.GagMod.SF2 DNA at 0 100:1 9 58 <1 wks SindbisGagMod.SF2 virus 25:1 7 42 particles at 4 wks 6:1 4 13 <1 SindbisGagMOd.SF2 100:1 5 38 <1 virus particles at 4 wks 25:1 4 18 <1 pCMVKm2.GagMod.SF2 DNA at 0 wks 6:1 3 13 = 20 pg b 10 particles * Challenge with recombinant vaccinia virus expeessing HIV-1SF2 Gag at 3 weeks post second immunization (week 7).
Spleens taken 5 days later. Ex vivo CTL assay performed by standard 51Cr release assay. Values seen represent results from 3 pooled mouse spleens per group B. In vivo Immunization with Env-containing DNA and/or Sindbis particles Balb/C mice were immunized intramuscularly at 0 and 4 weeks (as shown in the following table) with plasmid DNA
and/or Sindbis-virus RNA-containing particles each containing gp120.modUS4 sequences. Treatment regimes and antibody titers are shown in Table 26. Antibody titers were determined by ELISA using gp120 SF2 protein to coat the plates.

PC1'/US99/3 I 245 -Table 26 Treatment Bleed Bleed I Bleed 2 (8 wks) (10 wks) Animal 1st 2nd 1st 2nd 2 Wks Immunization Immunization Imm'n Imm'n post 2nd 8.3 6.3 EO 458 25pg 120mod (None) 6.3 8.3 8.3 8.3 8.3 8.3 8.3 EO 463 25pg 120mod 25pg 120mod 8.3 DNA
8.3 8.3 6.3 , 8.3 8.3 E0 468 50pg 120mod (None) 8.3 8.3 8.3 8.3 EC) 472 8.3 8.3 EO 473 50pg 120mod 50pg 1.20mod 8.3 .
.

DNA
8.3 8.3 8.3 =
.
=

=
8.3 8.3 .
EO 478 25pg 120mod Sindbis/Env 8.3 8.3 8.3 8.3 8.3 8.3 8.3 8.3 8.3 EO 483 Sindbis/Env (None) 8.3 8.3 8.3 8.3 8.3 8.3 8.3 8.3 EO 488 Sindbis/Env Sindbis/Env 8.3 8.3 8.3 8.3 8.3 As can be seen from the data presented above, all of the mice generally demonstrated substantial immunological responses by bleed number 2. For Env, the best results were obtained using either (i) 50 Ag of gp120.modUS4 DNA
for the first immunization followed by a second immunization using 50 pg of gp120.modUS4 DNA, or (ii) 25 pg of gp120.modUS4 DNA for the first immunization followed by a second immunization using 107 pfus of Sindbis.
The results presented above demonstrate that the Env and Gag proteins of the present invention are effective to induce an immune response using Sindbis vector systems which include the synthetic Env (e.g., gp120.modUS4) or Gag expression cassettes.
Example 15 Co-Transfection of Env and Gag as Monocistronic and Bicistronic Constructs DNA constructs encoding (i) wild-type US4 and SF162 Env polypeptides, (ii) synthetic US4 and SF162 Env polypeptides (gp160.modUS4, gp160.modUS4.delV1/V2, gp160.modSF162, and gp120.modSF162.delV2), and (iii) SF2gag polypeptide (i.e., the Gag coding sequences obtained from the SF2 variant or optimized sequences corresponding to the gagSF2 gag.modSF2) were prepared.
These monocistronic constructs were co-transfected into 293T cells in a transient transfection protocol using the following combinations: gp160.modUS4; gp160.modUS4 and gag.modSF2; gp160.modUS4.delV1/V2; gp160.modUS4.delV1/V2 and gag.modSF2; gp160.modSF162 and gag.modSF2;
gp120.modSF162.delV2 and gag.modSF2; and gag.modSF2 alone.
Further several bicistronic constructs were made where the coding sequences for Env and Gag were under the control of a single CMV promoter and, between the two coding sequences, an IRES (internal ribosome entry site (EMCV IRES); Kozak, M., Critical Reviews in Biochemistry and Molecular Biology 27(45):385-402, 1992; Witherell, G.W., et al., Virology 214:660-663, 1995) sequence was introduced after the Env coding sequence and before the Gag coding sequence. Those constructs were as follows:
gp160.modUS4.gag.modSF2, SEQ ID NO:73 (Figure 61);
gp160.modUSF162.gag.modSF2, SEQ ID NO:74 (Figure 62);
gp160.modUS4.delVl/V2.gag.modSF2, SEQ ID NO:75 (Figure 63); and gp160.modSF162.delV2.gag.modSF2, SEQ ID NO:76 (Figure 64).
Supernatants from cell culture were filtered through 0.45 pm filters then ultracentrifuged for 2 hours at 24,000 rpm (140,000Xg) in an SW28 rotor through a 20%
sucrose cushion. The pelleted materials were suspended and layered on a 20-60% sucrose gradient and spun for 2 hours at 40,000 rpm (285,000Xg) in an SW41Ti rotor.
Gradients were fractionated into 1.0 ml samples. A total of 9-10 fractions were typically collected from each DNA
transfection group.
The fractions were tested for the presence of the Env and Gag proteins (across all fractions). These results demonstrated that the appropriate proteins were expressed in the transfected cells (i.e., if an Env coding sequence was present the corresponding Env protein was detected; if a Gag coding sequence was present the corresponding Gag protein was detected).
Virus like particles (VLPs) were known to be present through a selected range of sucrose densities. Chimeric virus like particles (VLPs) were formed using all the tested combinations of constructs containing both Env and Gag, Significantly more protein was found in the supernatant collected from the cells transfected with "gp160.modUS4.delV1/V2 and gag.modSF2" than in all the other supernatants.
Western blot analysis was also performed on sucrose gradient fractions from each transfection. The results show that bicistronic plasmids gave lower amounts of VLPs than the amounts obtained using co-transfection with monocistronic plasmids.
In order to verify the production of chimeric VLPs by these cell lines the following electron microscopic analysis was carried out.
293T cells were plated at a density of 60-70%
confluence in 100 mm dishes on the day before transfection. The cells were transfected with 10 pg of DNA in transfection reagent LT1 (Panvera Corporation, 545 Science Dr., Madison, WI). The cells were incubated overnight in reduced serum medium (opti-MEM, Gibco-BRL, Gaithersburg, MD). The medium was replaced with 10%
fetal calf serum, 2% glutamine in IMDM in the morning of the next day and the cells were incubated for 65 hours.
Supernatants and lysates were collected for analysis as described above (see Example 2).
The fixed, transfected 293T cells and purifiesi ENV-GAG VLPs were analyzed by electron microscopy. The cells were fixed as follows. Cell monolayers were washed twice with PBS and .fixed with 2% glutaraldehyde. For purified VLPs, gradient peak fractions were collected and concentrated by ultracentrifugation (24,000 rpm) for 2 hours. Electron microscopic analysis was performed by Prof. T.S. Benedict Yen (Veterans Affairs, Medical Center, San Francisco, CA).
Electron microscopy was carried out using a transmission electron microscope (Zeiss 10c). The cells were pre-stained with osmium and stained with uranium acetate and lead citrate. Immunostaining was performed to visualize envelope on the VLP. The magnification was 100,000X.
Figures 65A-65F show micrographs of 293T cells transfected with the following constructs: Figure 65A, gag.modSF2; Figure 65B, gp160.modUS4; Figure 65C, gp160.modUS4.delV1/V2.gag.modSF2 (bicistronic Env and Gag); Figures 65D and 65E, gp160.modUS4.delV1/V2 and gag.modSF2; and Figure 65F, gp120.modSF162.delV2 and gag.modSF2. In the figures, free and budding immature virus-like-particles (VI,Ps) of the expected size (approximately 100 nm) decorated with the Env protein were seen. In sum, gp160 polypeptides incorporate into Gag VLPs when constructs were co-transfected into cells.
The efficiency of incorporation is 2-3 fold higher when constructs encoding V-deleted Env polypeptides from high synthetic expression cassettes are used.
Although preferred embodiments of the subject invention have been described in some detail, it is understood that obvious variations can be made without departing from the spirit and the scope of the invention as defined by the appended claims.

einevovaq oosi 6olopope63 peo6534133 ovoale6goo oplquew444 0048161088 6682086828 ottI 63361;66e36 ee68033430 0108808888 6866866664 2466enqqn6 eftbeefieno 08E1 800=883142 ouftEmone6 vo6e5e3440 144488556e 3D66law66Sy eouqualloo ot 6633qe6eviS 56elq4444e aq3568oe5e 5864380644 8688e6aese 33e3e55e86 09eT 6See663,638 SuE62464o6 SSupeueSbe 33333666e3 6448888800 6848080666 ocon euEceue3663 56 46ev446que 6telaw6wevo 886681444e 8065868680 otrE 64126que.4123 vegobwouqe veoe846880 368548un5e 1433664434 6e68836eve 0801 28406603ov 56666516p6 E6o163806 vo864863ey yfte6equeo 8436euftop out 855634836g ve1243437alo liftell643e6 v=0888064 8888004662 096 eu86.486834 2Ee 668peollo6 venee6336e Seeququype Ineqaqq66u 006 0868364834 v6868444= 866eveop e66veuefte 4808664044 soSeporloo 0,8 35eqe464128 688468388e 723128824865 6400488486 6186888818 08L 846en3uqul noeooleele evoubwe663 e667eqesq/De 7:0568344o30 OZL v6612o684/23 Q64E886666 ee33ee6748 6488800568 upe354.4843 0666e36480 099 64SgooleuS 462681966S que6e36336 v126512648123 Tglog6T2612v 009 6323068o5w voavola6668 6616govogy 843648opro eee44486es 3epoupeoo6 OtS 8668868018 4483683141 264euouele elfiveSeupo 6e31440668 081' eqbeeveq66 6qe363speel 33ove6lalou eogg4you86 sogeo124664 e365668u OZt elopee6e36 162184aupe 148888=68 o366upo6eo SieneeeMeo e366336e36 09E 4358u6e3Se tinbeavo66e eemeGuelbe epeopeevo6 e6ee664/61,4 v61:14467233 00E loBee65evo peueSegewl 6486847/6Es 88348o8464 6e3 We06e26V0V
OtZ 4881c/4844e 332684238y B8834865 epubleol4no D48=68384 05vo865644 081 elevemifto 63o66ge683 4;231;214r:ill S3o4664334 128.336836o4 OZI Ev66683Ege u6664i4684 eqeoeeeell 688284888,2 8868886666 09 663q3e21288 86661ereqe 681qs7e6v66 66635ee118 3660460585 <00t>

enaTA A3ue101;epounwwT uewnH <ETZ>
NO.la <ZTZ>
60ST <TIE>
<01Z>

O'Z '48A u/411048d <OLT>

06 <09T>

TE-ZI-8661 <1S1>
S61''1-TT/09 sn <OST>

0E-Z1-6661 <TWT>
SWEIE/66811/Wd <WE>

T-M8E961' LYd <OET>

SWIOIDIYA HMPI-WHIA AO
NOILOCKIOAd ONY SECIIJAMAZOd AIH AO NOISS3WCH Cl2A01111WI <0E1>

uoTleiodaop u04T1.10 <OTT>

DNIXSIrl aomnoas . ......

08t yftwein66 62g062eval 32 TivSeqop imgy4woo66 Ti3qepeq66q pepo6666123 OZt eloamafto6 q6slin000g gwypepoft pq6SvooSep Em3way66wo 12366136wo6 09E q3623Sia381? goEmovaD6Ext mayliEgy1672 smspeeseo6 g5 6E5 eftg6v6leql 00E q36y266vvi3 ovovEvetain 5211SinvE611 tupww2164 84qtn3q3o3 vvo6eq&apy OtZ qinmellelqva oquftqlawa 6wvfto4e66 eorkvo33o oquooftwaq 35os666q1 081 smagwou6vo Sqp66,1i5,20 lineve6,222 6233862004 12131E413501 le6312115v10 OZT 61/665eo6 3666w16,q glsovvvrill 6velinInge vv6wevESS6 6.03366/m41 09 66043valege v6E45qvvillip 5wqqvg6w56 66606VIMW 2E603E0E026 v60635661e E <00t>

eniTA ApusToT;apounwaT ulawnH EI2>
Iota <vre>
ETEt <TIZ>
E <WIZ>

Stet 1951qs 3o663riv36 elq6evee33 366 6& 6612336veln 0081 leveg16e03 w1613vIre61 qv4331S*33 v030343412v villqogq6q4 66q11412313 otLI e633633411v w6s662qtre lwalreol6lo ogosloov66 inftlagq6s 3vq667elvqo 0891 SeveqspeES lElounmSe 3633ovquee 34,1163v4.6e3 e6vvq6wie3 1.12q3.4355e6 0E9T 6qTev66666 72.4736q7evelew optinm6Sqva ve66goo611 valaqwgri6v w6e3TelZeo 09S1 v4v64126,206 1368,23Talvi6g 11s1o2o6ye 66greloweo 666666vu5 Eveuelm/201 oosi 6ol3poor63 ev366342o1 3pply6y3q3 op4q3velqq oDqe4Sqoge 66wvora6Q4g otti 6po6/2662o6 waSstoqpqap oqoulaxamew 6p661266663 1165epqa36 v626'6%6233 ogET gapp35s3w2 poSeSoopri5 up6e61,3223 qlllev66612 3366p1.66612 v3Talopq1D3 OZET 5666 66v1441449 121366123)76w 612633173621 efte126.2sse oovos.6673e6 09z1 66tala66q6qg Sy66146q36 6666e 133=656= Eqqvarreseepo 6666 poet veSeire3651 6q112voqqq6 36einq6qav ftev6Tarivop es.66vq434v go66s6s6eD
ont 6q126q1o24123 lon.36w3oqe seoww36sup 36,4112335y 12630664142 6126lite061tev 0801 av3366333s 66886616*6 662 6235 yo262s63,21? 26y11,62govo ,2436,236e33 oug e666q1eD6s epsqq43v243 26v216q1e6 vp33lre2361 seelapp1661 382Z0012Em6 096 wou6.4266q1 ve2mq6qe 55epri3Ta36 2e3ple6p3S1 Emeqoq3222 eq2olq663 006 326 62 2526 o3 apv66vompo 265imov6279 va3w6643q4 wo5yoovqop 0,8 36124g163wit StrelSwqinni eqweelle66 6l3oq2vavE 52v6v2eelv 231e1m6c155 On s16233312q 3pv3312212 ev3ta.426Sq 2662 22 y661231q333 1216y4og43e OZL 1265193617412o 2646waS6E5 egpaggEmSe 6wevasoo662 owe36q3223 36E6236223 099 6q62333yo5 q626silyE5S TegSvo6q36 ee66,26qe#0 1e30,36v6vg 2e4154/221.0 009 61e336e362 e26666 5816volao2Q ino6Teoovo e6e preop3ogoD6 OtS 2661m6yoqu 44s06/20113 1832o33ine gq6Eve6e333 623413662 rep6pe5eq5 081, sq6lre2e266 STeo6qmq qqopy52333 yols.49o366 g3llawa4661 riveD666623 OZt 2133226236 461avoqaposi lquesmoaft 31661=61m Semnivafto 2366236236 09E 1362362062 vo6g32o669 veyySyyqbe immwevvvo6 26,212561.6rn 26,2125taelq 00E q36e1.662wo opoithetreeq 63,26vq7462 legDqviolaq6q 6341noqaoo 2eo6e26232 OtZ zevq,elvq4v ollaftqqouv 812126goqt786 gov6volqop 321/336g3in o6or6661.4 08! valvevorSep 6lo66ve6vo qvowee6inq 6563; creoqfivo6o4 quEspettheqo OZT 6285623622 3866112152 EmlnelVvve v176212'26666 6e00662211 09 65011gssee it66622#4,2 Emqviv6v65 66.635im4v 166346361/6 263656611?

Z <00t>

enaTA it3ueT0T;epounwwT umunH <Vie>
VIM <ZTZ>
St8T <TTZ>
Z <OTZ>

08L 5622622652 0622422221 2222222222 2352222266 22666120,6e 0eLE S23523222 226226235e e6e6 6252=6225 2223252362 2662222222 099E 222,2266226 v23222322 6222512222g 2562222256 202262262o 2522522325 009E 5222522=6 2252652222 2362=5222 1222526225e =52252222 2622222622 01,5E 6226233233 6233222232 2626223662 2235252652 2222623232 raw/262522 00tE ovv6ve5gwo oo66vaiely5Q 2812664V/262 2114213,346 2226623422 5612546231 pen 6222222226 v252232262 v2256126522 12,266vrav3leo vo6woovq68 6423552=y 09EE 22255221226 52212222222 2262252622 2222220262 =52215252 3422526262 00EE 2226203223 22522=22o 222662222o 52222222= 22622212262 quovv216ve 0trE 52222666= 27266225222 26223272232 2225922222 2262225226 22221223223 091E 222522622w 322252262 222/2226226 626222522p 2252242662 0522226621 0zTE 2222332625 5522222362 2656542622 52222222ov 226236265v 26222222es 090E 6222526223 62=22562v 2422252622 2=0200222 2222361116 2555162522 000E 2222552232 2352236532 2252562266 2682228225 5522322256 22,22222,222 OV6Z 0212222212 2222=2226 2226565222 222622226g v262223322 2522222262 090z 6/235625232 222520/2222 2622622223 2020306156 66/26126622 3612262226 9 e 62322225= 2222222222 =62522022 2222223222 vou65ureoo 662235666y 09Lz 3822623222 226235226e 2232622223 22333E52122 2222262252 22/2262=se OOLZ 5222220222 828562222e 2522652322 5223526206 ev62,6gova 2222222221 O19Z 5226202222 2262272=ww 6626222222 D88,2281V12 6236222252 v322256622 08SZ 5421222620 1622266842 2252222226 652622252e 6222222262 2222523266 oese 2362225222 226236226 222222226v 3225232562 22221282332 2=2322622 09tZ 4266642654 4100422332 3322622262 222222222, 2262=2322 3222225565 001,z 256262262o 223523E526 2222662622 222222226v 222522666g 222252222v OtEZ 63=266225 2226222262 256222222v 338304E336 22222520= 2E62322226 08 2222223526 222=22222 pv82226226 222=22222 2252=2222 6622268226 oeee 6622233523 6282222225 232125222 2685232232 5262222222 lElftq00132 091e 2332222236 2322226/ewe 6222232622 V2E6/223000 4161204q413 w11206112646 00TE 6525226622 246232,2262 =22222262 gegvg22856 v36=22232 3222226622 OVOZ 1523416226 661322252 v23226222 22212223225 26232226p 2622322226 006! 2652222=2 26/m26222e 225es/22222 5141215200 2021220222 2012222540 0e6T 3666222222 2222222225 662266222g 6622225222 262222525e 2622223622 0981 2222222226 2262228222 3056222252 2225222233 366226622y 6622262222 0081 2222225200 21643221262 1210016212 202=11222 2241222522 6512252220 OtLT 262252222/2 26122662222 223222252o 22022=256 12252222282 3226622223 0891 6222223256 28222vesEee 252=22125e 3226222523 252225222o 2222226625 0r9T 5222265666 21,26vineme =2914.611m 22.56232622 222522225e 12622222522 09St 2226226226 256232226v 222230522 6522223223 6565562226 6222223202 00sT 5322322262 2235622222 3222125,2323 3322322222 3322q62322 5622226822 01,1,1 6336266236 29523333 =32222222 6266256552 2266222226 2626225233 08ET 203262322 2262823326 2362623110 2111226562 3366226552 2222=2233 0zET 662326226 662222222y 222562225y 6262020622 2622252222 3323266225 09E1 5622562622 62 6622622S 6622221256e 323366622 64qTrecliviDo 6222223666 poet 2252223652 6222222225 2522226232 6222522232 2255211112 2266262620 0prt 62262222pp v222593322 2202226223 3625220252 2610661112 6262206222 0801 222256=3/2 6556562625 6523252226 222622622e 26226122323 2405225200 0e0T 266641235v v222222223 251112282225 2333222252 V2VE332664 164303We26 096 2225226522 2222222622 6620231226 223226=52 52222222/272 2222=265o 006 22512262222 28262422= 3225522233 2562209522 2232561021 9352322232 Ot8 3524226229 592262222v 22E2222255 6233222225 62262#2122# =22226266 08L 2252233222 3323322.22/2 2222622652 26522212232 2562222233 22622322ov OZL 2562352222 2628225665 9933926962 62222=56e 33v3522922 3666235223 099 5262332235 2E26222666 22#5225226 #266252923 22222625c2 T2222522220 009 5213352062 232225665 65Ee E3623393 2922222622 3232332336 OtS 2562252329 2222623222 2622=0222 2269262333 62322065v w926126.61216 LT-60-TOO 1.1709E2O VO

apuenbaS TeT0TIT3211 <EIZ>
VNG <ZTZ>
ES8T <TTZ>
S <OTZ>

SIST ygq6e poSeobepoo OOSI or6opro65o 1q6qoo6eD6 p6qDp5 65 q06v662e0g 603P0D0EP6 OWL 6tioSev5ep 6poopopeop e6v5e6BeS o66333o5po lqo6REv.66p 5oopoo33o6 oRET oorpoo6r6o pooSo361216v n6qopqlpee 38600apaDD 6566 eD33661olv OUT 6vvo6E6loo q;Dveop6Slia oa5D6e6poe 3533e.66ee6 ar6epogoo6 88e5o6o356 09c1 36136o6613 63o666ee6 b000ppoS 36336qove6 6yoo63oeov op666266E2 HET DE6o6lopro .3136q5eeol 6oogGee66o 6/2Dogeo6oD q3oevD56o6 obeoBleBar ()tit 3quooe6365 oo3eg6ov51 56roo6e6le 63662Boo66 lo6q636o3o 66evovo366 0801 D303653666 36366fiepo6 lo3Eo3e6qv 6qe6)2651266 qo33spo66o 666ogo OZOT 30661m6.4Do qv3oavea6 qov6popove Do6ove6rob 386q361opo v6e600e6Te 096 6665 363e6,6epo6 goo56eD6v6 zo5o6D6lop pg6evola;pq qo600v66q6 006 ov3pe6o6o0 qlopo6,46v goDoo656eo o6poqe3r66 looleo6233 voppoSeDeq Ot8 5TeB6o5q6o q26veose61 pa6E6lo33p 33e66.466o6 reoe3Dqv6e 6o666q6000 08L plEopop000 reore33e6q ,266qD66Dqv 56666 goopeoEmoo popeo65op6 OZL oTeav636,23 66p5opoo6 6o5o6qe5o 36603o3363 lropoo65o3 Eop36q5Doo 099 3e3616063o E.6656eSpo 6ao66.266e6 Deeolgoov5 v6Ecew6qobq u6uo63.2D36 009 opEEreoppop 5635664533 vaes.6q463e Soeoue6qop e66gopoopo e336o66Se6 OtS p6w6qopo63 6voq6qrop opayfigE6e6 p0006pDlqo DEB 666 66q56166wy 08' Sq6663353 ee61331;,36 opopo6voqu. oo6612Dovo6 466qu6uooS 66e3633oer OZt 6e0E1631/23 poae4ouv6e 3367e6q66ep obvp6voego 66ope66op 6005po6036 09E oo66vo6roo 355 ES epplEmvoee 6pD61256v66 w6oqe5wii5s. 66loap66e6 00E 6ep3oe3p66 wepq6314.34 sp5o6eooeo 66356 z33og30561 600vDer3v3 OtZ 5566 qp6e56126o6 yoSsooebso 65 vo61o6vao6 565e3 08T 36o363o666 r2536yopebe 66qo5looS6 opoovv8q6o p63323635r 6,6136v6o63 OZI 35e36666 q6p2rappo5e y5qo6eosn 5yy5yy5pro 66366o5 D6loo6004v 09 6e26v556046 Im3e6Sqo6e 635536635e 513616382o 3636ao3636 666 / <00t>

6v0-AIH
3T39113uAs :apuenbas IvT0T3T41V 30 uoTlciTaosaa <EZE>
<OZZ>

emianbas T eT3T3T12"V <ETZ>
VNO <ZIE>
STST <TIE>
t <OIZ>

ETEt beg quE666 rDe6r36gro 66q6163Te6 Te6365y356 qs6w3vveu6 09Zt 61v1e665e 31volErepv 36peve6ey6 uepo6q6v45 yveeTeovea Svqeele6vs 00Ct peqsvq6v15 Eo55661m6q 65Que56qa3 paw5eevo6 epoe66eve6 6qqlooDolv 6vevaeleov5 66s3e11p13 18550341qp 212voq;evev pop;levvo6 veueov30e2 ogov Beevlovveo elvori6voww obeweqeog Svq6eqesbe vel$666po6q 6voeqs6666 clui, 634;26565E6 eues6evegq qllvroepoq pplqvq6e36 53xlmovq6,2 a6epe6veqq 096E opeore6.436 5p3le6v6ee 366123g6Emq pqwetreftv inqee6ze22 vs63v33.Ter 006E 5e1E4246e56 ripD46eveDD opqvVDP30p 03qvo6611q web5e36veo 32566723565 crvgE q66qq6qoo6 3366eglaS6 orloplEveop v3.41412'23E42 356.4e-ra3v6v oeleaeqreo C-7-on_rn^, 00E 6evooe3e56 veoa6oe6o2 e36o6eo3eo Sl6o6qorlE. loopeo366q 6opeoevoeq OVZ ElooSeoboS 106e66/2636 vo6600e6eo 63oo6w0005 vo6qo6eooe. 666eo 081 35oo643665 eboBeopeava 56 5z66 a000pe616o p6o3aa6o5e 65136eS36o a6Qo3666q6 q6ogeogo6e Ebloftepel beefteSevo 66o6600006 06qoo5poqe 09 5ey6e665q6 geoe661o6y 636535536e Eqp6q5o6vo ofioS0006o6 66geopep36 9 <00V>

asezemAtod-6D-AIH
3TlegluA8 taouanbes 1eT0T;Tlay ;o uoTldTiosaa <m>
<OZZ>

aouanbaS IeT0T3TWV <ETZ>
visla <ZIZ>
6TEV <TTZ>
9 <OTZ>

ES8T eel 5E56 poEveol.66e eop3o66ov6 6266666 eeEr4obee64 0081 6o336q66De 6e6oqe3000 Evoqe0000q loee5q000e o6ao55ole5 e33os6106l OVLT opevo5oo56 oTeoaeove6 3600000200 03866166q0 6q600v0660 qeO066/2202 0891 oo6606qDqr 6e65q5poop le5eooe6o12 q6vo66o6q6 Seeo;eoqlo 6566666 091 6a66oqw6le 6evoao6e126 616epo56po o5qopee5le 6e66e663o6 163peoe8oe 09S1 60o6o653oe oe5olo6136 366e66evoq o6e0055o66 p1e6Eree46e Deoq60q0oo 00ST 3e6oppo661 q4o132oqe6 voqopoqqoe eaggoogeq6 qoer65evoy 6ele63oSe6 OVVI 6eo6e6eoq ol000logeo evee5e6figE, 65 65o lqo6e6e6eg 6eooe000D6 08E1 eoep3o6e6e 3pe6eo6e6e 01104441122 666voo6Eve 666eu3e3oo 4l005610le OZET Eve65E0244q qqqeeqo66e ovEm6e6qoe 3611e6eve6 3eepooeoe6 6ee6D60066 09ZT o61o6o653o 633666evEve vo6op00036 36o36qove6 6eop6ooeoe 3o666e66ey 00Z1 356353oveo qqoElEtevoq 600e6ee65o brooveoEtoo llove36636 36e36qe6qe OtTT 01eo3e5o66 000eeSpe61 55 66p 665666 .43646o63oo 66sepeoo66 080T p3oo663666 q6D666e336 looSooe6le 6le5e66e66 loope00660 6030365013 OZOT .4o65ee6qoo qeope5eeo5 los6opoope ooSoee6eo6 166qo6l000 s6e600e5q2 096 65E q6ne66eo36 poo86eo5w6 4o63636qDa oeSepoeqol lo600e5616 006 orqoe6o6oo qq3oo6e66e eopoo666eo 3600ae3s66 l3ole36ep3 e03006e0v1 Ov8 63'2663616o le6eyove61 oo666qoole ole66165o6 evoeqoqeft 6o66646apo 08L oleop0000n eepeepoe6i e6 66z 6eo6e66ea6 l000roftoo eposo66=6 OZL 3qeoe5o5vo 66o500006e So5o6ge6o 36633=063 qeoo3o65oo bovo645000 099 ovo636o6po e66616e6o3 6D366266e6 Dve3gpople6 65 &36 p6e36ae3o6 009 oo6623ov3o 66o666.4600 uove6q16qr 6ovove6loo e66epoop3o poo6o666e5 OVS o6e6qo3o63 Seoq36.4poo 3pq126166e6 oopoSeoqqD 55 656 556666ey 08V 616864006o ula54000so6 aoopoSeoqe op6Evoovo6 365qe6goo6 6Seo6qopee OZv SeobSolro 000eloee6r op6e6166vo o6vo6eoepo 65 66z 6006006006 09E p3E6eo6o3 obbeebeeft wooq6evose 6e36e66e66 e6oleSer5e 66l3oo66e6 00E 6ueo3eoe56 veoq6ou5oq epbobeopeo 645o6loel6 qoopeoo56q boovoyeopq OVZ 5.4005eo6o6 go6e66e636 eo663oe5vo 6qo35ea3o6 eo64o6epo6 65goole6o 081 o6=613666 eBobleoopft 55 666 oopose6q6o o5o2loBobe 65.4p6e6o6o o60066616 16oae3ro6e 263oEmeaeq 6ee5e6evo 56666 364005ooqe 09 6ee6e66616 evoe561o6p 6o66o56o6,2 6qo6q6ofto 3636o3o6o6 655 S <00V>

ageeqoad-6eD-AIH
oTqagluits :aouenbas TeIDT;TlaY ;o uoiviTsosec <m>
<OZZ>

LT-60-TOO 1.1709E2O VO

009E upo66e6366 Efes6ao6rop Sq6yeovS36 qo6yo36616 34,25.266evo 366q66;6o3 OtSE 33036403vv 0113p636vo z56 6E o66.4312236e Deopeq6E,e5 128Deo6v66e 08tE 66epoD66ew ow6Dquo66D ee6qopq6a 35366yepE3 pqro563o6D 6e6466a3E.E.
OZtE vov66.466vo EmEoevo663 bEtoTeoES6e govoopboop 665666 qoovq6.46612 09EE 25v6SweEmp Dge6qa6po6 v5ogleoqTa6/2 po6y6466qo 5e6p6e6v63 Em5ypor5D3 00EE 36233a66123 aqvoqp3666 goop6orqft ooftosEopp 615o3eage6 .466.2561op6 OtZE 5a612326fto 63opp6Sq33 yooqp3066e oB436e5opy 5/2v62oovvo oezavot.5Do 081E 6oqeo6e616 6q65TaviEsoo 6o366o6pou 6oxe515onl 366006Emro 6.66136r2Do 01E25e6o6pagE op6o06366o n6646oeloq loop6v6306 p666163qco o3Eri6ftv6s1 090E 661o6epovl 66161o6c/26 16543000pp 000vose538 pq3.6v66616 e6oDoole66 000E WpwooMpo 667.ovq6e56 qt.561663op 66v66513ov 6e66ev6eao lepoo6.43612 Ot6Z poqq6pp300 olebee3656 61o4,2646o4 po56w600e o6e6166ve6 vo6q63o66e 088Z 63ov6q36eo 5e12.6463p6o vsoppaeopp 665e o6o3o6peqb evo66poe6e OZ8Z v6qoove6ec oqloop6vEB pooin3lv6e oovqopv661. 6eo3666eoo 666vo6E-e6e 09LZ oply6p6po5 6q66q33145 evoSw000pe 6anoyq6q6 6e63vo5q63 p3SeS6e253 OOLZ op4e6g536o olev6y5Do66 qo6p6.6qoft 5oo66y6SeS opeeloppop ge6156gEop Ot9Z e6loo56pe poe36536o6 35qD6vv36 16qo6gobve 646Bevpaeo 663o6o12131 ogsz vEvooblaaa6 85.4ovv6w6 es3666q662 o6e6e333e oe6oee6q6o pe6B1D6vot.
ozsz 55Pe6v6333 61363poqeo ao6e36163D p6636yeD26 opoowo6q36 vEorqD665q ogtz v661613olq opp3aoft66 wv6eDopD6g uftvoub000 00e0DVD333 566610E051 00tz p6qopro5eo 36362o6e56 pEoq26eeop po63Dvofto 3563328w66 gooti6o6yo6 OtEZ 66q8op163p py63266gso 124Epoovq3q y6q6aqype6 oppoev6206 sepEpogloo 08ZZ 36v66qooge Beeporblvo 6vo6v6eool qolepoSopo Devo566re6 6E667epoo OZZZ 3610616ove oeqbropeqo 6pole36600 opov6e63ev 3weaqeo5eo oDoluoovoq 091Z loo5D3posiq. 61212D600lqo 26BeeoeS6q opoo53635e olloe.1.336o e6366616op 00IZ 66w6q6ope 61636v6ee6 eefteEveybq po66opE3po ovoppooqeo 666 636 OVOZ 66p5661313 ov66pooppo 636p2pee61 D6u5o6aolq pe66q6.6q36 gro60661Ev 0861 eoova6v0125 Eue6ge6uP0 1E00604361 6e oeqoppowe6 rEo3oo663q 0Z6T eftyp6voqe EvroBb51266 gebr6.61e6v 6o3.936goge 6v66466q3p o66PPoge6r 0981 e6v66y6ops, 6qop3366q6 yo6epq66u popo366ps6 61e6SE,6036 vv6go6ee61 0081 Boop5466oe 6y6ogeoppo Senlepoopi loyySlopoe 36q36631126 spoD125qp.61 ONJ 3oripp63356 ple3gyoeg6 q6opoovoo op666q66qo 61633e366D le3p66eeoe 0891 oD6636-4oly 6e55a6opoo leSpoop63e 16e366o6.46 6vvoqeoqlo 66666oge66 ozgT 6o6Sole6Te EepoDo6Pe6 646v236600 36qoovv6qe 666e666 q6Dosoe6or 0991 600.6D66Doe py6pqa6qa6 o661266veol D623366366 olv66epl6p peog6p;apo 0091 Dr60220663 43ozoepleE eoloopqlog elql.poqvq6 wv266weoe 6e665 Otti Sen6pe6pol DqoDpqovwD eseg6v6,6e6 65.6qq66ro 1q06e6rEve Se3peopop6 08E1 eDlivoo6e6v opy6e36v6e olzolqqqer 666eo366vp 666vepewo 43o,66qoqu ot 6ee665wall lqqee1356e og6p6v613,e D6411a6utre6 leyuppyor5 6rt,63.6op66 09z1 36q36366qo 6.43666ev6e vo60000po6 o6336;pe26 612306Doeop oo666v6Erep oot 366D63peEo qlo616vepq 6o3 66 6poovvo600 3.4ovva66o6 362o63v6av VII 3363E6 poovv63,264 65e3o6v6qe 6066v6=65 ao636o600p 6656 0801 opoo66D666 263656RoD6 lop600e6qe 61e6e66256 4opogoo663 60000663qo OZOT 1366ry6lop gepoe6vvo6 qov6oDaose op6opti..6e36 2683363=3 e6p6ople6le 096 661361m6 a6ouS6vooS eop6Svo6p6 q3636o6loo oebegoelol qp600v66.46 006 ovqoe6a600 lqpoo6e669 yoopp666wo o6oDqype66 qopaeobeao e3pooSeosl Ot8 61e56D6q6o v5iireope5q oo6661.3pae pqy6616638 reDgloqeft 60666gBoop 08L oqep000Doo eeovvoov51 e681o66ole 66e666 qa3owaSeop eopvD66336 OZL pleorSofto 6636oppo6s 6o6D6q1a6wo 356 Z3363 leopoo6600 6peo6lE333 099 3wa6163600 u66616e6op 60066266s6 3ee3qr33e6 p66w2.61351 e6o6qeao6 009 3366yo3e33 660666163o vorithqqeqva 81peowta6qop e66epopoDo e3353656v6 OtS 36e5363 6v3qq5qsoo aole5366v5 0000ftozqo 366pe6e65e 66666Eee 08' 61566qo36o 12261.o3peo6 3p0006vole oo6Erepogo6 q66qv6vD36 66e35aooer OZT7 6e36153qeo oppelormft 336v6.466v3 oEmpftogeD 6633E35633 6336336336 09E 336.6e36e33 356e6e5e 2pol6erove 65e65e65 TI63quEve6w 66q3335E,v6 SbI

0081 3q36639666 3666.4666o6 136669649e o66aeqoaop aD66aqopo9 ;666o3D6eo 04LT ao6664DR6 6906669600 o66o.46oqp6 69r000paea o369,316oe6 eq6E96oloo 089T R7206016606 v6=313969 9969639636 p6o616q666 aq9694DDD6 666 67&z OZ9T 6315313.9q1 16966.466.aq 56E6 66a6660Da qq6upaq6o9 66eovapp6o 09S1 q600egooso 99.46o9seog 9999969990 apo9991=1 9963e6oa69 po6vo6epoo OOST 3v6o9e3663 '4361336936 o61336e3D9 6qoop33ea6 q3696699D9 63q9apo696 ovvE 69062PEeop Brop000eoo 9699696696 366DaloB3o qao6v6966v 6ap3oopoo6 08E' oog0006963 3oD6o36969 362=1'439E 3663opo6pa E666 poDo661o.49 OZET 699366Eq3o .41399=66p op636963o9 36666 av6vootaoa6 66e6o6ao66 09ZT 05.4o6D66q3 6u6669269 vo6000DDo6 36336aoev6 69=50oepe op66696699 00ZT 36636qoveo aqp6q6p9pq 6por69966o 6eoogeo600 lloe9D66o6 o6r2o6q9.6q9 OVTT 3336366 opopw6o96a 66epo696q9 6o66y63366 q36q6o6o33 6699393366 080T paoo663666 q6o6669336 loo630P61v 666666 1003e0663 6633 OZOT 13669e6qop 19=969936 q396opoopg 336312.96vo6 q66ao6.4pop E653639 096 66qoew6996 q6396693D6 uo36690696 qp6o6o6130 oebee3P101 106009'6516 006 peq396o63o lloop69669 r3o33666po o5polgov66 lopqvo6eDo epooD69Del OV8 61966o6q6o 1967212o9963 op6661op.49 aqe6616636 evo9131E69 6o66616po3 08L aqepooDopo yeoreooe6a 966436,63q9 62o6966936 qoopeo6EDD eon9066=6 OZL oqeop6o6vo 66 63=369 6o636a72693 366Doppo6o qeDopo66op 6393616333 099 3e3616o633 9666a696Do 633669669,6 D99.319=96 966996qp61 9.6936193D6 009 336693pe3n 663666.46= 93.996.4a6q9 S3e3ve6q= 1266s000033 eoo6o66696 OVS 069610=6o 6533 ooqu6q6696 Doop6eoqq3 D669959669 6616616699 08v 66663363 9961D339D6 3opp369pae op669ope36 66 66 66906qp3eu OZV 69.3616olpo 3oovqo9969. 696q662a 362369ove3 6633v366op 6=6=6036 09E oo66906eao p669969r69 vo3169,9pee 6906966966 .263a969969. 661apo6696 00E 6E,E pepq6o9631 v36D6P33vo 6q636139.46 apopeop66q 6posperoya OVZ 61=693636 ao66696z,6 Tio66oD969D 6q3o69poo6 ep63369336 6613D1969D
081 36Do6qp666 96a6Epoe6e 66q361=66 opoo995a6D 36311p6o612 56366363 OZT 3693366646 16ogypeo69 ,26a36vgawq 6996996990 66o66opoo6 D6app6pole 09 67296966646 9.939661o6e 6366366369. Sa36q6o693 0636=3606 665 L <00V>

airpdadAiod uotsn; eao3-A3H/6v0-AIH
oTlaqluAs :eauenbesEZZ TrT3T3TlaY 30 uoTlciTiosea < >
<OZZ>

9ouanbas retaT3Tqay <ETg>
WIC <ETZ>
TEOZ <LIZ>
L <OTZ>

6TEt 694396696 ov6612=6= 69az66q636 q3teoe6366 oo66q96936 9936639qop 09gt, 6363Dqvpar 69933669eo 6D36 3o6 66166e23qe as605goveD e66e00qe6a OM, 66a6006o66 6963666996 6a6qa6u6.9. epa6pDpo66 69966q6up poo9669939 OVIV 9396363oeq 3eq6q6o6op aq39969331 969poproq9 6.906996936 lo69669epo 080t leftopaeorS DoepoBoavo leop65a631 vo6o696366 po63612o9ao 66666 6366699063 699pqapwwo spoquoaq6q 6=6619693 6a63D63396 996a33906p 096E 6=669=96 3636q66rop 66pqro1969 969.96q3696 ovepee6q423 69696666q 006E 636669=69 6poppooveD vuoopaeo6 63qq69669p 633653 3666q66ao6 0V8E 1336336699 646oavopeo 69o3rolloy 93690663pe 3963909.00 Teop969964 08LE 633366363 0663366136 996436q3p4 l3vq33633w 696693366o ae6e6006DD
OZLE pole6q6696 op6696oqgo ea366369o3 666366 o366a6613o lvoq969906 099E 66966apago opro6q3956 q369066q31 9p66333369 366666 eoo6639D61 891 <11Z>
6 <OtZ>

SZOZ 6wqqo go6qq66qop qloove666e oveo63sqor r648366op6 0861 ve66401q66 600353663V o6oEbq0006 66roo6.4o6o 65v66qqo43 pooflo66og6 OZ61 olobooplro p15666qvoq oov6006oqq o66o5q6oeq l000eqs5oq yolEfteqb6 0981 Eqqweo6o5 oq66eq6o66 oopooe6rov p0006666qo EvqopE6oqo qp6616o3oo 0081 43164=136 6gy6663666 q666o6q366 6e6q2eo66q vqaqoaoo56 lq000eq666 0Y7LI poo6vo.4366 6666 66s600066o 160q06fteo 000;v1005e 016ov5e155 0891 e63qopreo6 316636r600 qqoefteeft 6nt.636o6o6 qE666726 vqo3o6666/2 OZ91 obo6336q15 qqolaqqq6t06 64664160.4v Se 6566 666poolqBe roq6osEavo 091 e3oo6olbo3 eropeoveq6 ovevovever e6e velpplee5D 12545vogo'4 00ST 6oqop3ov60 vvoS6q1q34 ovogsiZeoqo poqqoevqqq ooqvq63pue 66peov6eqr 01,PI Boo6e6Evo6 euSeoqoqop oqovroveve 6/266-e65552 1155eo1105 v525rv5v00 09u eopooftose oo6e6re3ov6 po6v51231qo Trnse666v. oo66vvi66612 12024D01430 ozET 56e6ee5 6E2q4qqqq2 eqoUvoe6E SeEgloeofiqq e6e5eee poeorBSee6 091 66ee6545qe 6r65q263o6 Meverv6be lop3o666e3 631vvepp3o 6gleoe3666 001 eebeee3661 SqTee3lqq6 16E921464ov ElevvElaimoo v12562qq4qe vo56e6v5vo ()KT 5412511m4120 euq0612ooqe Evogrqfteo o6e6leo36e e62o66a113 SeSeepfter 0801 qeooM000e 666686q6v6 662316qe36 v3e6Tri.61ev e6e.025egov3 vqo5o6so3 onyt 2556;q2o672 evu,41411243 u6e3514y6 v000eveo61 evevooq561 1B1looeveS
096 vor5126611 eyeeeeq63e EGeovoq1D6 vinve6006v 6epqolovve eqelaq4663 006 op6p16Tell v6e6eqqqoo ove5612esoo e6512eae6ee qvol266qoqq eo6roosqoo Ot.8 3e.pq-ez64ev 5e6e eqeeellv66 SlooTeelrE 6qe6ever1e 3012ev5vE6 08L eq6yopoTel opeoolvvQg vvole.63v56q e6.61n2cmoy e66voqq000 eqbvqoupe OZL 12.66vo6eqvo v64612126666 peoose6y6e 6wevoa66t, opeo6a1v30 0555eo6leo 099 65ee6 q6v6pqr666 lev6e361o6 e266p61pro qploe6e6ee evq.46qvgwo 009 62poo5eo6v eoqeoe6666 66q6woviovw laqo61yoovo eevqaqe6ye og33p3ro36 OVS la66vs5eoqe q3u05e0all 461yo33re rqBeebepoo SeolTIo66e e66e6 081, sl6eeepa66 Elpo64Eppq qqoee6elpo voqeqvoo66 voqviovq651 geyo6656po OZt vloovv61236 46eq2400pe gleewvooft. oqE6Roo6eo Sepert,66yo eo55qo5eo6 09E qoftoftoft 2D6woep66e eeee6ee182 eveovvveo6 126w266126/2q 126t1126e6uq4 00E l36ev65eeo oeov6vvvy; 5126w4u65e egoquovq51 641e103000 egobe15Eoe OtrZ qveqeqvlav 33s6elq3yr SveSeole8S voyftolloo oleoo5pogl D61231266E44 081 vqeevorbeo SloBEreefto agoveviftqq 6loo56qooq vuolevo6oq qe6ove6e2o 0Z1 Es.66612o5rag 3666112a6p1 v7roeser13 fte3v1reev .226vve.6666 6e3o66velq 09 6Boaqelnee v666q2eelp 6v1qee6v66 6663621713v q663.4636i26 w636q6E5qv 8 <00t>

aPT4dadA1od uoTeng 9.1(30-A3H/5'20-A1H
DTletpuAs :souenbas TeToigT3ay go uoT;diapeaci <EZZ>
<OZZ>

aouanbaS 1ET0T3T12V <ETZ>
ItNa <Z1Z>
SZOZ <TTZ>
8 <01Z>

to 5 vlqolo5q45 643oqlo3et. 666eovvo61 vlovv61636 Sov6vv66qo 0861 43565ooq63 E6Teo63661 3oo666vo36 qD6366/266q qoqp0006o6 6oq6oqD63o out vqeovq5666 lsioqoov5oo 5a4405505'3 5Duqq000e1 e5o4e33551? v165531Tee 0981 3636oq66e3 6366opoope Emov000366 66136eq3o6 5oqoo5616 0000lo36qo _ sousnbsS T2T0T;TlaV <ETZ>
VNa <ZTZ>
OE <TIE>
II <OIZ>

OZ
nip 2TV 21V nTO

GI OI
nip way ei/ itly nip IsAq neri qaw yip qaw raw eiy yip sTH AID AID

OI <00t>

oLocl apTqclad 6120-Am :aDuanbas T3T3Tlay go uoT4c1Ta3s9a <Ezz <OZZ>

apuenbas 1vT3T;Tqay cEIz>
LEd <ZIE>
OZ <IIZ>
OT <OTZ>

09Z1 0643636643 6135662262 236333333E 3633643225 EvooEoplaos2 3366626622 00z1 3663543223 4435462234 6332622653 6233223633 4432236606 062364264e OtII 3420326365 3332263264 562336264E 63652633E6 4361636333 6622323366 0801 0333663665 4636662336 4336332642 64262661265 43339.33653 6333366343 006 0240253633 1133362662 9333366623 3633423266 4304236833 2=3362324 Ot8 6426536463 4262232264 336664334v 3126616636 223243425v 6366645333 081. 3420333333 2232233261 266436634v 6236966236 4000205200 2002055005 01,5 0626100060 6234264233 3342615526 3333623443 0662959669 6646646622 08t 6466643363 2261333236 3333362342 3356233236 4664262336 669361332e OZt 6936463493 3332432.262 3062646520 3623623223 6633236633 6336335336 OtZ 6433623636 436266E606 2365332693 6433623336 9364062336 6540042520 09 6226266546 v232664362 63663E6362 6436463623 3536333636 6612032006 6 <00V>

uoT69a UOMWOD
620 xpletiquAs :93uanbes islotmay ;o uoT4d113eac <Ezr>
<OZZ>

8puenb9S 12T0TJT02V <EIZ>
VNa <ZTZ>

<220>
<223> Description of Artificial Sequence: primer GAGS

<400> 11 aagaattcca tgggtgcgag agcgtcggta 30 <210> 12 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer p55-SAL3 <400> 12 attcgtcgac tgtgacgagg ggtcgttgcc 30 <210> 13 <211> 34 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 13 atttgtcgac gaatcctaaa cctcaaagaa aaac 34 <210> 14 <211> 31 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 173CORE

<400> 14 tattggatcc taagagcaac caggaaggtt c 31 <210> 15 <211> 21 <212> DNA
<213> Artificial Sequence --------..

<220>
<223> Description of Artificial Sequence: primer MS65 <400> 15 cgaccatcat ggatgcagcg c 21 <210> 16 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer MS66 <400> 16 aggattcgtc gagtcgctgc tggggtcgtt 30 <210> 17 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer XPANXNF

<400> 17 gcacgtgggc ccggcgcctc tagagc 26 <210> 18 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer XPANXNR

<400> 18 gctctagagg cgccgggccc acgtgc 26 <210> 19 <211> 20 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: HIV p55 Gag Major Homology Region <400> 19 Asp Ile Arg Gin Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Thr <210> 20 <211> 60 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: synthetic p55 Gag Major Homology Region <400> 20 gacatccgcc agggccccaa ggagcccttc cgcgactacg tggaccgctt ctacaagacc 60 <210> 21 <211> 15 <212> PRT
<213> Human immunodeficiency virus <400> 21 Ala Pro Thr Lys Ala Lys Arg Arg Val Val Gln Arg Glu Lys Arg <210> 22 <211> 5 <212> PRT
<213> Human immunodeficiency virus <400> 22 Lys Ala Lys Arg Arg <210> 23 <211> 4 <212> PRT
<213> Human immunodeficiency virus <400> 23 Arg Glu Lys Arg <210> 24 <211> 15 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: aa of mut7.SF162 cleavage site <400> 24 Ala Pro Thr Lys Ala Ile Ser Ser Val Val Gin Ser Glu Lys Ser <210> 25 <211> 15 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: aa of mut8.SF162 cleavage site <400> 25 Ala Pro Thr Ile Ala Ile Ser Ser Val Val Gin Ser Glu Lys Ser <210> 26 <211> 15 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: aa of mut.SF162 cleavage site <400> 26 Ala Pro Thr Lys Ala Lys Arg Arg Val Val Gin Arg Glu Lys Ser <210> 27 <211> 15 <212> PRT
<213> Human immunodeficiency virus <220>
<223> Description of Artificial Sequence: aa of native cleavage site in US4 <400> 27 Ala Pro Thr Gin Ala Lys Arg Arg Val Val Gin Arg Glu Lys Arg <210> 28 <211> 5 <212> PRT
<213> Human immunodeficiency virus <220>
<223> Description of Artificial Sequence: aa of second cleavage site in US4 <400> 28 Gin Ala Lys Arg Arg <210> 29 <211> 15 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: aa of mut.US4 cleavage site <400> 29 Ala Pro Thr Gin Ala Lys Arg Arg Val Val Gin Arg Glu Lys Ser <210> 30 <211> 1419 <212> DNA
<213> Human immunodeficiency virus <400> 30 gtagaaaaat tgtgggtcac agtctattat ggggtacctg tgtggaaaga agcaaccacc 60 actctatttt gtgcatcaga tgctaaagcc tatgacacag aggtacataa tgtctgggcc 120 acacatgcct gtgtacccac agaccctaac ccacaagaaa tagtattgga aaatgtgaca 180 gaaaatttta acatgtggaa aaataacatg gtagaacaga tgcatgagga tataatcagt 240 ttatgggatc aaagtctaaa gccatgtgta aagttaaccc cactctgtgt tactctacat 300 tgcactaatt tgaagaatgc tactaatacc aagagtagta attggaaaga gatggacaga 360 ggagaaataa aaaattgctc tttcaaggtc accacaagca taagaaataa gatgcagaaa 420 gaatatgcac ttttttataa acttgatgta gtaccaatag ataatgataa tacaagctat 480 _ Ea 0081 ovqqeeov6a qvc.e6v5e5e 66636e661v 66qopv6leo vvqvc.65111 vEvole5610 OtLT qolveelvel 6v66116elo 61y266qloo 6q6qa6qovo ov36qqqeD4 3eeve56q0q 0891 3eqq66651q qw666Tagpoq D6yoyepae6 6evszoos2e 6see662623 663poz6e6e 091 vo66epoqo6 vo6evolro6 6662D1Svo2 oqopro61q6 lolvo6vope nEoE6e64qt>
09G1 loSp6e6qp6 llqweope5v D6voriep6q6 eqgq6613-46 qqeqqvuoe6 voo66yoyq6 onT 6ov6436o.e6 louoq55ovo 63666qg3v D6v66eo6v o6.6661wq 166Elwoql ot.yr 6qvqp6v66e qa6o726.16eo 66e6 e6v6vo6166 45/261m612612 eepUeeDoe logET 000epEveq6e 56g4quoo6v 65 elftvalvqe veqe2eqlee 836ee6e6E1 ozu q2v3r666v6 agle6r66q6 6e661poe6e 31qpleET25o 3v3oviDgeq6 leo4v6e5tlav 09rt 1661661e6e 6v2Dtreqq/aq 364ov66uDp qq,equeyoqv 3136av&elq eseps6Be6e 00E1 DqezDoqDop 36qe261evo 6666 Pea.v366q6 6ppeeelvqq vsepeevele wit ebeobaeoin qopopalpqo ve,6612121,3-e ovelwagoDS 66eee varey66qqov 080T 462'4)2124111 qobeopoeeo 13eel6qps1 031113ev66 66e66Ee 211436pora myr 6.4eva6q3ve e600pe666 8v6EvoqDol geoftrq110 lEmlee3eve u42,2666444 096 epop36levoe .117222voleqq Selwevaeee eqqlovouvq vu5Sqegsve 6666e 006 oviii/q5q4vDu obeyogftel rle6E6Beqv elype6v66e opeo6Teq11 gyo6e62655 Ot8 600p65eleq oppleqBeer se6egovwe qsvoesw3Ta 62epeq611v elqeue6eq6 08L 4oweE6v126 qo6oel6e1 epqvqoveee 1351veoeft ovolTTerve Eloqe6eqle OZL y36e16666E. eber6eo624 ol6vo66gee eq161o6qqe ti?plevaq6q 6vq5eopE6t.
099 131m6E.Teave ovq6Tevowq EeDe36o.46 qeev3gq6le 33 6e6 61veolq6ee 009 6eyav6qvg2 6167eve3lq e6381q1166 1366onop61 61qinlvDTaq eopoqqtmoo OtS ye6131oplv 466yegooq6 wa667apraou lqeol5e3qo peovrq6qqr eelv6q1ver 08' qvqobweogq epqe5weqs 6e5 eq6qe8llor eeqeq1q111 opo6qv4ee6 OZt 2ee6so6qp6 erleee8vpq vo6egorpop oq66euoqq1 Dw6qqrieue evqeer6v66 09E 26pov65q726 slEmvs.66qqe el6eq6y6eu popqyegorl 361yr62e61 2q2pqopo63 00E qypuloqoel 36161o3oep pope2316ee v161.61gooE eev1D16pyy oTe666qeqq OVZ .45epleeqpq v66/25Teobq 726212,e6e46 Bgepeeqeev 2e66q6qe3e e6 081 12De5q6qeye e661.4elErel TavsfteovDo oseloopebp oeponeq616 wo6leoppe 36661315q eeqpo2166s. EvopovEllel oo6vvivilD6q eftoleo516 qlqqvaoloe 09 opleogeoft a6veS6q61 51poeq6656 lvlaewl6e 3123166836q we2ee6eq6 1E <00t>

enaTA AptiaTDT;apounumt tleWnH <ETZ>
VNG <ZTZ>
ZE61 <11Z>
1E <01Z>

611.1 u6eevEv6 e55eoS366 16e6py6e6p eep66eepop ogET oo3e3Ereq6e 6e1Tepo5p 631epeev16 eq5verelgqe veqelvq4-ev 655661 out levoe666e6 qv4v6e66q5 6e66qoDv6v oqlole6v63 ovoorpeeq6 role6e6vet.
09Z1 466q66qu5e 6svorylTel pErloe66pop qq.eqeevoge oq36quEoaqg esq/De56e6y 00zT 33.epool333 36qe151evo Emwve56e15 es66ED66q6 6epeerleaq vreorveele ovvi 126po6.4gopo qovoeoqeqo re6612eqp2 osEqrveop6 Ebelelovqv vqvc.664.4o2 ogoT q&eqev31.33 loSvovoepo qTeR.15qpvl Dlqq.qq-es66 66566qqv valql6goeo 001 6.4ppl6qqee v62Dpov666 6u55yowol geofte2110 15.2qeppeee sqee6661.4.1 096 eeoyD6eepe alvvevoelq Se3R62012We eqqqopplevq v12664,e2vew 6666eqqu 006 Dee163avov 36peov6vel eqv6v66e412 sqyov6e66t, 3se36qr12q Te36e62666 Ot8 633v667aqsq ovsluqftee 2e6groe2vg leporeloop 6evoeq6qqe elqesebeq6 08L loqss66vr6 l36e3pq6e1 reTeqpimeu qoblevovbe ovoqqweRe 6103v6241e Cu el6p15666p e612126go5eq 016y0663vg v336136312 '2013223163 66366v 099 qqyv66qvov ovlEaeleoPq 5p 6p5 quvevogq6qg opeUeolv6 6Teepqq6s.
009 beelebqerq 6q6vegloqq s6364q.4466 w65opoo51 6.43rale3rq eopoqleepo OtS vv514qooqv qUE2e3016 loo6Emovor 11e3q6volo ovvieq5qqvi vine6qqeve VOZ

1.9tZ vegeqo6 qqqa566ree 64qa3665ep ebeeave6ye belopelene polo1111p6 001pz e6e166qqee 5ereoeD6e3 Speftlelle E666 666126qoSel 62u6eqsla6 OVEZ e1e0361e81 1461116eq1 666Tagee Sweeq3ee66 eoq3e55qqs 46suSloolo Tau qes65666q4 gq6evul000 6ee666q666 66vo6os666 quqluee56q Eale66e636 nzzz euSqqeSqqo leeqloe6e6 e61qa6ouvo oeqo6vozqo quo61Squo6 e66oewle5 09TZ oe,665qoqvo queoftql-eq qe664vo6q6 elqvu3l6e3 o4e6goe6e6 eoe6r6e6e6 OOTZ e65a56ee6e eSee5ogee6 6ve6D3365e De6Dope666 Segoopp6so opqqoEouoe OtOZ 6v0331e0Te q;eozwuque qe666po65e qq6e6elve6 16e3e13311 064B3De111 0861 116eze56ee q1165eq6yq 1.366e66p16 eleSgreqeo llewegvel e4e1S6q6qo 0e61 6Eqeeeeolle qeue611,q66 lqes66.454-4 q5evuE6646 seq1266qqvr 6e41e11ee6 0981 ev3es6que6 euee6eeoee opeebea6o4 esSeeElqee qloopopleq peqqoeveoe 0081 oeqlevueba Teee6e6ebe 666q6e551p 66-4D3T26.4go se4ve66qqq eSeuqe6610 OtLT loleeelveq 5e65.416equ 6qee66qqoa 6q61351ovo oso631aeog peeve661o1 oggi u6q466661q le.666you2 D6rosepae6 Emeelooeqe 6yee65161,p 6513o.46126e 0Z91 eob5eooqo6 vo6evoleo6 666loqftoy oque236.4.46 loleo6uoue o6D66e6q1e 09S1 quE12625q36 iqqevueeft o6voyeD615 eqe1663oa6 lqeqleeoe6 poo66eDy16 00ST 5oy53363e6 lopplESpeo 6p666qeloy p62266yo6e D6e6661qDq 166600qq OttT 61eqp6e66e o5oe6q6e 6e5eueeep6 e6e6e36155 q6e6ee6e6e peoffiveope 08ET opueo5e16e 66eqqepobe 66 eq6eeeqeqe veqeqeqq/av 66666q OZET geroe666128 qele6p6636 6e66qopeSe pqapqeSeBD 3e33e3peq6 volvEr6eve 09n .4664661e6e Seepeellel o6que66eue llelpevoqe oloBleBegg eveos662612 nnel papooploo3 361e1Bleep6Qeve66eq6 2;266e366q6 6eueeequqq reepeeeeqe ntrt e6voSzeopo queosuqequ ve66qpeque Deeleeeop6 Melelov1e Plev6644De 0801 16elee3331 aoSepepeea .evq6queq pq111qee66 66664qe vq441,612oso OZOI Eeavel6qlee ebeoDue666 6e66voqopq ee36eeqlqo 16ezeeoeve eqee666q31 096 eeDeuEreeue qqsueepelq BeleSeoeve e2313e3eel pe664eeePe Be6616elle 006 Deva61.4v3y 362eDe6eeq eqe5e55ele egeov6w6Se ovea6qeqaq Te3626p665 0t8 63pe66)2.4eq oveleq6eee euftepeqey qeepeeloor BeeDelGqqe elleee8216 08L 3ply25See6 qobepel6e3 elnelpeeee 136geepeft ovoq44eves bloquftqqy OZL. eq6eq5666g vthes.612o6eq pq6eo661eu eqq6q36q1e eplpero161 Bel6e3o66e 099 qqee664por orqBaevoeq 6epeo6s346 reeueq6.4.e De66voq,a6 6leguqq6ee 009 Beelp6Tepl 636eeequqq e636414466 -4366000p6q 613elqeova spopq3evo0 OtS eeSqqqaDge q66eeeooq5 lop66euvor llepq6epqo peoveq611e vele611vey 08t 1elo6ee3eq ee1e6lrele 6e1eP30e35 eq6q126440e ee4eqq4q1q oru6Telee6 OZt eee6vo8Te6 evqvgg6e,e4 up5weovaDv oq66.erp3a1 D10611eeee eeleeeBeB6 09E y6eoe561e6 efter6Sqqe elbeq6eSee opelvequel p5lee6via64 qqyyqueobq 00E lepeloapel 16q6qpqneD uouveglbee gq5.46gepo6 eeelolbeee ply6661vaa OtZ 46,23wegyq e66e6qvu6q 126epee6el6 Blepeeqeer pe66q6Teop eq114evev6 081 voeblbleee e661qe16pq QV26eVOVDD OVV4=36.6Q 3eDopeq6.46 qpubqeospe OZT op66613q64 velgogq65s 6epepe61/22 336 g35 eSvoqt.3616 qq124oloe 09 uouppreoft e6ere66161 Eloovq6666 lellegoq6e oeuq66646q qeepee6eq6 ZE <00t>

enaTA A3ueT3TlepounwwT uewnH <ETZ>
YNC <ZTZ>
LS VZ <TTZ>
ZE <OTZ>

ZEGT eq eqe166q613 nnt 66leeev3le qe31264qq6.5 qlve654611 36ve3666a6 vely6Ellee Seqqe34ev6 0981 ev3es6.4E.E.6 veve6eg3ve 33ee6e363q eefte6q11212 lqoavoeqeq ee4lopepoe SOZ

on, oftEmyoogo veopeooSor .261m6qoove opeo6q3vo6 g3oov6q6o6 16qop0000v 09E 61o6ee6q63 6qop35y126q ooftSgoovE. 66q6qoo6o qeoaeov66e 63eo6ggEreo 00E 6u56q66qgo veoeg6ye65 16avoeeoql oev6p600eS gEoppErS61 oS16o1e6p6 OtZ 6y000p3r2o 000e6o3po3 36qS3B333b 3eoope3366 61516ormog 364667a633y 081 oe63eg3366 evoo63v636 vao636qaqq 6lo3opooeo oroo66e65 vE6q6;6000 OZT 6163663elo eq5163ovS2 65616qo6v 626635ooSo Sropo6oqq1 63lqol6e36 09 e661Sq6go6 lo61o616.16 la643q3666 126v51426q122 36 6633 v3o6oqlee6 tE <0010.

ZA1EV'Z91.iSPow*ortd6 :9oli3nbas TwpoT;Tqay ;o uoTldTaasea cuz>
<OZZ>

eouenbes 1rT0T;Tlatt <ETZ>
YNa <ZTZ>
LOET <TTZ>
VE <OTZ>

EStI 661 0000Syboqw 101,1q 6ee6366166 evoeq6egow q6136,26352 o5o563peg3 p636o6qvoe 6365366o66 08E1 33po63o110 qs6v6o0epo eoreo6volv 6v66pro66o 6632636000 p61o6.136lo ozET 3663ovol2o ego6po6po6 lobooTefto 365363oqv3 aoop33363e q6.4goo66ee 091 oS66q56y66 go66qoboae uoquolufto Bseoleo600 Sl000Sq000 eolpoop366 00Z1 oveoproevo ee3333663q go02312V02P 66lo3v36v3 eeolq6qp612 000woftowi, ovET oSgoviollo qq6v6p66o6 6o6qolimogq 36 z66 q6oqv5e533 33v6366o66 0801 oftobw6vo6 epolq636oq gooeftvore obSollEmoo 366e36go6s, enos636oge ooi 6eo6ve.63oo peoevoev66 q6226v6o66 oSvoleoevo 6.4ow00066e 3363oTeov6 096 o663Teow3 e6o66oovoo 6peqolqoo6 o60065oopo 66olvooeoq eoSeEmeoSo 006 ooupespeeo eep33363p3 eo6qoepole 6e661636e6 v66vv6qo6e 36.46oquoqu 01'8 33vEmp3363 eeo126o3v3q qove6e636e 3633qE5266 363666v65s 600681006e 08L 366ovu6qo6 qp6qo5eopo v35e636615 3oop600Teo 66oroopeo6 q62o5163ovi.
OZL 3Bv6.46oeeo peoblopooS 636v3653w2 o146geftvo uSovvoSqft e6lo3lgoo6 099 3q43663363 00006o5qoy2 qogooqepoo olr0006v6o qqo6e6166E ro00061005 009 6ro3ovo2e6 16o6noorop eoBloyeolr 61o622o2qo 61n3vovalog Sovvouboqu OS 33o5166q63 w661o6eyow qoqq6g0006 3u26e66ye6 ro6qv6ee3e eoboaqeoBe 08t 3pe33e6366 euoqqofto6 lovv&evoqe 6E6366363o e66qs26v6612 e66qoveo62 OZt oftSeeopeo pe33y3363v e6ee6l33ve oovo6q3w36 lo3os61636 q62o33333r 09E 61o6e12616o 6.4poo6e6a aoft6goor6 66163oo6o Te3gyoe66e 63eoBle6e3 00C 6p65q66qeo eeper6ee66 461voepoll ove6p600s6 163;212E42.66.4 36q6oqeSE5 OtZ 5goopooveo poov600rioo 36q6o6qoob peoopeoo66 6q546oveor 36466p63pe 081 av6oinoo66 2v3o6oe636 eo3636qolq 6loopeoovo o2oo55125612 v6616.46333 OZT 616o66opqo v36.163oebq 66616q35v 6v66153363 6233363123 63413**e36 09 1266.46q636 qo6qp6q5q6 .4363o3o666 e6v6ei6lve o61e661voo v3o63qwe5 EC <00t>

Z913SPow'0z1d6 :eouanbas TeT0T3Tl1v ;o uo-pdTiosaa <EZZ>
<OZZ>

eouanbe S 1eI3T3T3aV <ETZ>
titi0 <ZTZ>
EStT <T1Z>
EE <01Z>

ozET oqoveloE36 rpE.E.63636e o616616o6o o6o6peD366 esoogozopo 56q60666q0 09ZT po6e63q726 vv6466q56Ta wasq5yeopl 64D6v5o6ro 6o66logype 6o636aeop6 00ZI 366a66o653 poo6331q33 vEmBoorpor 3evo6e3q26 e66.peo65o6 6opEoBoDor WET 6qo6q3.6qo3 6.6poe3lepy eo6vo6eo51 D6ogs.6.12op 666eop oppopo6Dva 0801 61poo66euo 666.466y66E. 3661D5oDee 3aeolr6v36 veolea6335 lopobloppe OZOT 01r33e366o eeopeoppoe v0000Moly 3oppeepep6 6woeD6voe e3;16wEorep 096 Dov06e2v0 643gq04;3q 45e6D56366 D.6qovuoqq3 5E012061v5q 553D
006 pe6oS6o660 Svo5e6ro6v vD1361Solp opteepoepo 66o1q6poop 566ve Ok8 Dpe616pqp6 eD6Ev64poo s3evoglit66q 6etiee6366D Svoquoevo6 lovopo6Svo 08/ 36oDqeDv6o 6Solsolepe 6o66opeop6 oelpqlooSo 6=6.6oDoo6 Boleooepqv ou 36vEveoSoo peopporpot. r00005o3ov obqovvolu6 e655356e 66reEloSE,D
099 6q6oqvaquo bveooSos. aDe600polq ovv6e6o6vo 633 S55 63556v55e6 009 3366336v3 65oee6236q 36 6D3 36e6165q6o 3op6oTeo6 6-epoppo6q 01,9 6e361600vo 6e6q6pcsoo Q36 366 3EolaD65pevo ql5se6voe 66er 08k Sgo3qyao5o qgo65op533 ooD6361oeq peopqrappo qeoop5ebol w6e6166pe OZT, opoo6qopE6 eoppeoleSq 535 5z 56E 363665&5 qBl000DaDe 09E 6qp6v26qEo 6qopp6ee61 po6e6vooe6 66q6loo5o qeolepe66e 6oro61gBeD
00E 5v66155Teo ev3leeeorze56 1520weolq 3ve6v633p6 53 655 o6q6.4v6e6 OkZ 5rp000pveo oopeSpovoo 36635qo36 oe000vo3E5 616q53ee3t, 3.6166e500e 081 ovEoeloo66 eeo3Eov636 e336361olq Elopopopeo Dv3366e66t. eb636163po OI 6153663eqo el5q53ip84 656q63oE2e 6g56.463o6o EmpoD63411 666 09 w66461536 q363o6q61.6 w6apq3666 v6e6ev6qTre 36qv6Sie33 poo6pqqe.e6 SE <00k>

ZA1A19P'Z9IdSPow0gTd5 :apuenbaS IPT0TJT2IV Jo uoTqciTiosea Ezz>
<OZZ>

aouanbas TwpTg-Tlay cucv.
WO <Z1Z>
EZET <ITZ>
SE <01Z>

L8ET pooeoop 08E1 oo66q63566 qoDoo6,2601 eftve.465q5 fteoeqfievo vq6qobe6o6 eo6365qopv ozET ov536o6qeD v635E36636 EopooSpoqq D62600vo 3voeuo6eol v5e66eo65 onT D66op53633 olaBqa6;36q DoMoDeole oveofto6ro 6qp633lp6p oo6836Dole ootopooDaoo5o rq5qvoo66s po686166p5 6ro661o600 evo412o12612 36evoqeD6D
ovIT 3.61330633 peoqvaoep6 bovvoaeoew oev000056o lroproevoe pEo6l33e3fie 0801 oveoqq6.1o5 yoppeoftor sofiloelol 3116e6066o 6636qoeppq qofteDE.qe (not 5E663 33or636638 6p6voSe6v3 Bee3446q63 weoavbrepe so56oql6vo 096 oo66p36q35 vcope6a5oq e5o5e633 oproreove6 66656 605e0;s3liv 006 36l3r33366 yoo633Te3r 6366olepTe 3e636533123 36eqpq;a3 536 6&z 01,8 366olp33yo qpo5e6eo6 popleoegovu DUE003D500 pro6a3grol eft66q60.6v 08G Se.66r/sEq35 eD6z63lv3q rope6eroo6 peroyboovo glove6.2636 vo633q,a6.46 OZL 6q6356BrES e6=66qo3b e36631225q3 54p5w6voo ovo625455z Eoppobooqe 099 3663e33123 6q5.2D6q6po 1236e5.16per 33e361poon 6836e366op eoqq6e26ev 009 3e63ey35g5 we6q334e3o 6olo66o36 oppop536qo elovpogypo 33lep3366 OkS 3lg3be5q66 evo33o6qop 65opoyaqv 53636yoovo evo6q0geol 25135P2365 08' 0063666q66 evoqqa6e36 lpeefteolv 6e6o6635op p65q726e66/2 u663Dve36e LOZ

ZA1eP'Z91SPow*0tTd6 :aolienbaS 1eT3T3TlaY 3o uoTqclia0saa <EZZ>
<OZZ>

apuanbaS TviT0T3Tqatt <ETV.
VNa <ETZ>
6T <TTZ>
LE <OTZ>

SZOC 62502 0222022022 6626236525 2206202E0e 602266232p or 6626200520 366626220e 6620625620 61062561205 263226226v 562062032v out 5200625265 2602262030 2322022620 0220 20220 220260226e 6060626862 0981 6265226620 0262232202 2562022523 0265233625 2202236256 235200532e OtLT 6e00/266w26 400vq06362 6646006620 6260530056 2062062062 2022065662 0891 5253026205 206236200e 0623623305 6260220060 6052362002 2322620623 0951 64e0020620 660 600606 6620011056 5230225223 0605662003 262500605a oosi 6225260606 2062662506 3060622036 6220023003 36E2605662 0300625022 or 6225256266 2202262202 252362605e 0636520223 2636362202 6366365066 0zET 0560020223 2206206206 2063022520 0650600220 Dopopop5oe 362epoBBee 09zT 0665255266 2366206002 2022022620 6220220600 6200362030 eoggooya66 cion 0220020220 2200336532 200202202e 5620020620 2202262062 0332362022 0V11 36402q0440 1462636606 5062022022 052320622B 2602262603 3025066056 0801 05235E6205 2202262632 2002622022 0653226200 366236236e 2332625022 not 5206225203 02022012255 2622695355 0620220223 6202003662 0060322025 006 0023220220 2200036000 206202202v 6256260525 y562252052 0625022022 Ot8 0026920060 2e0260020q 3022625052 35 0226266 2506652669 630562006e 08L 3663226236 2062062000 2052626626 0000630220 5632000206 262362603e OZL 0626260220 0236230036 605206502e 0226226223 2502235262 2620022005 009 6230020286 2606233202 2062322022 6206220230 520020220v 50g20e601e OtS 0006256263 2662362202 2022520005 0226266926 2062262202 9060022362 08' 3023395266 2232206206 202252202e 5963660600 12662268569 2662022362 OZt 0625220020 220020360w 2622520022 0023620206 2033262606 2610000002 09E 62062E5250 6200052252 0362620026 6626230620 223220266e 60120622620 00E 6v66466120 2232v62266 3612322021 0226260026 2502262652 06260226E6 OtZ Supopapywo oo600 0625062006 3200020056 625263223g 0525626002 OCT 6263650223 2262500252 66615o6se 6y6616336o 2 O53 5322026205 09 2562525206 2062062526 qa61333666 26e6#e6lee p61v66Tpoo 2oo6aqqe25 9E <00t>

Z9IdSP0uPOVT(15 :a0u9nbas 1210 TIT 2ay 3o uoTlciTapsea <Ezz>
<OZZ>

e3uanbes reT0T;TlaV <E1Z>
VNa <ZTZ>
SZOZ <rig>
9E <OTZ>

E7-80-T00Z !t1rqr7-OZt 362622=23 2232=632 262264=22 =23633236 3=32.63636 1633333=2 09E 6336226163 643362264 =6262=26 6646=3623 32=232662 6323632623 00E 6266366323 2E32262266 261120ST/032 322626=26 1632262661 3636=2626 62.333=223 3332633233 3646361=6 32=32=66 6463632123v 36466125=y 081 312637243366 v2=632636 2=6361=3 6=0023020 D200662662 2663616=0 OZT 64636632= 23616=263 66636362e 626636=63 623=6=11 6=416236 09 2663636136 135=61646 3364=3666 262622642y 363126612= E3060322e6 8E <00t>

ZA/1ATeP'Z9TASPow'OVId6 taDuanbeS TriT0T;TlIV ;o uoTqdTapseCt <EZZ>
<OZZ>

a=anbes / eT3T3Tlitt <EIZ>
WIG <ZIZ>
VV6T <ITE>
8E <OTZ>

Vt61 6263 3322133232 36616=664 0Z6T 6223623323 2631466=2 266464=6e =66636223 2663362661 36=626623 0981 6263226226 2662362=e 2623z62626 6E633261= 02321=261 3022=2024 0081 322326=26 2636362666 3626612664 =26323223 122663=262 3326633362 cm,/ 62.232.23626 63362=632 26643=616 =6=2=23 6331263362. 2366362363 0891 3666613323 666=6336e 362=2.6622 53=2=636 T2663633663 363636=36 0Z91 62361362.36 v2=236666 4616=25= 62363363= 23623623= 6626=2=6 09S1 36361 363= 2232262362 3623636342 3663626136 1362336=3 6623646=v 00GI 633=263= 6236333636 6542=2362 366=6=63 66633336 663=44612 coot./ =636664= 3126363z636 3622626363 6236466363 6=63622= 662232=3 08E1 3366363666 13=3626= 2622636636 6223216223 236=62636 2363663322 OM 3263636323 2636636636 6333363334 342626=23 3232236233 26266E2366 09Z1 366326363D 3261353363 3366332332 pv23623623 6336=326y =66363342 00ZT =3333363 216123662. 2366646626 62366336= 22342=262 3622=2363 Ot'II363333.6333 3eDqvoaeo6 Eoseopeove 32E3333663 3233232232 26643236e 0801 3E2=36=6 2=3236232 2361324=3 =16126366o 6636432234 =62323632 00/ 6463326263 3332636636 636E362623 622=36160 le0DE6PP02 v3660146E0 096 3366236=6 22=2616= 26236226= =232232)26 6362262636 6362332322 006 3613233366 23363331232 6366332332 326366=2o 3632131133 636=66=3 Ot8 366342=23 1236262236 p=2322322 322=336= 323632234 262664636s 08L 6268226=6 2363631e= 2332622336 322326=23 3=2.262636 236=12636 OZL 6463666266 263663=6 236632263 6136136233 3236261664 6333363312 099 3663233323 6162361633 2362616322 =2361=33 6636236632 v33622622 009 3263223616 2E64333233 534=66=6 =3=5363 2=2=1233 001v0D06e5 OtG =43626366 2233=63= 6623332332 636362>=23 2236132231 2643622366 08t =63666466 22=136236 =226223312 612636536= 266426266e 266=2206r Oct' 36262123323 212332=632 262E62=22 =236=236 1=3263636 3613==2, 09E 6=6226163 6233362261 =6262=26 66461=623 32=2,3266e 6323612623 00E 62663663E3 y2321262266 3632322=3 322626=26 2632262.661 361632626 62=3=223 33326331233 363636136 3233323366 636363223e 3636626=e 081 3263233366 2233632636 2336363343 633323323 32=662662 2662616333 OZT 64636632,43 2463633263 66626=62e 6126636=6o 623=6=11 6334316236 09 2663636=6 3363363616 3363333666 26262263/22 3632661v33 2336313226 GE <00v>

-7 00-TOO' LT-60-TOO 1.1709E2O VO

096 DE63qe3lvo e6o5Sopeop 6peq31l3o6 p6=66p000 66oleopyol vo6126seo6o 006 pogovvogleo eezoaDb000 eDSqoulgoqg 6e66.q8o6v5 12,66yEE.qp6g DEqSoqsoTe Ov8 ope6epo63 leyoebooy31 love6y63612 3.6p3226q86 11.366SeESe 6=66q336e 08L p56312e6136 lo6.436rpoo yo6e616646 popo6poqvo 663233pclo6 q612.36q600t.
OZL 36v6.453virup ovo6qapoo6 606ep66per pa26ey6evo e5oeeD6q6e ebloogeopE
099 olqo65oo6o 3poo6pEloe loppolvDoo oqp000SeEo qq36v61661?
23006q0.6 009 66 4635v33voe vo64Dveole 6qo6uDeqD Seoopoevor 6osvoe63ae OVS opo5q66.463 e6.63o6gros q32q6qpoo6 oeq6e6See6 ea6T26evoz.
ep5ooleo5e 081' oppoop8166 peolqo6e36 loeeSevoqe 6e6o66o6oD 2661e6e66e e6E.oevo5e OZV z6e6swoDeo weapeDaboe u6pe5qopee pot.D6lovo6 loppg6q836 361popoppe 09E 6q36v.e6q6o 6a33o6ev61 3o6e6voove. 66q6qop6po leplepe66v 6ov.D6q/25v2D
00E 62661664po seovp5v256 q6qvaegolq 3ue6e600e6 q6oev6e66q OVZ SeDDoopeup oppe6opv33 35q636.3336 oeopoeop66 61.61.6oepoe o6165v6ope 081 ne5ovloo65 peo36oe6o5 poo536loqq 6qopoy3olzo oeop664,66e e66q5.46oDD
OZT 6q5o66oeqD vq6163DT26z 666q5qo5v E4266q8o36D SeopoSoql; 5635 09 s.661816qo6 qD61o6q6q6 qo6qolD666 v6v5vv64ev o.6472664voo eop63qqes..6 6E <00V>

:9Duanbas 1eTDT;T41V 30 uoT4dTa3gaU <EZZ>Z9Tasp0w-lnw=o1'td6 <OZZ>

epuanbas 1eT3T3T32V <ETZ>
WIC <ZTZ>
SZOZ <T1Z>
6E <OTZ>

1'1'61 6v6o qoevqogeoe 166q633651 061 ftviSeoleo '26311.6613e e664613.612 op66.6q6weo 65 556 364a6e66up 0981 6-e6oev6s6 la56,1236epow eErepo6v6EG 6v6oqe6l33 ovovqoq263 ooeepoe3P1 0081 ovpop6oqv6 v6p6o6v686 46r6.61e.66q por8qeovvo ve56qoqp6e ola.56qoa62 01'1.1 665 64DEmoo6D12 e66qo33646 oo6oDeoovo baoqu5qp6e ep66o6e363 0891 D6566.4p1yo 666qD5qp6r a5ope66ve 5qoov33636 e6616=66q D6.46p6opo6 0Z91 Evo6loSe38 peoleo6668 ;6q6Doe6qo 6voSqp6qop so61236woDo 65e5ogeo36 0991 o636;36q33 treoevEceoft 35o5q6pqe 38635e6w6 235e0o6opo 68e361633v 005T 6qo3oefilop 6v36=3636 661eopeo6v 365op5o06a 665336 65qo3qq64v OVVT po6p6661op 3v646335o6 36 5e6353 5o6q6625o Boo6o6veop 66eeooeopo 08E1 op6516D665 loopp6r6pq e6ey5.46615 Sevoelfteo v16qo6y636 236366;ove ov6o6o6Teo e6o56a6635 5000p600qq 3qe6e6Doeo ovoeuDEpoq r6e66vv356 091 36563633 ov6q36qp6q 336533epqr 3evo6eofto E.336poTe6e 33563600lp pion 33oo333363 eq5qp3366e eD666166r6 5eo.664oBoo spoqeDqube 36evoqva6p ovur 36l3aEcl3o 3Q Q3336 53vvoosoye aula3333663 q.eopeovvoe ebbappeoft 0801 DevDq15106 eoppeoftog 23630e3033 oqq&e,63563 66o6qpre3l lo6e3v36qv OZOT Eq5oqp6p63 333e636536 6o62o5)25y3 6ecto116463 qeoaefteoe vo663qq6yo 096 ap6612o61D6 svoop616oq v6e36e)2633 opgovvore6 55666 636231voev 006 361peo3366 pooSpoqepe 6a66oleolv 326o66povo obovqqqo3 6o63o56333 01'8 366ogyp3y3 quo6g5TivD5 DODeDEPOVE oevoo3a6op 3ro6qovvol r6e66q6D6e 08L 56655 vD616pleol p=e6e1233.6 oppoe6Doeo q3ve5v636 Ti3533lla546 OZL 61.63666e66 e5oo661p36 yo65oge5qo 5;p6gobeoo 3vD6y6166a SpoopEopqe 099 365ov3o3p3 6636533 v35v6q53ep ooeoblopop 6638E.366oe p3345ee6ev 009 pe63evo626 pe5goolvop 6oq1365336 op3oo536.43 wq0e001eDD
0a3eD006e5 OVS 336666 ev33336q33 56waaogDqv 5q6o6voovo eea6qoevol e6q06212366 081' 336366.6q66 eepq136e36 2ovefisvoqp 6p6365D6op e661126e65e ri.66qpIre3612 -nr OIZ

0pt-1 0063666100 361556 p6ey6126360 Seo6q6.6.450 603606srepo 56evopepoo OM 0066460656 qop006,2601 v6vg6466q6 5eg0gq6EP0 v16z06E606 v0506510ev ozET ow6o508q120 v636836636 600036302q Dae62Booy0 oroevo6vol v6e66ve0E6 091 D66oe6360o 3E610E136'4 33663Deo4y 312206/236s3 Sq060ogv62 po66o600qp oon DOOODD0060 gq6qeo066e vo656.366p5 620563060o eepqeoqe6e obeepqp363 ovur 0610006q03 ovole00e06 60ego3ppee 3ev0000660 le30e01m0e T26640o1206s.
0801 3eepl45106 voopeobeola v361ovq0.44 0q36v6D550 66354ovE02 206e0e061e ozoi 64604u6E60 0030.06605 Ba6y05126e0 Eve0qq616o Te0De6v0E, v3663146go 096 00Ebe06106 vv30e5lEoq v6eD62e6q0 pavoseove6 6q62e6s606 606v01r0vE
006 364o6,33068 lapoB00qppv 50660qeolv 0e605500ep obovqoqq33 636036603z 0t,9 06503e33p3 1.205vSee06 00peogpowe 3ee33oD60o Dv36qpvgaq y60,61506v 08L. 666636 e06.460.4v0.4 voDv6v12336 Deepy5poyo 320ve6e606 v06001e6q6 OZG 55365666 w6o065q006 s0653ve620 6106106v00 3p06e5q661 60p0pE3pTe 099 366or000v0 636e061600 e36v6q6ocre 33ri6loo00 660613366De u03q6vu5ey 009 012601220646 gv6;001e00 604q066006 00000606q0 el3ep3lp00 00.4e0006e6 OT7S 0a206v6q65 een0006q03 66e0o0vole 6q606.203v0 wv06.401n0q v61062e066 3365666 uwaqqa6a6 los,e6svoge 6'260660600 e6611e6e6Sp eSfigoey06y 06e6vr00e0 evo0,20360e vb2e61002e 3oe3613e36 qpope64606 q6q0Dopope 09E 6qp6ee6q60 6100061m6q 006476g0ov6 663633o6yo qu3qs0e6.6r 63663 00E 6y66q55quo eepvis5u66 q6qe0ey012 3ve6ebooy6 4632e6e66q D6q6o1e6e6 OVZ 6e03000eR0 000geoppoo 361636.4=6 oeD33123066 645qE3cagos, 366563e 091 opEovipp66 v1200506,806 vi=506q041 6q003v00e0 0e0065e6fir v681646000 OZT 615066011q0 v363600v6q 66616q06we 6e66163D63 6eD306oqlq 6aqq0qEozi36 09 y661616qp6 qp61o54615 16qoq0666 sa6y612s6gey 36q-e66qe0D v0350qqe26 Of, <001r>

uvrep.maspow-qnw-ovTdE
:90uenbaS Tur0T;Tqay ;0 110T3dTi3saa <EZZ>
<OZZ>

amianbas T eT0T;TqaV <ETZ>
ria <ZIg>
11,6T <TTZ>
Of. <OTZ>

SZOZ 6p60q orylogypeq 656666 Tiv6voqe076, 53qq6640ee 0861 66q6q006e0 0666q672120e 66106r/66w 6q06e6E906 v63ele6s6 66236v00ve 0z6T 66E65 1250qr5lopo 123E103e6qo oevooepelo ve012634e5Ta 6666664 0981 6v66Te6510 0e61e0eepri. w66q0qw6vo Dv66q006v6 up0ee06r66 106e0060ve 0081 6613036q6D a63ola33e06 101E6106er 06606e36q3 6666q31e06 66go6106y0 OT,GT 6e00e56vv6 qopelo636e 86163o6610 5a60600056 Ta06q06e067e s0e06666q 0991 6q60pe6-136 eo5q36;pola 36w36120aD6 6633363 665e p3eefiro6v0 0Z91 65633 6606u63052 06v0360036 6e36.36Doe6 1000e61308 vo5poo5366 0991 6qeoppD6po E633603636 661=44065 6q=4.463vo o50666qo00 u6q600606v 0051 62v6v63E36 w36q6bz606 00506ve006 6ev001200D0 36616366Sq o00o6v604r 0T 5ele6q5636.6 er0e2Eve0e 36106e606v 36366q3e20 1260636.4v0e 6066066086 08E1 00005001q0 Te626aDvDo eDewo6soqv 6p56e13.0660 660v606000 e6106106q0 0u 3653333 es06e06g06 10600qP6p3 35636301r0 300030360v 1620066es.
09r1 DESE.q66e66 12066q5001e w0Te0qtr6w3 6ee3ly0600 63336333 202e00e068 001 OVVIDOEOVEJ ev0300650q uppeovrper 56q00e06e0 ev0116306e 000e0620eg 017T1 0610v1D120 q261.606805 60610ve0qq 06v3y36qu6 460v6e600 30e6056066 0801 36e36e6v36 evoqq61.53q v00e5ge0et, 06502'45'200 056206406R 1200261602v OZOT 6s06eu6q00 0e0v170ye66 26es6y6366 06e0qe0ve0 6q0230366s 30630qu3s6 IIZ

9E81 626=0 2230123216 616336536v 2362312326 008T 3326633226 6163=62= 66646223726 5436266436 4362662362 6322622526 OVLI 62362=226 2=626266e 6342633=2 323=263= 220323E302 2326=2626 0891 3606266616 2663265433 2642022322 663=262= 2.563036262 2022362664 OZ91 362=63226 633=646= 633232364 34263352E3 6606206136 6663=2366 0991 6436.406206 2=2662254 =23363626 616366106 4636=066e 3633620622.
00ST 33206666.45 36=263362 364364=23 623623=66 26=2=636 36=53=22 OttI 32,26236236 23635=236 63626=6= 62=6=066 206363263 330261=62.
08E1 36=060666 32=236236 5335305356 6=04=666 43313542.33 6366633=2 ()CET 536=63625.2262636362 3636646353 36062203E6 evoogoopoo 55163566=
09z1 33526326 225366366e 2324622323 6=6263623 6366332202 6363642326 00ZT 36E0663660 3006331134 2.62,6=23312 322362=26 2652236636 632636oppe ()tit 64364064= 5633234232 2362362354 3630326e= 66363332= =33336323 080T 632=6622o 566166266e 366136=22 =2=26206 2204206006 43=610002 OZOT 0323023663 2V20012D2V02 2.333366332 30232E3226 64332362,32 231163620 096 =23623220 6432131102 2E263E6066 361322=13 6202,363261 6326126333 006 0253563660 6205262062 2=4646342 3326220223 5633352o= 662363362e Ot8 3326463426 2352263o= 202232E65a 6226263563 62=232206 4323=6623 081, 36=323263 6634203232. 6366332335 323=3336o 6336633=6 6332=232 OZL 3625223633 323223223e eaoppEopoe 36=22=25 266360625r 6622643623 099 635=233,20 32622=532 232532=1 3226263620 5=4263664 6366626626 009 33661=620 6632254363 36406123=w 3625366363 0=6=3206 SDrooDroba OtS 62.36463323 62646322= 2361=3366 0623663220 1362262232 5322364622 08t 6333323363 310E633633 0006361321 323342=3p 42=3526= 1352636622 =3064=66 y3=234263 6362=2623 36=22366o 0606661536 3510=0=2 09E 5=6225360 6133362262 =62623326 66263=623 3203232562 6323642523 00E 6266166120 2232262266 2612322=3 3226263z26 3632262661 0536032526 OVZ 68030332'PD 0032530203 0616363=6 02=323365 6163632232 06466263ov 081 3263233o66 22=602606 2036364024 64333,23323 32=662662 v661616=3 OZT 516066323o 236463o264 666264062v 626636=63 623=6=31 6023336236 09 2663636306 1363063636 3063310666 26262126122 36326642= 2=634226 Tt <00t>

ZA/1A1aP'Z91dSp0w.lnti1 0v06 :epuenbeS T2T0T3T12y ;to u0T4dTaosea <EZZ>
<OZZ>

aouenbas TuToT;TlaV <ETZ>
YN <ZIZ>
9E81 <TTZ>
Tt <OTZ>

tt61 6263 30223323e 3663610663 0Z61 622362=23 253.4466102 266163336p 3366536223 v66;36266; 3633626523 0981 6263226226 256236233v 262362626 626326100 323 326 301,200eDel 0081 ovflowEow6 2636362666 2626632664 32642322o 22663=262 326643062 OtLT 6223223626 6436233632 2563=0636 3363323323 63=263352 v066362063 0891 366664=23 66636362 3623326622 64=213636 2663633663 0636363336 0391 5236106206 223236666 36163o2643 623636433 2352362333 662632336 0991 0636135333 223226235e 3523646342 0663626206 3062336333 6623536332 post 6433325433 6236333636 66123o236e 3663363363 666133436 6633D1363e ZIZ

ZA1eP'Z9TASP0tu'LlnuvOtid6 :eouanbes 12T0T3T32V lo uoT1dTa0gaG <EZZ>
<OZZ>

epuanbes IT1T1JV <ETZ>
YNO <ZTZ>
t1/6I <VIZ>
Et <OTZ>

SZOZ 6v633 zveqoleogq665566 upoftoTeoe 6331661022 0861 66363336uo 366636,nor 66335r6613 6136v6Emo6 63 6e6 66e36eopep 0z6T 6e336e6p66 e6331261333 voeq3lv633 ow1233,23/2q0 evosEloqyft 656666a 0981 6266112663o oe6qiiroeeoe p65qoqv6123 ov661336v6 eleorep6u66 1.3623363et.
0081 66qopp5363 3633e33eo6 133e5136ey 36636v3633 6666.43geo6 66336336w3 OVLT 6eppe65we6 loovq3636e 66.36336633 6163E33366 vo6136eo6v y3q2366661 0881 64633126q36 e36136qope o536e3336 Ere6ols.3363 63613E43ov epvg6v3Sea 0Z91 6e363633e3 6636e6q361 36P3363336 6e36.3603,e5 3333;263335 y363335366 09S1 6420020620 6600600606 6610033366 61331161e3 3636663333 e61633636e 00sT 6e65366 ep62663636 vo6e3Teop6 Empoorp333 3651636663 3333812633e 01,1,T 666665 2eovq6Trioc, 36336e636e 36366wee3 e636361e3r 6366366366 08E1 00306303w qe6v6opv33 epeep6v3le 6v66ve3663 663e636333 1263363363o 36603R33e3 vea6e36,e36 13633.4v6Tio 36636poqvo DOODODD6OP 261v3366re 08ZI 3666q56w86 y3663363ov eozeaqr6s3 6prale3Epo 63333613pp e55 00zi orroDpoer3 se30336631 voprovrove 66q3x236123 we3q16.436/2 poolzioftoee VET 36q3.eloqq3 qq6y636636 63643vv3qq 36oy363e6 3631s6v633 3oe6366366 0801 0620626206 2201163603 2002622022 0663316poo 3667e36336e e33p61533e OZOT 6v36ep6loo oppvpoep68 q62g6p6366 36123Te3gwo 6q3croop66v 336333rov6 096 3663qe3qe3 v636 633u33 63s333.3336 3633653333 663 33e3 ro5e6ep363 006 33epre3ee3 pr33336333 p3613ge3qe 6v66q636e6 ?66T:24;6336e 363633e33e Ot8 33e6pe3363 Evoci633w3q lova6v6o6s 36333e6166 1636662662 6306630062 08L 366 6z6 3363362=o 236p5q6616 3333633geo 663e3oospo5 3.6v36gE3pg OZL 36E.6163geo oc.35333335 6361a366oue 3315eese3 v6peeo636g 2613332006 099 313366336o 33336363os azeooqvpoo pqeoopErEo .3336v6q66e epoop5.4336 009 6go3prole6 3636vo3eop ep6qovvaqt. 6336wapyqo 6ppovoyeoe 6oeu3e63lv OtS 3336166453 g66336/avou qp3q543336 pel6e65ee6 v361262232 2060002062 08' pou33v6366 Erolgo6e36 apep6peolr 6v63663603 v663r6e66Q 266goveoft Et 36yEme33123 yp3ot.3363e 26v126qopet. opeo633e36 qop3v53636 163033330e 09E 6q36ww6q53 633336vg6Q po6v6epor6 5616233Spo lypTeop66y 6oeo6qe5ro 00E 6y663661e3 yypee6.2266 36qeove3q1 ovvbe6pog6 363e1252663 363633e6v6 OtE 6v3opoove3 33aw600epo 3636363336 pe000e3365 616q6oveoe 0616626302 081 3e63e33356 egoo63/2636 v336363331 6333Deporp 3v33661266e w66363533o 6363663e33 .2363600labq 66636436ee 6s66363363 EQ03363131 635235 09 2663636336 3363362636 2363323686 e6y6vv6lee 362e663eD3 vo36334e26 Et <00t>

nTaspourLlnurolita, :90u9nbas ItIoTJTasy ;o uoTlciTiosea <EZE>
<OZZ>

eouenbas I2T0T3T4aY <ETZ>
IINO <Etc>
SZOZ <ITZ>
Zt <OTZ>

Li-60-1OU L1709EZO VO

LIZ

OZV 33=6=366 23=233262 6362=2623 3533223663 3535564536 1540=0002 09E 6136225463 53=362253 0352623326 65353=623 4233232552 6320632623 OVZ 52=3=220 3=26=2= 361636=06 323=2=66 6364632202 0645626=2 081 0250230066 223602605 2=6364044 530=2=23 32=662662 2651653=
OZT 6260660213 2363633263 666163362p 626516=63 62=063411 6333316236 09 2664635406 136=64616 =54333666 2626122532v 36326642= 23o63441226 Pt, <00t>

ZA/TAI910'Z9T3SPow'Lqm.r0vId5 :23u2nbas IpT3igT4ali go uoT4dTapsaa <EZZ>
<OZZ>

eouanbas T2T0igT3zy <ETe>
VNC <ZIZ>
9E81 <LIZ>
VV <OTZ>

0c61 6223623423 263445643w 255354=62 =65515223 2664352663 3533686620 0981 6E63226226 2662062=2 252=52626 62633261= 0232131261 =22332321 0081 3223253326 2636362665 4626532664 3326423223 2266433262 332563=58 ovLI 6220223585 63062=532. 86633=615 =60020020 6121261062 2066062061 0891 356653=2.3 6563363362 362=26622 51=243636 8561633664 363636335 onT 6236136236 8934836666 4636=9630 62352363= 2362358=0 6526=8=6 0991 36353363= 2238962368 3620636332 3663626336 1362=6=3 66236263z2 0091 533332.53= 593633536 553232362 3663363363 6653=3406 653=3364y ()PV1 0053566333 3263633535 y6E2625352 5235365153 62352312= B6PV302033 08E1 3355363665 333=68633 2622616616 6223216923 2363362636 236366332w ozET 3253535123 2636606636 6=335=34 332626=23 3232235233 2626522066 09T 06602636= 3864363353 366302312 3223623623 6135=126e 336506=32 pon =3333363 23642=668 2365536625 512365336= 923420126e 0622322353 ()VII 3633=5333 32332=236 6322=2322 322=33663 12=23223e 2661=2362 InoI 6463426253 3339536635 5362352620 6223326162 3233262232 8366011620 006 3633233366 2306331232 6366=2,342 326356=23 363233130 6060056300 0v8 3663423383 3235262236 0=2022322 3223=36= 3236332234 2626615062 08L 6265226336 2361633231 2=2622=6 322025=20 4432262636 236=32535 OZL 6460566256 8633653335 8356382633 5405106933 3236861663 60=363012 099 066323=23 S1620636= 2362636322 332363333 6636836532 8044592692 OtS 3333596366 2230336333 6623=233v 646362=23 9236332203 8613698366 08' 360656166 2203436206 4322622042 586066363:) 8654862668 2653322362 OZt 3686983383 8800800502 969953392 3323530236 433326.3606 1633333332 09E 6436226353 6133362261 3362623396 5536333623 123323266w 53723632523 081 3263233366 2933639635 2336364333 64=320023 0833668662 266453503:) OZI 5463660243 8q6q53ov6q 685q6a36029 6265150363 52=060111 6011016206 EP <00V>

VIZ

0801 36eo6v5eo6 evola6q6o; vooe&eyoee oB5oal6epo 366yo63oBr epov6a6oae onn BroSprSloo opoveave66 q&e.e6126o66 36eoTeoevo 64ov0006612 po600qvoe6 096 obBoleoqeo e6365o3v33 bowqoqloa6 oboobB0000 Moqvoovoq eo6e6eva6o 006 opuoyeaevo ee00006000 voSqoye32e Em66.46o5e6 266ee6qoey oblEogyole 01,8 ooebreop6o geov600voq loee5p6o62 o600qs6466 q6o6666.66s 60056goo5e 08L 365oveSqo8 lo64o6w000 vo6e6q66q6 op3o600leo 66or000eo6 a5iao6a63oe OZL 356163eeo oeo6l333o6 6362o5Sotiv olq5ev6peo p6oreo616c, p6qooTeoo6 099 oqq365oo6o opoo5o6loe qovaaqv000 oqy0006w6o qqo6s6.46642 e00006qoo6 009 Emo33v3qp6 .46o8vooroe vobloevole 61oftvoel3 6y3ovoye3r SorropEole OT'S 000646535o v661oSerov qo116.43op6 ovq5e55ee5 vo6qv&ev3l2 voSo3qya3S2 08' a3vow5q66 imoqqo6o6 qoes6evoqe be6o66o600 66 665 v66qovvoSe OZ1, oft6evooro 2eoovoo6oe vEee6looep oovo6qoeob loopy5q6o6 q6lop0000t.
09E 6.1o6we536o 540006v26.4 oo6r262ooe5 6616.4006eo TeoTeor66v 6ovo61v6to 00E 6266166geo geoev6e1255 .461.2ovvoqq ovvEleboopS lborv6/2661 o63603126y6 6voopoolevo 000v600voo 3616o5qoo5 ag000vo366 54646oveoe o6466e600e 081 owbovloobb vavooSoy6o6 epo5o6loql 6lo3peopeo peoo6E466e, 26Sq615oop OZT 616o66peao v161.63ovEl 666.451o6vp 6y66q60053 6Eolq4 Soqq346go6 09 y66q516go6 go6qo646q6 4o8gogo666 26y6ye6gire o6q126,6112oo poo6333yE6 SV <00t,>

:aouanbes TvTaTTPay ;o uoTulTiosea <EZE> Z. 9LISPou19lnw ovid5 <OZZ>

eouenbes reTDTIT;ali <ETZ>
vNa <ZTZ>
SEOZ <TTZ>
sir <OTZ>

5e6olo peloleoeq6 6q6qo66.4612 vo6voqeoe6 0081 oqq66q0v26 6;6go36eoo 6565e6 63o6p66g36 qo6e66vo5r 53eeEveSe6 0I,LT 6vo5eopev5 goo626256e 6o3g6qnoov oelpleEloo ypopeoeloy yoebogeBy6 0891 o636e666q6 12664e66qoo 126quolmovla 65qole600 e661D06u5v P3ve068653 0z9T o6roo6orr6 Eqopo,61600 600eopeobl 3lp6lo6vo 56o6po5lo6 655 z66 0991 61o6qofto6 e33e66re64 oovqp6o6126 6q5o3661o5 35o8000662 06305e0ftv oosT ogyo6665q6 q6ope6.4o6v o6qo5looeo Seo6v00066 e6oqpoo6o6 obloSqoove 01,VT 3rv5eo6o6 vo6q6oqi236 6o6e63o6qo 5eoo600365 eo6q63os6q poov5goo5Q
08E1 o60036o666 Teoovo6eo6 65566 6looqqa865 qooqq6q,roo 606661.000v ozEI 6q6006o6r6 ev6e6356e o6q6625o6E o6poleo366 VROOPDOOOD 666656qo ogn poo6p6oqv6 ep6166166p e3e1.6212oeq 5436125o6vo 6o66qoev3e 00ZI o66o56o6Bo poobooqqoq y5y6opeooe oevoSeolv6 6E 66S
6oe6o6000r loviT 63o6.3o6qop 6Booeoqrop po6voEmo6.1 o600lv6eoo 6606DOZe0O
33DD006312q 0801 Sqv3366vv3 666q66:266e o66qp6opee oqeolpftoS evoqeo6006 l0006q000v myr oqepoeobSo 220320VEDP eopoo6bole opeoveoev5 6lopeo6goe voqq5-4o6go 096 oos.o6p3vvo 613vqol;oq 15e6o66o66 oBlopep140 SgOV064v64 60ge55300 006 oe63663863 5ro6e6go6 eoqq6q6ole ooeSegoveo 66o146eoo3 66vo6qo5eg 0178 poeEq6oge6 eo6ee6q000 poeeove66q 612e6s53663 66 qoepooMeo 08L a63ogwov63 663qsoqvae 6o6633roo5 oelolqoo6o 6opEb00006 Solepoeole OZL 356y2353o opopporrop PODD350DOP o6qovvoTe6 s6645o5y6y 6612e6oGeo 099 6363leo4e3 3p5ee3363p wouBoogoqq ove6v6a6uo 63 665 6o656t66Q6 009 oo66goo6o 553 636 o62o6y000v oSe6166q6o opoSooqvo6 boy000eo6q 0175 6vo.61600vo GeSq63vvop vo6l000066 o5eo66ogito qq6se6eg3e 63ev35q6ee 0817 543aqv3363 qq36633633 333636l3el 3333333 4s3336e63q 13Be6166ee ci 09S1 36363353= evorE5E36e 36E351631r 36536E5335 135E3o6Pop 66E3536pos 00ST 63=3E61= 6E353=636 561E33E36e 355336=63 6661=3336 661=3161e otti =636663= 3E636=636 ESEE6E635e 6E3636515o 5e36epTe= 531E00E003 cigET =66363665 =3=6E6= v5 E2636616 6pepel5eeo E36135e536 E3636613ve ozET 3E536361E3 v635636635 6=336=33 Ple6e63DE3 peovE36e31 e6e66EEP66 09z1 3660E536= 3E61361051 006600201e oweD6v P6po 6136333e5.2 op6536333e onT 0000=0360 72353E3366E v3656366E6 6E365136= eepqepqe6s 35EEP3E363 otTI 353=3633o 3E31E33E36 53E233E32e osepo=663 1200E3220e E66130R06E
0801 oee336236 23=E36epe v3633E3313 0116E50560 660640E201 436E0E061E
not 616=e6E63 =3E636636 635E36E6E3 6ve3336363 3eops6sepe E3653335eo 096 3366E35336 2E33E636= e6Ea6p633 porowenee6 615Es6E635 535 pp 006 3533E3=66 epo5oolvos. 635531E33e 3E536533E3 363e333q33 63633663=
Ot8 36631e33E3 qe36.6,6eu35 opoepeeove osrpo=6= pep633Eepl e6r653636e 08L S66636 p361631vol voov6Evoo6 oyepy6=e3 333Ev6w636 Q36333E635 OZL 63E3656E66 v6=663336 e3663pp5qa 6335136e= 3E36E61663 53333633qe 099 3653e3p3e3 636E3636= Ep6E636pee popp6qoppo 6636E3553e E3315ela6y 009 op63ep3516 ve51333v= 6=33663z6 3=3363633 eqpeozqe= Po3e0306E6 ots = 33336E5365 yeoppo6q= 66E333E31e 63635E33E3 Epp6logeol E6335eep65 08V 33536E6366 .pv33136E36 loeyBeepqe 5E636635= Q55 65S e5633eE36e OZT, 36E6,2E33E3 lag=v3363E e5ri533ve 33 6p35 1=3E61536 1630=300E
09E 6336sE6363 623335ee53 =6E6E33E6 66361=6E3 leplE3E56E 53E363E6E3 00E 6E661661E3 ee3ev5ve55 36323y/2311 ogy6126=e6 16PEE5E661 363603P6E6 OtZ 6e=o3Ppeo pope5opepo 3616363=6 propoe=66 636363EPPE 36.166e6=E
081 3E53E1=66 se3363e536 epo6o63311 6=33233E3 3v=661g66s. y66363633 OZT 6363663/233 Q363633E61 6653633512e 6E66363363 6E33363133 6=1=6E36 09 2661636336 1361361636 3363333566 E6126es.63ee 36 66e33 voo6313E126 9' <00t>

ZATWZ9TASPourelnuvwcd5 :wouenbe S TIPT0TJTlaY ;o uoTulTiosaa <EZZ>
<OZZ>

aouanbes reTpT;Tqay <Eln yin <ZTZ>
tt6T <TIZ>
9t <OTZ>

SZOZ 6E5= DP 3P3 6636336535 ee36eplepe 5313551oEs 0861 56353336E3 366636eppe 65336E6510 6136255E35 e632e6vp5e 66E36E=Tav 0z6T 6E336E5E66 E633Q63333 v3E333E633 peepoepelp grog6=E5e 63636E6663 0921 6E66e6633 os6leogype v66331E6E3 3E663=6E6 eeoeE36E65 33612=53QQ
0081 66333D5163 3633E33E35 131/e6335Tim 36636E3613 6666=3E36 66336336E0 0t,L1 6E33E5642E6 333E33635E 6636336613 6363633366 E36136e36E P33E366663 0891 61600E6106 936106100E 06E05E0006 5E531E335o 63633633w epee6E36e3 0r9T 6E363633E3 6635E53363 36e3363336 6E361533E6 3333E61336 v383336366 0991 63E33E36E3 65=6=536 6613331366 61=3163E3 36365533zo v636336352 0091 Emp6e636e6 e3.63663635 v36E33E335 oquopupopo 3561636661 33336E633E
Otq,I 6ve6166166 Eepe36Evoe 16136e5o6e 363651pero p636351E3e 6366356366 08E1 333363=13 lav5p3E33 v3se35123e 6Q66 366z 663E636333 v533633633 ozET 35533E33E3 evio51236vo6 336=3.26ep 36636=1E3 oopopopEoe 161e=56ee 09z1 3665166E65 e366136=e v3qp3s6123 Bevoqvo633 6333351333 y31233E356 clinT peepoepepo ee33336633 720023VV3IM 663=1236E3 Es3145405E 333eD6v3ee ()K1 3633E13333 336E636636 63613vv3lq 36E3E363E6 1631E6E633 33s6366356 LT-60-TOO 1.1709E2O VO

LS E <TIE>
86 <OTE>

9E81 6v6Dgo eeqaqeovq6 56 666 e36e3leoe6 008T D1166lose6 Sa6lo36o3 666q6ve3r6 Bqp6e56q96 DE 5D6 66E66 ovcr Svo6voolee6 epo6v6e66g Eoqabqoaow 32qaqe6qoo ewoovoeqav epv6pqp526 0891 36o6v66636 66 563 v64e0esore 66233126e= p6Elo3Se6e povro6661 0E91 oftopEoveS 6qopo636po 633eopeo5q ole63o6eeo 6636vD6w6 665 66 09S1 61361o6235 )2pp/26664 ooeqp6o6v6 55666 q53600366s 362o6v06ee 00sT oqeo6666.46 3633p5.436v oSlo6qpoeo Bro6ropp66 s6oleop636 36qo6400ry OWE ove6vo6e36 e3616oqe36 635256z, 66 12D6q6pae6q popySlooft 08ET o600D63666 qeaava6go5 6006po5o65 6l3olqa666 1333363e= 6366613oop OUT 616o3536y6 ve6gBaSe6e o6q66q6o6e 3612pleoo63 geopv=000 66q6o666qo 09E1 po36e63qu.6 ye6g6646612 epeq6espeq 61D6u6D6up 6o65qoveov E.DED5/e0v6 00E1 D66D66663 o36o33=401. 2Es6Doe0oe oveo6voqe6 v66eeo8636 6De5o6poos, KT 61361p5qop 65p3123312ov vobwoftobq oSooge6epo 65o600leop oopopoSpea 0801 6qtifoo66e2D 6.66q66,266E o66ao6oove pleiqeEvoe. yvolvo6op6 13=61op3e OEOT 3lypopo663 eropeoppoy eaop365ole opeoewoinG 6qopsD6epe eagq6q3623 096 pos.362pewa 6.43eqoqqoq q6v6o66366 obl3eeoq33 6eov363e61 6oTe6e6poo 006 ov6p66o663 6ep6v6po6t, polq616pqe pop6evoeep 66o.1.16popo 66e3661212 Ot8 pov616ole6 yo6pv5q=3 u.vinaovii66q Syy6e6D6So 6eDqvoveD6 qovoop66ya 081. D600qepe6o 66oquoqeov 6366=72336 3vlo1233.63 6=6Boopo6 bogeopepqr OEL o6e6epoSoo oeorgopeop epono6oppe 36e6 Ta6545o6s6w 66e1264o5eo 099 616ogyaqyo ola6svo36ole e3v633eol3 opv6e6p623 63 6266 5o666r66e6 009 33663336e3 663lee6ao61 obqoBepoot. 35y6366.463 3oo63ole36 6pepoDeo6q OtS 6po616ope3 6v6.46ogeoo vabqopoD66 o6e6632vo 1q6ey6rov 666ee 08t 6gooluoo63 qq35600600 33363633121 oeooqeoppo Tep33612634 136e6q66se On 3oo3613356 poopeolebq 636woow6po oGloveo66D 36o6561636 16apoopoov 09E Bqo6ee6163 6qo3ofive63 op6y6y33e6 661623o6o qvolvoe6612 SpeoGgefto 00E 6y6636612D vEDeveve66 161voeeoll ovv6e6Doe6 q6Dee61266.4 366e66 OVE 6yoppoovvn DootaboDepo a6q6o6qoa6 ovapoeop66 61616pegoe 351E62630E' 081 agb3e43366 evap6312638 2=6361331 6q333e33r3 3eop66y65e y66q6q6333 OET 63636S3v13 v164633.961 666q5qo5 67e66q5=63 6cioao64q1 656 09 12564546436 qoaqo63636 lo6loqp666 v6v6ce6qee 361e663v3o poo6oqqee6 LT? <00t>

EA/1A1eP'E91ASPow81nurot1d5 :93uanb95 1eT0T3Tlav Jo uoTulTiosea <UV.
<OEE>

aouanbes prpT;Tqay cEIv.
VNQ <E1E>
981 <TTE>
Lt <01E>

Vt61 66qoPs3oleoV q561610661 0E61 6ww36eolv3 e63a3663oe y66q6loo5e no66616peo 66 565 06135266'6'0 0981 6e63pp5er6 e6Evo6vooe 126vooSlaSe6 EvSoqw6400 De3eq34g6q Dorepovoe3 0081 3re3y63qu,6 )263536s665 q6p661y663 ope6le3ego ee6E133eSe 3pe66lo36e OtLI Seeoev36p6 633Eva3E3p e6633366 apbooepovo 6gogy6436v v36636eo6a 0891 36666q3qe3 56666e aftoogaee 6qo3elo536 e66q533652 36q5353oDE.
0z91 6vo61,36)236 ve3le3686.6 163600vEzo 6ea6q36qoo epSvoSeopo 65e63le336 LIZ

99tt <ITZ>
6t <OIZ>

LtSZ EvEo;ov 2361D5q000 5oBo6e6o;4 OZSZ o566voo600 qeo6oD6000 D34120e0610 oT1Do6o5Do 6531eo5o6 poo65.366e6 09n 3quoqro633 e600rp6662 S336616336 3qy3o6oqeo 36or6o4l6q po6e6.4Eoo5 00VZ 36eoevEmp6 q361266e3oq e66;ovq6vo 5qa5qooveo 6656qovq6e 26556 OVEZ 66406606o 6=666qo6q o56616oqe o6opoboo63 126.433.4e6q opv6o63Eqo 08Zz 3600eopeqo 6eoq164=6 16qooSvo6D 6gooe5o7266 6qoqQ6qopo 65566 OZZZ ovo6q66loo opo5o6rio5 oov6D600e6 o6o6e6366o 666r66266y 6ple3666e6 091z o3oo6o3e63 opo56o5000 DooS0000ql oboopeSepo 1136vEl000 oo6uoeqo66 ootz 6eoo63616o 600ve646oq eo6264o6q5 opeo4q5.46o leoSoBloob 6616633356 OtOz a666q6oqu6 avoTeolaol eftvaleoeq 6616qo6616 Pe36Po1eDe 63116610er 0861 661613o6eo 3665q6reop 56qo6126510 65656 e63gyege6g 66v36e3aee 0z61 6voD6w6v66 126oqiiiSqopo youqoqeSlo ovEopeorqo rv3e63lv6s. 6666EEq 0981 6y66.4r663D orSqyoveop e66iolvevo oe66qop6v6 vroevo6e66 go6vo6ova 0081 66qo33646D o6pouopeo6 qolia5qo6ee o6636s.o6o 6666qole36 66335ao6eo OtLI 6upoe662e6 qoprloSoft 6636o36613 616a63op66 robloBeoSe yolvo66564 0891 6153DP6336 r36qp6q=12 D5o6w0006 6ti6oqeoo63 6o6w6gooe vDev6ro6eo 0Z91 6123646ogvo 66o6u6qo63 36E336=36 Beo6q600y6 2oopp6qpn6 eo600p6366 09sT 5qeooroEmo 66336=636 6556 Sloo346412o o6o666.4poo Q6q6006o5o OOSI Evv6e6o5o5 vo6456q636 oo5o5eepo6 Sepopeopoo 366463665a oopobeSogr ottcr 566665 evDelftvog .463o6e6o6e o8o661oero le63636qepy 6066o66o66 08ET 3o33633ll3 qv5e6002oo powaoSeoqv 6146E-6,356o 663126o6000 u636a36qo OZEI 366oDeo;eo pe36po6po6 3oBooqe6vo 36636pole3 opopoop63e 161eo366ep 09ZT o666q65v66 po66qo600v eDTpolefto 6ve3Teo63o 6l0006qo3o voqeo3e366 00Z1 3V123320WR3 wupoo36634 vDoeoseoes 66qooe3623 veo336306e 00Deo6epeR
OtTI 06102304'3o 1q6e6o6606 636qoeepql 36or36qe6 q63qe6v53D 3ow6o66366 0801 36ro6eEvo6 ev3l.4646oq v3ov6vu3in 366oqq6voo 366ro6qo6e ro3e616olv ozoi Evo6sebloo ovolmovv66 26ev626o66 D6yogrovvo 6loyoop66e po600lvov6 096 D6Boqeoqvo e6o6600vao 56 o6=66000a 66oqeopeoq voSeftvo6o 006 DOVOIMOUIRD 880ODOBODO uo6g3evoly 6e66163&26 EE 5z6 3616oqvoqe 0t8 oovbeepoSo eeo26002oq l3esee636p 3600le6466 453666w6Se 60066.4ao5 08L D66ope6436 qo6lo6v000 wo6w5.466q5 00006oDqeo 66e6 q62061500F
OZL 366q6oeuo opo6lapoo6 636o65oev 33qbee6evo e6oep366e v6q3oq23o6 099 3gl3S6o3b3 opoo636l3r qopooqv000 34e3335v63 qqa6e6q66e eopoo6loo6 009 62000waq426 q636tiopeov vo63oveDqe 61o6vvpvlo Spooporvoe SoeeDv6olp OtS 3336q66.463 e66qp6re3e qoqq6loop6 ovq6v66vg5 eo6T,261avol2 voSoolvoft 08, Dovoos.6466 evoq4o67236 loeefteaqs. 6v6o66D6op e661e6e66v v6.6q3epi6E.
OZt oftftrpoeo evooepoSop eSve6qopee poe6loeo6 4D33s.6.4536 46q00000v 09E 6136e6q63 6q3336v426q oo6126voole6 6646qoa6o apoleop6Er 63vo62e6s3 00E 5y66q66Teo eleovs6er56 q5leoproll opp6v600p6 16ove6e65; 35q5o4126e6 OtZ ft0000peeo poorboorpo o6q6o6;oo6 ovDoowoo66 646q63ey3e o6q66s633e 081 0P60v43066 v*20060E/636 voo636101q 6l000ro3l3 3e3366e56y p6Sq6163o3 OT 6q6365oel3 y36q633vB3 66Sq6qo6e 6y66q6o36o 61203o63qqq 556 09 e6616q6q36 lo63616.46 lo643.43566 -96,26ee6.4ev 36 5633 e33633qee6 8' <00t>

Z9I1SPou10906 :eouenbas TeT0T3T4-vd ;o uoTulTaosea <EZZ>
<Ott>

apuenbaS IPTDT3T32V <ETZ>
VNG <ZIZ>

LT-60-TOO 1.1709E2O VO

8SEZ <ITZ>
OS <OTZ>

0917Z e216105430 060606260q 4366623363 3.423633633 3331232361 polq336363 00tz 3663q23636 y333663662 63323q2363 3263323666 2.63,366q633 63q23363q2 OVEZ 3363263146 q336264633 636232262v 6q35266233 3266432462 3633633322 08zz 366663e6 226q333662 666'4366363 3633666q36 136266q631 2363336336 ozzE 3q26133426 1332636364 3363323324 3623446433 6463336236 3633326326 09Tz 6643326433 3664364306 6323616633 3333623623 6332636332 6363626366 OOTZ 3666266266 2634236662 633336=26 =33663633 3333633334 qa63332623 OtOZ 3q33626433 3336232436 6623363646 3633226463 1236261361 6332344616 0861 3123636q33 6664663336 636663.6312 6423323.4ga 126223323g .4664633661 OZ61 6223623123 2631q66432 266354336v 3366646223 266q362664 36336266E3 0991 61263226226 2661236233u 2623362626 6263326133 3232q3126q 322332321 0081 0223263126 2636362666 16266q266q 3326q23223 2266q34262 0326643362 Otcl 6223223626 6q36233632 266q333636 3363323323 6332261362 2366362362 0z91 6236136236 22332366E6 q646332643 6236336133 2362362333 6626312336 09S1 3636436333 v232262362 0623536342 3663626136 q362336333 66236q6332 00ST 6q33326133 6236333636 664233236v 3663363363 6556 6643336q2 OttT 3363666333 3264603636 3622626363 6236166163 6336362233 6622332333 02E1 335663566 4333362634 26226166q6 62232q62,23 2364362636 236366q322 OZET 3263636123 2636636636 63333633qq 3426263323 323223623'3 2626622366 09Z1 3663263633 326436q36a 3366332322 3E23623623 6136331262 3366363312 0OZT =33=3363 2361233662 2366616626 623E613633 v20423-4262 35e363 OVIT 0613=6433 3231233236 6322332322 3223333663 1233232232 266133236e 0801 3223qa6336 2333236232 236332q3q4 3346263663 6636432234 q362323642 OZOT 6163326263 3332636636 6362362623 62.23136q63 4233262232 236631q623 096 3366236336 2233263631 2623622613 3323223226 616'2262636 636233232v 006 3633233366 2336334232 636E332342 3263663323 3632q34433 6363366333 0t8 3663423323 4206262236 3332322322 322=33633 3236q32233 2626616362 08L 6266226336 236q63123q 2332622336 3220263323 4q32262636 23633q2636 OL 6463566266 v633664336 2366322643 6136136233 3236263661 6333363342 099 3663233323 65236633 23626q6322 3323633=3 6636236632 23q467:22622 009 32E3223636 2264333233 6344366336 333335363 2wepoq233 3332333626 OtS 3443626466 ee3333633 6683332342 64636233E3 223613223.4 2613622366 08V 3363666.366 2231436236 43226223q2 6263E63633 2663262662 266'43E23Se OZt 3626223323 2233233632 2622633322 3323633236 233326q636 1613333332 09E 535663 6133362263 3362623326 6646433623 323123266v 6323642623 OtZ 623333322a 3332633233 36q636q336 3233323366 6q61632232 3646626332 081 3263243366 2233632636 2336364344 Sqopospovo 3233662662 e5665333 6463663243 246q633264 6661643622 5256E3363 6233363411 6314346'236 09 266q616436 136136q6q6 3361343666 2626226422 36T2664233 23353226 <00t>

ZATeP*Z91ASpow'091d6 towtenbos 1vT3T;T41li ;o uo.pciTioseci <EZZ>
<OZZ>

awieribn 12T3T;T2213 <ETZ>
WIG <ZTZ>

snaTA ApueToTlepounwarr tionnH <ETZ>
vNa <ZTZ>
V6VT <TTZ>
TS <OTZ>

8SEZ Eveoqovw q6w6w336 OtEZ 0606e50443 656/2336o3l vDeopeopoo Dqeoleo5lao 33336o5.336 SoleoSoSpo ofnz po66166e5D 12pleo6D3r Sopy3668e5 Da66q6o36o leop5oTeop 53126oqq6qo ouz D6p6163363 6,2Dvv262e6q o6v6EmpoTe 66q3246yD6 qo6q33Ero6 5663or35e 09TZ 613DoS6v56 6136636336 =6663361p 6e66163ep Bo3o63363q e6qo3le6lo OOTZ oe63636133 6povoovq3E voqq64336q 6loo5ep5o6 qo3v6ovS66 aoqe6qopo6 opoz 6.4o6q336So vo5q65qDoo opfto6e063 Dr6o6poe63 Eo6e6o66D6 66e66e66vB
0861 pqr356fiv8o 3op6o3v600 oo56o600po op63oDolqo 633ov6sDoq lo6v6q3030 0z61 o6veqa666 12Do6D6q6.36 opee6q6Dqv 366 66 ovoq3.615oq eo6o6a0056 09RT 6466.33o653 66516o1v61 eDqeolloqe 65 66 5E6 voSeo4woy6 0081 04156q3pe6 636q3pEpp3 6661812gova6 54a51256q36 .1361965y3Se 6ovv6ve6e6 OVLT 6,ao6vDowe6 voo6e6p66y 6olvElopay oe3o3e6loo eepoporqoe poe6pqr6v6 0891 o636,266816 e651e6Elo3 p6leopeove 55logy6yoo v66.4p361262 vogri36e664 OZ91 36voo6Dyeb 6loop6q6Do 6o3voDepE3 oqt,6136Evo 6636e362o6 666 .e366 09S1 5666 eope66ee61 opeq3636e6 63633663o8 q6o6opp65p 3536E.361e12 00ST plyo666616 163326136v obgaSqopyo 61236sDoo65 e6oqeo36o6 o61D6qo3yy Otti ogy6o6v36 vo6q6olvo6 6o6v61o6lo 6e30633366 ep6q6opv61 3ope6qop6e 08E1 363oo5o666 leoDe36vo6 E3p6005366 6665 1004q64Q0D 60666W0DE
OZET 5E35366 ce126e636a6v a6q6636363 36o6gepo66 evoov0000p 6516o656qo 09zT Do362633v5 lev6q66256v eneqfteopq 63o6e6o6po 6D66q3evoQ 6366e6 00ZT 06E0660660 0005003404 26e63o7aDov oewo6yolv6 e66666 6ot.63600De 6436-436goo MoDeoqept, v36vo6ep6q DEopqvSepo 66o63oTpo3 op00006oeq 0801 63e3366gro 666q66r66e o66qoEopep oqeoqii.6eo6 v/20;1206005 q0Do6q0DDR
clua Dqvoaeo66D lawoDvorrepe voopp663qv 3Deore3rv6 6a3oep6eoe e31.46136e3 096 3DvD6goveo 610v1oalol 36e6366366 364peeplqo Evogo641a6q 63s.6e63oo 006 0e6066D6.63 61236726cD612 uoqq6q5oqg ooe6uvoeuo 663qq5e3oo 66e36qo5ee Ot8 oplit6163qv6 e36v6lopo vopeowe661 Eve6p5o66o 66 qosopp56vo 08L pEopqeop6o 56olvol2oe 6566 pygoqqop6o 6.3356pp336 631ropeoqe OZL o626vero6= peavvoevoe goopp6000p o63orroap6 P666366v 66ev6qo5vp 099 6q63leolvo aeftrop6oe pap6opeoql oee6e60520 5034v5456q 6656666 009 no66qoa6vo 66ov/264364 o61o6y000e oft6366q63 Dpo600leo6 6oppoor083 OtS 5ep61600vo 5e616oveop eo8qn3oo56 36 6533 qq6ee6evs. 656ue 08T7 6q33lepo63 q4366po5oo ooD636q3.24 312004VDODD 1u0006e601 q356466Pe on, 000p610066 2000ED3E6q 6o6eoorfto 36 z653 36366616o6 q6loDp000e 09E 6a35e6163 Bl0006ev6a 33666 65151006y3 Wolv07266P SDe051v6PD
00E 6e66466Teo evovv6ev66 q6qt,oevpq pc,e6e633e6 16pyr5e66q 364631v6e6 OtZ Seaopopero opogbooleao 3Eq536qo36 peoopeop66 5q616312gos 36.466v600v 081 oeS3eq336E pe3363v636 g33636qoqq 6qopeo3e3 3eo366v66v v663535333 01 6q63660e40 236q600,26q 665.36136pr 6266q63o53 6rD3o5o311 66 09 eB6q6q6q36 lo6q3616q6 lo6qp33666 w6sSey6qes. 36qe654e3o s33e3qTer6 OS <00t>

ZA/TA1aP*Z9TaSpou1 09IdE
:apuenbes IvT3TgT4av Jo uoTulTapsea <EZZ>
<OZZ>

eouanbas TvToT;Tqay <Etc>
%MG <ZTZ>

Oz WET 3reaqqe3pe epeolypelv el611y1311 qqqee668611. 66161leell 44612Deolqq 080T e161qeveft. pooe6556v6 6.1ao;o1234 4vv441pqee qgeouveeqv eqev666111 OZOT 23ve6u6e2 lqtrevve63q 666 elllopogeq os.661ovev3 56P11e 096 prE163Tene D6ee3261m1 y3e6v66y1r eqvqe6q652 oveo61a4q4 qeo6E6e666 006 vooe66gqe1 speqvq6ese euSeuovqeu zeepeeop3e 6eqr163ae e33eee6v16 0t8 q0qPe6lue6 loSept26v1 velropvee2 136qRepeSe peoqqqppee 6;D3v6eqlp 08L eq6elvbe6e vfty6eo6v1 3462o66qge y4q6qD6qoe voqoyeoleq Bvq6rDDv6v OZL lqvu.66.4/2o12 ovo6wesouq 66e6 lvverelble poe6ftope6 Slev0136eP
099 5rle6er3 616e21213q1 .2636q1.4166 qp65oppo6q Blqvggypeq voolqegpo 009 ev6qq1q3le 166egvooqb ;o0612eoeot, qqyoq5voqo ovqeeqbqlv relebalv5P
OtS W405e305q vP1e6Teeav 5ele2porq6 2361e643op weqeloqloq oqolleTee6 or eve6e3616e erlebe6t,eq 5q6vvosopv aqvilvsolq4 oqo5q3esue evqeuv6e66 OZt ev6006qe6 ut1212666416 v3v610e16e leeloel62 0P16elwelo v06616e1"
09E qftqvelovo E6161noeq6 elevepeo56 lvelovq6laq 66723e6qq6e eqe6109451 00E To2v444094 46464010e0 0opevqawes 2q6161e=6 eevqopftee ols.656.4elq OtZ 46roaevly3 e66e6q1;2363 rEvose86q6 6geovrTeep ev65q6q12312 vq411ewsla6 081 epe6q6qvee ovvq4quevaq E421266votiop 3egooDov6s. ovopovq6q6 qop6avoe3y qa66643q8o veqeopo56v 6e36re3el 2o6eelo6; vEvole3636 qqq16134py 09 oaro3ee36v e6ves.66.461 6336566 leqw43162 3voq66616q loq6eoeepv ZS <00t>

onaTA ADueToT;apounwwi umunH <ETZ>
vta <ZTZ>
LOOZ <TTZ>
ZS <OTZ>

t617T ebee ev6r5e6yee o6.466.46.2612 e600212wa55 VOODEDOOVO 6E16e6Erell Otti voave6q4ve Evegq5elfte vq2212vvlel v14ex.616ye 6e661wepe 66ve5gpoep 08ET y66e666661 3pe6eoll33 p6e6o3voe6 ore5pe66,2q veqewoevqo vq66q66qe6 ozET v6121.peeqqe 4o6lo66612o 121;equev3l voqq6lveel qeevoe66v6 voleopoqop 09Z1 oo64E-35.4vp o6v1221266va ErvEveo661 Eqpovvelel leepoefteq evE205T1200 00Z1 olopqvoqel pene6.4evee Bleveqoefte qvgra.466e6v 26qou;qeqv ve6600vq5c, OtTT 112eqqqeq3g vovoluovqe eq63cloql qlqet.5666e S6q611eell 316e0P0114 0801 v16qqeee6e 000v5666v6 6e34Dolvol qev4qqoqes. qeyoweveqv eqvu66S123 OZOT veDev6126w2 q4eTreve61q .612.4e6poev6 v211Drovel oe66qoeeeo Seerl&elqe 096 oPv161qeov oBeeprfteq roy6e56eqe glelp6166e oefoble411 4e36e6e666 006 eope66eqei epeTelEvvie vivEmeallaqvw queoupopple 6eyqr3B11v vqqese6v18 Ote qoqwv6qva6 qoEmov36y.3 yy2ro3yeep qo6lep3p6e peolllyeee 6qoleftlqp 08L rlbelvbeft eSev6ro6q 316e366qe2 riqq6qa6qou voqovvoqeq 5eq633e6e OZL qqvp661E.D12 ovobqvearn 6eoPp6vol6 weeeel5qe 3pe6Er3evE SqevoqqBer 099 ftvq1267eva 6a6vvv3,o11 P60E313166 1066000D61 544e44)2Dv4 20D0;que00 009 pv514.41ole q66grp3o.46 4006geavot, qqyaq6voqo oelev2633y eelv631vbe OtS 4vq36vqo6q evqufiqveze Seliegoovlb 2161e6q3op velploqqpq 34341elvici6 08t vvv6ei615e yeTe6y6evq 6q5s.vogoos, oqu;eepq1q 03D610ewee gelvee6e65 On, ve6yo36q,a6 veee665q16 2.4v6lov36y Tweqoelbeq oelEmqveqo ep65q5eqog 09E 16eleel3eo 6666 elveeva66 qrreqoeqbvq 65vov6qq6E. vqe633eq6q 00E qevellqo21 q6q6qoqDvo opovuaqeev eq616qgoo8 reelooftee ole6654eqq OtZ 46woqeuTeq v56e611zo6q s6votte66q6 6qvoleeleve vieb6q6q2Du aqqqqveeu6 081 e3e61Blvve ovellletreq 6e06eola= owe000peft ov000eq6q6 loo6leDvot, OZT la6664316o veqtaDvao.66y .61236yee3eq eo6eseq351 v5voqeo516 11q1Eqogov 09 ooeoDevo6v e6ee6S363 Eq33vq6665 v6vov34666q6a loqftoueov IS <00t>

,¨

IZZ

0981 v6ve126666 r6.611266qop eblvqtepleS 66q14e6e61 0,96.4310Ter e3/22162664 0081 q&eqpqoee6 6q1o36164o elolapovo6.4 lqa3qatages. 6556 655qqqe.666 01,L1 vqo3q36423w voqw66e221 00v1seelag6 636106640o qeeEmvoS6v poqp6eover 0891 p120666610 166oeoopp 361q6loqpo 6wove36366 v6q1eqp6e5 125436qqgve 0Z91 02v6206202 v061624216 6101611211 ey0e6epo66 eov3660v63 D5oe6z6201 0951 606205o656 q2;3206y26 66EE5 61q0136664 1203161110 666E6 00ST 663E6e pe6p6v6ewe o5qE6q5v6s e6126ewleo56 VDDDVDDOVO 62q6p56211 ottT woove6ggyvi 6ewl6eq5ee vqvalpee421 24322646ye 6y663qvvoe Meebleove 08ET 2662666661 002620qq33 e6eBooepe5 pee6oe6B.eq weqvapsvq0 2466166426 OZET 2621022112 4064066620 2442422204 2011642224 weeov66v6 eoqepooaao 091 Do64v46.4.ee DftelevS5v4 Bee6s366q 6120222121 1222026221 2262061200 00Z1 010212012,4 0P0e6lernm 62,evqoe6e/2 lev1215613612 w6qogqqvle v.65qoovqft otti qwvqq4vilou, eDeDqvaylv eq6q124041 21qv2666.62 6626112211 116eproq11 0801 21611erv&e. poop6866e5 Sp3l3oleol '4221140122 41wDelivinqe 2422666441 onT ve3ve612612T2 qlvelvel251q 6equ6oeu6 e21.1020221 0266102220 6222362112 096 Dep1511so2 36re3rE2el voeft66elv eqeqp6q66p oveD6q/eqq4 412o6T2672666 006 eo3v66eTel envqpq&eve ve6wvoincra queoevopoe 6euqeq61.42 211evr6e16 0t8 goque54pie6 qobrovlSeq 22q2002222 1061220262 0204312222 6101262410 08L eqSvae6e6v yEepSeobel ol6e3E6qee 124q613613s. woqDgeogy; 6vq5eopeft OZL gley561voe Dgo5gevezeg 6povo6poqb geevse36112 Doy66e3ve6 122011622 099 SwegySeurq 64612eelo2 e6a.643qq6,6 q.06633336q 61Teqlpoea popoqqvepo 009 2v641.43pqr 166eeepoq6 looSepovoe q4123q62310 02q22q64q2 2212611262 OtS q2406wq361 eele6q1n3e 5eqepoot.16 v263261402 2212401101 0104Teqee6 08' verftp64.6e evq2Beftel 616evoe3ov ogeqve33.44 pqo6qatiliev syq2e726v66 OZt ve6v=6qvb eglag6663;6 2126102462 Teel3el6r1 ov36eqepq3 e366qEgl3e 09E 35elvegoep 666 evevos066 leelov6v1 6672o1264q6e ele54owq63 00E lpyylqqo21 q616.4purip popeeqq222 2161612006 2221006222 0126664243 OtZ Be s66t.6q12o63 E6e3ev6636 Sq2oevqeve 2266164202 2111122226 08T voefilBlewe peleqqleseq 6weE6vos.Do oeviD00026/2 ow000s4616 1006120202 OZT 106664alEc veqvioria6Eak Seoftypoea vo6evela5l v6voqinb16 qqlq6loqie 09 00e00e2p52 vftve6b.463 6q331216666 lelly1D16y peo165646q go.4612ovape ES <00t>

ensTA A3uaT3Tj9pounwwT u2wnH <ETZ>
VNG <ZTZ>
ZES Z <TTZ>
ES <OLZ>

LOOZ v41241246 Sq6.4o664oe euouuqeq26 0861 1.116611ep6 Sq6q14BrpirD 686q6eg,025 eqqee662q.2 11eeBeeper 6lEvamer6 0Z61 2/2o6epoeee eoeoBuqcoev 63q22a.4122 02123221,10 6620212412 2066142226 0981 26eee66Sq6 v661E66400 e6qelleeq-e6 6644qe6g64 oeSqoqzqeu v1v216e661 0081 46eqoqoge6 6q43064613 eqoeoomo6a 1.1.rol.ovvele 664pqp61.16 6661.34e665 OtLT 2100306voe epqe66ppyq opygs6vey6 6461o6.6433 qs,26eeo56e p3go62DuEs 0891 014236666qa q6Sovpqouli 06.4q64olvo 6eovvoSo.66 v8a3ploSe6 p613614qee 0g91 oueSeaSepe e364621e1E 61316qTelq 12e0v6epo66 rizg456ov64 o601e6;5eol 09S1 636e363665 Teqoe.06)226 Evo6o66.66 5110q46663 1203361110 6266210266 oosT 646uQ51e6we Ev5e6v52ey 3636616v6e eftEreen56 v000ppooso 62q6126612qq otvE epore631e2 Sepq6vq6gy Invlyeeqvg eqqtzvbqBee 612654qespe 662264e3ve 08ET e66e6666.6.4 3ov6voqqoo v6e600eor6 ove6o26621 irelpeoevqo eq66q661p6 ozET eftlaeele 4o6q3856eD vq4elpieleoq epq151,11repq 1,27223v66,a6 voqepooqoo 09ZT 0061216122 0622226623 62s6sep66q 54wavevqva q2220262e2 ve52361epo pozt Dqovqvaqul ovoeSqvpee Svee1oe6e2 '4222166262 261021321e 2664002462 zz ()SET <TTZ>
SS <OTZ>

66S1 eeigqDqoDq eBbaqeqe6e eqo636er6s 536o6ro615 09gT 646D63o6D6 gro366e33o ep000p6615 3866aDoop6 Q5 636 66165ev3eq 00ST 6rp3eq5136 e6o6v235DES lorev66re 6qu3eeo5So 66o66opaa6 opq400e6e6 01 pospe6Dreo oeo63ope3e epeepoeo66 3663e6o63p ps6qoEqp81 o366poelqe 08ET qee36voSe3 63Sreoqe5e p366o6p3le op0000006o wq6466/a eD6E6q56-e6 OZET 6eD.651.61eD evoqvioqe6Te op600quo5o oBwoo610D Te03Q00g0V 60ee6e66ee 09Z1 DosbeepseS 165e66rE33 voleoee66q opeoSeopeo 1164p5e005 e3oroee0E1 00ZT Deloll3qq6 e6365356D6 qpepoq1D6,2 ogooqq6q6o qw6g6p000e Bo66a66o6r.
oviT 35T26e.312Tao qqaqeoqeoo eftuoveore D6531.36e06 e605D6336e e6e664601e 0901 6e36e6ogoo otmeepopE6 loepo366er o6voleoevo 5.43epo366e. opEo3geos6 ()NI 366olvoleo 1263663woo 6De4o1.436 36Do663o3o 663qeprool. voSeSeeqE0 096 6pEzeepevo erpoopbool ro6loveolr 6e661600l6 eboee6qa6e o516pleogy 006 poe6reo36o egoeSpoepq 412126r6331 o6o61o6q63 qr6e56e667e 633661Do6e 01,8 36632e6qo6 qo5436epop ya6e6166q5 oopp5opTeo 663yo3peob q6e616Dae 08L D6e6163rp6 ero6lDoop5 6oDeo66oee oq1612v6seo s66eo6q5e E63Doqeop6 OZL o41o6.6=6o aDo36o6qDe wepolleopo oava005e50 3405e6366e E300051336 099 6epo3e33e5 1635epoe3r eo6lpeeple 5qo36opplo 6roa6oevoe Soggovbaqs 009 000Eq65.46o e66q36reoe 134.46qa3612 Deq6e56e125 eD6q55evap 636616D5 01,S 0DrooeDqe0 eeaq4o6/236 qpeefteale 6e63665ebo paBle6er6e 665 6z6 081, poeobsoreo peo6eopeo6 voreoor,66 oSeoprofto esoovo6636 epoeoftoey OZ1, opeo563eeo 31236)23663p e6436sepe6 opeo61Der6 appor6qE36 16qoppopor 09E 51o6ue6q6o 63Dop6re6q op6e6epop6 6616qoo6o qp31e3e66e 665e3 00E 6e66q66qeo ee3ve6ge66 q6412oevoqq ove6eSpoe6 36pueDar61 33re6q6526 01,Z 6eopoopeep po3r633e33 oSq6o62oo6 3pp3peop56 6q6q63evoe oap561263D6 081 6ee3plqp66 eepo6pe6D6 roo6a6qoq4 Sq3DDVDDVD DeDDS6e66e e6656333 OZT 646a6.6peq eq6q6poebq 655555 opepoeop63 SeappEoglq 6356 09 e66q636q36 qp6q36q6.46 .4364313666 r5e6re63we 36q11664e3o e65 <00b>

1pSnpourozid6 :aouanbas 12T01JT32V Jo uoTulTaosea <Ezz>
<OZZ>

eouenbas 1eTT3T3alt <Etz>
WIC! <ZTZ>
66ST TTZ>
VS <OTZ>

ZESZ er geg3rqq.436 OZSZ 66e6e664qo 666soe6egq ee5ey6e3oo eaeDeollee 1Sqobe6eql q;lyebeeso 091,Z eq5e2reebe leq4e6Sele 6poe656er6 .436E-4612o512 qeeobroeop 6611 001,Z 16e1364o51 6wq6e6eeln o6e56eog6y 6666 l3oloqre66 166qqvg6re otEz olo3o6e66 6q66666e36 pe6664oqlo ee664641e6 61263621644 P6410qDE11 08ZZ oefie6e6q13 6poeaDeqo6 epqloq336q 6.4305e6636 lole6ov666 33qe310e3E.
ozEz 6.4qeqqp56q ro6q6eqqe5 oleepoqe6e 3e6r6eor6e 656E65 6er6ve6re6 09TZ DleeSEree63 3n66eoli6op oe6666e6eo 40612000'40D 600De6e051 le01e3eeDo OOTE epqopqr.665 vo651eqq6e6 yqee616e3e 20212peq81 36q.qqq16eq re6eeqqq66 01,0Z eqe6q4o66e 66e16eqe63 pegeolqele e6wegeqe16 6q6;p65.43e evoevqrleb 0861 111564Tev6 616q446eep 65665 eqqvu66q1e qqerfteore 6ee&eree6 cimE pe36y200/21272 eovoSuleee 53leeqqqee peqeqeeqlo 66roelelqe leo66qqgeeE

EZZ

099 6900023396 3606930902 v3613993;9 6100600930 6900609808 638809603e 009 030636636a 2661068909 3033633369 0816966996 90638629ov 6060636369 OtS 0393023390 v931136206 302,269933e 6960666960 006396296v 6661369026 08, 0390690993 3906800906 9399002066 0690380620 E900806606 200906E0re OZTT 3090663990 3906906600 e6306ve396 0020633996 1030e6q606 361000003e 09E 6306996360 6303369961 0062690025 6616303690 q903939662 6390639680 00E 6266166390 2932962266 36120990;3 0896863096 3639900963 33ee636626 OVZ 693033382o 3008600203 0636061336 0903083366 6363609909 0006626005 081 6220.913366 9900609606 2006363011 6qo33e03e3 0900668669 9663636033 OZI 6060660210 v363600961 6661630616 0323093353 6900360333 6333336906 9S <00t>

tSnPair0$.Td6 :80uanb8S T2T0TJT1aV ;0 u0T3dTaosea <Ezz <OZZ>

aouenbas T9T0T;TlaV <UTZ>
Vbla <ZTZ>
ZITE <TIZ>
9S <OTZ>

0SET 26930100q8 66032296re 3360699696 0ZEE 3606936366 3606006368 830662.0339 3003366360 6663003069 60'49060636 09Z1 6166923216 v902061369 6369360663 0993966996 3907236606 6065003060 cion 3310026960 0202602933 9060092088 0990080660 6609606300 9610630630 ot,TT 06600231ea 980690E906 169e0q9690 3660600190 0003000609 363900668y 080T 0666166966 206636390y 20390196E0 0600390633 6403063001 e012039086 ourr 0996266820 0968908963 66966960op 3190996630 0906209233 3630693069 006 0660660620 6e06909901 1039319039 6820990290 6603162369 606063069v Ot8 69661633'96 906263100o 9099009661 0990066990 6903909906 3323036680 08L 0600320960 6631203939 6066008006 0900130063 6006633306 601909003e OZL 0626883636 090983.990e 803306303e 0633990396 2663600369 6099630680 099 6363390190 0e69930639 809600E0 269600qo 6063064633 8626686626 009 3366300690 6609263063 063068000e 0626366160 3306331236 6090009064 OtS 6806160090 6e636ae969 9063000066 3090663990 3369969239 6699363628 08' 6103123060 1336633603 3036063083 0203380003 q803362633 4062636628 OZt 0303610066 9303903961 606'9309696 3610826662 3666663636 363000a00e 09E 6136996360 6300369963 3062693096 6635300690 le03909662 6120618680 00E 6266366390 8909869966 36380e833q 08269603796 3632830963 3022636686 OtZ 6830303P20 3038630e03 0616064006 De00090066 5464608808 0006586006 SS <00t>

46t-8g1 Ielp-tSf1P0w-ond6 :80uanbeS T2T0T;TliV ;0 u0T3dTi39aa <EZZ>
<OZZ>

90uenbes TeT 0T;TlaV <ETZ>
vma <ztz>

t7ZZ

OZ01 obbolsoqva e605600v0D 60eq3qloo6 p63366Doop 66oqvgDoq ea6v6evq6a 096 EOPDVEOPPD esp000600; soSqoevo;ri. Se56.460046 Eeouv&aaft p6a6oqroqe 006 326v120360 geogSpolepq lopv6v60o3 36353563 ae6v6E0266p Soo663306e Ot8 366osu6336 qp6qz6epoo vo5v6.46616 opoo600lvo 65peop3eo6 461;n6q63oe 08L obr6163ee6 peoEq00005 6Dovo6Sowe olq6ee6weo v66vvo5q6p e6q00Teo06 OZL 3qp56=63 Doo3E3Sq0t, 1.012o02v0o3 01vo036263 1136e6366g PDD3361006 099 6r3ppeole6 .45D6v03eov eD6lopeogy 6qopEopyqo 66ee Speepe6ple 009 3oo645663 1256qo5seou qD1qSwo62 3rl6e6Eme6 ro6.466eeor 6360636o6r OtS povopuolvo rroaqp6eo6 qove6ppolv 6e6o6657263 op6.412612126T2 5661o5epv6 081, DoeD6eogeD ovo5cgoova5 eptIrepoeD65 oftopeofto rvooe06606 e03236epee OZt poso66oPe0 oro6o5630 e6136evoe6 3oeo6qoprE. goo3v51635 qE.qoppas 09E 6goSevEra5o 643336ye6q po625/23o126 6636q3p6vo leolypy66t. 66EE0 00E 64653664eD ev0ve6ee66 4,61soee011 Dev6e600e6 16ieepor6q 3pee666e6 OtZ Sepp000ryo oppeEppeoo 3616oBloo6 3v000p3366 6.46q5ociev 00066263p6 081 6evoe.41066 2,2336ay6o6 v336o64343 54003eDovo ov3066v65e v561516opo OZT 645o56Deqo vq6q600e61 566162353B 33)233e0363 6*(133360141 6044346v0S
09 26636q6.3o6 qo5qo6q6q6 ao6134D666 e6v6Tatie5qse 36qe66q12D3 vpD60a37e6 LS <00t>

tSITPowqrtwotid6 :aouenbas TeT0T;Tlre pz, uoTulTinema <EZZ>
<OZZ>

aouanbaS TeT 3T3TlaV <ETZ>
vikla <ZTZ>
ZTTZ <TTZ>
LS <01Z>

ZITZ 126 eqolooeSE, pot 66464 o5,63oeeoav oqeov63315 6q0re66153 005vD06561 ot.az 6esoe66qo5 e66106105e 66po6r6ofee 6pe6p66eoB VDO1226WODO 5Dq12512Eole 0861 blopreopqn 1.26.4o366op eovqove356 31126v636a6 u665q61266q e661,poe6qe 0z6.1 oeeas666qo 4e6v53pe6q opbeftvolee o6.2683a5eo 5eoev66qop p61633voe 0981 o0e06qolv6 labee36636 vo6qo66661 olv35664o6 .43612o6eaDe 565wo21 0081 3636v66463 p56looleo6 3066e36qo Svo6upoqeo 666626a633 p6136e3.613 ovLI 6qoouo5eo6 e0006Emboa v0a6pSoblo BloppypeeE po6eo6eo61 6olt,366o6c, 0891 6q36q06e33 6po366e36a S3pe6goog 6q6DaqDo6D o5o6 66.3e30 v36v565036 0Z9T 0050666400 q4p66pleo q5qopo6p5.6 630D5ES46o 3,636o6e6 6o636eo6q6 0991 616060o6o6 veo366e=0 eoop,o366.46 565 3z6 v6oTeD5o61 6611.6ee0v3 Cost 6vpoe16436 v636vo6366 q3vpoe66vre 6qt.Devo65o 6E06630006 00110DP626 otti Doe0v60eep probooepop eoevopeo66 366peElo6po p726qo6q061 0D6600v11v 08E1 levo6vo8e3 616eeoqvEce oo,6606Doqe pooppoopEo v361:23o66? eD666666 ogET 6v356q6.4eo vvDTeoaeft 336Dolp36o 3Eloop6l3o qeo4eaolaove 6ove6e86ve 09ZT 3or6vvo2e6 166e66p6oo eoqgoes66.4 povaSepego qq6w6e0o6 e0p2oPe061 loon oplolq3qq6 Ta6o66o6636 qpve0q136.e oeo0q16363 1r6e6oDowe 6D66366o6p ()VET 06v06PoveD 1332v3quoo e6groveolar 36601q6e36 v63636qD62 eSe55q6oze 0801 6e06e6o1op oeoevooe6b qavapp66we oft0qeovso 610epo066e 0o6301epe5 OZOT 36,6oqwoq123 E.636600eoo 60v1022=6 oboo5Spoop 66oqeDeool vo6261212463 096 6oe3tvoe120 ve00006poq eo6qoveaqv 6;166q6o046 6D 6z6 364601e0qP
006 3ov6Pe3363 evolaboovDq qavv6e6301 0606q0516D leBeS6v66e 603661306v 0t8 0660vs5105 305136epoo P36e6q66q6 3o336opzeo 66Deoopeo6 15eD6q6Dov 08L 36e6q63rp6 evoSqoopab 6Dos056opy 04aSee6evo ebbeeo6q6e v5qopleop6 OZL oqq366006o oo0o6061ov qoeopqe0oo plepooft63 3406126q6Se R000D6q0E, SZZ

OftT 3323263223 3236=2232 2322332366 36632636= 326436.4364 3366332q12 08E1 qvapEaao6eo 6.46220.4262 3366363=s ===3060 e46123066e 2066616626 0zET 623664.6q23 2231231262 =63=2363 361=361= 32312=232 6322626622 09n 3326223226 .16626626= v=2322664 ODBOSPDVED q164362=6 2332322361 00ZT 07210440'416 2636636636 33E231q362 32=41.6463 12626==2 6366366362 OtTT 0620623223 113323q233 2622321232y 3663q16236 263636336e 2626646=y 080T 62362631= 32322=266 332236622 362342322o 6132=3662 =633.42326 out 366342=23 26366=2= 6321333=6 36=663=3 663123'2=1 2362622163 096 6323223223 223333633q 2361322342 626646=46 Q6 55e 3,6363q2342 006 =2622=63 22326=234 q322626331 3636136163 q262662662 63366q=62 OD8 3663226q36 13643623= 23626q6616 =336=423 66323=236 q6236q6332 081. 36726463226 2236q==6 6=2365322 3qq,6226223 2662236162 263=q2=6 33q3663363 =3363613e 132=123= 3q2=36263 q13626q662 233336.4336 099 623332=26 16362=232 236432234v 64336332.43 62=632232 63223263.42 009 3D36366463 2664362232 .43.1361=62 32a6266226 v3E1662232 6363616362 OtS 002002=20 2232q36236 1322622=2 6263666263 =6.4262126e 6664362326 08t =23623223 32362=236 2322=yo66 362=23623 22=236636 2=2362322 OZt =23663223 32362366= 2643622326 =23613226 43=261636 16q3333332 09E 6436226q63 643=6226q o36126va3e6 6646q=623 42=232662 6320612623 00E 6266166qeD e202e5e66 163e02eD11 322626=26 3632'2=261 3322616626 623=3/223 33326=233 36q636q=6 323=2=66 6.46q632232 336626336 081 6'0207243066 e6636 20060640'41 6'43=2=23 32=66266e 266q616=3 6q63663233 23616=261 6666366 =2332=63 623=60444 6311316206 09 2661616136 435.436466 13643q3666 2626226422 3632661233 2=631q226 89 <00k>

m1powW.1,01,06 :aouenbeS Te TDT3Tlay 3o uo-r4dTao8ea <EZZ>
<OZZ>

apuenbas 1IPT3T4Tlatf <ETZ>
VNG <ZTZ>
T8TZ <rig>
85 <OTZ>

ZTTZ 26 23==q266 001z =24262243 1232q66462 3661322=2 =23263q4B 6;32266464 306e006661 otoz 6223266136 2664364362 6623626322 6226266236 2=2262=3 63q2626312 0861 64=22324o qu6=36633 2324322366 326263636 2666162664 2664=26.42 0z6T 3223266613 12626=264 =625223122 362663362D 6232266q= 36632332 0981 =236.43126 =62236636 236q36666q =23666436 q362362332 662264323 0081 3636266163 366q3=236 3336623613 6235223423 6666q646= e6q06e06q0 OVLT 6433236236 v3=66263'4 y3363636= 63=223226 2362362361 63q2366362 0891 6136436233 633366236q 6=264=32 61633q=63 363666q2= 2362656=6 0Z91 00606E6300 1136604201 4643=6366 64=666463 3636262262 63636236q6 0991 646363z636 2233662=3 2=3=6616 3666.43=36 263123636q 6646622021 005T 6223246q36 2636236366 q322326622 642322366o 663663336 33'4=32626 ovvr =23263223 3236=gwow 2322=2366 36632636= 326a36.436q 3366302q12 08E1 4223623623 6162231262 =6636332 3=33=363 21642=662 2366616626 OZET 62366.46123 y23423262 3363=2363 3643=6433 q234233232 6322626622 09Z1 33Ta6wevio6 '46626626= 23q2322661 =23623223 1461362=6 233232236q pozi 32336 v636636636 132231'4362 32333q6163 4262633332 6366366362 OtIT 3523623223 41342=233 yftpoveore 356 :6235 2636361362 v626616=2 0801 6236263133 3232233266 q322336622 3623423223 6432333662 33633q2326 OVLT 6136266406 4362662062 6322622E26 62062002126 233360q262 5342643322 0891 0243426q00 660323243e 20660426E6 3605266646 2661266400 2642022326 OZ9T 6640426260 Q264336262 23223672661 3620623226 640336q630 v302332361 0951 312640622p 6636206406 66613412366 6436436206 2332662264 3324060626 00GT 6463366430 423633366u 36 5z6 3120666646 4600261062 3630610020 or 6236/233066 2634233606 361064302e 0226206206 2364604206 60672643643 pm 6203603366 20646331264 333,2646334 3363363666 4203236266 6006006066 OM 6403440660 12'34164333 6066643366 6460360636 2262636062 3646616063 09ZT 3636223066 VO3OPOODOO 6616366643 3336263120 6364664662 202462232a 00E1 6436263620 63664329ov 6622642322 3663663663 3306031203 2626002026 OVIT 0220323633 223223223o 2366066326 3630326406 1364336633 T2442122362 OZOT 642322012o 4S6e306001 2DS3O63000 6430120123 320263225e 6622332622 096 3226466266 2603234232 y664032362 3223446436 230623320e 2361021041 006 0446263660 6636432204 1062020344 6463426260 3332636606 636206236y Ot9 3223143423 423026220e 2022066041 6236260636 43621262664 6342623626 08L 310=2022o 3266432233 5622362042 pv23640200 3662336034 2326066312 OZL 0423263663 32=632434 4036063366 3003663423 2304236262 216363232v 099 0220223Q30 630423643e 2042626646 3046263226 4362064634 2312332622 009 3060220260 020443226y 6334363643 6463126266 2662630664 3362366322 Ot5 6406106406 2300236264 6646333360 3420663233 3236462364 6302062646 08t 02e6220610 3006603206 6322344622 6E23266220 6462264304 2336311066 OZt 336333=60 6402402034 200031203o 6260110626 4662230336 40366120366 09E 306366646o 6430062/264 3362623326 664643362a 4204202662 612361262o 00E 6266466420 2202262266 1632.322014 322626=26 1632233E61 3022646626 OtZ 5230333223 0332603203 3646364306 0233323366 6464632232 33066126036 081 6p/23244366 tivoo63ta6a6 2006364344 6133323020 3203662662 2664616003 OZT 646356324o 2464633264 6664610646 002DO2D363 623306344; 6344046206 09 2664646436 4361364646 1364313666 v626226422 0642664230 2306344226 6S <00t>

ZA/T41eP'tSflPow-OtTd6 :aoll3nba5 TeT0T3T321d ;0 UOT3dTa0Saa <Ezz>
<OZZ>

apuenbes 12T3T.VTlilf <ETZ>
v140 <ZTZ>
8181 <VIZ>
65 <OTZ>

09Tz 6163423626 4364603634 4646342363 6403663426 1306606661 6012612312 00T 0140423633 4232166464 366.402233r 3123260146 632266464 3362336664 ovoz 6223266436 266436436v 6612352632e 6226266206 vooev5eopo 6312626312 0861 6q03223240 4264306630 2324322366 0426263636 P666462664 2664332642 OZ6T 3223266613 426263026'4 33626E2322 3626643623 62322664pp 3646332302 0981 3323640426 40627236636 2364366664 3420666106 1062'362'002 66e2613024 0081 0636266460 3664334236 0336623.643 6236223123 666646463o 2543623643 0t,L1 6430236206 2303662634 2036363643 6433223226 2362362364 6312366362 onT 3360666403 4.436634231 4643336366 6403566460 0606362262 6363623646 0951 6460633636 Ta123366v333 v033336646 3666q03036 2604206064 6646622024 00ST 6223946136 12606206066 402202662e 6123223660 6606600036 3344302626 _ LZZ

eouenbes 1eT0TjT4JV <ETZ>
YNC <ZTZ>
8181 <TTZ>
29 <OTZ>

TEOZ e 812333333e8 632eqs8esq pleoe16636 136633eeoo .233E3E6311.
0861 6633ee861.6 3038e33666 18erpe8833 6e66336136 e861236e6oe e6ge6e661ao 0g61 Seopee6e33 3633e6e633 26333,2123e1 33e8333683 pe3eweeo8 603e6e6380 0981 81268636e66 3268qope63 eogeoe6862 03e6e633e6 3336e8pepe ep6p68336e 0081 06e3e98633 3053633ep3 e=p3633Te 6336eep663 6g36136666 333e366613 OtLT 6136e36eop e66ela6qople 33636126636 3385.3031ro 633368e383 38e36veoqe 0891 3566636163 3e6308e363 363o3eo6123 8e33366e63 1E33636361 p6qaptreolas 0Z91 6e36e36e36 2.8331238638 v6336336123 3633366e38 1803e63033 e616333338 09S1 00806663e3 peo6s66633 6336386633 33306833e3 3163333836 6633386636 00ST 0360636ve5 e63636e363 6636363363 6vvo366uoo Deopp03863 6386633333 OWE 6e633e3836 286366epoia 36seoe3613 6e636123838 83preoe68e E61eoppo66 08E1 3663663=o 6poll3pe6e 6nproe8ove poe0803eeo ep3e2337236 60663w8363 OZET por8336136 1336633241 232)2381238v 3636ev3le6 v338636002 v333333336 09Z1 peq83e3368 evo668366e 68p366362e 3eeple31e8 epo6ople36 336q333823 0OZT 03e0le33e3 e6pre6e66e epoe6eepee 6366e88e83 3,233;237/T465 330e06spee OtTT 0416136eoo 6eo3epeep8 33e3033033 6e83663663 6336 voepaqq61E.
0801 oqe6u800po v636636636 e36e36p3er 33131e3le3 pe6ve3ev3e y3883236123 OZOT 6e63838336 ev6e563834 e6e36e8313 Doeaveope8 62pre03662 leoftpleaee 096 3623e33368 ea36333epe 636631e3le 3e606833ep 363e333333 63833863pp 006 38631e3e33 le36e6ep36 06DEDV20V12 ove3333633 qu363ev3l e8e6628331 0t8 6666 ep63833eal Eopefteo36 3ve3e8o3eo 110ee6e600 1360610646 08L 33e6p66e68 e633.663336 e3863ve613 6136138e33 3e08e63883 833336303y OZL 0863e033e3 616e363633 uo6e836pue Eee36l3ppo 86poe3663e e3qq8yeSpe 099 ov66geo61.6 ee63303e00 6032368=8 3333363633 eqpeoo2e33 333e333626 009 01338e6386 peopop6qop 88epope3ge 83636po3eo eep6weeoq e6333633.66 OtS 33636633v3 2,233336v/36 weeEee0qe 6e60666e63 3361eSee6e 668136epe6 0817 apeoftoevo 3e38e=e38 eore33e366 36933e3.6e3 we3ov06836 e6ee OZt poe366pee3 3e38T236633 e63361agoe6 30p3630ee6 1330e61638 461333333e 09E 6238ve8363 633036ee63 336e6epoe8 68164006e0 le31e0e6612 64v064126e0 00E 6e863883eo eepee6ee6.6 3612pee333 3/21267e633s6 36peepoe63 pore6366e6 OtZ 6epo333ee3 333e633e33 3618362336 peoppeo366 816160eepe 33366e6336 081 fte3e11366 ve0363e636 v038361014 6433ogoavo peo366e86e e863636303 OZT 6163663e33 Ta163633w83 6661613636 33e33e3363 8233353133 83313161206 09 y683616336 3063363636 1363033668 e6r8ve6qee 363e663e33 2336333ve6 09 <00t>

ZATGID'tS11P0IIPOtTd8 :eouenbes TeT 3T3T41V 30 uoT1dT-1080C1 <EZZ>
<OZZ>

eouanbes 1eT3T2Tqay <ETZ>
Ama <Zig>
TEOZ <TTZ>
09 <OTZ>

8181 e6e30103 qe8633e3e6 0081 weq3qe3e16 636136623e e33e3le3e6 3436630er6 6161036,200 6666E3e6 00E 6y6616Sleo veovv6es66 16q2opeolq 3pri6e600125 35oevooe6q Dove61662.6 6rop000veo opop5opeoo o61636goo5 ovopowoo56 6.4646ovuov 00066e6006 OBI 61P231211D66 ug3DEDe606 e006361011 61o3oV33e3 3v3366)266v p661645000 OZT 516o66oelo el636one5q 66615qo6q6 oorpoyoo5o 52oo36o41q 6o440461205 09 v661616436 qoE4364636 4o6loqo665 eftSevElee o6qe66qroo eop6oaqvg6 Z9 <007>

Y061-8Z1 1eP'IPSDP0w'017.05 :aolienbaS TY2ToTJT1ay ;o uoTldTiOsaa <EZZ>
<OZZ>

aouenbeS TeT0T3T121i <ETZ>
IdNa <Z1Z>
8181 <ITZ>
Z9 <OTZ>

8181 vbeloqao qs6631.2126 0081 evq04eovi46 6q6qo56qow eoovoquDe6 oq156107e6 816loo6eoo 666q6epoeE
0vi.1 56666 go6e6612o6e Soee6ee6e6 666 y0006o1v6g BoqeSqopea 0891 oplole6qop BEopeosqoa vo66oqe6e6 36o61265616 e.6.6.4e66qoo p5geoeeor6 ont 66.4oqe6a6o 3v6qoo6g6e vorro6561 oftobeoepS Swoo61600 eooeoaeo61 09ST olvEloftpo 66o6eobloS 666 z66 63361o6vo6 vooeSSApabq 3oeqobo6e6 oosT 6460066qoo qeo60006Ere oSqo6o6ev oeo6666q6 3600eS3o5e 06qoelooeo 6Po6s33356 e63qe3o636 36g36l3oey peeEmo6vo6 eo6q6o4vo6 6o6e6qo6qo 08E1 6poo6003.66 )236463ov/6g apop6q6oaq oo6op6o666 apooro666 6006006o66 OZET 6qoolqo66o qroqq5q000 6oS6Bloo66 6a6006o6v6 er6v6o6o5.2 a6166q6o6o 09r1 o5oErsooE6 poopeop000 66463566qo opobaSoqeo 6o6q66q66e vorlftsoel 00E1 64o6y6o6vo 6o664oevoe 66ve6qe3we 066366o66o p3o600lloo v6e600eoe6 0TI11 ovrooeoboo eeoeepeeop e366365op5 o6opoe6lo6 4o6qoo6600 eqqwweoSe 0801 36o616evo TeEmoo6636 oaqsp00000 pobovq&aeo 36Bpeo6.661 66555E3 ozoi 61voeeogyo ly6epo63oq yoBooSl000 6looqyogyo peor6oweEce 565ge 096 ove6166e65 e600eolvoe y66looyobe oveolq6qo.6 yooftoovoy eo6qovloal 006 oq46a636.6o S6a6qolevoq qoSeopooq 8363qv6e63 op3e6366o6 636vo6ro6P
01,8 oevolqoqvo leopeEveroe voreo66oqq 6vo6r5o636 lo6e6e66q 6oTe6o5s6 08L ol000voeeo oe66qoaeop 66vea6oqe oevo6qoeoo 066v306001 eoR6066ole OZL 3leos5o660 oeop6oelol qoo6o63o66 000066o4po pooleoftE2 e46o6ovoee 099 oveorgoopo 600lv36qoe woqe6e6646 ooq6e6oee.6 go6ro6q6o1 eo1epov6Pe 009 ooboupoeSo oeoggoevS2 600lo6o6qo 663 666 p66y5oo661 oo6ao56ove OVS 63o6qo52o6 e000po6v6q 663600006o 3qao660ao0 0e0645e061 6poPD6e616 08V nye6eyo6qo popS600s.6 6oveogl6e2 6teo,266reo SE.reEklool poo6oT4o65 OZV oo5000006o 640V1ORDOZ r0000Tepoo 6e6oqlo5e6 166v1203006 10066eD066 09E 336o666363 6l0006e61 poSe6eope6 6546loo6eo arolgot,66E 6q2oSle6o 00E 6T2661664120 v2oev6ew66 16qcoeuoql oep6e600eS 16oevooe6q Doev6q66e5 OtZ Sep0000eeo oope6o3eop 3666 ov000soo56 6.4646o2eov opo6.6e6006 08T 6sepeqlo66 awoo6oxi6o6 eoo6o6loqq Sl000eopeo oeoob6e66e e6616q6000 OET 6q6o66oeqo va6lEope61 666566 ooeooeooGo 6120006oqqq 6oqloq6E36 09 126646363o6 qo6.4o6q6.46 436.4o4o66.6 eftSur6Tee 063e682v03 2306011vv6 19 <00V>

ZA/TA19P'1,Snpow.qnur0vid6 :aouenbes TeTDTJTWV lo uoTldTaosaa <an <OZz>

096 o3eoev36qo 6DS6o6.6o61 3vv3qqD6eo p33q16q63.4 2.6g63oao26 006 p66366o6yo 6yo6vo*voq qpqvioqvaae ElireovvD122 66oqq6e36y 6o6o61362e 0t8 6g66.46ogy6 TaD6y6oqooD rovinoe661 oveop5512wo SepTeoveDE, qpeopo66ep 08L obooTepeeo 66plepapoe 6366 35 pvloqlo363 63366o=6 6pqQatioDqv OZL 36e6evq6o6 ovoespeclow v0000600qe o6loepoqe6 v66q600ler 6oev6q36eD
099 Eq5Dleole3 ov5veppEog vor6povoll oep6ebooyo 636q36a6o1 v61266e66126 009 o3561306eo 653 6E D6q3612D3oe 36e6.466163 opo63oqyo6 Speoppeo5 OtS 6vo6q600eD 6y6q6ase6Q 236qoopo66 opeo66preo 11Erey6ep3r 66er3616ye 084 6lopappoSo T436600600 333636layl oTaDo4y0000 qs,Doo6ribpq qp6e5466.ey OZt 0006i3366 23poxioqw61 6362ope6p6 36qoes.866e 3666662636 16qopopoop 09E 6qo5ee6q6o 6lopo6e63 op6eSepov6 66164=62p leolgoe56,2 6Teo646,6123 00E 6266.46E3pp ppoppbee65 461eolmoqq 3ve6v633e6 q63erDay6q opey5q66e6 04Z 6v000Do2va 000e63peop 36q636qo36 pr000epo66 6161Eolagoe 3=66.96=6 08T Eompe31356 eep3E3so6o6 ep3636q3ql 6lopoepovo 3/233661;56y v66q616oDo 616366zynD Ta46163aw6.4 666666 poyooepo5o EvappEolaq 56e6 09 v66q636q36 lo6qa6q6q6 lo6lo13656 eftbee6lve 36q1266woo v3o63.4Tes6 9 <004>

46t-8t TWItSflPow.qnurovId5 :80uenbas TIPT3T4TqaY go uoTqdTaosea <EZZ>
<OZZ>

apuanbas TuToTJTlaY <ETZ>
vNa <ZTZ>
981 <I'M>
9 <01Z>

8181 TaSeloloo 1v66olvw6 0081 2e301r3eab 61613561Dy vopeol2Dv6 ol.46543v26 66 36 6656 OVLT 66566 q36e66vo6 6oev6ela6u6 6uo6soove6 epop633E6e 63le6gooee 0891 ovqoqy63o 663 3Z voSSDTeSeS 35366666 e56 663 v6q2Dravae6 0Z9T 5Eaple6e63 De6q336p6e epep35v66q 36w3b2D1m6 64o63600 rooeoovo63 0951 3.42636rig3 6656 666qaqe358 61o63p62o6 epot.56webq 33vqp6o6e5 005T 6q6o3663op le3633386e o6qo6vo6et. ole36666q6 163o/26q36,2 35436qpeo Ot171 6666 e63;leop636 36 63e 3ey6vo6vo6 sa616ogyo6 63605z ogET 6ep36po356 ep6.15Dov,63 oope616331 =63363666 lepogo61268 5oo6p36p66 OM 61=113663 leoqq6qopo So6661oo66 6.46o3636v6 ue6e63636v o61551636o 091 3636vv3366 vooDu0000p 661636663 3306v603e0 806165456p eps1612e0v4 00ZT 6o6e8o6e3 6o661Dpeop 6Eree6gyove 3663663663 oDo6opqqao eftboogos6 OtTT ove33v3633 22JVVIDVEDD vo66366oe6 3566 D61306633 e41v1ee36P
0801 36e36q6ep3 le6poo6636 ooqepoopoo ooSpeq6leo o661e723666q 6666Q36&
myr BlexevoTeo qpftop6pol voboo6qopo 6qaDquoqso peoeSpgrft 66s3oe6pe 096 3gy6q66y56 253oeoTeor e5613ovo6c, oe2aqq5q3E yoo6vooepv eo6lpegogq 006 3q46e63663 .6836g3evol qo6epyo3l4 61634s61263 33e636636 636vo6v36e 0t8 3vv3l134e3 ;e33y6riv3y e3ee356.3qg 6vo5v63606 q36re6266q 63qp6e36e6 08L oqoppeopso 3e66132r33 BEIrepEmoqe 3rp36q3e33 3553D6Doq 23e636634g OZL 3ly3e63663 3p3363eq3q q336363355 3333663qe3 e0ols36s6s 216o8opoee 099 oevolaeoppo 633qe36q3e yolp51266q6 33.46e63ve6 q36e36q6pq eolg33e6ee 009 3363ev3s.63 ovoqqoveSse E3pq36D6q3 6q63qv6T266 T266v6op663 335p3663er 049 6136436436 v3p3v36e6q 66163=36o 3qr3663p33 3e3616eD61 500E05v645 08t peufteoSao 3336S33e35 E3vvDqq6pe 61m31266wir3 66 633 e336oq3066 OZY, opEoppopEo 6qovlovoaq vi3334ie333 6666 q65sT00005 ;0065v0066 09 336356563 6433362e6q 336/26e33v5 6563363 lv3lv3e66e 64;206q126720 Cr-OEZ

0z91 o36o6663oo qq366oavol q6l0006366 6103666q6o o6o6o6ee6e 6o6o6v3646 09sT 6q63600636 seo366eopo v000006646 36661poaa6 e6oqeo6361 66q66euouq post 6vire3eq6q36 e636wa6o66 loevoe66ee 61129ve3660 66o6600006 po2qopeEe6 ow( opeor6oevo oeo6operor eovep3e366 D55 66o 3e6lo6go61 3o663oegge 08ET qgeo6po6e3 6q6veo qs6e oo663600;e 300003oo6o e6leoo66E eo666q66s6 out 6vo6616qpo veoleoge6e oo600leo63 o6l000bloo leoleopeor 6pee6e66ee 09ZT poe6eepee6 166e66e600 voqeove66q 0320E42Di:1.WD 446go6voo6 gooeoeeo6 0OZT 31240q4o4q6 e6o66o66o6 q3evaqao6e opoo11636o 126,260030p 636636E06r OVTT 06P06epeeo qqoqeolpoo e6eeperove o66o1q6eo6 e6o6o6.4o6e v61266460q2 0801 Ero6e6oq33 ov3livooe66 qoegoo66ele o6eoqeoveo 6qpeop366e oo600qeoe6 OZOT D6E0Teo4e0 s6065Doeo0 63 D335 3633663=3 66pqr3vo3q ep6e6eel6o 096 6oepeeopeo eeopo63og eo6lpeeolv 61266q600q6 e63eu6qo6E 3616ogeoge 006 oo126egoo6o eeoe6opeol qore6e63oq 3636ao6q63 3e6e66e66e 63366qop6e OV8 36666 lo6qo6eopo eo66666 opoo600Teo 6636 q6eo6.4600Ta 08L 36e6q6ove6 weo5qopoo6 600120660ve oql6ee6eo e66eleo6q6e e6q3oae336 OZL olqo66006D 00006363oe gpeoolr000 olepoo6e63 lq36e6q66e e3poo6loo6 099 6eoppeoqe6 q636e33p3s eo6q3ee3qle 6qop600eqo 6eoD6oveoe 6peeou6oTe 009 0005466q63 e66406eeoe 101163oo6e 3el6e66ve6 vo6166eepe 6p6361606e OVS Doe3ovoleo eeplqo6eo6 qoveSeeoTe 6e63666e63 oo6qw672e6e 6664o6e3e6 08V ooso6eoveo 3rio6vo3eo6 eaveopeo66 36 36z ge33e3B636 eopeo6eope OZV oovo663veo ov36e36633 e6qo6eeoe6 3peo6qope6 loope63636 q64000poos 09E 6qo6ee616o 61poo6pe61 oo6u6epow6 665 z6 geoqeoe66e 6qe361e6eo 00E 6e66466qv3 ePoue6e66 16Zeoee041 ove6e6ope6 .46oeepoe61 33ee6166e6 OVZ 6eo3p33er3 on3e633e33 p6.46363Do6 peoopeoo66 616q6oveDe 3oa66e63o6 081 6evoeqqo66 veop6oe6o6 woo6o6qDqq 6wooepoeo ogoo66s66e e66q6163oo OZT 6q6a66oeqo e3646=e61 66616q36q6 oDrooeDo63 6popo631q1 666 09 e66q646136 4o6qp6q6q6 lo61o43666 v6/426es6Tee 36qe66qeoD v3o6oqqee6 W9 <00V>

VSLIPow' 09'06 :csouenbes 1T3TT1Y ;o uotqdTaosea <EZZ>
<OZZ>

eptianbas 1eT0T;T3JV <ETZ>
VNO <etz>
tE9Z <ITZ>
V9 <01Z>

E981 e6e 0981 qoqooqe.660 4eqs6eelD1 epeq6616qo 66q3evoovo 4eo2634.466 wee6615qo 0081 36eop666q6 ee3e664o6w 66 6z56 6665 ee6r66eoft poee6ep3o6 041,LI 3qe6e6aqe6 looevorloq e6loo6600e 3eq3pro66o le6P636062 666461266;e 0891 663ooe6qeo peoe6661oq e612600e6qp 36726evovi23 6666 vove66loop cint 61600p3ov3 3e36qo4u6a. 36 36636Q 36q3666613 leo666qo6q 36vo6voor6 0991 6re6qopelo 536e66363o 66qooqeo6o o366vo6qa6 vo6uvoqeo6 6664646=e 009/ 6655 lo3e36e36e 3oo66e63qe oa636363o6 qopeeoee6r 06.eo6eo636 OtV1 3ge36636e6 la6lo6e336 3oo66ro6q6 p3e6q33pe6 1E00100630 506664go3e 08E1 36e6663363 3636661331 436603e0q4 633363666 ;D06661600 606s6e6e6 ouT 36361236466 q63600636p 366 30Q 3333366463 666q33o36e 6oqeo63646 09Z1 6656 ev3e163o6e 636236366q 3ug3w66ee6 qeoevo6636 6366opoo6o oon olq3oe6e63 peog63evoo e363pee3ee 3ee33r3660 663e636333 e6q36l36a3 ovTi 36600el3eq ve36ro6e36 1.6ve3qe6eo 3663633qv3 333333363u 46qe3366ee 0801 36661.66e66 e366161e3e eoqeoqgfto 36333e3633 6qoao6qool volpooeovb ove6,266ve3 326 3826 662662603e 3420226610 3236 3223 46106v0062 0051 po6o666ap3 666.463D6o6 367ap6/26o6o 61236366q6a 6po6p6weo 66v000eozo oo6636o666 3Doao6y6o1 ep636q6636 6vepeaBeep v1633626 6 236o663ove 08E1 ov66Ev6e3 prD66o66o6 6poop600la 3op6p6o3en yEoppopeo6 DDEV3PeORP
OZET 3oep663663 p6o6papp61 p61o6loo66 opt.1423-evD 62a6123646u vaqv6eD66 09n oBooqeopoo 333o6ovq63 eDo6612eo66 6366e66v36 6q6qeoeeoa vole6e3363 UZI oTeo6op6lo op613311233 e3oepe63pp 6p66epope6 eepee6q66e 66v6opwole WIT 3ev6613peD 6voele3163 o6leop6eopt? E,o6loy3o 133336e6o6 6p563633yr 0130.1 olw6epeo3 3161631126v 6op3ol26D66 p66o6p3623 Empevoqpq eoqpoDe6ep 0Z01 orvoireo66D qq6e36e6D6 D63o6e176/26 6666 e6o3pooeog epoe66aoyv 096 oo66evio623 Teaeeo6qou oop66e3360 oqvot.63663 lvoleop636 6opeoo6opl 006 311336D63o 66p0006633 poro31vo6v 6peq6o6orp evoimolimpo ao600qea63 01'8 oveolv6v66 163p161763/2 .263o6vo636 ple01u00P6 ee0060vvor 600e0130ev 08L 6v600qo6o6 3o6q6o1e6v 66e66e6336 6looSpo663 vg61361D61 o6voopeo6v OZL 6366360=3 6o34e3663v 3D 366Q 6q6336o6v6 36.ove6v36 oppo6E.pov 099 06602e0336 12v6Tivoe66u eD616E,E6 E3633 6663333 6363opl3g3 009 oqgoopolvo 336p6331o6 26.4662e3o3 361o3661233 3vo4126q636 eDDviovii.61 Ot5 oveoqe6loo 63oe3367233 63ggotir6ove 3taBoqieooD6 366363e663 36evorqow 08, 6qop6epy16 y6.61m6ro61 66vvoy6o6o 6.4636epoe3 oeoleovvoq qp6e36;oee OZt 6vvole6e63 66 66,6 661o6veov6 3ova363Dve6 l33pe63636 163oopo00.8 09E 61362e6363 63poo6e6a po6y6eope6 66q62306ep le3le3y66e 61po61.26ep 00E 6e66663v.o peoee6pe66 q6qp3peoql opv6v533126 q6oveopv61 oDve6366e6 OtZ Seooppoirep 000liSpoyoD 363663oo6 3e33orp366 666e 3o366e6=6 or 5366 ve0060e605 e006061311 64poovoovo oeop66v66v Q663636000 OZT 6q6366walo eq6163v63 666461o646 povoovoo63 6sopp63133 6311a16e36 09 Q663636336 lo6w636q6 lo6w13666 v6y6reSqvr p6661yop yoo6o3lee6 59 <00t>

1AIaP'W5111001v09Td6 :a0uanbe5 TeT0TJTlati 30 u0T1dTa0s9a <EZZ>
<OZZ>

apuenbes TeToTJTqay <Eiv.
AMC <ZTE>
8ESZ <T1Z>
59 <OTZ>

tE9Z v6pq oqp332664 vqs.61m16qo 61Doo6o636 e661=666t. 3D60o1r063 08SZ 0630o0ole3 eD3qv6363p 6o600lwae 3636e06360 1e6v601voq eo6o326032 cizsz 3666e6pD66 q6D36oTep3 6opeop6ove 3lq6qo36sa6 36006o6eo6 e6v6136v6 09pz 6,2336e6633 vq6vo63363 oare661663 3vq6re6wo 366e6664o6 6a6006=66 00tZ 61363o6e66 1631ro6poo 661Eolv6lo 63363ao1263 636 363 3ovqa62o34 OVEZ 6100636100 6e0636400w 6ou666qoqu 613o3661D6 lo366pe36 663036pop2 onz o6eo600t,63 633y6p636y 6366o666e6 6e66e6pqep 666p6o33o6 oDe600po66 OZZZ 0636e33363 oo64036poo v6vo63po6ri 03e0D36e0 eqo666s336 06460633ee 091z 616331236'26 qo6q6Do6oq q61633vo6o 613366ple6 lo366o6661 633r6le3qg ocaz Dqqalg0500 qeop16616q 3661Derpoe 3qyao126oq46 63312µ266464 006v006663 OtOZ 6p6636 p661o6qD6v. 66go6w6osp 65665 ropev6v000 603P6E601e 0861 6qopeu3va3 qe63336633 e3sweeo66 ple6p636o6 e66636p664 266133e6qu 0z61 3ve3e6663o le6p633e6q 3361262eolaw 36,266w6vo 6voev66qop 36a6o3eoos 0981 33eo6q31w6 336.12E36636 eD61066661 32v366Elo6 qo6e36popx. 66e6103E1 0081 3636e66q63 06630336 33366eo6lo 62o62,23qvo 666666oo 126w6eo6qo citcr 6qope36o6 vo3366v6oq eao636363D 6ee5 eo5ea6e361 603e06606v 0891 6136136123o 633366eD63 6337263=3e 63633qoa63 363666312Do 236e666336 ZEZ

ovti 5e631e3636 q66166.evol2 q5evos.46q3 66666 6goes.ov66e e6qeoeu3.66 08E1 0663650003 5=qq=u6e 600voe6oev porp6opero reoreppeo6 63663E6363 ()EU 00e5135136 4036603e11 cilev36e36,e 3616eT233v5 p=66363z3 v====6 09E1 peq61e=66 evo666466e 65 666Q pewo115.3q25 e=5=qvo6 336=336qo 00E1 34123qe=e3 e6oue6y65,2 v=r6veovy 6366e65y6o 3e o66 133e362pee 06ii 3336136e= 6e=eose36 qoeqoqqoql 6e63663663 61oevoqq36 vospoqq6q6 0801 33.e62.63333 v636636636 236e36epep o;qoqeoquo op6evoevog. u36531a5ep onT 566366 ev6e661633 e6e36p6313 33e3e.epoe6 6qpepo366.e eo6e3le3ee 096 3613v3366 e3363alleav 63,663qeoqu. ov636633123 363eqoqloo 636=66=3 006 3663qupepo quo6e612s6 363eprteoee 3eep3op6= 3v3613evol p6v6616331 068 6e63e26136 po6q6oTe3q. vo3v512v=6 ov12312600li3 qqoTati6v633 q3636=636 08L 347a612661/66 v6=661.336 e3663T2126qo 6436136e= pr36e61661 600006004R
OEL 3663vpooep 636v361633 po6e616nev 5ve36=333 6633)23663v volq6ve6es 099 3e66er364.6 es,61333voo 6666 =3=636= elou=Teoo oolva=6e6 009 3q1o6p6q66 egoo=6333 6623=e33e 61636230vo ev061Dee31 6'6130E3066 06S 3363663qeo epoqq35v36 lopv6yea32 61e63665e63 3364y6eu572 666=6uou6 086 331236volmo3so612=e36 goevoopp56 36e=v36e3 ve=v36636 e=gobeDee 0E6 o3eo663uvo oep6e36633 e6136vrepe6 ooe3613eR6 qoope6q635 q63===w 09E 6.436ep6163 5q=o6Iv264 336126v3ov6 66.46q3o6vo leoavoe6BE 666go 00E 6v66166qvo ee3vs5er66 16qe3gr3ll opp6e6=e6 36ove=e61 pore5q66v6 OVE 6ropopowe3 333p6=e= 364635=36 oe333,23366 64616oeupe 33366v6=6 081 6v20121q066 P1100E012606 v00E061013 6lo3peoppo op=66e6.6p e6616163=
OET 626366pielo e3616=y6g 565665 3otopago.363 6e=o5oqq1 5oqqa.46v36 09 v65q6.46436 43613646q6 43633q366.5 v6e6eu6qee 36412662e= 3363qqre6 99 <006>

EA1ePAPSnpow091d6 :03uenbes 1PTDT3T11V j0 uoTadTiosaa <EEE>
<OZE>

93uanb9 1TTJT4.Y <ETE>
vra <ETE>
ESSE <TTE>
99 <OTE>

8ESE e61243qop qe6634equ.6 OESE evi64361= 363636v661 33666e=63 34E36=6= 3333voe=q e6a6=63E3 096E plaD4e0605 v062601g6E 6oleoleo63 pe6=e3.666 e6=66363 631123363372 00vz 3363ev3qq6 qop6v61633 636123.6g6vw 6=6266s= 6e66qovq6v 0530503PV
otu. 66656 vp6333366y 6663366363 363666136 q36e66q6og v36=36616 08EE 3le6136135 q=e63636.4 336=epogq p6voqq6q= 6163336e36 3666 ()ZEE 66104e6q03 0564361336 63v36166qo 3633eep6r3 633e6363 63536p6366 09TF 3666e66s66 E631.p3666.e 6=336=e6 3=3653636 w3=6=364 035333e6e0 OOTE 61=6123qe3 pooEvola.4o6 66e3363636 p6o0ee6160 4V06e63063 60363q1636 ovoz 34)23636qop 6633e6=36 63666q63qr 61e3qe=q3 qp3.6=qpos. q664643664 0861 otee=e3qt.3 w63.4q6633)2 .666154336v 33666467eva E.66=6p664 36136v55vo onT 6263ve64m6 Q65 6z uSepoo5olt. 6e6oze6q03 ee3Rq33e6q 036600P0P1 0981 3ee36633s6 v63636v666 16e6E1e66.4 ope6lpopv3 v666434y6s. 6=e6q006e 0081 666 6q36v3.612312 1966q=a646 DOEDOEDDED 5loa,e5lo6e vo66o6e363 0t,L1 366664olvo 666136136e oft=e66er 6133e33636 r6616=66q 303e363306 0891 6e361.36v36 e36665 161.6=e6q3 .60:Q61364= ep6236eapo 66s633e=6 onT 363.6436q= eu3ee6e35e 36e361631p 35636v6=6 136v=6333 6623616=v 0991 61000E6363 pq33.633.606 66le33pp6 66633536o 6661=q106 6e353 EEZ

ogET 5poo5oopE6 236q63o264 poos6q6opq oo6006o666 avooeo6v55 6006005o66 OZEI 6400410660 4e0q46qopo 63666loo66 6;600636o6 ev6p636o6e o616636D6o 09z1 oSo6v3o66 epopeoopoo 6816066610 000ErSoqvo 6o666166w volnftvoeq 00ZT Sqo6p5o6e3 63664ovvoe 6e6qtowa 366o66o65o poo600lgoo p5e5opeoeS
ov11 oeeopeo600 euovvortoo coS6o6SoeS o6opor6go6 lo6lo36600 eqlvlveoft 0801 oSeo6a6eeo qe6voo66o6 ooleopoopo ooSaeq5quo 366vvo668.4 66E,56eo66q OZOT Eileovvoqw0 qe6voo6004 uo5oo6l000 6loogyo4yo oeoP6oeeft 66ev3or6ep 096 3ye6q85e65 e6opeoqeoe E66qoogobe ovvol353o6 epoftoDvov eo6qoeloqq 006 0136v63660 66064ouso4 qobeoeool3 6.6oqv6e6o opov6p6636 6o6poEmo6e Ot8 oveo1qoqeo qeoovftrole vorpobBoal be36536o6 lo6Pv6w6Eq 504v5v206w6 08L ol000roevo oe5Eqneeoo 6fteo6voqe ocrea6qoeoo o66voo5ool eov5o663le OZL 0q20263660 0e0060eqoq qoo6o60065 opoo65oqeo vo3lpo6e6e eq636opoee 099 ouyoev0000 6Doavo6aoa eolp6126616 ooq6e6ove6 qo6vo6q6aq eoqyooyfty 009 ooSoprov6o opoqqoveSe Booqo6o6qo 6q6oTe6e66 p66e666q oo6vo66ove OtS 61364o6w6 poo3eo6e61 6616333obo olvo6Bopoo ovo6z6v364 600lao6,2648 08t osvbegoblo 3o3M3opo6 Eovvoqq6v2 6woe66eo 6q6vu6qooq eopBoa3o66 OZt pabop000So 64oeloeooq ep000lepoo Embolao6e6 166pe000D6 loo66eoo56 09E o36366615o 61=o62e61 po6v6epor6 6616qo36eo lvoqeoe66e 6qpo61e6v3 00E 6y66q66qeo geolm6sq266 461eoveoll ose6e6=26 16oeepoe6q opev61660.
OtZ Stoopooyso 000ebooepo oSq6o6lo36 Dvoope3o65 6q646oewow 00066P6006 081 Egeolinqo66 evoo6o12636 voo6o54o4q 6wooeopro 3v3o66y66e P6646.46=3 OZT 6q6o66olno vq6abooe61 666q623635 oovoopooSo 6sopo63q4q 63qqoq6ga6 09 v661535q35 1061361616 go6gol3666 125y512141ve 36qe6BqeDo e6 L9 <00t>

ZA/1A1GP'tSnPow-091d6 :aouenbas TeToTgTqly go uo-pdTaosea <Eze>
OZZ>

emianbeS 1rT0TIT1Y <ETZ>
YNU <ZIZ>
OVEZ <TIE>
9 <OTZ>

ESSZ gbe qolooqe66o qeqr6ev45q 36qopoSoEko OZSZ BE.66goo668 e3353olvo5 poS00000qe oppoqviSq6o 363600qqol eo636eo616 0917z 3le6p6oqv3 qeo63oe5oo Tgo656p6006 6q6o3601e0 3633r00601? e33164008e oot,z 645oo6o6eo 6v6veSqoEle 66 3665 3vq6eo5406 4001n66466 qpv16Pu60 01,u 3o66p66610 66666 66qa6qo66 6q6olvo600 35616oqp61 3613E1036 ogzz o6o64006oo epovqo6rol 36loo6q6lo o6eo636qoo 7253v6664o1 e6q00066qo OZZZ 6lo366opoS q66loo600v eo62o600eb 36 6.6a6 e53663566v 56e56e63Te 09Tz 3666p63000 booTaBoopoS 6o6o6epoo6 pooSqooSoD ov6vD6qoo6 vo4s00006v OOTZ 3yg3666v33 636q63600p e616oleoft 6;o545oa6o qq6q6o4eo6 o6qop6.60/y OtOZ Bloo66o666 .46o4w6gpoq eoqqoqvio6o 3lv3eq65a6 lo661oppoo Ppgroe6o11 0861 66666 loDBuoo666 36vvoe663o 6e66136go6 e56e36e5ov la5ee6e66uo 0z61 SEopeeftoo 363 56o eSqopesoul oqw64DoS6o oroeweeo6 6oTe626o63 0981 6666665 qv66qope6q eouvop6563 oav6e600r6 loo6p6peoe vo67266q0612 0081 oftoue66;o oo6253peoo PD 363P 536PED663 666656 qoqeo66610 of,LT 6336e36Po3 1266we6qoow 436360.6.46 3365q33lro 533o6Se38q o6leo6veolv 0891 o6666q6163 3v64362o61 36q33ro6e3 6e33366v63 lg33636364 o6qooueors 0Z9I 5eo6Pobeo8 q6oqeo6636 v51o636v3 o600065vo5 a63oeS1000 e616031D36 0951 o36o6664v3 3v36s.6663o 53363666q3 olq06601P3 1161300506 6640065616 oosT 3363636sT26 1263536/m61 66q6o5oo63 612voo5612oo ogo3333661 60656loopo _ 09S1 6/2851=2.33 63586635= 663=3836o 3366836336 83688=836 6661636=8 00ST 6=6836=6 333836836E 33658632 =63536336 13 8838268 3683683616 0661 3v3663686 =5=68336 336583616 =263=386 36==o6= 6356638=2 08E1 36/25663363 3636653333 3366338333 633=63666 =366635= 5063628686 02ET 3635836366 3636=5368 23366833 366363 6661=3368 6=8353636 onT 61668.23816 883836358 6362353663 Pes3-856885 3838836636 536633=6p 0021 0130386853 38386388= 835=88388 388=83653 66386363= 85=6=6=
06TT 3663383321 8836836836 3688338683 36536=183 ===3638 3538=5688 0801 3666366866 83663683v 2=831868o 3633383633 6333363333 8=8=8386 020T 3886866883 3858838862 5686685=8 =83886613 3836838p= 163368=62.
096 3080880613 81341=36v 6366355361 328333683 8=43636= 85863=386 006 3653663583 68368388= =38318=2 6883283883 66=46836e 63536=688 068 686636=86 83626313= 2388338663 3883z6688o 68=838836 138=3668P
081. 36=323263 56338=e3e 6366=8=6 38=133363 5335533336 633838=38 02L 3686283636 3e3 3e3 8333363338 3613823385 86536=36e 63886=683 099 5160383180 0858803608 8086008=4 pee685=13 636=615= 8686685686 009 3366333683 663886=63 3613683338 3586156163 3336333836 6383=8361 OVS 6835353z8o 686163886v 236=3=66 3383653823 3168862123e 6688363628 086 6333383363 33366=6= 33536=84 3800380000 1800362603 3068636528 026 33=63=66 83=8=261 6368=8586 36=82665p 3666663636 16===a8 09E 6=688636a 6133358853 =6858=86 6536=3680 4801808658 6320618680 00E 6866156383 2838868255 1538388311 388686=86 16388=863 3388616626 062 68=3=883 =325=e= 363535=36 ovo3ovo3S6 636353883r =35685=5 081 628381=65 8833538636 8335363333 633323383 38=568658 8663616=P
OZT 53636638= 8161633863 6661613536 338338=53 52=3531= 6=3=6836 09 v661636=5 =6=63536 =5=33656 2526885388 3638661800 2006031886 89 <006>

1,6T-82T I8106S11Pow-091d6 :apuenbaS 18T0T;TlaY ;o uoT1dT13s9c <E22>
<022>

80u8nb8S I8T0T3T4JV <Eta>
viva <ZTZ>
S8EZ <TTZ>
89 <OTZ>

OVEZ 8683333318 563812688 36=633=5 36368663= 6668=5=1 806=63=0 08zz 3383833326 3533636333 =18363683 635=85863 1833836338 5=8366686 ozzz 3356353363 3803633833 6388=3513 0625160060 6806862864 068668=68 091z 6613816836 361338856 366=81688 630366266 6106605006 0065630610 ocaz 685636=83 63=563631 86=6=613 38636361= 6338=836 8011630064 01,0z 513D6.83635 1338632566 312533336 6336133653 8363661336 3388368363 0z61 3363336133 6333268363 3368338333 368383656 2336361535 396163e 0981 0626136153 36=1616= 2363613365 3386333663 6563601861 8038011312 0z91 6613186863 3853306868 2388368661 3623583285 6133361503 2302338361 oosT 6163366133 1836003668 3633683688 3123566615 1630861358 35136133.83 ()vv.( 5835830365 2631833536 3813633382 3226836936 8361631836 6062613610 gaccagcagc tgctgggcat ctggggctgc agcggcaagc tgatctgcac caccaccgtg 1620 ccctggaaca gcagctggag caacaagagc ctgaccgaga tctgggacaa catgacctgg 1680 atggagtggg agcgcgagat cggcaactac accggcctga tctacaacct gatcgagatc 1740 gcccagaacc agcaggagaa gaacgagcag gagctgctgg agctggacaa gtgggccagc 1800 ctgtggaact ggttcgacat caccaactgg ctgtggtaca tccgcatctt catcatgatc 1860 gtgggcggcc tgatcggcct gcgcatcgtg ttcgccgtgc tgagcatcgt gaaccgcgtg 1920 cgccagggct acagccccat cagcctgcag acccgcctgc ccgcccagcg cggccccgac 1980 cgccccgagg gcatcgagga ggagggcggc gagcgcgacc gcgaccgcag caaccgcctg 2040 gtgcacggcc tgctggccct gatctgggac gacctgcgca gcctgtgcct gttcagctac 2100 caccgcctgc gcgacctgct gctgatcgtg gcccgcatcg tggagctgct gggccgccgc 2160 ggctgggagg ccctgaagta ctggtggaac ctgctgcagt actggagcca ggagctgaag 2220 agcagcgccg tgagcctgtt caacgccacc gccatcgccg tggccgaggg caccgaccgc 2280 atcatcgaga tcgtgcagcg catcttccgc gccgtgatcc acatcccccg ccgcatccgc 2340 cagggcctgg agcgcgccct gctgtaagat atcggatcct ctaga 2385 <210> 69 <211> 144 <212> DNA
<213> Human immunodeficiency virus <400> 69 gacaccatca tcctgccctg ccgcatccgc cagatcatca acatgtggca ggaggtgggc 60 aaggccatgt acgccccccc catccgcggc cagatcaagt gcagcagcaa catcaccggc 120 ctgctgctga cccgcgacgg cggc 144 <210> 70 <211> 144 <212> DNA
<213> Human immunodeficiency virus <400> 70 ggaactatca cactcccatg cagaataaaa caaattataa acaggtggca ggaagtagga 60 aaagcaatgt atgcccctcc catcagagga caaattagat gctcatcaaa tattacagga 120 ctgctattaa caagagatgg tggt 144 <210> 71 <211> 144 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: synthetic Env US4 common region <400> 71 gacaccatca tcctgccctg ccgcatccgc cagatcatca acatgtggca ggaggtgggc 60 aaggccatgt acgccccccc catccgcggc cagatcaagt gcagcagcaa catcaccggc 120 ctgctgctga cccgcgacgg cggc 144 0891 Bqa6136eoo 6003,66eo5q 63pa6000py 61600looBo obo66Sgeop eo6e566006 OZ91 oo6o666qoo 41o56posoo o600po6o66 6000666o6o o5o6o6ye6e BoSo6e0516 095T 52636006o5 eepoS6v000 y000006636 oB6Sqopoo5 e6oqeo6o61 66166eepeo nos' 656 e6o6eo5o56 qoaeo/256ee bovoeva663 66366003o5 oolqops6e6 powoe6oaeo ovo6opevou voevooro66 o563r5o600 oe6q361362 ooE600elle 08ET lesobeofto 6oEveoleSe oo66o600ge opo333336o el6oeoo66e yo656166e6 OZET 6e366o6ovo evoleooeft ao6Daqvp6o o6l000S000 3e0PDOVOe 6oev6v66es 091 ooeftvoyeB q56a56e600 voleoweS6o opeobeoevo 13600ftoo6 epoeopro61 00ZT 336 e6366o66o6 loveoll36e o2oo.416.46o qe6w60000s. 6o66o6636e 061236Roveo 1401201eD0 g6veoesoee 055oq16eo6 e636o6q362 e6ES635oqe 080T 6vo6e6oqoo peosepor66 qoveoo65ee obeoleopeo 6.4oepoo66e o363oopoe6 0z0T o66oTeoqeo 25365oovoo 6oeqoqqao6 o5oa66a000 66oluoeool eo6e6eyq6o 096 Boyoevoeso ev0000600g eo5qovr33e 6e66q600l6 a6ove6l36e o616oleoqe 006 ope6eo36o eepa6opeol qoee6e600q o6o600.646o 2e6a56e6Be 63066qoo6E
()VS 36Boee6006 ;o600Sp000 vo6e5366q6 opoob000eo 66or000eo6 16eo6o6ope 08L o6e.616oev6 peo6q00006 600eo66ope oll6ev6peo 266ge36o6a eboopqaoo6 OZL ollo66006o p0006o6ope qoeopqs000 oqv0006e6o lao6r6a66e eo3oo52=6 099 6eopogo3p6 1635eo3eoe eo6loevole B133633'213 6poo5opeoe 6aeeoe6o;e 009 0006q66q6o p6600Seeoe qoqq6qoobe ov6w66e126 ao6o66evos, 6o635q6o5e OVS oolepavo;vo peolqo6o5 gouefteola 6p6o666e63 336oy6ee6e 5551o6voeS
08V poeoftoeeo 3eoEmoovo6 enveopeo66 obepoeo6eo eeopeo66o6 e6voee On, opeo66oewo ov36wo663a v6136avoa6 oovo6loae6 l000e6o636 o6qop0000e 09E 6006e5q63 63opoSee6o oo6r6eope8 6616loo6eo qeoleop66e 63e.o6le6o 001 6e56q6Boeo eeove6ve66 q6ogorreoq4 3ve6v60oe6 15oegooe61 ooRe6366e6 OIPZ Beopoopeeo oaosSoovoo o616063006 0E033v0365 63616012e0v 0D066e6006 081 Beepelq365 ev3363e636 eoo6o6qolq S0000vooeo ovoo66e66w a5616q6000 OZT 6.48o66ow4o eq6o600eS1 666163o636 poeoop3o6o 6eopo6oglq SoglogSeo6 09 e66a5q62o6 oo6ao5q616 qofiqoloB66 e6e5ev6qep o6Te66;eoo vo36344yv6.

EL OOT, ZdSPOw'ft6'tSnpow'cisIdE
:eouenbes Te ToT3Tlatf 30 uoTlciTiosaG <EZZ>
<OZZ>

aouenbas TETOTTT4aNt <ETZ>
NC <ZTZ>
99LV <TTZ>
EL <012>

o66o 663ebob000 2640613610 OZT 36633e3le3 evo6y36P3E oo600leBeo o66o5oogeo oop00006os q64eopE6ey 09 o666466e65 vo5600600e liDquoly6up 6avoqeo5oo 6l0006q000 voaeooro66 ZL <001,>

uoT6aa uowwoo Z9TdS
Aus otler.pudie :eouanbas 1eT0T;Tl1V ;o uoTulTioaaa <EZZ>
<OZZ>

aouanbes reToTIToalt <ET z>
vNa <ZIZ>
ti7T <TTZ>
EL <OTZ>

LEZ

99LV E6E4oq 6evo6e6Dlo e6o44pe6E
OVLV 246epo6ea6 epoope6ove p663q16=43o 6E36362=6 epoES3poop 3vq6qo6E66 089, EE3E834e3o 36E66e36E.E. 6,23p6vopop pro3126ev612 66e6366D-4q 36opq4o6e6 om. 266e6appoo oop6poeoop 6e6pooa6po 6e6e3613o1 3DEED66000 p6o3666geo 09SV E436e33366 aoqe6evo66 Eloolloepo 36.6pop6o6e 6o3ED6qp26 66e6epo 00SV epo666126o6 336636w6D 664a64o666 asSwvoEopo Doa6o6o36q 3uE66eoo6o OVVV 020e03666x2 66geD66061 DEv042o6q6 Evoa6poe6E e6ee p600lloveD
08E 66o636e361 E.63p34pooe 6o6633oet.6 oe6q662o36 E6q126a66126 ap6643646D
OZEV 633366-eepy o366oppo66 3666.46o6.66 eop6qoo6op E6qr6e6e6 6e664popeo 09Zv o66363oo36 6o4o1366ve 6l3pqe33e6 isep64oe633 DOPPOD6OVP 6E36466136 00Zt lopov6e633 e6e65ee 6E02646p1266 voa6woo66E 36e6136p6o 64opoe6yEa OtIV e404406Doe 56e6 o6334qpoo6 E66vezpoo6 66ep36opqr De664polpo 080V 6ropleopop6 23E161E663 6.46o3e6veo Ey64op6661 op4vDqe664 6636yeoego OZOV 426E6o666q 6opopqypDo poppyvorro DE6qt.664o6 6ole6E36e6 6eo64popro 096E 6E33E33E36 6336oqeor6 p623663633 oo6e6o6D64 e6voo65pao oD6o4lappoo 006E 566 o54 60000vo6q6 o6o3e666q6 e6p363D66e 66p6oveo2e opy6e66Ey5 otgE lo6.4e6e364 goo6oD66ED oeo366o666 a6oppoee64 461e6peopp 61Doe66poo 08LE oo3opoo6o6 66e6p6e61 oo6p6po146 4Eoppole64 6.6y6poop62 pq4p366ue6 OZLE E66E66q664 66se6q666q Da6oey6loo orp6opoop6 epqvoo66po op36166qe6 099E epa666E361 ooev6ED626 32Epooppqo Ev6poo6E61 66po6eD6E oevo6600va 009E 66po6006po 6336o366vo 6EDDa66Es.6 ve6esooq62 eowv6vo6E6 6e66E6o1E6 OtSE Ev6e66opo 66E66yepot. oE66evolbo E6plep6o6e ope361636q op164popyo 08VE 36646ope3e roe4613362 o6o64361266 42606/236630 Ta6wo6goo6y ao36E36436 woo6S6qpoq E6epo60061 p666e636ED ov6e661364 op66p3opeE 64633631qo 09EE 636E66136e 636006eoo6 661636pqED epEree6136e pow46ps5ve 6evo66D66a 00EE poo6o6lop6 o4,26v2E6E6 6616Eepy66 go6E606636 636E61o636 36rop5p600 at 363666qEop Eqeine6ovo everE6q313 o431466q6o e6666ogoov E6aopoop66 081E Elog6oveve yEe4466e63 46E114646; gpE4;4p6qw peo6466pqo o6666101v6 OZTE 1x;v6661e4 644Ep000vl 66Ep6spoo6 ae662E6q36 666eposeoq 4e1636Epoq 090E polow6612 erol6E6Eve 6646146ely 66116E6164 q6312D3646e popoyypea6 000E 6066egE364 ooeoeqw6gia 4E1616os/op 6peueDo66p 6133=6166 v3E6366103 ov6z eopoopovE6 636E366eo6 lllopoe636 12.36w4Bove oveepp6ve6 T4331362E6 088Z 6131poqq6e ofte66pe61 Eo461pc.641 64p;66pwo6 ger266wEEDD 6a4o1Dopoq OZ8Z 44x;6666e4 paTavo6e6o E6T4o12o16 2o3366loos, Er66opo666 E6361peo66 0912 1411346306 11E1E3DEpo 1111E4464E 4E4o16q416 o646466op6 5eeee66qq ooLz o6336eg633 66qpriqq6ow eqozop000p OD3D00301D DOOOODOODO 0000300360 Ot9z 00,lue6E6E3 oloD1E6634 .6.4E612E463o 6q=o6p6o6 v664=666v op6pogeo6o 08S o60000pleo wo34.2515oo 636Do;4o4E o6o6ED6q6a 4E6e6olvoq EDEopy6ope OZSZ 0666E6D066 46ao6oqeop 633eop6oer alq61=6E6 q6op6o6ED6 p6ee6;o6E6 09VZ 6Epp6e6610 R46E361361 =2E661661 peq62e64Do a66g6664o6 6p6op6op66 00VZ 61o6436E66 -4634Tio6oDo 66-46oQE64D 6.136wor63 636q0p600v 00e106v011 OVEZ 6q336464po 6E3636qoxe 63e6661olp 64=066136 qoo65ovo51 664Do6opeTa 08ZZ 36ED6o3p6o 6apy6o6o6E 6366o666e6 64266E6o4so 666e6p0336 opE6000p66 OZZZ a63672poo6D oo6qDo6opo ESED6lop6E pleopop6E3 eqp666ep6 0636o6popy 09TZ 616oleo6e6 q3616036o1 1646oleo6o 643o65o4v6 43o66D6664 6oqE6leoze OOTZ 01434yo600 4E3E466461 o664oeuDop oqeDE5oqq6 61ove66161 poSepo6661 ovoz Seexe6.6436 E66qa61p6e 66e36ESpee 61m6y66e36 eporeft000 634E6E534w 086T 6qpoeEpe4D Te6qoo66o voe4Diasa66 p4e6e6o6o6 e666q6E66q E664=e62e oz6T oveou.6664a 4196e6poEB1 oo6e6Evolev o6e66qp6ED 6eope66qop p6463ovoop or porp61o2E6 qp6E1.36636 po61o6666q plep666406 436v361209 66v135303e1 0081 36o6w6646o o66400lvo6 aoo6613o54o 6E36Esoqva 566636463o E6136go643 otLI 64poso6ro6 E=ooD66E6pq E33636o6qo 6133Egoev6 po6p36ED61 63112n6636E

01,9z 5166o366vg am663q363 3See6o366q ovq1Eoeelo ao3oop3oo1 Dooqolopop 089Z opp0000Doo op0006o3qq vp6e6v1o16 lawa6,263qop eq61o64000 635o6w6pq4 OZSZ 06661200633 4eDE0D6000 001Rovo610 ol3o36o633 6632s353.612 33o66166v6 09VZ 01golro6po y63oe3SESE, 6o35618=6 3lypo6plep o6Debo1151 op6e6.463o6 oon 36eavvEme6 qp61256epoq s55qos.15go 6q36400eep 6666.43eqft e6qapo66v6 OVEZ 6636636op 633556w6q o6e66153qe 36oo353360 qe&woqeEl 3oe6363610 08ZZ 05=e0oelo 6eoqq6qo36 q6lop6ez63 6qoola5oy66 64264o33 66665 ozu ogo6466qoo ooD6ea6p6 3os.53633v6 36D6e63663 656E661266e 6ozeo666v6 091Z 000pSopeSo 3oo66o63oo oo3633ooql D60Dov6200 1406v64D03 006v0v4066 ooTz 6voa6o646o Eopuu.646D4 eo6w613646 poepqq6q6o qeo636o36 66663356 0i,oz 36666E leolvo2aoq yftspgrovq 5EE655 peoSpoleop 6p11661oee 0861 66q61306vo 36566eyov 661a5v6643 Blo666236 126Dwy6,2125p 66eo6e33ye 0Z61 61no6e6y66 ebaqvSgoop eoe;pqe6qo ovvposorgo evov5oleft 63555563 0981 5p661e6633 pe6qvoeene 12.65133pEro ov6633D6e6 o5e66 3a6voo63ve 0081 5613D36463 363ovioDvo6 l3qp6qa6122 o66o6eo5qo 6566qoqe36 66106q36ro OVLT 6yoouE6pe6 lopelo6o6g 5635DDE6qo 6q636opo66 vo5q0512oere roqp06666q 089T Erl633v5lo6 po6q361332 o6o6epoo6 6v63qv3363 636w6qoop voev6eD6po 0n1 6e36q6zzeo 6636v6436q 36op63oo6 61236363326 lopov613a6 ep53oD6356 ogst 61r3peo5eo 6633633636 661o311D65 61331q6leD 3636G63. 12645336363 00sI 5vie55o636 wo6q66q636 oD66evDo6 6vvoav0000 o55a636,66q opoo6e632e OVVT 5v6156166 erovq6seoe q6 136e6362 ofio6Bqopeo e5p6oBqvps 6566566 SET 000pEpolao Te6v6opeoo 12372wo6wo4v 6w6617123653 663e6a6333 v51o5q0.6q0 0ZE1 3663ovx4eo geobsobro6 wboolefto 366o6poleo 3ooDpoo6oe q6le3p66re 091 D5651662E6 '20661360ov e3le3qe6vo 6r3le3533 61.3=6.4333 vo4voaeo66 00zI 3VVOOVOV20 avooDo66aq eDoepeeDes. 66gooe35ED vupqq613612 36es 01,11 3610e30313 16e636636 636wee3ql 3ftorp6qt#6 1601126P600 00v6066366 0801 06PD6e6v06 veolq64501 e00,261m01212 D66045voo 365 56 vooe6q6aTe OUT Seoftv6wo opoeyoye66 l6eSe6366 pftpleoveD 61De333E6e opEopgeop6 096 o66oTeoleo v6366opeop 5ovq314036 0503660000 663 333 s366u360 006 poliaaweavea eu33336333 eD6q3ey3lv 6e5616o6e6 e65eebloft, o616ogeogy 0178 33v6ee336o ve32633e3q loev6e636p o600le6q86 .45o555v66e 63368.4336e 08L 3563e536 .4o6qa6woo w36g645646 opobooTep 66Deopov35 q6e061600r OZL 36v6q532vo ovo6qopoo6 536vo663ev plq6ee6weo vEopp36q6e v6l33qeD36 099 3213863363 333p636q3v 3e331.2333 3qv3336Q63 q436w6156w voDD35qDp6 009 6g33pra3qw6 4636w33e3e e35l3ve33v 51361220e13 6P3DeovvDe Soee3e6ole ()VS 3o35q66163 v66q36epou loqq6l0005 3eq6y6Emp6 y36ge5yeop v3633ge36la 08t 33e33e6q68 vv3l.4361236 43721261m3le 5w6p56o6op e66e6E65e v56qovraft OZV oftfteppEo vv3pe3353r 126er53o3re 33e3643r36 333e51636 46l3333oov 09E 536553 6wDoEve6q 3366e3ppE 65q6lop5123 qvogla3s,65s. 6Depeqv6o 00E 6e66q661e3 ve3ele6e66 q5qeosvoll 3ee6v533e6 1.6ove6v66q 36463ge6e6 OVZ 6r33333ee3 popeEopeop o6.1636qoa5 3e333v3355 646q6ovne o5q56.e533r 081 3e53vq3366 vagoo6ov536 T233636q3qq 64000e00s0 3e0056v65e v653516330 0Z1 5363563eg3 el616=262 85616136ee 6a66163360 Ere33363qqa 631.4316e36 09 v661646q36 qp513616q6 436133666 126126;m641;72 36T956qTapo e3o633qee6 PG <00V>

EdSpow.6e6'E913SPourogid6 :eDuenbes TeT0T3Tl1y ;o uoTqdTiosaa <EZZ>
<OZZ>

aouanbeS TeT0T;TlaV <ETZ>
VNC <ZIZ>
689t, <TTZ>
<OTZ>
=

OZt 3363333363 643e43e331 P3o331e3op 6666 166evo3o36 13366e3366 09E 3363666.16D 64=36ele64 336v6epov6 6646q336e3 -41234yoe66e 656vo 00E 672664664e0 vi2012T26T21266 464v0re044 pre6e6o3e6 46ogvope64 oovr6a66e6 OtZ 6roo333ee3 333v633v33 3646361=6 pv033723366 6q6q6oepoe 33366e6336 081 666 eV006012606 w006064014 6q333vo3eo 323366e66v e66q64600p OZI 6463660v40 124616001261 6661543616 33233/glop63 6e33360q1q 6311316e36 09 v6646q6.436 q364064646 4364343666 e61261m6qcm 364v664voo e3o6314ee6 SL <00t>

ZdSpow.6e6=zA/TATeP'tSfiPouvo906 :aouanbes TeT0T3T4ay jo uoT4dTaosaa <EZZ>
<OZZ>

eouanbes TE10TJT12V <ETZ>
vm <ZTZ>
ZLtt <ITZ>
SL <OTZ>

689' 126eq346vg 089t 06e6010R6e 034ee6212q6 T23336e33 33e6oevo66 Dqq64336u3 636q336e3o oz9t 6.6433oppv4 6136e66eleo s6pavo33612 66e36ee6e3 36eopoopeo 3v6pe6v66p 09S1' 6066041060 011367eSe66 v633333333 666 33336336-e6 1236403143e 00St P366333363 3666ww3e43 6s3336613q u6peo66613 oqqoepoo66 ep3636e633 Ott, e36401e66ee 64126epoepo 666e6o6opE 636q363661 361o666ee6 ep35333333 08Et 6363361ovy 66v3p6p3ep y3366626612 v3663643es 3443646eva 46opefte66 OZEt 06v0012e060 0443ee3663 63623611264 eoleo3e636 556 166e006e61 09Zt e6366e63o6 6135463633 366evovo36 6o33366366 64636661= 6433633e6q oozt 1264s6266126 64333e3366 3633336604 34366ve610 Dle00e6vP0 610v60000e OtTV e0060ee6v3 6366a36433 ov6e6o3/261 r6613pe6e 64631266v3o 6366612 080t 6106060610 00T2612v01240 443633e664 63ewu6o60 3413336r66 eeop33666e OZOt 006004e0v6 63353 3v33336r3e 161e663616 3Te6pe3pe6 133666133q 096E le34v663663 Emeoe13426 v636661633 334v333333 3121zoveopv6 4v66406604 006E 261236v661R3 64333wo6e3 owoovo6633 634v3v636/2 3663633336 v636361v612 ot.E3E 3366333336 3qe3333663 363e3616Do poep6q6363 oe66646v63 363366v66e 08LE Soevoleopv 6v6672e6436 4E6,20641200 60066e00120 3663666463 prove61164 OZLE y6ou3ve6q3 ov66e33333 oroD60666e 636e6qp336 366, 3331e6q6612 099E 63336e314 3366ee6e66 v66q66166e v646664336 3es6433ovo 6333336v01 009E y3366goovo 6466qe6sop 666e06430e v6e36463.4e opporqpeE6 eop6p6166e 01,5E 336e36e3ee 366=6.3663 36 3633633 63366e36vo 336612e6E.E6 et.3346eeoe ofo.E v6e364266e6 6v6o4v612y6 s66433366e 656 6ev3463e6o le36o6gooe OZtE 06460610e1 64333e3366 q633123Peoe 161336r363 5436e66e63 61236633e68 09EE 361336e333 6e06136eo3 6664334126e 036336q366 5555 e664364336 00EE 665 3363413636 v66136v6o6 336e336664 666 pe6106ee0e oi.zE 46ee6veSee 366366=33 636q3o6pol e6ee6e6664 6gaps66436 e636636635 08TE v64364636p 3363633363 666qupoeqv v4vEoporvp v264410011 3166463e66 onE 66peoove6D 333=66740 160geePPQP 116696016P 111616323v ;41064113vD
090E 6466313366 66131e6131 e6664v464q g3333e466e e6e30064e6 6ET6106666 0HE eeaes344e4 636ppo4331 34366almeo 46R6eve661 6146elv661 16e6q64163 01.6z vo3636p333 3ge3v36636 Emee36433,2 3laqe6w24124 6460v006ee ee00660610 088z 4336466.123e 63664o3eo3 3333ee6636 vo66e36141 000e606/216 10360eR0ve OZ8Z 120v6e126210 1106'2126610 400136vo6e e66ve64634 64e/264464o q6612e36qve 09LZ 66ege33634 3133334440 46666124004 le06u60P64 13413164pp 355qopees6 00[2 6333666e64 61evo66411 10463o6q11, leooro0111 1g3161elel 0164446064 On oeLE 66q6op3l epopoonove peep3v6Te6 Blo66o;e6e 36e66v3613 3312p6eDoeo 099E oe366op6pq yog.635266 D6=3361253 BD6qw6e3a6 5oppoo6oqu. opoo66=63 009E wo6q6zooae o6q6p5ooeS 58151263o6D 3661265vEor goTepoe6v6 Ever64361e6 OtSE ro6le3o633 6666 3566q600ro ve6qq5qe53 voye5;DoE6 beooDDoovo ogy,E 353666e6o6 e6l0006o5e 31164vaaop qe646612Boo op6eoqqoo6 6up5e66e6.6 OE 465466ve64 6.56qo363sy 6lo3oeo63o 3036 33 .66e3ov36q6 6le6eoo666 09a ep6q30ve6e 3636ole33o 3iel3weEm33 5726q66/2336 la.6voseo66 oovo56op6a opEE oboo5oo5po 66wa6eooD6 bupbevfteo oq6eovv672 o5e65v66p6 olle6ee6e6E.
OtZE looD66266v vooeov66ee oz6oe6oqep 6o6epavo6q 5p6qovq6qo opwoo66q53 08TE ovDewo2464 op61236a6qo 6e66e6o6uo 65ooe6o6q op6goo36o 6lo6E33666 ozTc qopqv6rop6 op6qp666e5 oftp3e6E66 loSqp366op opee616=6 33.43636y66 090E lo66.636006 eopE861616 33Q36QW6 4o6seovq6,1 e6ee6e366 o6.6opoo6o6 000E goo600qe5v e566616rm oeS6qp6e63 66o6636e61 3.63636rop6 p6oppE3666 01,6z 4ropeaeeae Speowerve6 3.1.1=11q16 6380e66663 vaorieG0000 oo6512qpq5o evvimes,;36 6126DQ6eq34 63649De4'44 36geogo6q6 Epqa36666q Dqe6q33e66 0Z8Z 61eq61Tepo opeq.66ee6e poo5;v6Eve &06666o vpoqqvq536 veoqoo4ola 09LZ 661peeo6e 6pev661611 6eTe661.46.2 646qq6peDo 6q5ep000ey pea66p66ye oux wo6qoaeoe4 e6evaqeq6q6 DpooSeerso 366o5qolop 6166e3e636 6qoop333o3 01,9Z ove66p8po6 GeaSqlqoao 5o6 6o 60veolirevoe 6e64q0440 6121265104=
089z 116eD6TaQ66 121)6q6oq64e e6 6o66 evo6gee66y weaD6ol3q3 opolgloq66 OZSZ 66v4Dolleo Ere6py61q33 qol6l00066 qopeeyEBoo p656vEq5412 vo66qq4qoq 091,Z 600641P1120 02334144e4 46412qeqoq5 qq16o6q6q6 60066veqes 553136op6 00tz e600661otn q6oevloopo opp000qpoo 3oloop3oop 0330000000 0D603;Tet.6 OPEZ eftloqople 5.631e1r6vp 16qo5q=36 o6o6w66qoD 666eapEopq ea6po6opoo 08ZZ olvoepoq126 q6op6o6D1 qageo6o6e3 6q6oge6y63 qsaavofiope 633e3666y6 OZZZ ao66160o5D leop5opeop 6Deeoqq6qo DEm616o36o 6eo5eSee61 o5126672Da6 091z 66qoel6e36 1361Dove66 166.4ov4642c. 6o6666 6q366o6006 oo666qp6qo OOTZ 6v65q6ogleo 6poo66q6o3 e62.361363o pe5oBobloo Booeopeqo6 2014610061 ovoz 61336eo6o6 qope6ov666 131e6qpoo5 63364o366a vo6q6613a6 Doevo6eo63 0861 3ie63633s.63 6o5g6o56o6 655656e6 oqya.656r6o poo6pol2600 op663636eo oz6T 33633D6lo3 6opoe6vo53 oobrolr000 36v3v13666 voo6o646o6 oDera6q5oze 0981 o6536463 oBD3q64.6o4 236383po66 03e6D0650 6661603s52 v0qe01103P
0081 36332e3v16 63633660e eopeolPor6 p1166qoev6 6q6q336coo 65646ve3e6 0tL1 6qo6y6.6qp6 go6p66v36e 6oev6ee6126 6s36epope6 v=D6o1p6e Eole6lopyy 0891 avqpqs.64op 6600eDe.4De ro66ole6v6 o6o6v6566 e6Ee4e681Do p6qeoprop6 on' .66qole6e6D ovEcaoofireft vosvo6p661 o5eo5pove6 64zoo6q6Da p33v3os36q 09st ple6qo6eo 66o52364o6 566qDqs.a6.6 53o6136vo6 eoor66ev62 oo/2336o6e6 oosT 5a6ao56qoo qvp6opo66v o63o6.236we ole36666q6 3.6pos.61.o52 o6qoalooeD
01,17/ 6eD6epoo6.6 e6olvoo636 35q361poray oweEmoEvo6 2o6q60qEDE. 606g610640 08E1 6epo633366 ep6163DeSq 000u6q6pol, =6=636E6 qeooro6eE6 6=6336366 ozET 61DoqlogEo qeoqz6qpoo 6o6661=66 66=636D6 ev6y6p6o6y D6166q6o5o o636elepo66 6.000720OODO 653666o opo6vSolvo 636166356e epel6eroel 00ZT .636E6o6vo 6o56.4peeoe Ebee6lvoep o66356o663 DopEop11.33 vEg600eoe6 of,TT oeeporoBoo eeoveovviDD vio86356D,26 o5Dpoe6qo6 336q0366op EllE3PPO6e 0801 oftp6.46Peo qe6oD6636 oo3ep000po oo6peqS1po o66evo6661 66v66v0564 out Sqlepepoleo q126.2063D3 vo6Da6loDo 6400lvoqeo peoe6oep6 66esp3tSee 096 ove6166266 e6povDqvDe e661oxeoft oveoqq6a36 eopEepopop po6;ovqx4.4 006 3.4461763663 66361oevol. lo6eogooqq 61631y6e63 00025365D6 636vo6eo6 0t8 oveolqoqeo leooe5Peoe eovepE6q4 612o6p6o636 o6 666 603R6v06v6 08L agpopg3veo 3e56q3e233 5.67aeo6toae orpoElpepo 366yoo6pol epy6p56pqe OZL ozeoeS3663 pe3p63eloq q33636=65 33336634v3 e33qeo6v6v eq.6p5ovo2e 099 ove3ww0003 6aDlwo6loe 9oqe6e66q5 ool6e6oev6 lo6v36363.1 e3leope6ee 009 3363re3e63 oolqoev6E. Sooqp63610 636D4y67266 v5612600664 006,20660ee OtS Eqa6q05336 goa31236126q 66q6aapo5o pluo66oepo 3e3616v363 600pp6e6q5 08, pue6eo623 3336633906 63evolqEme 6ppop6Bee3 6q6ve6looq epo6o4436.6 OY,LT 6ee3epo6p6 6136e3o63e e6613=636 op63312opeo 6.4Dqe6go6e wo6636e6q 0891 o6666qpgeo 666 65 36e.o-e66ye 666 26615=66a 3616363=6 0Z91 6666 ve03e06666 36363pe63D 6e36336qop ep6e36eopo 66e6pleop6 0991 p6361361op ego2e6eo6e o6e3616oqe o6636e64o6 4o6voo6000 66yo6q6ope 00ST 6400p/a6lao 6-eo63=636 66qepoyo6e 366op6op6o 666looq336 661333164e 0T 3363666qop or615o3636 obee6e6363 6eD6q66.46o SoDboSeeop 66veooppo 08E1 336616p666 q000p6e6oq p6226.466q6 6.eepeq6eeo eq6.4o6e6o6 ep6D661pee OZET 3e6p6a64yo e6656635 6oppo600q3 pae6r600ro pepeeo6pol e6e66ero66 09Z1 0663p6D63o 3e6.4pElo61 30663peoqe oveoSso6eo 64p6opqs6e po66o6o04e Ott op0000po6o eq6qya366e vQ6666626 6eo66p6op repleo3e6r 36eeoqvp6o 01,T1 063poo6q= ovoleporo6 6preooepee opeo3o366a leooepeeDe e66loavo6e 0801 peeo146406 eppoe05e0e v0540121014 aqq6e6o66o 66361peeoq qa6voro6le OZOT 6q6oTe6e6p 33pe636636 66 366 6eepq1636D lepoeSeepe e365pqq6ep 096 3p66po6q36 eeope6163; Q6 66z, oDealmosv6 666e636 636eaTepee 006 364Deoo366 eoo600qgoe 6o66plyole oe6o66poya 363eqoaloo 636op66o3o OV8 o66pleopeo lea6e6eup6 330POVVOPV oveopoo6Do oep6qapeol e6s66q6o6e 081. 66666 e36463q.eoq popeEmeo6 DesDe6o3eo q4oue6e606 e06001y616 OZL 6666666 pEop66q336 eo66oes6lo 836136eo3 pe36e6166q 633op6p3ge 099 o66ov000e3 646p36q633 e36264.6o2e pogo6woop 66o6yo66ou epqq6ee6e 009 ola6ageo6q6 ee6qopqpoo 6oqqa66o36 popo363633 eqoepolepo 33leop36e6 OVS 013o6r6q66 eeppoo6loo 66yoopleolg 6636vooea eep6love34 e6q36ego66 0817 336o666q66 eepqqo6i2o6 wee6eeo3p 61263666z 661e6e66e 26633eeo6r On? 3626eepoep eeppeop6oe e6e6.433es 3orp6qoep6 loppe616o6 ;6qzoDopze 09E 6136e/2616o 6qo3oSee6; Do6v6vape6 6646qop6ep leogype66e 666ro 00E 66166eo egove6eu66 q6lepeyoll oes6e6ope6 6pee6e66.4 p6163qe6e6 o 6eopopore3 opoe600epo o616o6loo6 og000e3366 646q6oireov p6466-e600t, 081 pe6oewo66 122Do6e6o6 eDo6061D1q 6qDopeopeo osoD66e66e 1266161.633D
ot 6q6a66oelo u362633v61 66616qo6ee 6p6616=6p 6eopo6olqq 6Dqqp;6eo6 09 e661616qp6 a6 665 4o6low666 )26126e26qwe o6ge66qeop epp6ogger6 91. <0017>

ZdSpow.6e6'ZA1eP.Z91dSPow'0906 :aDuanbes TeToTjT1ay lo uoTadTaosaa <EZZ>
<OZZ>

aolianb0S TEIDTJT12v <Eiv.
Iftla <ZTZ>
809V <VIZ>
91. <OTZ>

ZLirt e6 eqpq6rep6e 6oqoe6eo;4 ve6eel6e3p OVVV 6eo6p0D0oR 63veD6634-4 6go36eo6D6 qop6poop6q 00000e1613 66663 08Et. qeoop6e66e ofte6e336e opopoeooeb ve6e66e636 6o3;o63olq o6e6e66e63 OZEV op000po6op epoo6e6000 o6Do6v6ep6 laaqqoeeo6 633o36o366 6seDeloBe0 09ZV op66.4pqe6e, eD666.400qq pueo366ep3 6o6e63oeD6 loe66ee6qe 6eopp3o666 00Zt, e6o6006636 qa63661o63 o666e.e6geo 63333336o6 oo6loss667e Do6opeDuDo OT,TV 666e6Eve36 6364ovvoqq 06461m0460 0e6re650ft Doev060011 3veo663636 eo61e64wol eooe6366op pec6ow6q66 v336E631263 66e6o366qo 6.46p6oa366 ozov eepepo66o3 o366o666a6 3666eoo64o o6Doe64e61 e6e66e6610 03v0066360 096E o3366343qD 66,ev6qDole ooe6epo63o e6D000eepo 6pee6rD6q6 6336q000r6 006E e6o3e6qe66 qove6ee616 or66eao6po o66e36e6qo 6D606qopog 6eupeqollo 01,8E 633'26616ov qps.63533qq oop6e66seo 33o666poo6 ooleor6633 0q206e00e0 08LE opa6epel6q v66366312 62Ppee6130 55543nleo e66q6506v2 Dv304v6v50 ZVZ

enaTA A3tieT0T3apounwmT uewnH <Eta>
'MO <ZTZ>
0891 <TIZ>
LI. <OTZ>

809k 26222252 2262622226 23222262e2 6222622620 3332622226 09St 6222622252 2505222623 226423032w 264262E622 22E2223035 265226225e 00St aD6ea3ppov 2325226265 2626522205 332225E6'26 526322222o 366p Ottt 50323E3262 623E202220 2226623035 2266622222 0622206622 ;262206652 08Et 3024222206 6200E25250 020622266e 2522620022 3666262632 662E236256 OZEt 1053066622 6223602202 2606226232 2662236222 0220E56265 2236606222 109n, 224426262e 0450026226 6252222236 0222322066 3636205226 1201230260 00zt 6632222602 5256202E25 4E63662E22 6E22626262 2266222222 6630225626 OT' 6E262566p3 26233E2325 4262e6,2662 6622222226 5052200662 2020662262 080t 22222025y2 36202E10030 22005222E2 062652252o 222E2E3226 2266222252 OZOt 2625326522 2523266e0E pE23536262 302v6pe322 2222603266 2622222E06 096E 0011330E25 6223302655 Q236032202 562022235e 0022302620 22622E5052 006E 5222622322 62326E622o 22322662E5 25222e222e 5262656262 OODTPODOOO
OV8E OOVVDVROOP 62e6623653 22620525E2 262030v352 3022320560 2622202606 ogLE 3325662E26 2252366266 2602222232 262E622622 52726226220 360066sopy 099E 3266366626 23v2,226425 2262202252 232562222o 00222E3656 2,6262,62322 009E 6362022522 003322645E 2E32236222 2226622625 6266266256 v252666202 OVSE 622262222p 26222325vo 22336620ov 0625622682 2666236230 2262351602 08tE 2222322322 5200625265 230620620E 22E6222256 22532E2262 3523562262 09EE 6622346226 2222625122o 205463620u 252202E026 6260223220 2263306206 oca 0E23526626 36235E3225 2262226poo 2623623622 2666223226 2236306405 OtZE 66e536222v 5266236223 5522322262 6306222052 5265225E63 6305203666 OZTE 2622226623 6e62653563 6262062536 12336o6D336 3656223324 2222E2222e 090E 222E224221 12;562522E 5E60233225 2332306622 02E3222222 2226626326 000E 2222625223 22222622pp 2526622326 6662222522 2255542254 22220222E6 0V6Z 2262322642 66v-2620566 Bge0220422 2635223200 4220652222 3262522255 088Z 2622E22265 2262526245 0233525222 2222222663 662222522o 2222252222 ozse 2E2E02336e 2222256354 323362552o 2636623020 2002022,660 6206620522 09L 2000253622 6222602222 2222622622 32235226E2 2202225236 22E622526o OOLZ 2612262161 2156223522 2558223263 2322222222 225665e422 221225253ri6 OV9Z 1121131622 23E622322s 5E223E6626 254eg25522 2232622522 2223223222 OS Z 0303033033 D33 D333 33 333333 2022205232 4e25262222 6220625022 09tZ 2246236233 0635252602 2066620053 3223600602 2332232352 2322336352 00tZ 2550223535 2232662652 622222226o 2252220566 2622662E0o 6322226022 otEz 3260252446 2336262632 5362022522 52252E5200 2266132162 0610613022 onz 3666523226 2252333552 55523E6362 3523E66228 2352652632 2363336325 ovot 2222626222 2335232426 5623352625 3530225250 22352523E2 5232221626 0861 0222E25220 6652562336 526652E32e 8223223223 2262232202 2562622654 EVZ

08L pooppepeep 3e6q1a66qQ6 666 6y35qoopeo 512312oDea6 Goo6oqvo26 OZL o6o6636op opE426o636q e6vao663op oaEtoqvapoo 56op6orp6q 6poopeo636 099 o633v66616 e60063366e 66126aeeo2e opa6e66ee6 lo6qc6v363 voo6Do66vo 009 orpoS6o6B6 6D3 QE 15qv6ovave 5lope66.12po 0000vapa6D6 66/e6o6e6qo OtS =6o6goqq6 qeo=oqu6q 66e6DoDo6u o2qop6Eve6 56 656 56er6q6661 081, poSpey6233 peo5oo3op6 eogyooS6vo opoSq661e5 eop66.6ep6q opee6e35q6 olv0000pqo vvEvap5e63 66voo63612 oviso66aeo 66006poSoo 6aD60066eo 09E 6666 2u6vepolbe raper5e36e6 66666 ve6v6Elo3p 56e56epone 00E oe65evoqEo e6pqyo506e opeo516p81 3eq6qoope3 o6616o3voia eDwq6;po6e OVZ 36p6436256 126o6v3563o e6eD6qap6Q 3oo6eo6qD6 go3666q3a2 126e3363361 OBT 0666u606e0 026e661363 03663003vg 636036013o 636e663o6e 536336p3o6 OZT 6616q6olgo vo5e126qa6Ta eolnEmg6Iva 6cm.366366o oDo636qDo6 oaqv6e6e6 09 6Eq6eov56 qa6v636636 636666 D6006oS33 363666qro3 v336oe6316 8L <001,>

IdD :eouanbeS TsT0T;Tqay lo uo-pdTaosaa <EZZ>
<OZZ>

aouenbas TvIDTJT1IV <ETV' VIC" <ZIZ>
5981 <TTZ>
81. <OTZ>

0891 eq0P26wee6 5volev6530 648e316ell vevqe6e.462 easp6qwv25 66566 ont pevolepepEre pori4666.4eo 66qo3sqa.46 6elavpS6vve eecleval6e oft&elpeqe 0951 Pepq6e036v 136126eoqer 6a6s6vee5 rooveoeoft polleoqPe6 6sq;e36qpq 00ST ee3roq3v6E, owelbeleoe eeq6vv6eqq 12666qqs.66 vi.D6q4436vq oaeoqleepe ot,pi eeotaqqvliSq ot262e6eoqe EVDEROVOU6 qa6e2P0310 1.6226evewe orbev65P6v OBET 0e6q0e3481 eTe66vofte 55 pp lop6g566v3 eelp6e3565 666eq ozET olqqoPeeft p6v55,2361aq sopowithlawy 6736w.4162po eq66qeqlve e625v12opo 09z1 qapozyqvuo 46qqq6v666 16e6qoaqqe 66looplo6 po66qqeq62 661e661661 ootro6ee666qv oppe66vvev ovlw000wlo vel2;qqwevq opagebeuv6 6666 ovuE saqvio62,2126v aeoosq6ve veep616eo6 666 eovevel6le 51reqpeoeD
0801 33566666 lebEme36le q6eee66pop v2,26334ewe eT2414eo06T/ BeeoTeqqqe on' egoqeqeo126 6qvcioa66se 66.65va6ee BypvTerefir 36r26r3lor Sereeplepo 096 ouBle;qeze qfte63ear3 broperEceee e655 beovegybeo 6Elpey6s.33 006 6v6roSeeft 26vopelpeo oeqwelE02126 voeeqvaSe eepose66126 P220030PPe Ot8 qS4eqq5po6 vepa6eveql v666e361r3 lqeSepqbep o666qqwe61 leeee666q6 081. va36er6e3e qeopEqevol 61oe65qoBe ov5epe6u op6w6qyvq eqopftova6 OEL rop66leeel 26qop4too3q Dwe6w4;65 6266q2apo 33e301Doee 6ePeSP31PD
099 yeetregoe6E oppopoxell q26666165e 6636 eoe6e6;oee 666ee 009 goReB1231236 P3666e4eve 6eqlov6q34 e661248q1216 qqwe6qe661 eDt2geD1ez OtS oqwqq6,2412o w6gooqev62 3vvET6e311. looSeSeqqD leeppepe6q po6eq6e2ep 08V 3qqelve36v 3op3Te6622 v66.4e5E6ep v3o6;o6q63 ev0)2462Dle qe6qle666 OZIP 2o32326261 ppousialvq6 e3opeqeDoe 311e0630ea P16eee6e31 1Deever1r6 09E 121;D33qq6 oqq3loplgo 666666 Te.6641vq5s. 12q5voqew ewevbeeeve 00E yqq6662363 papPoepovq tm6612qq6so qq6eu66640 12oeftpolo se6eree1e2 .41012126126ED q;v6236e3 3rge26e663 pEpapelSpo 2662 223614;
081 el6e33qpin peoplepole ewebqoo566 qq,avvvvoql qimee655eu 66e2266e OET pv6ept.161e qv6v6,216v1 vioftewelt, ervee6e282 0g63320066 1ee36Fell8 09 eeeepoo66q 2662/ev66vo oftvpqqvve el5eopeq54 ovev6112q3 oq6vq4epoo LL

OttI 6v333q3333 3vv3vvev612 662666633q 66v34.436e6 26ev6e33p0 0a3612012,200 08ET 6v6e33e6vo 6v6123q3311 llev666soo 6672126661mo vq33413366 qoqv6ev666 OZET v141'41412;24 068v3v5v6v 610vo6q3126 eve6qvvvo3 v31266ve836 3366364363 09ZT 6633633666 ve6eva633o 3338363361 3v1266123363 ov3v33866v 66122366364 0OZT ovvolq3646 vv34633w6v 126636vo3vv 360344ovvo 663636e364 v61voqvaoe OtIT 6366opovv6 3v6166vo36 e61v6366e6 3366136183 633366vvoe =66333366 OROT 3566q63666 v338333633 e6qv84e6v6 61268q33o23 3683633336 666sv no' 8.4opTe33T26 vvo643T2633 33u 6z 66666 lo3pe6e633 264v66qpve 096 6vv6463v66 voo6v3366v 36E6436363 64333126evo vq3q13633.2 66463243,26 006 3633443336 v66ev33336 6612336334e 3126643olvo 6v3pepo336 spe163e660 0tP8 6483q/26wvo v1264336661 33qv33e663 6636vepelp qe6e63666.4 633334e333 08L 0000EV3EPO 31261e68436 6o1v6v36v6 6,236.433312o 6/23ovoovo6 66e6 OZL 36v3663633 338e636361 12612306633o 33631voopo 66336ovo6q 6333323616 099 3633e66616 c263363366v 66e63vvolv 3ov6v86vv6 qp64w6v364 123363356va 009 pv33663666 q63owovv64 q64v6aeove 6433e66voo poopeop636 652636e633 OtS 33636e33q6 3v3op3qe61 66e633336v 3q43366ve6 v66v661664 66,2126.48664 08V 3363ve6.433 pe38333336 wo4v3386123 3e36486q726 v33566vo8a 332e6e3646 OZt 34123333vq3 ve6e338e6.4 66ropEivo6e ovvo6833e3 S633603633 63363366e3 09E 8v3o366vv6 vv6v123316e 123vv6v36126 6e8612634v6 wv6v66q3po 66e6Eeopv 00E ov66ve3463 v634%2363612 3peo64636q 3eq6qopova 366163ovoe epvZ61036v OtZ 3636436v66 v6p6v36633 v6v361336e 3336236436 v336661334 v6123363364 091 366612636vo ovE4266136q 33663333vw 6463383qqa 636v66138e 636336v336 01 6646q8pqvp ep6ve6q36v vovq6vv6ev 6evo663663 3336364338 polv6v126126 09 66a6ev3l266 336v636636 636e6q364.6 o6voo6D633 0606864voo vo36ov6aq6 6L <00t>

ZdO ta3uenbe5 TeT3T3T33V 30 UOTUIT2088a <EZZ>
<OZZ>

aouanbas IeTo T;TqAllr <ETZ>
VNG <ZTZ>
5981 <TTZ>
6L <Ott>

S98I 3q1ve 0981 5ev.4613333 66q6vo6veo 366evoo338 566666 6336ev6136 pv64633364 0081 663e6v53le 3333612Dqvp 33344312v64 3331236q366 34v6vopoe6 43613ovvo8 otLT 3366341234v 3ev6183333 ou3333666z 66q36363312 36631e3366 peov336536 0891 131e6v6636 33031v6e3o v63v16v366 36466,27204g 0q40656660 qe66505601 onT e61e6veop3 8.26.6616veo 66333613ov v6qe6v66e6 6136363ovo 283e633636 09s1 633vae63qo 6136386v56 evolo6e336 63663qv66e eq6e3v3463 .43333126312v oosT 366a333.43v 3.4126voqopo 4432)214qoa qvq64ovv66 vvov6u1v63 36e66vo6ve OfIK 6v34343334 ovvovevv6e 66e66663q4 66vo4q36e6 v8ve6voovo 3336vpveo3 08E1 6v6v33e8vo 6v6e3413 qqvv666poo 68vv666v123 v;334q3366 q3.4e6ev666 ouT rlqq34qevl 366volii6v6v 6q3e3644v6 vvv61.vveop cov66ve636 33663643E3 onT 6643643666 vv5ev36333 3336363361 ovv66e3363 ovoe3o666v 66evo6636q 00ZT Devoq10816 ve04803v8v 128808200,2v 3633q43vv3 683636v063 v64volepov otTI 6366op3ev6 ov6q66voo6 v64e63661.6 =66336163 633366,2v3v 3366333366 0801 3666a63668 v336333633 1261v64e6v6 6v66q3o3v3 3663633336 63q31366vv OZOT 6goolvoov6 vv3643v6po oopeD363er 6e36466q36 loope6v6po v64v66q3ev 096 6vv6463e66 v03812336612 3,6v6136363 6qoope6ev3 v134363312 66463v43v6 006 36333,4=36 v66121233336 8E02306334v 312664334v3 6e33e33336 epeq61e663 01-8 6463qe6vv3 vv6133666q po3v04e661 6636ve3v e6v63666q BODOODOO

_ StZ

ovoe 26333623pp 6623312042 366643336o 2162005202 6302645312 0225155256 0861 1036636232 66236q3336 6430233q23 366236q062 6332622623 32233233E3 0Z61 2533634236 263661662e 6236633666 6=2633264 6321366336 6223666436 0081 2262664362 032466q643 6226466q30 330333320e 2.6a60q1526 6516260003 0891 1052201162 233334262u 3666643426 4631236262 6332362616 6226236463 OZ91 366.2633264 3623622615 326322332o 2333636636 DE 636 3236223663 09s1 or62261332 2.62234q333 626623324o 4262332qop 2664623366 5230566236 00ST 22623341262 6336646643 326622362o 33328023ov 46q6626323 6q63336266 01717T 226133262 6360322626 3366q36266 1362633662 662633264o 3333126466 08E1 26332643pp 662.2332366 3636136436 2236q64362 36226q6622 3123663363 OZET eqoq262336 2336661322 6306223666 .4661362262 3312326322 6163326543 09ZT 623266226p 63336136q2 oT23336236 463326646v 232633332o 61362632qo 00Z1 6664266'464 3344333333 626622623o 2062262232 6333332332 3140666613 WET 506108233y 362336364o 6266263126 22=205302 36233660q2 6266433263 0801 5206651602 1543000006 62032'40426 q604232633 3o22623622 3633113336 ourr 266 362 23326q2362 3626233113 T233633336 236662266q 3666233336 096 136163223v 1623324363 oq23663333 32626322ov 2312362333 03233201q3 006 0500232162 20530'44326 6223266100 3064636231 lorq3p6326 3668363266 01,8 q36463326q 6362622622 622622613o 663363333v 33=342366 6q36236q66 08L 2.666134q32 662333236o 6223226q06 2636334q32 66q6633.622 3636616223 OZL 3236232662 2622622312 3360qq6q63 3333232232 1333322626 3333663q26 099 2236234262 2366626622 6266426263 3236q34262 566636 62'20326226 009 2562500251 q23366q223 6223466223 =3663266a 2666633622 61q6226q63 OVS 3363663262 6112333362 342=33443 22644332.36 436.6.3q2623 3326146134 08' 2226225611 22q2322316 433u3vqoae 662q62;421 62321667242 q362223232 OZI7 6.6q6q31222 62q6loorqe 6233263216 236626q662 23423q4366 65636666 09E 6624264222 223322266q 2222662336 qq2261222 665 2021261252 00E 36266232Tc 6343643635 2266223132 2366666631 26622122ov 3463433332 o 6322366141 3.332332623 4333413224 qq33q24643 2266223262 1263062662 081 3622623;aq 3331322322 2262662666 611q662011 0525262262 0020000623 OZT 2203626233 262362623q 4311442266 6233662266 52232qopq4 33663262 09 2565211111 1221056202 5262510235 31262226qp 2233232662 2636336636 08 <001,>

NA.1(10,urqoeuTazd.(+)sd :831.13nbes Te T0T3Tlay ;0 u0T1dT...7322a < EZZ >
<OZZ>

epuenbe S 12T0T3T11V <ETZ>
VW! <ZTZ>
SOEZ <TIE>
08 <OTZ>

0081 6632626112 q333623.423 3331132261 1302351056 0126200025 1164012226 0a,L1 2266.4422T2 0223461332 32433;26621 6e26232 1662421362 2212026615 0891 4342226216 q332426803 12632162366 26q6522012 0113665550 1255666624 OZ9T 2612222233 2226642222 662336q442 2512225226 24q2162320 25112623526 0951 6232q26343 6436362/266 2234322066 666633266E 216E320150 1030026322 00ST 365332 3426231333 41322q1133 1216q322.66 2232624263 3626623622 ozzz 2332q34264 6342366366 4263123663 22.64334464 3646622363 3423663363 09TZ 6264664362 2312664662o 6263223663 6634236662 speo336333 6366643366 001Z 333246662 2626622622 3426436236 263423q262 3362636613 6263626v63 OVOZ 6262232633 3623336623 3123123656 4333632q62 3362326332 6463423226 0861 1662664336 636232662o 640336613o 2333233662 362362633e 6226233E23 061 3eopeo2633 6342362636 6466226236 633666633e 6=26;6324 3663366223 0981 66640622pp 2626063322 3363363663 v664632433 1302626006 06663633e3 0081 3362662;26e 6643623321 6636436226 1663333333 3332322646 3446266646 OVLI y633334266 4=2336623 6643216266 426646633o 66266643ov 6266226233 0891 1v3D364062 233462230o 3426223666 6434264633 236e62633.2 36e6166226 0Z91 2364633662 633E643623 6226163263 2233232333 636636364u 3633363236 09S1 223663326e 264332262y 3413336266 2332333262 3324332661 6233666233 00ST 666236226e 3342626306 6466433266 223623330e 6324324646 6263236463 OPPT 3362662264 3342626363 3226263366 435266436e 6336626626 3326zoopoo 08ET 426466263o 264333662y 3323663636 4364362236 1613623622 636E22342p OZET 6633632134 2623362=6 6643226406 2236664664 3622623332 3263226463 oni 326643623e 662262633a 6436q23423 336E36463o 2663622326 3333236136 00ZI 2634233364 3344333333 626622623o 236226223e BODODOPODV 3133666643 OUT 636136433e 362=6364o 6266263426 2233236332 362336634e 62662332E3 0801 623666463v 4643333336 6233233426 3631232633 332262362v 3633143336 OZOT 2664334262 2=264236e 3626233443 3233633335 2366622664 36662=336 096 43616322ov 462332;36a Dqvp66opoo 3262632232 v342362333 342=2344D
006 3600202162 2363331326 62232564pp 3361636234 loeq336326 0666q631266 0P8 4364633264 636262262y 6226226433 6633633=2 333042066 6106206366 081. 2655 32 6623332363 6223226436 2636334432 6636643622 3636646223 OZL 3236232662 262262234e 3363116463 DOODEOW1208 4333322626 =D3663326 009 2662633264 4233664223 62231662pp opo6632664 2666633622 6346226363 OPS 336166326e 644eq33362 332333443 2264103206 10650126e3 03'26336403 08f, pv26226644 e242322346 4332323332 66246244E3 6232466212 4062224202 OZP 664E434222 6216q33242 6233263246 2366264662 204204q066 5653E556 09E 66.24e5leire v2332122564 2222662336 3112264222 6226211216 2023261262 00E 3626623212 6343643636 226622343e 2366666634 2662232232 aq63q3p332 OPE 6322366411 343234262o 4333433224 1;33424643 2266223262 126336E662 081 3622623434 =3332232e 2262662666 6344662344 3626262262 3323=362a 09 2666234444 4212436623e 62612643236 4426222642 22=238662 2636336636 18 <OOP>

WMPLU1d0.121'332uTo1d'(+)Sd :aptionbas ToTJT1ay lo uoT4dTa3saa Ezz>
<OZZ>

eocranbes iliToT;Tqay <ETZ>
VNO <ZTZ>
66U <ITZ>
T8 <OTZ>

SOEZ 34422 646633236e 4366663331 onz 436222233w 6342662333 3663663623 6663632461 3326326642 32362=24o ozzz 3264631236 63664263q2 0663226433 3464364662 8363342366 3363626466 001z 4662262662 2622342643 6236263323 126233626 6640626052 6263626880 LPZ

90EZ 033ev6 a66opeo&el o6866opoql 08zz aBeeveqqr6 olv66eqooD 65366o6e36 66163rq6qo ovEoe661vo el6e0o724D4 OZZE e65E6 o66.4e6oqeo 65ovv6;poq 45q36q667a2 DEoDqeo66a D5o6v6q56q 091 DBygoe6616 EmoBleboueo 66D66oqe36 65eepropo5 3oo6a6B6qo o66loos16q OOTZ 66vv6y66ye 5voqx.6136 ep6e6olpoq 26poo5v6q6 6.4o6126D6e6 13635e6eepe OtOZ 6p3o6ppao6 612ogyoqep 566qapp6ou 46epo6ov5 p3v636olep pe6166e661 0861 op6636e3r6 6e3533op66 qopeopleDo 6612o6.4o6v6 pole6ve6app gwopeopypy cimc 600SoqeD6v 616646612126 Go6&oo6666 ool6ope6q6 oeqo653366 pv3666136E.
0981 voDu6v63Eo Duvo36336o 66 666D 133300e6v6 po6o666q6o Teopp6v6642 008! v6v66q36vo 3pq6816136 vv6q66qD33 OODODOWOWR 6q6oq;6e66 6.46e6Dopoq OtLT e661o3eop6 Eva66govq6 e664g66q66 lopE5t,6663 =e6e66er6 vooqe3p061 0891 o6euplq6er o3poqe6reo 6666qoly63 63 o666 app3626q65 /212679D6q6po 0Z9T SE.E.6=e6lo 636 6z v6Devoov3e 3o36366D63 SqvD6papSo el6'e36633 09sT 725121a6q33we 6e Z336 p66tooeq33 eSeoDeqooe 66633666 e3o666e36e 00ST v6epoqe6r6 Do66q66qop v66e12.36poo 33263,eqpvl Sq6Elpbowo6 1Soo36u66e 0/ v6333q26126 o600c.25126o 366qp6e6Sq 36e6po56s6 SpEoovEloo 33ole6166v 08E1 63363336 6ev3pe366o 6364oElo6p vo616qo6eo 611m6q6512v3 qgo55op6ole ott104e6ropft op666qowv6 qo6Qtro666a 66qp6ple6o pqeov6pele6 q6ope6Eqp6 09ZI vou66vv6e6 0Do6136Teo leopp6e364 633e666ep pe6poopeo6 lo6v6osloS
00ZT B6qp6EqSqo plqoDopoo6 e66ee6p32 3666 oa000t,Doeo 3q36666106 WIT 36qo6go3vo 6e336o61o6 v66.263qr6e spoepEopeo 6i2D36634e6 e66opp6o5 ogoT vo86616oeq 61D333oo66 goorqoqvb; Soleorb000 avieftoftvo booqqpooft (not 6.64=1726ev ope6q1336vo 61:26goDq1Dq yooSpoopft 3666vE.66qo 66Ero3ooBq 096 36.46aveoeq 6eoaeqp6op lroBSpoono E.6,2SoveDelp oleoEropoo ;soosoqlop 006 600eoeq6ee 36pollpe66 epop66qopp 36q636voql 3vqoo6ou6o 666150v661 Obi? 363633y66 36e6svi6s6 ee6e6q3o5 6306 3333 op33qr3666 136yo6466e 08L 666q3qqot.6 6spoopo636 eporp6ioft 606Doql3v6 61561a6rawo 636616evoo Cu vo6vol266we beeftuoqvo 36oqq616po oppeoeepeq 3303ee6263 p3o65DTe6e 099 uo6volv5ve 365666e6 p66Te6126op po5lole626 6.45643o366 yvoge6ey6e 009 EfivEopv633 ooD6618eo6 ge3q6Ean= DoB6ou65qy 65563o6v26 lo6ve6lEpo OtS D5'4663E6126 ole000afta qep000qlor e6loopeo61 o6633e6poo ovSlo6qoop 08t epEoo66oqv oqeoes616o popovo335 65366qo615 oDeD653qeD 055evoeD06 OZt 6361pqr626 1600004e6 eoorthoeq6s. 366o6qE6e oTeD333655 6601e66636 09E 6311251y6Re poo6ey6636 rep6Sopp6.4 porr61v6v6 6p664o6q5D ovoiaBoithoo 00E 636533leog6 3.136q36366 v6.6vvoqoEv Da66o66pqe 66gogy3oE6 1653opoop6 06120664610 opsaTe6epo oaDlloseol 236r635oop o666ena600 v5opEo65oo 081 66E636E633 obeoevoee6 v606636666 16.466126qo 6v6o6po600 oeopooSeov OZT e036050009 5v36T165/20 6e3lq69636 000669eo66 66333 366qope66p 09 636003303q 1ye20661201? 526T/610e36 qle6eve611? Tilnowal266e 86o6Do6638 Z8 <00t>

w.vulojAppowqoad-(-)sel :aDuanbas TeT0T;Tlay o uoTqc1Taosaa <Ezz>
<OZZ>

aDuanbes TeToT;Tqay <ETZ>
YNG <Z1Z>
90E <TIZ>
Z8 <OTZ>

66ZZ olgey5156 Doeo69qo66 ogu 65po3qqoft 999319631v 66vqopp653 65pEozo666q 63,246333e6 pe66qeDE16 ¨

Zia <TIZ>
t8 <OTZ>

00EZ 031ee6166D pv36,213666 ogu 63331136.er vv33e6ole6 6eqao356o6 666665 oe;6qoot.5o E663voeq6p ouz oolaqaTe615 oweo66o66q v63qvo66op v6q=1.4610 6q66evo600 lvo66006o5 091Z e616S3o6ve 3v66q66eo6 e63evo66o5 6ollio666via oe00060006 1666qo3663 ootz Doe.46455sp 61266ve6eeo 126qo6eo6v Solro2e6yo 3Ev616Elo5 e6o6v6e636 OtOZ uftroe6000 6y0005SED3 lpoleo666.4 Doo6o2q6e3 3Sing600s.6 q6oqyoee6q 0961 666665 DEpop6612D6 loDo66;oou oolvoo66vo 61o6e633e5 ve6eoperao 0Z61 goovoe6006 oweo5v6156 166ev6v366 oD6666por6 oo2616oplo 663366eeo6 0981 56qoEme3or 6e6o5ooreo p5o36366oe 66.46oel3lq oo126e6006o 5666oTepo 0081 36eSEme6v6 6qo6poovq6 6q6qo6ee64 5840000303 poroee6160 41SpEE6.46s OtLI 6opooqe661 ooepo56vo6 6.4pe3Sp561. e66366qoo6 65666 v66e126eD04 0891 v3oo6q36ve olq6reopoo 11261212o6666 qoweEq6oqy a5126.eBoovo 6v6q66re6e OZ9I o5.460066u6 3oy6lo6eo6 vg61.6ov6oe poppop0006 36 636 600p6oe;512 095T e36603e6ve 8.1.00ele6ev3 lqop35e552 Doe3o.1126in 3e e656 soo656eo36 00ST 651236e196/a3 3qe6y63o66 q55qope66e voftopooef, oeqoeq6.466 e6opo6163o 01.17T o6e6Eme6lo 3qe6e6o5oo ee6p6o3664 36P66go6y6 op664256y63 oeblop000l 08ET e6166g600e 6qopo66amo 3eo6636o64 361o6evo5l 6qo6eD6p26 q66eeole36 ozEI 6006ouqoqv 6e336eoo66 61oleeElo6e en56616610 5ee6v3oqeo e6ove6q633 09e1 v66136eDe6 6ee6e6po36 qo6leo3voo o6eo6.45Doe 666 6o oposoBqp6e 001 603eo30540 oq40000005 u66ve600e oBreftroeS op000voopo 1q366661o6 ovur oblo6qopeo Evo3636qo6 266e631e6e yo3e3633e3 Se33663qe6 s56qopu636 080T po666q6peq 6qopo3oo66 gooe4o12&4 boquov6000 ovefto6evo 600ll3oo6e OZOT 564004P6eu poe6qeofto 6e6vo31131 eon6000p6e 3666vv66qo 566vo3oo64 096 oblSoreoel Bepovq36op Tea65oo3oo v6v5ouvoee oquoftopoo leopeoqloo 006 boovoelEoire 3600q;oe66 evog66qopo 36636ogl oeqoo6oe6o 666153pE51 0t8 36l600e636 35e6geBriv5 ei262v6loo5 63363000v3 opo3qv3666 qo6ro6q66v 08L 666g3ll3y6 6v000li23636 eepee6gobe 63600qqoe6 61663oSepo 656evoo OZL Po6eou66ue brefttpleo 36oq1616o3 oopeppeoyl 3000lv261263 3oo663.4v6v 099 go6Polv6ve 3666e66ev6 e66qQ6w600 eo6q3lv6e6 6166100066 ePpleSeRbe 009 66v633v6qo 3oo6616eoB eeoa66vvoo Do66oe66ae 6566opEcee6 lo6es.64B33 OVS 051660E5e6 03e03306v3 leoDoollos eSl000vo64 obBaquftoo ou6qo63ooe 08' P3S3o653qe 3qv3s,Ta6q6 000pep0006 66366qo6q5 poeDESoqeo 366evoep36 OZt 66e66 6g600poqy6 yooP6oeq6e 36636q66pe 3ieo440666 6604e66606 09 63.3y6qe6ep 3po6ve6616 we3663opEq oorm6qe6s6 6y66a3636o ovoe6oe633 00 6366 Q6 3qo6qo6366 e66 36 Do663563qe 66voleooe6 166.4a00006 OVZ 36o663Slo nopoTeSeop opollosvol lo6v6q600e o566eoo600 s600636600 081 66v636i2613 36v3eeove6 126o6636666 1616620613 EP60600600 0203036e012 v33636333v SuoSeSoSeo 6eoqq6e63E opo66o66 612o5400qqo o66qope66e 09 63600lloll Trvelp6Bviog 6v6y6qoeo6 qleBervbqe evooeor6Se eSo6005636 8 <0010.

wmicx.4do/s.powqoad=(-)sd :apuenbas TuToT;Tlav ;o uoT1dT1ogea <EZZ>
<OZZ>

souenbes TeT3T;TlaY <Eta>
WIC <ZTZ>
00EZ <TTZ>
E8 <OTZ>

DEMANDES OU BREVETS VOLUMINEUX

LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.

NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

NOTE: For additional volumes please contact the Canadian Patent Office.

Claims

CLAIMS:

1. An expression cassette, comprising a polynucleotide sequence encoding an immunogenic HIV Env polypeptide, wherein the polynucleotide sequence encoding said Env polypeptide comprises a sequence having at least 90% sequence identity to SEQ ID NO: 71 or SEQ ID NO: 72.

2. The expression cassette of claim 1, wherein said Env polypeptide includes sequences flanking a V1 region but has a deletion in the V1 region itself.

3. The expression cassette of claim 2, wherein the polynucleotide sequence encoding the polypeptide comprises the sequence presented as SEQ ID NO: 65.

4. The expression cassette of claim 1, wherein said Env polypeptide includes sequences flanking a V2 region but has a deletion in the V2 region itself.

5. The expression cassette of claim 4, wherein the polynucleotide sequence encoding the polypeptide is SEQ ID NO: 60 or SEQ ID NO: 66.

6. The expression cassette of claim 4, wherein the polynucleotide sequence encoding the polypeptide is SEQ ID NO:
34; SEQ ID NO: 37; SEQ ID NO: 40; SEQ ID NO: 43; SEQ ID NO: 46;
SEQ ID NO: 76 or SEQ ID NO: 49.

7. The expression cassette of claim 1, wherein said Env polypeptide includes sequences flanking a V1/V2 region but has a deletion in the V1/V2 region itself.

8. The expression cassette of claim 7, wherein the polynucleotide sequence encoding the polypeptide is SEQ ID
NO: 59; SEQ ID NO: 61; SEQ ID NO: 67 or SEQ ID NO: 75.

9. The expression cassette of claim 7, wherein the polynucleotide sequence encoding the polypeptide is SEQ ID NO:
35; SEQ ID NO: 38; SEQ ID NO: 41; SEQ ID NO: 44; SEQ ID NO: 47 or SEQ ID NO: 50.

10. The expression cassette of claim 1, wherein said Env polypeptide has a mutated cleavage site that prevents the cleavage of a gp140 polypeptide into a gp120 polypeptide and a gp41 polypeptide.

11. The expression cassette of claim 10, wherein the polynucleotide sequence encoding the polypeptide is SEQ ID NO:
57; SEQ ID NO: 61; or SEQ ID NO: 63.

12. The expression cassette of claim 10, wherein the polynucleotide sequence encoding the polypeptide is SEQ ID NO:
39; SEQ ID NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 43;
SEQ ID NO: 44; SEQ ID NO: 45; SEQ ID NO: 46; or SEQ ID NO:47.

13. The expression cassette of claim 1, wherein said Env polypeptide includes a gp1160 Env polypeptide or a polypeptide derived from a gp160 Env polypeptide.

14. The expression cassette of claim 13, wherein the polynucleotide sequence encoding the polypeptide is SEQ ID NO:
64; SEQ ID NO: 65; SEQ ID NO: 66; SEQ ID NO: 67; SEQ ID NO: 68;
SEQ ID NO: 75; or SEQ ID NO: 73.

15. The expression cassette of claim 13, wherein the polynucleotide sequence encoding the polypeptide is SEQ ID
NO: 48; SEQ ID NO: 49; SEQ ID NO: 50; SEQ ID NO: 76; or SEQ ID
NO: 74.

16. The expression cassette of claim 1, wherein said Env polypeptide includes a gp140 Env polypeptide or a polypeptide derived from a gp140 Env polypeptide.

17. The expression cassette of claim 16, wherein the polynucleotide sequence encoding the polypeptide is SEQ ID
NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO: 59; SEQ ID
NO: 60; SEQ ID NO: 61; SEQ ID NO: 62; or SEQ ID NO: 63.

18. The expression cassette of claim 16, wherein the polynucleotide sequence encoding the polypeptide is SEQ ID
NO: 36; SEQ ID NO: 37; SEQ ID NO: 38; SEQ ID NO: 39; SEQ ID
NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 43; SEQ ID
NO: 44; SEQ ID NO: 45; SEQ ID NO: 46; or SEQ ID NO:47.

19. The expression cassette of claim 1, wherein said Env polypeptide includes a gp120 Env polypeptide or a polypeptide derived from a gp120 Env polypeptide.

20. The expression cassette of claim 19, wherein the polynucleotide sequence encoding the polypeptide is SEQ ID
NO: 54; or SEQ ID NO: 55.

21. The expression cassette of claim 19, wherein the polynucleotide sequence encoding the polypeptide is SEQ ID
NO: 33; SEQ ID NO: 34; or SEQ ID NO: 35.

22. The expression cassette Of claim 1, wherein the polynucleotide sequence encoding the polypeptide is SEQ ID
NO: 55; SEQ ID NO: 62; SEQ ID NO: 63; or SEQ ID NO: 68.

23. A recombinant expression system for use in a selected host cell, comprising, an expression cassette of any one of claims 1 to 22, and wherein said polynucleotide sequence is operably linked to control elements compatible with expression in the selected host cell.

24. The recombinant expression system of claim 23, wherein said control elements are a transcription promoter, a transcription enhancer element, a transcription termination signal, polyadenylation sequences, sequences for optimization of initiation of translation, or translation termination sequences.

25. The recombinant expression system of claim 23, wherein said transcription promoter is CMV, CMV+intron A, SV40, RSV, HIV Ltr, MMLV ltr, or metallothionein.

26. An isolated cell other than a totipotent stem cell comprising an expression cassette of any one of claims 1 to 22, and wherein said polynucleotide sequence is operably linked to control elements compatible with expression in the selected cell.

27. The cell of claim 26, wherein the cell is a mammalian cell.

28. The cell of claim 27, wherein the cell is a BHK, VERO, HT1080, 293, RD, COS 7, or CHO cell.

29. The cell of claim 28, wherein said cell is a CHO cell.

30. The cell of claim 26, wherein the cell is an insect cell.

31. The cell of claim 30, wherein the cell is either a Trichoplusia ni (Tn5) or Sf9 insect cell.

32. The cell of claim 26, wherein the cell is a bacterial cell.

33. The cell of claim 26, wherein the cell is a yeast cell.

34. The cell of claim 26, wherein the cell is a plant cell.

35. The cell of claim 26, wherein the cell is an antigen presenting cell.

36. The cell of claim 35, wherein the antigen presenting cell is a macrophage, monocyte, dendritic cell, B cell, or T cell.

37. The cell of claim 26, wherein the cell is a primary cell.

38. The cell of claim 26, wherein the cell is an immortalized cell.

39. The cell of claim 26, wherein the cell is a tumor derived cell.

40. A method for producing a polypeptide including HIV Env polypeptide sequences, said method comprising, incubating the cells of any one of claims 26 to 39, under conditions for producing said polypeptide.

41. A gene delivery vector for use in a Mammalian subject, comprising an expression cassette of any one of claims 1 to 22, and wherein said polynucleotide sequence is operably linked to control elements compatible with expression in the subject.

42. Use of the gene delivery vector of claim 41 for delivering an immunogenic HIV Env polypeptide to a subject.

43. The use of claim 42, wherein said gene delivery vector is a nonviral vector.

44. The use of claim 42, wherein said vector is in a particulate carrier.

45. The use of claim 44, wherein said vector is coated on a gold or tungsten particle and said coated particle is in a form deliverable to said subject using a gene gun.

46. The use of claim 44, wherein said vector is encapsulated in a liposome preparation.

47. The use of claim 42, wherein said vector is a viral vector.

48. The use of claim 47, wherein said viral vector is a retroviral vector.

49. The use of claim 48, wherein said viral vector is a lentiviral vector.

50. The use of claim 42, wherein said subject is a mammal.

51. The use of claim 50, wherein said mammal is a human.

52. Use of the gene delivery vector of claim 41 for generating an immune response in a subject.

53. The use of claim 52, wherein said vector is a nonviral vector.

54. The use of claim 53, wherein said vector is in a particulate carrier.

55. The use of claim 54, wherein said vector is coated on a gold or tungsten particle and said coated particle is in a form deliverable to said vertebrate cell using a gene gun.

56. The use of claim 54, wherein said vector is encapsulated in a liposome preparation.

57. The use of claim 52, wherein said vector is a viral vector.

58. The use of claim 57, wherein said viral vector is a retroviral vector.

59. The use of claim 58, wherein said viral vector is a lentiviral vector.

60. The use of claim 52, wherein said subject is a mammal.

61. The use of claim 60, wherein said mammal is a human.

62. The use of claim 52, comprising transfecting cells of the subject ex vivo for subsequent reintroduction of transfected cells into said subject.

63. The use of claim 52, where said immune response is a humoral immune response.

64. The use of claim 52, where said immune response is a cellular immune response.

65. A gene delivery vector comprising an alphavirus vector construct, wherein said alphavirus construct comprises an expression cassette according to any one of claims 1 to 22.

66. The gene delivery vector of claim 65, wherein the alphavirus vector construct is a cDNA vector construct.

67. The gene delivery vector of claim 65, wherein the alphavirus comprises a recombinant alphavirus particle preparation.

68. The gene delivery vector of claim 65, wherein the vector comprises a eukaryotic layered vector initiation system.

69. Use of the gene delivery vector of claim 65 for stimulating an immune response in a subject.

70. The use of claim 69, wherein the gene delivery vector is in intramuscularly, intramucosally, intranasally, subcutaneously, intradermally, transdermally, intravaginally, intrarectally, orally or intravenously administrable form.